diff --git "a/ACAD.csv" "b/ACAD.csv"
new file mode 100644--- /dev/null
+++ "b/ACAD.csv"
@@ -0,0 +1,4932 @@
+Date,open,close,Price Change %,Article_title,Textrank_summary
+2023-12-28,31.65999984741211,31.38999938964844,,,
+2023-12-27,31.1200008392334,31.770000457763672,-0.8528125681142041,,
+2023-12-26,31.75,31.1299991607666,2.0886876638859544,,
+2023-12-22,30.100000381469727,31.39999961853028,-1.9527585487666093,,
+2023-12-21,29.559999465942383,29.520000457763672,4.31893428765823,,
+2023-12-20,30.07999992370605,29.049999237060547,-0.13531464445659372,,
+2023-12-19,30.200000762939453,30.1299991607666,-3.4242044190756817,,
+2023-12-18,28.5,29.020000457763672,-0.23179337882254444,,
+2023-12-15,28.299999237060547,28.57999992370605,1.8245630096970944,,
+2023-12-14,27.239999771118164,28.059999465942383,0.9894017462686944,,
+2023-12-13,21.5,28.46999931335449,3.0102779064397875,,
+2023-12-12,21.309999465942383,21.170000076293945,32.418601457462735,"Biotech ETF SBIO Sees Buy Signal Amid Hot Returns | Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid | Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News | Citigroup Initiates Coverage of Acadia Pharmaceuticals (ACAD) with Buy Recommendation | Guru Fundamental Report for ACAD | Deutsche Bank Initiates Coverage of Acadia Pharmaceuticals (ACAD) with Buy Recommendation | Health Care Sector Update for 12/13/2023: ACAD, ZLAB, VRTX, PFE","[/caption] The main stock rising in SBIO’s holdings, per YCharts, is Acadia Pharmaceuticals (ACAD), which has risen significantly in recent weeks following a win in a patent lawsuit. ACAD has gained 32% since that win. Biotech ETF SBIO's Approach SBIO holds both as part of its approach. | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD announced that the U.S. District Court in Delaware passed a judgment strongly in favor of the company in its litigation against MSN Laboratories Pvt. | Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Editas Medicine, Inc. (EDIT) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. ACAD Surges on Patent Ruling: Acadia Pharmaceuticals Inc. ACAD announced that the U.S. District Court in Delaware passed a judgment strongly in favor of the company in its litigation against MSN Laboratories Pvt. The court granted summary judgment to Acadia confirming the validity of the '740 composition of matter patent of lead drug for Nuplazid (pimavanserin). | Fintel reports that on December 13, 2023, Citigroup initiated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 17.33% Upside As of November 27, 2023, the average one-year price target for Acadia Pharmaceuticals is 33.40. The projected annual revenue for Acadia Pharmaceuticals is 597MM, a decrease of 5.51%. | Of the 22 guru strategies we follow, ACAD rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). | Fintel reports that on December 12, 2023, Deutsche Bank initiated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 58.39% Upside As of November 27, 2023, the average one-year price target for Acadia Pharmaceuticals is 33.40. The projected annual revenue for Acadia Pharmaceuticals is 597MM, a decrease of 5.51%. | In corporate news, Acadia Pharmaceuticals (ACAD) shares soared 33% after a federal court granted it summary judgment in a patent case related to a Parkinson's drug, according to a Wednesday court filing. Health care stocks advanced late Wednesday afternoon with the NYSE Health Care Index adding 1.4% and the Health Care Select Sector SPDR Fund (XLV) climbing 1.7%. Vertex Pharmaceuticals (VRTX) shares jumped 13% after the company said a phase 2 study of VX-548 to treat patients with diabetic peripheral neuropathy resulted in a ""statistically significant and clinically meaningful reduction in the primary endpoint"" of change from baseline in the weekly average of daily pain intensity."
+2023-12-11,21.170000076293945,21.09000015258789,-0.6569657116706379,"Wednesday's ETF Movers: FBT, URA","Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 30.4% and shares of Vertex Pharmaceuticals, up about 9.3% on the day. In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 2.2% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Uranium Energy, lower by about 13%, and shares of Nexgen Energy, lower by about 4.8% on the day."
+2023-12-08,21.729999542236328,20.979999542236328,-0.37789288340928345,,
+2023-12-07,21.51000022888184,21.790000915527344,-3.4514496815438696,,
+2023-12-06,22.479999542236328,21.3799991607666,1.3017233085360114,,
+2023-12-05,22.690000534057617,22.290000915527344,-4.893240230734888,,
+2023-12-04,22.520000457763672,22.850000381469727,-1.7628894187546418,Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?,"Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. One other Medical stock that has outperformed the sector so far this year is Acadia Pharmaceuticals (ACAD). Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 19.1%."
+2023-12-01,22.350000381469727,22.600000381469727,1.4653637522120415,Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS | bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How,"ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD announced that it has initiated a late-stage study evaluating the efficacy and safety of carbetocin nasal spray (ACP-101) for the treatment of hyperphagia in Prader-Willi syndrome (PWS). | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Entrada Therapeutics, Inc. (TRDA) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of other top-ranked stocks in the biotech sector are Entrada Therapeutics TRDA, Dynavax Technologies DVAX,  and Acadia Pharmaceuticals ACAD. While TRDA sports a Zacks Rank #1 (Strong Buy), DVAX and ACAD, each carry a Zacks Rank #2."
+2023-11-30,22.39999961853028,22.280000686645508,1.1185682135704738,Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised),"ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD announced that it has initiated a mid-stage study to evaluate the safety and efficacy of its investigational candidate, ACP-204, in the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP)."
+2023-11-29,22.39999961853028,22.1299991607666,-0.535709526465814,"Avidity (RNA) Expands Collaboration With BMY, Shares Rise","Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Avidity Biosciences, Inc. (RNA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of top-ranked stocks in the biotech sector are Dynavax Technologies DVAX and Acadia Pharmaceuticals ACAD, each carrying a Zacks Rank #2 (Buy). Loss estimates for Acadia have narrowed to 33 cents from 41 cents for 2023 and earnings estimates for 2024 are currently pinned at 94 cents per share."
+2023-11-28,22.15999984741211,22.290000915527344,-1.2053592069721402,Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study,"Acadia Pharmaceuticals Inc. ACAD announced that it has initiated a mid-stage study to evaluate the safety and efficacy of its investigational candidate, ACP-204, in the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here."
+2023-11-27,22.190000534057617,22.1200008392334,0.5866474233320726,Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why | Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan,"Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Olema Pharmaceuticals, Inc. (OLMA) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the overall healthcare sector is Acadia Pharmaceuticals ACAD, which carries a Zacks Rank #2 (Buy). Acadia Pharmaceuticals’ loss estimates for 2023 have narrowed from 41 cents to 33 cents per share in the past 60 days. | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Theseus Pharmaceuticals, Inc. (THRX) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND and Acadia Pharmaceuticals ACAD. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD carries a Zacks Rank #2 (Buy) at present."
+2023-11-24,22.020000457763672,22.290000915527344,-0.31545603037179715,"Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why | Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals","Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA) : Free Stock Analysis Report AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD, Allogene Therapeutics ALLO and AnaptysBio ANAB, all carrying a Zacks Rank #2 (Buy). Acadia Pharmaceuticals’ loss estimates for 2023 have narrowed from 41 cents to 33 cents per share in the past 60 days. | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. For Immediate Release Chicago, IL – November 24, 2023 – Today, Zacks Equity Research discusses Gilead Sciences, Inc. GILD, CRISPR Therapeutics AG CRSP, ACADIA Pharmaceuticals Inc. ACAD, Dynavax DVAX and Ligand Pharmaceuticals Inc. LGND. Biotech companies like Gilead Sciences, Inc., CRISPR Therapeutics AG, ACADIA Pharmaceuticals Inc., Dynavax and Ligand Pharmaceuticals Inc. are poised to outperform the volatile sector."
+2023-11-22,22.270000457763672,21.989999771118164,1.2261600915111552,MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study | Gain Therapeutics (GANX) Down 25% on Issue of New Common Stock | 5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright | Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson,"Click to get this free report Incyte Corporation (INCY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report MorphoSys AG Unsponsored ADR (MOR) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD and AnaptysBio ANAB, all carrying a Zacks Rank #2. Acadia Pharmaceuticals’ loss estimates for 2023 have narrowed from 41 cents to 34 cents per share in the past 60 days. | Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report Gain Therapeutics, Inc. (GANX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD, Allogene Therapeutics ALLO and AnaptysBio ANAB, all carrying a Zacks Rank #2. Acadia Pharmaceuticals’ loss estimates for 2023 have narrowed from 41 cents to 34 cents per share in the past 60 days. | Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Biotech companies like Gilead Sciences, Inc. GILD, CRISPR Therapeutics AG CRSP, ACADIA Pharmaceuticals Inc. ACAD, Dynavax DVAX and Ligand Pharmaceuticals Incorporated LGND are poised to outperform the volatile sector. Price and Consensus: CRSP Acadia is focused on developing innovative medicines to address unmet medical needs in central nervous system disorders. | Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report Can-Fite Biopharma Ltd (CANF) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Agenus AGEN. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD and AGEN carry a Zacks Rank #2 each at present."
+2023-11-21,22.76000022888184,22.450000762939453,-1.2572998692862405,J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant | Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment | Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug,"Some better-ranked stocks in the healthcare sector are Novo Nordisk A/S NVO, AbbVie Inc. ABBV and Acadia Pharmaceuticals Inc. ACAD, carrying a Zacks Rank #2 (Buy) each at present. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 60 days, estimates for Acadia Pharmaceuticals’ 2023 loss per share have narrowed from 41 cents to 34 cents. | Agios Pharmaceuticals, Inc. Price Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote Zacks Rank & Stocks to Consider Agios currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD and AnaptysBio ANAB, all carrying a Zacks Rank #2. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Agios Pharmaceuticals, Inc. (AGIO) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals’ loss estimates for 2023 have narrowed from 41 cents to 34 cents per share in the past 60 days. | Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Agenus AGEN. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD and AGEN carry a Zacks Rank #2 (Buy) each at present."
+2023-11-20,22.63999938964844,22.920000076293945,-1.362036304151725,Wall Street Analysts Predict a 37.65% Upside in Acadia (ACAD): Here's What You Should Know | Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why,"You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide. Acadia Pharmaceuticals (ACAD) closed the last trading session at $22.84, gaining 3.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. But, for ACAD, an impressive average price target is not the only indicator of a potential upside. | In the past 30 days, the Zacks Consensus Estimate for Acadia’s 2023 loss per share has narrowed from 37 cents to 34 cents. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Agenus Inc. (AGEN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Repare Therapeutics Inc. (RPTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Agenus AGEN."
+2023-11-17,22.290000915527344,22.84000015258789,1.2367521828358679,Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer | Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year? | Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug | Ardelyx (ARDX) Up on Xphozah's Orphan Tag for Hyperphosphatemia,"Click to get this free report Merck & Co., Inc. (MRK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report AnaptysBio, Inc. (ANAB) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD, Allogene Therapeutics ALLO and AnaptysBio ANAB, all carrying a Zacks Rank #2. Acadia Pharmaceuticals’ loss estimates for 2023 have narrowed from 41 cents to 34 cents per share in the past 60 days. | Acadia Pharmaceuticals is a member of our Medical group, which includes 1087 different companies and currently sits at #2 in the Zacks Sector Rank. To break things down more, Acadia Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, a group that includes 528 individual companies and currently sits at #51 in the Zacks Industry Rank. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Dermata Therapeutics, Inc. (DRMA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Anixa Biosciences ANIX. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD and ANIX carry a Zacks Rank #2 (Buy) each at present. | Click to get this free report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Ardelyx, Inc. (ARDX) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Anixa Biosciences ANIX. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD and ANIX carry a Zacks Rank #2 (Buy) each at present."
+2023-11-16,22.459999084472656,22.06999969482422,2.4674706795431947,Implied Volatility Surging for On ACADIA Pharmaceuticals (ACAD) Stock Options,"Investors in ACADIA Pharmaceuticals Inc. ACAD need to pay close attention to the stock based on moves in the options market lately. Clearly, options traders are pricing in a big move for ACADIA Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, ACADIA Pharmaceuticals is a Zacks Rank #2 (Buy) in the Medical - Biomedical and Genetics industry that ranks in the Top 23% of our Zacks Industry Rank."
+2023-11-15,23.170000076293945,22.56999969482422,-1.7364176560365805,,
+2023-11-14,23.13999938964844,23.200000762939453,-2.589557097514248,ACAD Makes Bullish Cross Above Critical Moving Average,"In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.24, changing hands as high as $23.26 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $14.45 per share, with $33.99 as the 52 week high point — that compares with a last trade of $23.14. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day."
+2023-11-13,22.06999969482422,22.420000076293945,0.2592972120727599,,
+2023-11-10,22.18000030517578,22.200000762939453,1.5858649130466795,,
+2023-11-09,23.270000457763672,22.01000022888184,0.09017338813563812,Guru Fundamental Report for ACAD,"Of the 22 guru strategies we follow, ACAD rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Partha Mohanram Partha Mohanram Portfolio About Partha Mohanram: Sometimes the best investing strategies don't come from the world of investing. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD)."
+2023-11-08,23.540000915527344,23.190000534057617,-5.414697911883595,"Esperion (ESPR) Q3 Earnings Beat, Stock Up on Strong Revenues | Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5% | Iovance's (IOVA) Meets Q3 Earnings, Lags Sales Estimates","Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD, Allogene Therapeutics ALLO and Apellis Pharmaceuticals APLS, carrying a Zacks Rank #2 (Buy). In the past 30 days, estimates for Acadia’s 2023 loss per share have narrowed from 41 cents to 35 cents. | Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD and Apellis Pharmaceuticals APLS, carrying a Zacks Rank #2 (Buy). In the past 30 days, estimates for Acadia’s 2023 loss per share have narrowed from 41 cents to 35 cents. | Iovance Biotherapeutics, Inc. IOVA incurred a loss of 46 cents per share in third-quarter 2023, in line with the Zacks Consensus Estimate. During the quarter, the company generated total revenues of $0.5 million — entirely from product sales of its recently-acquired interleukin-2 (IL-2) product Proleukin (aldesleukin). The reported Proleukin sales of $0.5 million also missed our model estimates of $4 million."
+2023-11-07,23.989999771118164,23.5,-1.4868324887738682,"Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '23 View | CRISPR Therapeutics (CRSP) Q3 Loss Narrower Than Expected","Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD, Alkermes ALKS and Apellis Pharmaceuticals APLS, carrying a Zacks Rank #2 (Buy). In the past 30 days, estimates for Acadia’s 2023 loss per share have narrowed from 41 cents to 37 cents. | Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other better-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD and Alkermes ALKS, also carrying a Zacks Rank #2. In the past 30 days, estimates for Acadia’s 2023 loss per share have narrowed from 41 cents to 37 cents."
+2023-11-06,25.100000381469727,23.979999542236328,-2.0425167811301126,Mizuho Upgrades Acadia Pharmaceuticals (ACAD),"Fintel reports that on November 6, 2023, Mizuho upgraded their outlook for Acadia Pharmaceuticals (NASDAQ:ACAD) from Neutral to Buy . Analyst Price Forecast Suggests 32.98% Upside As of November 1, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.88. The projected annual revenue for Acadia Pharmaceuticals is 597MM, a decrease of 5.51%."
+2023-11-03,24.0,24.06999969482422,-4.462154670165853,"Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales | Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss | Acadia (ACAD) Q3 Earnings and Sales Beat Estimates, Stock Up","Agios Pharmaceuticals, Inc. AGIO reported a loss per share of $1.64 in third-quarter 2023, narrower than the Zacks Consensus Estimate of a loss of $1.69. The company reported revenues of $7.4 million, which missed the Zacks Consensus Estimate of $7.7 million. Quarter in Detail In the reported quarter, revenues were generated entirely from product revenues of Agios’ only marketed drug, Pyrukynd (mitapivat), which the FDA approved for treating hemolytic anemia in adults with pyruvate kinase (PK) deficiency in February 2022. | Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Allogene intends to target an academic forum in early 2024 to provide an update on this study. Some other top-ranked stocks in the overall healthcare sector include Acadia Pharmaceuticals ACAD, Alkermes ALKS and Puma Biotechnology PBYI. | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy). Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Adicet Bio, Inc. (ACET) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD reported third-quarter 2023 loss of 40 cents per share, narrower than the Zacks Consensus Estimate of a loss of 43 cents."
+2023-11-02,22.90999984741211,22.989999771118164,0.2916653951009115,,
+2023-11-01,22.670000076293945,22.920000076293945,0.3491921616712337,Is Medpace (MEDP) Outperforming Other Medical Stocks This Year? | Novo Nordisk (NVO) to Report Q3 Earnings: What's in the Cards?,"Click to get this free report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. One other Medical stock that has outperformed the sector so far this year is Acadia Pharmaceuticals (ACAD). For Acadia Pharmaceuticals, the consensus EPS estimate for the current year has increased 6.1% over the past three months. | Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2 at present. Shares of ACADIA have gained 41.8% year to date."
+2023-10-31,22.049999237060547,22.56999969482422,1.1027789993764727,"Commit To Purchase Acadia Pharmaceuticals At $15, Earn 7.3% Using Options | STERIS (STE) Set to Post Q2 Earnings: What's in the Cards? | Perrigo (PRGO) to Report Q3 Earnings: What's in the Cards?","Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2025 put at the $15 strike for the 6% annualized rate of return represents good reward for the risks. Investors considering a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $22.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. | Click to get this free report STERIS plc (STE) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%. | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Perrigo Company plc (PRGO) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. Shares of Acadia Pharmaceuticals have gained 39.6% in the year-to-date period."
+2023-10-30,21.96999931335449,22.229999542236328,2.35827880161411,Gilead (GILD) Gears Up to Report Q3 Earnings: What's in Store? | Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season? | Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth | Vertex (VRTX) to Report Q3 Earnings: What's in the Cards? | Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?,"Click to get this free report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report uniQure N.V. (QURE) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD currently has an Earnings ESP of +6.76% and a Zacks Rank #2. Acadia beat earnings estimates in two of the trailing four quarters and missed in the remaining two. | Click to get this free report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Zimmer Biomet Holdings, Inc. (ZBH) : Free Stock Analysis Report Spero Therapeutics, Inc. (SPRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%. | Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%. | Factors to Consider Vertex markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. In the last reported quarter, international sales and expanded use in children (aged between two and five years) with CF in the United States drove up sales of the drug. However, higher Trikafta sales are likely to have caused sales erosion of Vertex’s other CF drugs and existing combinations | Click to get this free report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%."
+2023-10-27,22.56999969482422,21.76000022888184,1.1834330314420998,Incyte (INCY) to Report Q3 Earnings: What's in the Cards? | How Much Upside is Left in Acadia (ACAD)? Wall Street Analysts Think 38.62% | Hologic (HOLX) to Report Q4 Earnings: What's in the Cards? | Regeneron (REGN) to Report Q3 Earnings: What's in the Cards?,"Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. Acadia’s stock has surged 41.3% in the year-to-date period. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide. Shares of Acadia Pharmaceuticals (ACAD) have gained 4.5% over the past four weeks to close the last trading session at $22.50, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for ACAD, an impressive average price target is not the only indicator of a potential upside. | Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%. | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. Acadia beat earnings estimates in two of the trailing four quarters and missed in the remaining two."
+2023-10-26,22.559999465942383,22.5,-3.5888324186735785,"Notable Thursday Option Activity: CAVA, ACAD, PRGS | Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow | Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards? | Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?","Below is a chart showing CAVA's trailing twelve month trading history, with the $45 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 9,518 contracts, representing approximately 951,800 underlying shares or approximately 51.9% of ACAD's average daily trading volume over the past month, of 1.8 million shares. Especially high volume was seen for the $23 strike call option expiring November 17, 2023, with 5,579 contracts trading so far today, representing approximately 557,900 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $23 strike highlighted in orange: And Progress Software Corp (Symbol: PRGS) options are showing a volume of 1,722 contracts thus far today. | Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare industry are Dynavax Technologies DVAX and Acadia Pharmaceuticals ACAD. DVAX currently sports a Zacks Rank #1 (Strong Buy) and ACAD carries a Zacks Rank #2 (Buy). | Click to get this free report Zoetis Inc. (ZTS) : Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Ascendis Pharma A/S (ASND) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2 at present. ACADIA’s stock has increased 41.9% year to date. | For Acadia, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2023. How Have the Numbers Shaped Up for Acadia?"
+2023-10-25,22.76000022888184,22.59000015258789,-0.2659550858277314,Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?,"Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report Bioventus Inc. (BVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. Acadia’s stock has surged 44.3% in the year-to-date period."
+2023-10-24,22.76000022888184,22.979999542236328,-0.746924756521853,"Novartis (NVS) Tops Q3 Earnings, Ups Operating Income View | InMode (INMD) to Post Q3 Earnings: What's in the Cards? | CVS Health (CVS) to Report Q3 Earnings: What's in the Cards? | Dynavax (DVAX) to Report Q3 Earnings: Will It Beat Estimates? | Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?","Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider A couple of better-ranked stocks in the healthcare industry are Dynavax Technologies DVAX and Acadia Pharmaceuticals ACAD. While DVAX currently sports a Zacks Rank #1 (Strong Buy), ACAD carries a Zacks Rank #2 (Buy). | Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report InMode Ltd. (INMD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%. | Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%. | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. Acadia’s stock has surged 39.9% in the year-to-date period. | Click to get this free report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Ascendis Pharma A/S (ASND) : Free Stock Analysis Report Femasys Inc. (FEMY) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACADIA’s stock has increased 40.1% year to date."
+2023-10-23,22.07999992370605,22.280000686645508,0.9666050577421142,Labcorp (LH) to Report Q3 Earnings: What's in the Cards? | IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?,"Click to get this free report Labcorp (LH) : Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. In Eastern Massachusetts, Labcorp recently expanded diagnostic testing and laboratory services via an agreement with the leading integrated academic health system, Tufts Medicine. Further, the portfolio of solutions, which the company offers through the acquisition of Personal Genome Diagnostics (PGDx), is expected to continue gaining momentum with major health systems and academic centers in the third quarter of 2023. | Click to get this free report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Insulet Corporation (PODD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.76% and a Zacks Rank #2. ACAD has an expected long-term earnings growth rate of 43.4%."
+2023-10-20,23.059999465942383,22.15999984741211,0.9058005599208682,ACAD Crosses Below Key Moving Average Level,"In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $22.84, changing hands as low as $21.97 per share. Acadia Pharmaceuticals Inc shares are currently trading down about 3.5% on the day. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $13.73 per share, with $33.99 as the 52 week high point — that compares with a last trade of $22.14."
+2023-10-19,23.36000061035156,22.93000030517578,-3.9028605350121306,Roche (RHHBY) Nine Months' Sales Fall on Lower COVID-19 Test Sale,"Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare industry are Dynavax Technologies DVAX and Acadia Pharmaceuticals ACAD. Dynavax currently sports a Zacks Rank #1 (Strong Buy) and ACAD carries a Zacks Rank #2 (Buy)."
+2023-10-18,23.350000381469727,23.209999084472656,-1.8407546829653374,,
+2023-10-17,24.07999992370605,23.39999961853028,-0.5995772792713684,Novo Nordisk (NVO) to Acquire Hypertension Drug for $1.3B | Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback | UBS Initiates Coverage of Acadia Pharmaceuticals (ACAD) with Buy Recommendation,"Loss estimates for Acadia for 2023 have narrowed to 37 cents from 41 cents in the past 60 days, while earnings estimates for 2024 are pegged at 67 cents per share. Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A few better-ranked stocks in the healthcare industry are Acadia Pharmaceuticals ACAD, Dynavax Technologies DVAX and Sarepta Therapeutics SRPT, each currently sporting a Zacks Rank #1 (Strong Buy). | Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aldeyra Therapeutics, Inc. (ALDX) : Free Stock Analysis Report Bausch + Lomb Corporation (BLCO) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the healthcare industry is Acadia Pharmaceuticals ACAD, currently sporting a Zacks Rank #1 (Strong Buy). Loss estimates for Acadia for 2023 have narrowed to 37 cents from 41 cents in the past 60 days, while earnings estimates for 2024 are pegged at 67 cents per share. | Fintel reports that on October 17, 2023, UBS initiated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 33.54% Upside As of October 5, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.76. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 8.38%."
+2023-10-16,23.09000015258789,23.780000686645508,-2.823921542069152,"Roche's (RHHBY) MS Drug Reduces Brain Lesions in Phase II Study | Novo Nordisk (NVO) Raises Sales Outlook for 2023, Shares Gain","Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare industry are Acadia Pharmaceuticals ACAD and Dynavax Technologies DVAX, each currently sporting a Zacks Rank #1 (Strong Buy). Loss estimates for Acadia for 2023 have narrowed to 37 cents from 41 cents in the past 60 days, while earnings estimates for 2024 are pegged at 67 cents per share. | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare industry are Acadia Pharmaceuticals ACAD and Dynavax Technologies DVAX, each currently sporting a Zacks Rank #1 (Strong Buy). Loss estimates for Acadia for 2023 have narrowed to 37 cents from 42 cents in the past 60 days, while earnings estimates for 2024 are pegged at 69 cents per share."
+2023-10-13,22.63999938964844,23.13999938964844,2.9883089194362045,,
+2023-10-12,23.25,22.63999938964844,2.2084806249094346,Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now,"The bottom line estimate for Acadia has narrowed from a loss of 41 cents per share to 40 cents per share for 2023 over the past 60 days. Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ASLAN Pharmaceuticals Ltd. (ASLN) : Free Stock Analysis Report Nurix Therapeutics, Inc. (NRIX) : Free Stock Analysis Report To read this article on Zacks.com click here. San Diego, CA-based Acadia Pharmaceuticals Inc. ACAD is a commercial biopharmaceutical company engaged in developing innovative medicines to address various central nervous system disorders."
+2023-10-11,23.43000030517578,23.3799991607666,-2.6236585391464904,,
+2023-10-10,23.1200008392334,23.420000076293945,-0.21340650344820622,Why Acadia Pharmaceuticals Stock Is Rising Today | JP Morgan Upgrades Acadia Pharmaceuticals (ACAD) | Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?,"10 stocks we like better than Acadia Pharmaceuticals When our analyst team has a stock tip, it can pay to listen. What happened Acadia Pharmaceuticals (NASDAQ: ACAD) is having a strong session Tuesday. This updated price target implies a noteworthy 47% upside potential relative to Acadia Pharmaceuticals' closing price on Monday. | Fintel reports that on October 10, 2023, JP Morgan upgraded their outlook for Acadia Pharmaceuticals (NASDAQ:ACAD) from Neutral to Overweight . Analyst Price Forecast Suggests 46.07% Upside As of October 5, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.76. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 8.38%. | Amphastar Pharmaceuticals and Acadia Pharmaceuticals could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Click to get this free report Amphastar Pharmaceuticals, Inc. (AMPH) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. One other Medical stock that has outperformed the sector so far this year is Acadia Pharmaceuticals (ACAD)."
+2023-10-09,21.479999542236328,21.739999771118164,1.2975745076594647,,
+2023-10-06,21.11000061035156,21.68000030517578,1.21042939675392,,
+2023-10-05,21.6200008392334,21.959999084472656,2.7001405890282903,,
+2023-10-04,20.61000061035156,21.520000457763672,1.5726097689241043,,
+2023-10-03,21.34000015258789,20.780000686645508,4.415331491814984,,
+2023-10-02,20.690000534057617,21.46999931335449,-2.6241774223908427,,
+2023-09-29,21.63999938964844,20.84000015258789,3.7699311704362826,"Noteworthy Friday Option Activity: NCLH, STNG, ACAD","Below is a chart showing STNG's trailing twelve month trading history, with the $55 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,342 contracts, representing approximately 834,200 underlying shares or approximately 44.6% of ACAD's average daily trading volume over the past month, of 1.9 million shares. Particularly high volume was seen for the $21 strike put option expiring November 17, 2023, with 2,004 contracts trading so far today, representing approximately 200,400 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $21 strike highlighted in orange: For the various different available expirations for NCLH options, STNG options, or ACAD options, visit StockOptionsChannel.com."
+2023-09-28,25.0,21.530000686645508,-3.6968542496504524,Notable Two Hundred Day Moving Average Cross - ACAD,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $22.30, changing hands as low as $21.16 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $13.73 per share, with $33.99 as the 52 week high point — that compares with a last trade of $21.65. Acadia Pharmaceuticals Inc shares are currently trading off about 14.7% on the day."
+2023-09-27,23.68000030517578,25.57999992370605,-13.879997253417969,,
+2023-09-26,23.3799991607666,23.6299991607666,8.023646934307612,,
+2023-09-25,23.43000030517578,23.290000915527344,1.0692900298282253,,
+2023-09-22,23.559999465942383,23.559999465942383,-0.5975219284035224,,
+2023-09-21,23.700000762939453,23.39999961853028,0.0,,
+2023-09-20,24.440000534057617,23.790000915527344,-1.265827572791876,,
+2023-09-19,24.6200008392334,24.440000534057617,-2.6595728491269317,,
+2023-09-18,24.709999084472656,24.420000076293945,-0.7311141309505576,Acadia Pharmaceuticals is Now Oversold (ACAD),"In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $24.44 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $13.73 per share, with $33.99 as the 52 week high point — that compares with a last trade of $24.53. A bullish investor could look at ACAD's 29.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
+2023-09-15,25.8799991607666,24.71999931335449,-1.1736099511267946,,
+2023-09-14,25.96999931335449,25.850000381469727,-4.482225212629227,,
+2023-09-13,26.07999992370605,25.88999938964844,-0.46206752043715044,,
+2023-09-12,27.1299991607666,26.13999938964844,-0.7285296572601001,,
+2023-09-11,26.450000762939453,27.1299991607666,-3.6490962098879276,,
+2023-09-08,26.290000915527344,26.450000762939453,2.570882337288744,,
+2023-09-07,26.90999984741211,26.34000015258789,0.6085958228993845,,
+2023-09-06,27.56999969482422,27.11000061035156,-2.1181705613388724,,
+2023-09-05,27.64999961853028,27.56999969482422,-1.6684769298674185,,
+2023-09-01,27.170000076293945,27.790000915527344,-0.2893306503065845,Acadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?,"Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD). Will the recent negative trend continue leading up to its next earnings release, or is Acadia due for a breakout?"
+2023-08-31,26.989999771118164,27.020000457763672,2.281931680134055,,
+2023-08-30,27.170000076293945,26.989999771118164,0.11115482363809194,,
+2023-08-29,27.8700008392334,27.09000015258789,-0.6624965206858171,,
+2023-08-28,28.559999465942383,27.8700008392334,-2.79871066795046,2 Supercharged Growth Stocks Billionaires Can't Stop Buying,"Two of the fund's top holdings are Acadia Pharmaceuticals (NASDAQ: ACAD) and Roivant Sciences (NASDAQ: ROIV), both of which have delivered impressive returns in the past year. Acadia is a leader in the field of neuropsychiatric disorders, with two Food and Drug Administration (FDA)-approved products on the market for Parkinson's disease psychosis (Nuplazid) and Rett syndrome (Daybue). ACAD data by YCharts Roivant is a diversified biopharma company that operates multiple subsidiaries, each focused on a different therapeutic area or technology platform."
+2023-08-25,28.520000457763672,28.600000381469727,-2.415961623289956,,
+2023-08-24,28.739999771118164,28.39999961853028,0.2805046368233042,,
+2023-08-23,29.13999938964844,28.63999938964844,-1.1830207212790644,,
+2023-08-22,30.299999237060547,29.09000015258789,-1.715854531478191,Cantor Fitzgerald Reiterates Acadia Pharmaceuticals (ACAD) Overweight Recommendation | Acadia Pharmaceuticals Reaches Analyst Target Price | Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?,"Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome — Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds. Fintel reports that on August 22, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 2.27% Upside As of August 2, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.01. | There are 16 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $30.06/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $30.06 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $30.06, changing hands for $30.34/share. | A mid-cap biotech stock with room to run Acadia Pharmaceuticals is a California-based pharma company with two Food and Drug Administration (FDA) approved medicines on the market. All things considered, Acadia's shares ought to perform reasonably well over the next few years due to Daybue's rising sales, Nuplazid's entrenched market position, and the company's modest valuation. Acadia Pharmaceuticals (NASDAQ: ACAD), a commercial-stage biopharma specializing in treatments for central nervous disorders, is a potential market-beating play."
+2023-08-21,29.32999992370605,30.31999969482422,-3.9933964189434095,,
+2023-08-18,28.600000381469727,29.32999992370605,3.3753827947268342,Validea Detailed Fundamental Analysis - ACAD,"Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang."
+2023-08-17,29.229999542236328,28.89999961853028,2.552445917830476,,
+2023-08-16,29.059999465942383,29.25,-1.1289768350122935,,
+2023-08-15,28.06999969482422,28.71999931335449,0.653821533205096,Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?,"Click to get this free report SPDR S&P Biotech ETF (XBI): ETF Research Reports Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports BridgeBio Pharma, Inc. (BBIO) : Free Stock Analysis Report To read this article on Zacks.com click here. Looking at individual holdings, Bridgebio Pharma Inc (BBIO) accounts for about 2.37% of total assets, followed by Acadia Pharmaceuticals Inc (ACAD) and Halozyme Therapeutics Inc (HALO). First Trust NYSE Arca Biotechnology ETF (FBT) tracks NYSE Arca Biotechnology Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index."
+2023-08-14,27.290000915527344,28.01000022888184,2.3156381389278113,,
+2023-08-11,26.600000381469727,27.3700008392334,2.6383264536456417,"Immunovant (IMVT) Q1 Loss Wider Y/Y, Pipeline in Focus","In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 40 cents for 2023. Click to get this free report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Immunovant, Inc. (IMVT) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are JAZZ Pharmaceuticals JAZZ, Acadia Pharmaceuticals ACAD and Corcept Therapeutics CORT, each carrying a Zacks Rank #2 (Buy) at present."
+2023-08-10,26.6299991607666,26.64999961853028,2.8947385215079726,Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues | Here's Why Acadia (ACAD) Looks Ripe for Bottom Fishing,"Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the biotech sector is Acadia Pharmaceuticals ACAD, which currently carries a Zacks Rank #2 (Buy). Over the past 60 days, loss estimates for ACAD have narrowed to 41 cents from 56 cents for 2023. | If this is not enough, you should note that ACAD currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Moreover, a Zacks Rank of 2 for Acadia is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve. The price trend for Acadia Pharmaceuticals (ACAD) has been bearish lately and the stock has lost 8.9% over the past week."
+2023-08-09,26.71999931335449,26.59000015258789,0.07510498833640677,"Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales | bluebird (BLUE) Q2 Earnings Top, Zynteglo & Skysona Fuel Revenues | Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss | FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss | Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance","Mirati Therapeutics, Inc. Price, Consensus and EPS Surprise Mirati Therapeutics, Inc. price-consensus-eps-surprise-chart | Mirati Therapeutics, Inc. Quote A better-ranked stock in the biotech sector is ACADIA Pharmaceuticals ACAD, which has a Zacks Rank #2 (Buy). Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 30 days, estimates for ACADIA Pharmaceuticals’ 2023 loss per share have narrowed from 53 cents to 41 cents, while that for 2024 have improved from a loss of 11 cents to earnings of 47 cents. | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some top-ranked stocks in the healthcare sector include Acadia Pharmaceuticals ACAD, Amicus Therapeutics FOLD and Dynavax Technologies DVAX, each carrying a Zacks Rank #2 (Buy). Over the past 60 days, loss estimates for ACAD have narrowed to 41 cents from 56 cents for 2023. | Nektar Therapeutics Price, Consensus and EPS Surprise Nektar Therapeutics price-consensus-eps-surprise-chart | Nektar Therapeutics Quote Some better-ranked biotech companies are ACADIA Pharmaceuticals ACAD and Axsome Therapeutics AXSM, both with a Zacks Rank #2 (Buy). Click to get this free report Eli Lilly and Company (LLY) : Free Stock Analysis Report Nektar Therapeutics (NKTR) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 30 days, estimates for ACADIA Pharmaceuticals’ 2023 loss per share have narrowed from 53 cents to 41 cents, while that for 2024 have improved from a loss of 11 cents to earnings of 47 cents. | Click to get this free report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report Fate Therapeutics, Inc. (FATE) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector are Acadia Pharmaceuticals ACAD, Amicus Therapeutics FOLD and Dynavax Technologies DVAX, currently carrying a Zacks Rank #2 (Buy). Over the past 60 days, loss estimates for ACAD have narrowed to 41 cents from 56 cents for 2023. | Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report Amicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and ImmunoGen IMGN, each carrying a Zacks Rank #2 at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 41 cents for 2023."
+2023-08-08,26.82999992370605,26.71999931335449,-0.4865238177668113,,
+2023-08-07,27.170000076293945,26.799999237060547,-0.40999109453731236,JP Morgan Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation,"Additional reading: Joint Venture and License Agreement, dated July 13, 2023, by and between the Registrant and Neuren Pharmaceuticals Ltd. Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ (trofinetide) net product sales of $23.2 million - 2Q23 NUPLAZID® (pimavanserin) net product sales of $142.0 million - Expanded licensing agree Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome — Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP Fintel reports that on August 7, 2023, JP Morgan maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 14.04% Upside As of August 2, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.01."
+2023-08-04,27.200000762939453,27.190000534057617,-1.3617991836379395,,
+2023-08-03,27.979999542236328,27.200000762939453,-0.03676554632844514,HC Wainwright & Co. Reiterates Acadia Pharmaceuticals (ACAD) Buy Recommendation | Morgan Stanley Reiterates Acadia Pharmaceuticals (ACAD) Equal-Weight Recommendation | Canaccord Genuity Maintains Acadia Pharmaceuticals (ACAD) Buy Recommendation | Oppenheimer Reiterates Acadia Pharmaceuticals (ACAD) Perform Recommendation,"Analyst Price Forecast Suggests 6.19% Upside As of August 2, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.01. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 8.38%. Fintel reports that on August 3, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. | Additional reading: Joint Venture and License Agreement, dated July 13, 2023, by and between the Registrant and Neuren Pharmaceuticals Ltd. Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ (trofinetide) net product sales of $23.2 million - 2Q23 NUPLAZID® (pimavanserin) net product sales of $142.0 million - Expanded licensing agree Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome — Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP Fintel reports that on August 3, 2023, Morgan Stanley reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 6.19% Upside As of August 2, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.01. | Additional reading: Joint Venture and License Agreement, dated July 13, 2023, by and between the Registrant and Neuren Pharmaceuticals Ltd. Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ (trofinetide) net product sales of $23.2 million - 2Q23 NUPLAZID® (pimavanserin) net product sales of $142.0 million - Expanded licensing agree Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome — Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP Fintel reports that on August 3, 2023, Canaccord Genuity maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of August 2, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.01. | Additional reading: Joint Venture and License Agreement, dated July 13, 2023, by and between the Registrant and Neuren Pharmaceuticals Ltd. Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE™ (trofinetide) net product sales of $23.2 million - 2Q23 NUPLAZID® (pimavanserin) net product sales of $142.0 million - Expanded licensing agree Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome — Expanded agreement follows Acadia’s April 2023 U.S. launch of DAYBUE™ (trofinetide) as the first Loan Agreement Between Baker Brothers Life Sciences, L.P., 667, L.P. and Baker Bros. Advisors LP Fintel reports that on August 3, 2023, Oppenheimer reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform recommendation. Analyst Price Forecast Suggests 6.19% Upside As of August 2, 2023, the average one-year price target for Acadia Pharmaceuticals is 31.01."
+2023-08-02,28.75,29.200000762939453,-2.787701186768972,Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates | Acadia Pharmaceuticals (ACAD) Price Target Increased by 22.71% to 31.01,"Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $165.24 million for the quarter ended June 2023, surpassing the Zacks Consensus Estimate by 7.08%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Pliant Therapeutics, Inc. (PLRX) : Free Stock Analysis Report To read this article on Zacks.com click here. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, This story originally appeared on Fintel. The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 31.01 / share. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia."
+2023-08-01,29.25,28.940000534057617,1.5652200450067937,,
+2023-07-31,29.229999542236328,29.239999771118164,-1.0598272339910524,Moderna (MRNA) to Report Q2 Earnings: Will It Beat Estimates? | Viatris (VTRS) to Report Q2 Earnings: What's in the Offing? | ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store? | First Week of March 2024 Options Trading For Acadia Pharmaceuticals (ACAD),"Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +38.26% and a Zacks Rank #2. In the year so far, ACADIA Pharmaceuticals’ shares have risen 82.4%. | Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +38.26% and a Zacks Rank #2. ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 2.75%. | Click to get this free report Moderna, Inc. (MRNA) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +38.26% and a Zacks Rank #2 at present. ACAD’s shares have rallied 82.4% in the year-to-date period. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $29.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $30.00 strike price has a current bid of $3.70. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the March 2024 expiration."
+2023-07-28,28.75,29.040000915527344,0.03421221018969212,Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store? | ADMA Biologics (ADMA) to Report Q2 Earnings: What's in Store?,"Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD has an Earnings ESP of +38.26% and a Zacks Rank #2. ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two quarters, with a four-quarter earnings surprise of -2.75%, on average. | Click to get this free report Moderna, Inc. (MRNA) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals (ACAD) has an Earnings ESP of +38.26% and a Zacks Rank #2 at present. ACAD’s shares have rallied 82.3% in the year-to-date period."
+2023-07-27,29.479999542236328,29.020000457763672,1.008698836616848,Alkermes (ALKS) Q2 Earnings & Revenues Beat Estimates | Incyte (INCY) to Report Q2 Earnings: What's in the Cards?,"Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of other top-ranked stocks in the same industry are ADC Therapeutics ADCT and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. | Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals (ACAD) has an Earnings ESP of +38.26% and a Zacks Rank #2 at present. ACAD’s shares have rallied 83.2% in the year-to-date period."
+2023-07-26,29.59000015258789,29.15999984741211,-1.5603768372303073,"SPDR S&P Biotech ETF Experiences Big Inflow | Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? | Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results","Among the largest underlying components of XBI, in trading today BridgeBio Pharma Inc (Symbol: BBIO) is up about 2.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1.5%, and Twist Bioscience Corp (Symbol: TWST) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.1 million dollar inflow -- that's a 3.2% increase week over week in outstanding units (from 75,750,000 to 78,180,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $72.44 per share, with $95.18 as the 52 week high point — that compares with a last trade of $83.12. | For Acadia, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. The market expects Acadia Pharmaceuticals (ACAD) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2023. How Have the Numbers Shaped Up for Acadia? | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the overall medical sector are J&J JNJ, ADC Therapeutics ADCT and Acadia Pharmaceuticals ACAD, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents."
+2023-07-25,29.940000534057617,29.600000381469727,-1.4531946703561411,"Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts | Kodiak (KOD) Down as Late-Stage DME Studies Fail","Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Inc. Price and Consensus Biogen Inc. price-consensus-chart | Biogen Inc. Quote Some better-ranked biotech companies are Alkermes ALKS and ACADIA Pharmaceuticals ACAD. While Alkermes has a Zacks Rank #1 (Strong Buy), ACADIA Pharmaceuticals has a Zacks Rank of 2 (Buy). | Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Kodiak Sciences Inc. (KOD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023."
+2023-07-24,30.8799991607666,30.020000457763672,-1.1356050318072994,"Commit To Purchase Acadia Pharmaceuticals At $24, Earn 9.4% Annualized Using Options | Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche | Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study | Roche (RHHBY) SMA Drug Gets Positive CHMP Opinion for Expanded Use","Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares decline 20.2% and the contract is exercised (resulting in a cost basis of $22.55 per share before broker commissions, subtracting the $1.45 from $24), the only upside to the put seller is from collecting that premium for the 9.4% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the March 2024 put at the $24 strike for the 9.4% annualized rate of return represents good reward for the risks. | Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the same industry are ADC Therapeutics ADCT and Acadia Pharmaceuticals ACAD, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. | Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the same industry are ADC Therapeutics ADCT and Acadia Pharmaceuticals ACAD, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. | Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023."
+2023-07-21,31.59000015258789,30.799999237060547,-2.78496996883202,Validea Detailed Fundamental Analysis - ACAD | GSK Gears Up for Q2 Earnings: Will It Surpass Estimates? | Is ACADIA Pharmaceuticals (ACAD) Stock Outpacing Its Medical Peers This Year? | Alkermes (ALKS) to Report Q2 Earnings: What's in the Cards? | Emergent's (EBS) Cyfendus Anthrax Vaccine Gets FDA Nod | Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug,"Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Stocks to Consider Here are some biotech stocks that have the right combination of elements to beat on earnings this time around: Acadia Pharmaceuticals ACAD has an Earnings ESP of +38.26% and a Zacks Rank #2. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia’s stock has surged 96.4% in the year-to-date period. | Acadia Pharmaceuticals is a member of our Medical group, which includes 1119 different companies and currently sits at #8 in the Zacks Sector Rank. Is Acadia Pharmaceuticals (ACAD) one of those stocks right now? Acadia Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy). | Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals (ACAD) has an Earnings ESP of +38.26% and a Zacks Rank #2 at present. ACAD’s shares have rallied 96.4% in the year-to-date period. | Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals has narrowed from a loss of 58 cents per share to a loss of 31 cents for 2023. | In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 58 cents to 31 cents. Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report Astria Therapeutics, Inc. (ATXS) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present."
+2023-07-20,31.959999084472656,31.26000022888184,-2.5007942757563613,,
+2023-07-19,33.060001373291016,31.90999984741211,-2.1902342792334495,Adial (ADIL) Shares Up 43% in the Past Week: Here's Why,"Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Adial Pharmaceuticals, Inc. (ADIL) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents."
+2023-07-18,33.61000061035156,32.9900016784668,-3.47852836693463,Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets,"Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akoya Biosciences, Inc. (AKYA) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are ADC Therapeutics ADCT, Acadia Pharmaceuticals ACAD and Akoya Biosciences AKYA, each carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 57 cents to 33 cents."
+2023-07-17,32.7400016784668,33.470001220703125,-1.8446858691630368,Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock? | Cantor Fitzgerald Maintains Acadia Pharmaceuticals (ACAD) Overweight Recommendation | Acadia Pharmaceuticals Rights Deal and Bullish Outlook Sends Shares Surging 16%. Here’s What To Expect,"You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Tango Therapeutics, Inc. (TNGX) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) shares ended the last trading session 24.7% higher at $32.18. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 17, 2023, Cantor Fitzgerald maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 24.48% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | These developments coupled with Acadia's acquisition of ex-North American rights to trofinetide and global rights to NNZ-2591 for Rett and Fragile X syndromes from Neuren Pharmaceuticals propelled the stock's value upward. One area of concern: While the news has brought a positive movement on the stock, research on the Fintel on ACAD’s insider trading data revealed five net insiders have sold stock in the last 90 days. In a stunning two-day rally, shares of Acadia Pharmaceuticals (US:ACAD) have seen a 16% surge following the announcement of the company's acquisition of expanded commercial rights for the groundbreaking Rett syndrome drug, trofinetide."
+2023-07-14,30.06999969482422,32.18000030517578,2.229686942002972,"Citigroup Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation | HC Wainwright & Co. Maintains Acadia Pharmaceuticals (ACAD) Buy Recommendation | JMP Securities Maintains Acadia Pharmaceuticals (ACAD) Market Outperform Recommendation | Morgan Stanley Maintains Acadia Pharmaceuticals (ACAD) Equal-Weight Recommendation | RBC Capital Maintains Acadia Pharmaceuticals (ACAD) Outperform Recommendation | Why Acadia Pharmaceuticals Stock Is Soaring Today | Health Care Sector Update for 07/14/2023: ACAD, ELAN, UNH, XLV, IBB | Acadia (ACAD) Expands Existing Licensing Deal With Neuren | Pre-market Movers: ARBB, THRX, LESL, EDTX, LUNR, ACAD… | Miners help Australian shares notch fourth day of gains","Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, HC Wainwright & Co. maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, Morgan Stanley maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. Fintel reports that on July 14, 2023, RBC Capital maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. Analyst Price Forecast Suggests 2.06% Downside As of July 6, 2023, the average one-year price target for Acadia Pharmaceuticals is 25.27. | Acadia looks for third-quarter sales of Daybue in the range of $45 million to $55 million. 10 stocks we like better than Acadia Pharmaceuticals When our analyst team has a stock tip, it can pay to listen. What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were soaring 18.3% higher as of 11:03 a.m. | ACADIA Pharmaceuticals (ACAD) was climbing past 12% after saying it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug. Health care stocks were gaining pre-bell Friday, as the Health Care Select Sector SPDR Fund (XLV) was 0.7% higher and the iShares Biotechnology ETF (IBB) was recently up 0.5%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACAD also stated that all future payments to Neuren, related to the successful development and approval of NNZ-2591 in Rett syndrome and Fragile X syndrome, will be identical to the payments for trofinetide in both inside and outside North America. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Stocks to Consider Acadia currently has a Zacks Rank #3 (Hold). Click to get this free report ADC Therapeutics SA (ADCT) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. | ACADIA Pharmaceuticals Inc. (ACAD) is up over 18% at $30.51. In the Green ARB IOT Group Limited (ARBB) is up over 86% at $6.09. In the Red Theseus Pharmaceuticals, Inc. (THRX) is down over 65% at $3.26. | Among individual stocks, Neuren Pharmaceuticals NEU.AX closed 16.8% higher after expanding exclusive license deal with Acadia Pharmaceuticals ACAD.O. By Ayushman Ojha July 14 (Reuters) - Australian shares extended a winning run for the fourth consecutive session on Friday, logging their sharpest weekly jump this year, as bets that the Federal Reserve could pause rate hikes after this month boosted sentiment. Tech stocks .AXIJ gained 1.7%, while gold stocks .AXGD added 0.8%."
+2023-07-13,25.920000076293945,25.799999237060547,7.0169625266565765,Why These 2 Biotech Stocks Made Big Moves Late Thursday,"Acadia Pharmaceuticals (NASDAQ: ACAD) soared on a strategic deal that could be extremely lucrative for the company, but Theseus Pharmaceuticals (NASDAQ: THRX) suffered a catastrophic loss on discouraging news regarding a clinical trial. Acadia entered into a deal with Australia's Neuren Pharmaceuticals that expanded its previous licensing agreement for its Rett syndrome treatment trofinetide, also known as Daybue. 10 stocks we like better than Acadia Pharmaceuticals When our analyst team has a stock tip, it can pay to listen."
+2023-07-12,25.0,25.86000061035156,-0.46296619938342304,,
+2023-07-11,24.790000915527344,24.86000061035156,3.4400024414062353,,
+2023-07-10,24.270000457763672,24.770000457763672,0.2823706826907398,,
+2023-07-07,24.31999969482422,24.39999961853028,2.0601565330422407,,
+2023-07-06,24.040000915527344,24.229999542236328,0.32894705884016673,Acadia Pharmaceuticals (ACAD) Price Target Increased by 6.95% to 25.27,"Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID® net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatr Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA) action date set for March 12, Employment Offer Letter, dated December 19, 2022, between the Registrant and Doug Williamson. The average one-year price target for Acadia Pharmaceuticals (NASDAQ:ACAD) has been revised to 25.27 / share. For more in-depth coverage of Acadia Pharmaceuticals, view the free, crowd-sourced company research report on Finpedia."
+2023-07-05,23.96999931335449,24.15999984741211,0.7903436750131945,,
+2023-07-03,23.84000015258789,24.0,0.7926597392590041,"After Hours Most Active for Jul 3, 2023 : LCID, GT, TSLA, RIVN, ATUS, TAL, JPM, ACAD, AMZN, OUT, CHPT, T","ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.00, with 1,137,133 shares traded. As reported in the last short interest update the days to cover for ACAD is 7.945539; this calculation is based on the average trading volume of the stock. The total After hours volume is currently 41,090,446 shares traded."
+2023-06-30,24.15999984741211,23.950000762939453,0.671140295251806,,
+2023-06-29,24.15999984741211,24.0,-0.8692015140685121,,
+2023-06-28,24.350000381469727,24.170000076293945,-0.6622510282393388,Acadia Pharmaceuticals Reaches Analyst Target Price,"There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $24.09/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $24.09 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $24.09, changing hands for $24.22/share."
+2023-06-27,23.940000534057617,24.21999931335449,-0.7392209542335816,,
+2023-06-26,24.450000762939453,23.86000061035156,1.169585518172978,,
+2023-06-23,23.799999237060547,24.51000022888184,-2.4130884833435178,,
+2023-06-22,23.959999084472656,24.040000915527344,2.9831975402574944,,
+2023-06-21,23.82999992370605,24.09000015258789,0.3338974712504597,ACAD Factor-Based Stock Analysis,"Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang."
+2023-06-20,23.86000061035156,23.84000015258789,1.0910626509200767,,
+2023-06-16,24.690000534057617,24.06999969482422,-0.08382421312676418,,
+2023-06-15,24.14999961853028,24.38999938964844,-2.5111414573611026,,
+2023-06-14,25.200000762939453,24.13999938964844,0.9937878878226102,Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS,"ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Zacks Rank and Stocks to Consider Acadia currently has a Zacks Rank #3 (Hold). Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD announced adding a new phase III development candidate, ACP-101, to its rare disease portfolio."
+2023-06-13,24.63999938964844,25.030000686645508,-4.206354528567753,,
+2023-06-12,24.8799991607666,24.61000061035156,1.582797510786104,,
+2023-06-09,25.020000457763672,24.71999931335449,-1.0852032135145917,,
+2023-06-08,24.36000061035156,25.09000015258789,-1.1990453194260167,Why Is Iovance Biotherapeutics (IOVA) Up 7.9% Since Last Earnings Report?,"Click to get this free report Iovance Biotherapeutics, Inc. (IOVA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Over the past month, Acadia Pharmaceuticals (ACAD), a stock from the same industry, has gained 13.8%. Acadia reported revenues of $118.46 million in the last reported quarter, representing a year-over-year change of +2.6%."
+2023-06-07,24.07999992370605,24.6299991607666,2.9967139735050954,Acadia (ACAD) Up 12% Since Last Earnings Report: Can It Continue?,"Acadia Pharmaceuticals Q1 Earnings & Sales Miss Estimates Acadia Pharmaceuticals Inc. reported first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Karuna Therapeutics, Inc. (KRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD)."
+2023-06-06,24.020000457763672,23.989999771118164,2.284049995029661,,
+2023-06-05,24.36000061035156,23.96999931335449,-0.1248987763270882,,
+2023-06-02,24.100000381469727,24.61000061035156,-1.600990505851395,,
+2023-06-01,23.11000061035156,23.89999961853028,2.116183488834992,,
+2023-05-31,23.850000381469727,23.5,3.4184291965135687,,
+2023-05-30,24.780000686645508,23.790000915527344,-1.4675068170718337,,
+2023-05-26,24.38999938964844,24.780000686645508,-3.9951563506279353,,
+2023-05-25,26.0,24.450000762939453,1.599021347916025,,
+2023-05-24,25.420000076293945,25.64999961853028,-5.96153552715595,,
+2023-05-23,24.770000457763672,25.540000915527344,0.904797567057551,"SGEN, ACAD & BMEA Drove Baker Brothers Advisors' Q1 Returns as ASND and HZNP Were Culled","The top five positions in the fund currently by size are Seagen Inc (US:GEN), Incyte Corp. (US:INCY), BeiGene Ltd - ADR (US:BGNE), Acadia Pharmaceuticals Inc (US:ACAD) and Madrigal Pharmaceuticals Inc (US:MDGL). Another noteworthy addition was Acadia Pharmaceuticals, which saw a marginal increase in portfolio allocation of 0.29%, driven mainly by share price gains. Despite a comparatively smaller market value of $789.28 million, ACAD stock accounted for 4.2943% of the portfolio, showcasing the fund's diversification strategy."
+2023-05-22,24.31999969482422,24.799999237060547,3.1086009024369248,Guru Fundamental Report for ACAD | B of A Securities Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation,"Detailed Analysis of ACADIA PHARMACEUTICALS INC ACAD Guru Analysis ACAD Fundamental Analysis More Information on Dashan Huang Dashan Huang Portfolio About Dashan Huang: Dashan Huang is an Assistant Professor of Finance at the Lee Kong Chian School of Business at Singapore Management University. Below is Validea's guru fundamental report for ACADIA PHARMACEUTICALS INC (ACAD). Of the 22 guru strategies we follow, ACAD rates highest using our Twin Momentum Investor model based on the published strategy of Dashan Huang. | Fintel reports that on May 22, 2023, B of A Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 3.60% Downside As of May 11, 2023, the average one-year price target for Acadia Pharmaceuticals is 23.43. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%."
+2023-05-19,23.520000457763672,24.309999465942383,1.9736823530408252,"Friday's ETF Movers: FBT, KRE","Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals, up about 7% and shares of Acadia Pharmaceuticals, up about 4.4% on the day. In trading on Friday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 1.1% on the day. Among components of that ETF with the weakest showing on Friday were shares of First Foundation, lower by about 8.1%, and shares of Valley National Bancorp, lower by about 5.7% on the day."
+2023-05-18,22.5,23.200000762939453,3.3588392551154977,Acadia Pharmaceuticals Reaches Analyst Target Price,"There are 18 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $22.42/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $22.42 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $22.42, changing hands for $22.68/share."
+2023-05-17,21.989999771118164,22.68000030517578,3.111114501953125,,
+2023-05-16,21.790000915527344,21.8799991607666,3.1377923658001543,,
+2023-05-15,21.549999237060547,22.1200008392334,0.41302543119732477,,
+2023-05-12,21.350000381469727,21.46999931335449,2.6450191292470815,,
+2023-05-11,21.6299991607666,21.34000015258789,0.5620558770055694,,
+2023-05-10,21.709999084472656,21.64999961853028,-1.3407259335669477,,
+2023-05-09,21.59000015258789,21.43000030517578,-0.27636788794380146,Cantor Fitzgerald Reiterates Acadia Pharmaceuticals (ACAD) Overweight Recommendation | JMP Securities Maintains Acadia Pharmaceuticals (ACAD) Outperform Recommendation | HC Wainwright & Co. Reiterates Acadia Pharmaceuticals (ACAD) Buy Recommendation | Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates | Citigroup Maintains Acadia Pharmaceuticals (ACAD) Neutral Recommendation,"Fintel reports that on May 9, 2023, Cantor Fitzgerald reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Overweight recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 9, 2023, JMP Securities maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Outperform recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Fintel reports that on May 9, 2023, HC Wainwright & Co. reiterated coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Buy recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%. | Acadia Pharmaceuticals Inc. ACAD reported a first-quarter 2023 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 21 cents and our estimate of a loss of 26 cents per share. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report ANIXA BIOSCIENCES INC (ANIX) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. Total revenues comprised net sales of Nuplazid (pimavanserin) in the first quarter as Acadia’s second-marketed drug, Daybue (trofinetide) was launched in April 2023 in the U.S. market. | Fintel reports that on May 9, 2023, Citigroup maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 6.50% Upside As of April 24, 2023, the average one-year price target for Acadia Pharmaceuticals is 22.95. The projected annual revenue for Acadia Pharmaceuticals is 597MM, an increase of 14.76%."
+2023-05-08,22.06999969482422,21.549999237060547,-0.7410831231186025,"Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates","Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $118.46 million for the quarter ended March 2023, missing the Zacks Consensus Estimate by 2.66%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Immatics N.V. (IMTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.21."
+2023-05-05,21.65999984741211,21.93000030517578,-2.356141662682581,,
+2023-05-04,21.059999465942383,21.549999237060547,1.24653951830905,Viatris (VTRS) to Report Q1 Earnings: What's in the Offing?,"ACAD beat earnings estimates in two of the last four quarters and missed in the remaining two, the average negative surprise being 6.33% Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Oncternal Therapeutics, Inc. (ONCT) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report Viatris Inc. (VTRS) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3."
+2023-05-03,21.459999084472656,21.200000762939453,2.3266846322127286,,
+2023-05-02,21.6200008392334,21.3799991607666,-1.2115486142836065,"Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?","Expected Results of an Industry Player Acadia Pharmaceuticals (ACAD), another stock in the Zacks Medical - Biomedical and Genetics industry, is expected to report earnings per share of $0.21 for the quarter ended March 2023. The consensus EPS estimate for Acadia has been revised 7.5% higher over the last 30 days to the current level. This Earnings ESP, combined with its Zacks Rank #3 (Hold), suggests that Acadia will most likely beat the consensus EPS estimate."
+2023-05-01,21.18000030517578,21.75,-1.110090976644508,Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?,"Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia ACAD has an Earnings ESP of +14.65% and a Zacks Rank #3. ACAD topped earnings estimates in two of the last four quarters and missed in the remaining two."
+2023-04-28,20.51000022888184,21.32999992370605,2.6912166506670316,,
+2023-04-27,20.38999938964844,20.5,3.9980481992852526,,
+2023-04-26,20.049999237060547,20.309999465942383,0.5394831468577869,,
+2023-04-25,20.1299991607666,20.11000061035156,1.2967592956375273,,
+2023-04-24,20.07999992370605,20.13999938964844,-0.09934700073917449,"4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates","Here we have highlighted four companies, Sanofi SNY, Amgen AMGN, Regeneron Pharmaceuticals REGN and Acadia Pharmaceuticals ACAD — using our proprietary methodology — which are expected to deliver an earnings surprise in their upcoming quarterly results. Regeneron Pharmaceuticals, Inc. Price, Consensus and EPS Surprise Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote Acadia Pharmaceuticals Acadia has an Earnings ESP of +32.26% and a Zacks Rank #2. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here."
+2023-04-21,19.920000076293945,20.09000015258789,0.29880212236233994,"Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth | Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe | Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?","Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ACAD is developing Nuplazid (pimavanserin) in several studies, targeting different CNS indications. ACAD’s Nuplazid is already approved for hallucinations and delusions associated with Parkinson’s disease. | Click to get this free report Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. A couple of top-ranked stocks in the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents. | Click to get this free report OraSure Technologies, Inc. (OSUR) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) is another Medical stock that has outperformed the sector so far this year. Over the past three months, Acadia Pharmaceuticals' consensus EPS estimate for the current year has increased 34.3%."
+2023-04-20,19.989999771118164,19.96999931335449,0.8534140343516168,,
+2023-04-19,19.63999938964844,20.020000457763672,-0.10005231612144574,Validea's Top 5 Health Care Stocks Based On Peter Lynch - 4/19/2023 | Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK,"ACADIA PHARMACEUTICALS INC (ACAD) is a mid-cap growth stock in the Biotechnology & Drugs industry. Company Description: Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The following are the top rated Health Care stocks according to Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. | Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Bellus Health Inc. (BLU) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks from the same industry are Aptinyx APTX and Acadia Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents."
+2023-04-18,19.489999771118164,19.71999931335449,1.9348323825076907,Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug,"Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. Click to get this free report Agenus Inc. (AGEN) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 57 cents."
+2023-04-17,18.1299991607666,19.3700008392334,1.180090020201828,,
+2023-04-14,18.479999542236328,17.989999771118164,6.839502128329747,Mizuho Reiterates ACADIA Pharmaceuticals (ACAD) Neutral Recommendation,"Fintel reports that on April 14, 2023, Mizuho reiterated coverage of ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral recommendation. Analyst Price Forecast Suggests 23.92% Upside As of April 6, 2023, the average one-year price target for ACADIA Pharmaceuticals is $22.95. The projected annual revenue for ACADIA Pharmaceuticals is $597MM, an increase of 15.43%."
+2023-04-13,18.459999084472656,18.520000457763672,-2.6515139786570985,Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails,"Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aeglea BioTherapeutics, Inc. (AGLE) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are Aptinyx APTX, Acadia Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for Acadia Pharmaceuticals’ 2023 loss per share has narrowed from 87 cents to 56 cents."
+2023-04-12,18.309999465942383,18.34000015258789,0.325034540990226,,
+2023-04-11,17.780000686645508,18.09000015258789,0.16384864839188423,,
+2023-04-10,18.13999938964844,17.799999237060547,1.7435289874607387,,
+2023-04-06,18.15999984741211,18.350000381469727,-1.8743118193372967,Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio | Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug,"Acadia is currently evaluating Nuplazid in a phase III ADVANCE-2 study to evaluate its efficacy in patients with predominantly negative symptoms of schizophrenia who have achieved adequate control of positive symptoms with the existing antipsychotic treatment. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. price-consensus-chart | ACADIA Pharmaceuticals Inc. Quote Other Stocks to Consider Some other top-ranked stocks in the same industry are Aptinyx APTX and ADMA Biologics ADMA, both carrying a Zacks Rank #2 at present. Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report Novo Nordisk A/S (NVO) : Free Stock Analysis Report AEterna Zentaris Inc. (AEZS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the same industry are Aptinyx APTX and ACADIA Pharmaceuticals ACAD, both carrying a Zacks Rank #2 (Buy) at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 56 cents."
+2023-04-05,18.440000534057617,18.280000686645508,1.0462584562449389,Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update,"Click to get this free report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Aptinyx Inc. (APTX) : Free Stock Analysis Report Phathom Pharmaceuticals, Inc. (PHAT) : Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in the same industry are Aptinyx APTX, ACADIA Pharmaceuticals ACAD and ADMA Biologics ADMA, all carrying a Zacks Rank #2 at present. In the past 90 days, the Zacks Consensus Estimate for ACADIA’s 2023 loss per share has narrowed from 87 cents to 44 cents."
+2023-04-04,19.030000686645508,18.479999542236328,-0.8676781061724965,,
+2023-04-03,18.68000030517578,18.93000030517578,-2.8901793198312835,,
+2023-03-31,18.88999938964844,18.81999969482422,1.338329742589624,,
+2023-03-30,19.100000381469727,18.700000762939453,-0.37056483370021465,,
+2023-03-29,18.51000022888184,18.979999542236328,-2.094238798646002,Acadia (ACAD) Down 10.9% Since Last Earnings Report: Can It Rebound?,"Acadia Q4 Earnings Miss, Nuplazid Sales Boost Revenues Acadia Pharmaceuticals Inc. reported a fourth-quarter 2022 loss of 26 cents per share, just missing the Zacks Consensus Estimate of a loss of 25 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD)."
+2023-03-28,18.530000686645508,18.43000030517578,2.539164276298232,,
+2023-03-27,18.420000076293945,18.600000381469727,-0.5396674461096831,,
+2023-03-24,18.209999084472656,18.239999771118164,0.9772003497841288,,
+2023-03-23,18.71999931335449,18.31999969482422,0.164748424787615,,
+2023-03-22,19.38999938964844,18.5,-2.136750177362014,,
+2023-03-21,19.89999961853028,19.450000762939453,-4.589991839419947,,
+2023-03-20,19.989999771118164,19.76000022888184,-2.261300825211082,,
+2023-03-17,20.43000030517578,19.799999237060547,-1.150573010854313,,
+2023-03-16,19.799999237060547,20.6200008392334,-3.0837056226358865,"Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More","Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Seagen Inc. (SGEN) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report Aridis Pharmaceuticals (ARDS) : Free Stock Analysis Report To read this article on Zacks.com click here. Recap of the Week’s Most Important Stories: Acadia’s Drug Approval:  Acadia Pharmaceuticals Inc. ACAD announced that the FDA has approved trofinetide, under the brand name Daybue, for treating Rett syndrome in adult and pediatric patients two years of age and older. Along with the FDA approval, Acadia has received a Rare Pediatric Disease Priority Review Voucher, which can be used to obtain priority review for a subsequent application."
+2023-03-15,20.09000015258789,19.850000381469727,4.141422392774731,The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector | Strength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?,"Next up is Natera (NASDAQ:NTRA) at 1.52% of net assets, followed by Acadia Pharmaceuticals (NASDAQ:ACAD) at 1.5%. XBI SPDR S&P Biotech ETF $77.65 IBB iShares Biotechnology ETF $125.20 GNOM Global X Genomics and Biotechnology ETF $12.09 ARKG ARK Genomic Revolution ETF $28.38 IDNA iShares Genomics Immunology and Healthcare $23.25 SBIO ALPS Medical Breakthroughs ETF $28.04 CNCR Loncar Cancer Immunotherapy ETF $12.44 SPDR S&P Biotech ETF (XBI) Source: SHUN_J / Shutterstock One of the most popular entries among the best biotech ETFs to buy, the SPDR S&P Biotech ETF (NYSEARCA:XBI) benefits from strong volume metrics. iShares Genomics Immunology and Healthcare ETF (IDNA) Source: shutterstock.com/bangoland For those that want to go off the beaten path with their best biotech ETFs to buy, iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) offers an attractive alternate route. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia is part of the Zacks Medical - Biomedical and Genetics industry. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report EYEPOINT PHARMACEUTICALS, INC. (EYPT) : Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals (ACAD) shares rallied 5% in the last trading session to close at $20.38."
+2023-03-14,20.06999969482422,20.3799991607666,-1.1946230427840416,,
+2023-03-13,20.06999969482422,19.40999984741211,1.5445912837872513,Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome,"Acadia Pharmaceuticals ACAD announced that the FDA approved trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older on Mar 10, 2023. In the past year, the shares of Acadia have witnessed a fall of 8.6% compared with the industry’s 11.2% decline. Per the company, Daybue currently stands as the first and only drug approved for the treatment of Rett syndrome."
+2023-03-10,20.809999465942383,20.3700008392334,-3.288489573730858,U.S. FDA approves Acadia's genetic Rett syndrome drug,"Adds background, comments throughout March 10 (Reuters) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's ACAD.O drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition. The approval comes months after the FDA declined to approve expanded use of Acadia's drug Nuplazid to treat psychosis related to Alzheimer's disease. Acadia forecasts sales of Nuplazid - its only drug on the market - of between $520 and $550 million this year, above analysts' median expectations of $532.8 million, according to Refinitiv data."
+2023-03-09,20.86000061035156,20.51000022888184,-2.1143615473373054,,
+2023-03-08,20.459999084472656,20.770000457763672,-1.6778541286141448,,
+2023-03-07,20.690000534057617,20.36000061035156,1.5151582950278792,1 Top Biotech Stock to Buy in March,"So in a market that is no longer handing out ginormous premiums to biotech stocks, it's not unreasonable to assume that Acadia's stock may trade at somewhere around 4 times 2028 net Rett and PDP sales post-trofinetide approval. So, overall, Acadia's stock probably has a 21% near-term upside potential following an approval, and a possible 29% downside risk upon a rejection. 10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen."
+2023-03-06,20.420000076293945,20.6299991607666,-1.5949730071917998,,
+2023-03-03,20.51000022888184,20.34000015258789,1.0283990386290405,,
+2023-03-02,20.81999969482422,20.290000915527344,-0.8288643315301264,,
+2023-03-01,20.790000915527344,20.920000076293945,-2.5456233768756054,"This ETF Has 67% Upside Potential, According to Analysts","Additionally, top 10 holdings like Seagen (NASDAQ:SGEN) and ACADIA Pharmaceuticals (NASDAQ:ACAD) also boast 'Perfect 10' Smart Scores. Investors are always on the lookout for opportunities with considerable potential upside, and an ETF that analysts collectively view as having nearly 70% upside potential from current levels is the SPDR S&P Biotech ETF (NYSEARCA:XBI). According to the views of 3,677 analysts, XBI is a “Moderate Buy,” but the average XBI stock price target of $138.76 represents a scintillating upside potential of 66.8% from the ETF’s current price."
+2023-02-28,19.850000381469727,20.690000534057617,0.6252965610478142,"First Week of ACAD September 15th Options Trading | Acadia (ACAD) Q4 Earnings Miss, Nuplazid Sales Boost Revenues | Biotech Stocks Facing FDA Decision In March 2023","Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of $2.80. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 15th expiration. | Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 4% year over year to $136.5 million in the fourth quarter, beating the Zacks Consensus Estimate of $134 million. 2022 Results Acadia clocked revenues of $517.2 million in the full-year 2022, witnessing growth of 7% year over year from $484.1 million recorded 2021 and beat the Zacks Consensus Estimate of $515.16 million. Acadia Pharmaceuticals Inc. ACAD reported fourth-quarter 2022 loss of 26 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. | (RTTNews) - As another month draws to a close, it is time to reflect on recent regulatory developments that have made headlines and look ahead to what's in store in March, which is observed as the National Kidney Month. In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. On February 24, the FDA issued emergency use authorisation for Lucira COVID-19 & Flu Home Test, a single-use at-home test kit that provides results from self-collected nasal swab samples in roughly 30 minutes."
+2023-02-27,19.13999938964844,19.39999961853028,4.231738722645282,"Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $136.49 million for the quarter ended December 2022, surpassing the Zacks Consensus Estimate by 1.55%. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Telesis Bio Inc. (TBIO) : Free Stock Analysis Report To read this article on Zacks.com click here."
+2023-02-24,18.780000686645508,18.920000076293945,1.3584129423873252,,
+2023-02-23,18.96999931335449,19.100000381469727,0.7454706311485458,,
+2023-02-22,18.64999961853028,18.959999084472656,0.6852982225661962,,
+2023-02-21,19.059999465942383,18.6200008392334,1.6621955618399382,,
+2023-02-17,18.780000686645508,19.3700008392334,-2.308492334930029,,
+2023-02-16,18.850000381469727,18.709999084472656,3.1416407402340556,,
+2023-02-15,18.989999771118164,18.96999931335449,-0.7427124358824786,,
+2023-02-14,19.15999984741211,19.100000381469727,-0.10532100055153273,,
+2023-02-13,18.959999084472656,19.18000030517578,-0.3131496159718748,,
+2023-02-10,19.100000381469727,18.96999931335449,1.1603440470801267,,
+2023-02-09,19.96999931335449,19.1299991607666,-0.6806338508839049,,
+2023-02-08,19.940000534057617,19.71999931335449,-4.206310372911009,,
+2023-02-07,19.81999969482422,20.11000061035156,-1.1033160221202873,,
+2023-02-06,19.75,19.850000381469727,1.4631731583884475,,
+2023-02-03,19.540000915527344,19.82999992370605,0.5063310454163371,,
+2023-02-02,19.0,19.90999984741211,1.4841299620833766,,
+2023-02-01,18.96999931335449,18.93000030517578,4.789472881116366,,
+2023-01-31,18.63999938964844,19.030000686645508,-0.21085403071442868,,
+2023-01-30,18.549999237060547,18.530000686645508,2.0922817047604116,,
+2023-01-27,18.56999969482422,18.56999969482422,-0.10780890155016552,,
+2023-01-26,18.790000915527344,18.65999984741211,0.0,,
+2023-01-25,18.850000381469727,18.690000534057617,-0.6918630217192082,,
+2023-01-24,19.01000022888184,19.0,-0.8488055393855342,,
+2023-01-23,19.3799991607666,19.09000015258789,-0.05260509606226186,,
+2023-01-20,18.670000076293945,19.350000381469727,-1.4963829759383727,Acadia Pharmaceuticals Reaches Analyst Target Price,"There are 17 different analyst targets within the Zacks coverage universe contributing to that average for Acadia Pharmaceuticals Inc, but the average is just that — a mathematical average. And so with ACAD crossing above that average target price of $18.47/share, investors in ACAD have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $18.47 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? In recent trading, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) have crossed above the average analyst 12-month target price of $18.47, changing hands for $18.48/share."
+2023-01-19,17.850000381469727,18.479999542236328,3.6422083684895386,,
+2023-01-18,18.1200008392334,17.969999313354492,3.529406987691778,,
+2023-01-17,18.280000686645508,18.049999237060547,-0.8278229521608144,First Week of ACAD February 17th Options Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of 5 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 16% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 17th expiration."
+2023-01-13,18.14999961853028,18.39999961853028,-1.2582135719118925,,
+2023-01-12,17.030000686645508,18.34000015258789,1.3774104972694432,,
+2023-01-11,17.219999313354492,17.020000457763672,7.6923042461745235,,
+2023-01-10,16.860000610351562,17.299999237060547,-1.161433586328408,,
+2023-01-09,17.1299991607666,16.860000610351562,2.6097189251513884,,
+2023-01-06,17.3700008392334,17.299999237060547,-1.5761737515634304,,
+2023-01-05,17.0,17.219999313354492,-0.4030028715642882,Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $17.21, changing hands as high as $17.27 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.24 per share, with $28.055 as the 52 week high point — that compares with a last trade of $17.22. Acadia Pharmaceuticals Inc shares are currently trading up about 0.7% on the day."
+2023-01-04,16.399999618530273,17.100000381469727,1.2941136079676012,,
+2023-01-03,16.549999237060547,16.31999969482422,4.268297434278754,,
+2022-12-30,15.800000190734863,15.920000076293944,-1.3897253947981356,Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout,"Acadia is also studying pimavanserin for the treatment of other CNS disorders, Axsome Therapeutics, Inc. Price and Consensus Axsome Therapeutics, Inc. price-consensus-chart | Axsome Therapeutics, Inc. Quote Zacks Rank & Stocks to Consider Axsome currently carries a Zacks Rank #3 (Hold). Click to get this free report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report Axsome Therapeutics, Inc. (AXSM) : Free Stock Analysis Report To read this article on Zacks.com click here. One such company is Acadia Pharmaceuticals ACAD, which is currently developing Nuplazid (pimavanserin) in several studies targeting different CNS indications."
+2022-12-29,15.4399995803833,15.949999809265137,0.7594929374079901,,
+2022-12-28,15.329999923706056,15.279999732971191,3.3031103804549136,,
+2022-12-27,15.510000228881836,15.300000190734863,-0.32615910622116573,,
+2022-12-23,15.739999771118164,15.470000267028809,-1.3539654097227065,,
+2022-12-22,15.15999984741211,15.81999969482422,-1.7153717154735053,,
+2022-12-21,15.470000267028809,15.3100004196167,4.353561042579935,,
+2022-12-20,15.0,15.449999809265137,-1.0342588535897885,,
+2022-12-19,15.390000343322754,15.100000381469728,2.9999987284342446,,
+2022-12-16,14.93000030517578,15.390000343322754,-1.8843401909269457,,
+2022-12-15,15.630000114440918,15.06999969482422,3.0810450686160156,U.S. Parkinson's disease incidence far higher than earlier estimates -study,"Manufacturers of Parkinson's treatments include Pfizer Inc PFE.N, Roche Holding AG ROG.S, Merck & Co MRK.N, Novartis AG NOVN.S, UCB SA UCB.BR, Teva Pharmaceutical Industries Ltd VRTX.O, H Lundbeck A/S LUN.CO, Acadia Pharmaceuticals ACAD.O, Vertical Pharma Resources Ltd and Impax Laboratories. By Shawana Alleyne-Morris and Nancy Lapid Dec 15 (Reuters) - The annual number of new Parkinson's disease diagnoses in the United States is likely 50% higher than estimated, based on a broad analysis of insurance claims and population growth detailed in a study published on Thursday that could help increase funding and care for the disabling illness. To update the estimated number of people being diagnosed with the disease, Beck's team analyzed data from large health insurance databases and long-term health studies on more than 15 million adults across the United States and in Ontario, Canada, in 2012."
+2022-12-14,15.699999809265137,15.779999732971191,-3.582856145338733,,
+2022-12-13,15.789999961853027,15.81999969482422,0.5095536603691158,,
+2022-12-12,14.529999732971191,15.510000228881836,0.189991976210699,,
+2022-12-09,14.59000015258789,14.489999771118164,6.744669744809744,,
+2022-12-08,14.720000267028809,14.630000114440918,-0.6854035669902928,,
+2022-12-07,14.93000030517578,14.65999984741211,-0.6114140689893948,,
+2022-12-06,15.170000076293944,14.899999618530272,-1.808442412891774,,
+2022-12-05,15.619999885559082,15.239999771118164,-1.7798316177044704,,
+2022-12-02,15.18000030517578,15.760000228881836,-2.4327792395967536,Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?,"Acadia's Q3 Loss Narrower Than Expected, Revenues Miss Acadia reported a third-quarter 2022 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 18 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid, decreased 1% year over year to $130.7 million in the third quarter, missing the Zacks Consensus Estimate of $140 million. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here."
+2022-12-01,15.600000381469728,15.34000015258789,3.820816284887026,,
+2022-11-30,14.75,15.579999923706056,-1.6666680931025863,,
+2022-11-29,14.720000267028809,14.670000076293944,5.627118126820721,,
+2022-11-28,15.0,14.770000457763672,-0.3396752026347446,,
+2022-11-25,15.039999961853027,15.109999656677246,-1.5333302815755208,,
+2022-11-23,14.989999771118164,15.0,0.46542350400108856,Analysts See 21% Upside For FBT,"Similarly, ACAD has 34.45% upside from the recent share price of $15.04 if the average analyst target price of $20.22/share is reached, and analysts on average are expecting AGIO to reach a target price of $38.25/share, which is 33.41% above the recent price of $28.67. Three of FBT's underlying holdings with notable upside to their analyst target prices are EXACT Sciences Corp. (Symbol: EXAS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Agios Pharmaceuticals Inc (Symbol: AGIO). Below is a twelve month price history chart comparing the stock performance of EXAS, ACAD, and AGIO: Combined, EXAS, ACAD, and AGIO represent 10.00% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2022-11-22,14.899999618530272,15.039999961853027,0.06671266867597811,,
+2022-11-21,15.270000457763672,14.779999732971191,0.9395996436714356,,
+2022-11-18,15.3100004196167,15.149999618530272,-3.2089110026408094,,
+2022-11-17,15.06999969482422,14.979999542236328,-1.0450737864214463,,
+2022-11-16,15.760000228881836,15.1899995803833,-0.5972140305935301,,
+2022-11-15,16.309999465942383,15.6899995803833,-3.616755331347964,,
+2022-11-14,16.31999969482422,15.920000076293944,-3.8013482885375356,,
+2022-11-11,16.3700008392334,16.389999389648438,-2.45097810055188,,
+2022-11-10,15.630000114440918,16.420000076293945,0.12216584844094355,,
+2022-11-09,15.210000038146973,14.960000038146973,5.054382316498693,,
+2022-11-08,14.600000381469728,15.300000190734863,-1.6436554856870165,,
+2022-11-07,14.779999732971191,14.489999771118164,4.7945191162705205,,
+2022-11-04,14.270000457763672,14.670000076293944,-1.9621107381084457,,
+2022-11-03,15.489999771118164,14.81999969482422,2.803080628582949,,
+2022-11-02,15.670000076293944,15.93000030517578,-4.3253717636793665,"Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.18. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.71 million for the quarter ended September 2022, missing the Zacks Consensus Estimate by 6.40%. Acadia shares have lost about 32.1% since the beginning of the year versus the S&P 500's decline of -19.1%."
+2022-11-01,16.110000610351562,15.859999656677246,1.6592228948050374,Viatris (VTRS) to Report Q3 Earnings: What's in the Cards? | Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season?,"Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | This suggests that analysts have very recently bumped up their estimates for ACAD, giving the stock a Zacks Earnings ESP of +6.47% heading into earnings season. Given that ACAD has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and Acadia Pharmaceuticals Inc. ACAD may be one such company."
+2022-10-31,16.030000686645508,16.030000686645508,-1.551837021742116,,
+2022-10-28,15.760000228881836,16.1299991607666,0.0,,
+2022-10-27,16.100000381469727,15.699999809265137,2.347708924564,Incyte (INCY) to Report Q3 Earnings: What's in the Cards? | Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for,"Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report | Expected Results of an Industry Player Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Acadia Pharmaceuticals (ACAD) is soon expected to post loss of $0.18 per share for the quarter ended September 2022. The consensus EPS estimate for Acadia has been revised 3.7% higher over the last 30 days to the current level. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Acadia will most likely beat the consensus EPS estimate."
+2022-10-26,15.720000267028809,16.010000228881836,-2.4844755448886198,Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards? | Agenus (AGEN) to Report Q3 Earnings: What's in the Cards?,"In the last reported quarter, the company delivered a negative earnings surprise of 30.56%. This large drugmaker’s earnings performance has been rather weak, with the company missing earnings expectations in three of the last four quarters while beating in one. Eli Lilly and Company Price and EPS Surprise Eli Lilly and Company price-eps-surprise | Eli Lilly and Company Quote Lilly’s stock has risen 27.2% this year so far compared with an increase of 0.1% for the industry. | Acadia ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia’s stock has lost 32.7% so far this year. ACAD topped earnings estimates in two of the last four quarters and missed the same on the other two occasions."
+2022-10-25,15.609999656677246,15.720000267028809,1.8447834410109676,What's in Store for Gilead (GILD) This Earnings Season?,"Acadia Pharmaceuticals ACAD has an Earnings ESP of +6.47% and a Zacks Rank #3. Acadia topped earnings estimates in two of the last four quarters and has a four-quarter earnings surprise of 6.83%, on average. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report"
+2022-10-24,15.9399995803833,15.510000228881836,0.7046804149320353,"Will Eliquis, Opdivo Fuel Bristol-Myers (BMY) Q3 Earnings? | Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?","In the last reported quarter, the company beat earnings by 7.82%. Factors at Play Bristol-Myers posted 9% growth in Total In-line Product Revenues in the last reported quarter. Blood thinner drug, Eliquis, was one of the top revenue generators in the last reported quarter and posted revenue growth of 16% year over year. | Acadia ACAD has an Earnings ESP of +15.82% and a Zacks Rank #2. Acadia’sstock has lost 32% this year so far. ACAD topped earnings estimates in two of the last four quarters."
+2022-10-21,15.68000030517578,15.880000114440918,-2.697612062867601,Interesting ACAD Put And Call Options For June 2023,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $11.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of 60 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 34% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the June 2023 expiration."
+2022-10-20,15.640000343322754,15.68000030517578,1.2755089628354215,Immunovant (IMVT) Set to Develop Lead Candidate Batoclimab | Zymeworks (ZYME) Up on Licensing Deal With Jazz Pharmaceuticals,"Some better-ranked stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.7% for 2022 and 2.9% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | A better-ranked stock worth considering in the same sector is ACADIA Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions."
+2022-10-19,15.649999618530272,15.600000381469728,0.2557542261826286,AVEO Pharmaceuticals (AVEO) Inks Deal to be Acquired by LG Chem,"Shares of AVEO Pharmaceuticals AVEO surged 42.4% on Oct 18 after the company announced that it has entered into an agreement to be acquired by the Korean company LG Chem. Image Source: Zacks Investment Research Pursuant to the agreement, LG Chem will acquire all outstanding shares of AVEO for $15.00 per share, or an approximate amount of $566 million, on a fully diluted basis, in an all-cash transaction. The offer price of $15 per share represents a premium of 43% of AVEO’s closing price on Oct 17."
+2022-10-18,16.209999084472656,16.030000686645508,-0.31948395066631236,Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors | Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication,"Some similar-ranked stocks worth considering in the same sector include ACADIA Pharmaceuticals ACAD, BioMarin Pharmaceuticals BMRN, and Pliant Therapeutics PLRX, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed down from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions. | Gilead Sciences, Inc.’s GILD wholly owned subsidiary, Kite, announced that the European Commission (“EC”) has approved its chimeric antigen receptor (CAR) T-cell therapy, Yescarta (axicabtagene ciloleucel) for the treatment of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients who relapse within 12 months from the completion of or are refractory to first-line chemoimmunotherapy. Following the EC nod, Yescarta became the first CAR T-cell therapy to be approved for patients in Europe who do not respond to first-line treatment. The latest EC nod was based on data from the pivotal phase III ZUMA-7 study, which evaluated Yescarta versus standard of care (“SOC”) in the above-mentioned patient popu"
+2022-10-17,15.880000114440918,15.960000038146973,-1.1104158420315182,"NeuBase (NBSE) Up on Restructuring Plan, Set to Lower Workforce","Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Aeglea BioTherapeutics, Inc. AGLE, all carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions."
+2022-10-14,16.239999771118164,15.720000267028809,0.5037778534604955,GSK's RSV Vaccine Candidate Shows High Efficacy in Older Adults,"Some better-ranked stocks in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying a Zacks Rank #2 (Buy) at present. Loss per share estimates for Acadia narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions."
+2022-10-13,15.130000114440918,16.15999984741211,-3.2019674348403777,Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review | BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance | VBI Vaccine (VBIV) Inks Deal With Agenus for Brain Cancer Study,"Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD and ORIC Pharmaceuticals, Inc. ORIC, both carrying the same Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Other stocks worth considering in the biotech sector are Acadia Pharmaceuticals Inc. ACAD, ORIC Pharmaceuticals, Inc. ORIC and Atara Biotherapeutics, Inc. ATRA, all carrying a Zacks Rank #2 at present. Loss per share estimates for Acadia have narrowed 0.8% for 2022 and 11.7% for 2023 in the past 60 days. Earnings of Acadia surpassed estimates in two of the trailing four quarters and missed on the remaining two occasions. | Some better-ranked stocks in the same sector include Immunocore IMCR, carrying a Zacks Rank #1 (Strong Buy), Acadia Pharmaceuticals ACAD, carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same on the remaining two occasions."
+2022-10-12,15.93000030517578,15.649999618530272,6.807665070591123,"Albireo (ALBO) Up on Results From Alagille Syndrome Study | Acadia (ACAD) Thrives on Nuplazid, Overdependence a Concern","Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. | Acadia Pharmaceuticals Inc. ACAD is making good progress with its sole marketed drug, Nuplazid (pimavanserin), which is approved by the FDA for treating hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. Image Source: Zacks Investment Research Meanwhile, in September 2022, the FDA accepted for review Acadia's new drug application (NDA) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome, a rare neurological disorder for girls aged between five and 20 years. Acadia Pharmaceuticals Inc. Price and Consensus Acadia Pharmaceuticals Inc. price-consensus-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider Acadia currently carries a Zacks Rank #2 (Buy)."
+2022-10-11,16.049999237060547,15.880000114440918,-1.7576941700028308,scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval | Iovance (IOVA) Doses First Patient in TIL Cancer Therapy Study,"Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD, Aridis Pharmaceuticals ARDS, and Immunocore IMCR, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters, while missing the same in the remaining two occasions. | Some better-ranked stocks in the same sector include Acadia Pharmaceuticals ACAD and Aridis Pharmaceuticals ARDS, each carrying a Zacks Rank #2 (Buy). Acadia’s loss per share estimates for 2022 have narrowed from $1.30 to $1.29 in the past 30 days. Earnings of Acadia beat estimates in two of the trailing four quarters while missing the same in the remaining two occasions."
+2022-10-10,16.280000686645508,16.1200008392334,-1.059184614956799,,
+2022-10-07,18.21999931335449,16.290000915527344,-0.9828000040771332,,
+2022-10-06,18.14999961853028,18.6299991607666,-10.592746819768196,Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why,"Last month, the FDA accepted for review Acadia's new drug application (“NDA”) seeking approval of its pipeline candidate, trofinetide, for the treatment of patients with Rett syndrome. Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia Pharmaceuticals Inc. ACAD have risen 14.9% in the past three months against the industry’s decrease of 8.4%."
+2022-10-05,17.940000534057617,18.049999237060547,2.6446256326433444,ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shift From Loss To Profit,"We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. NasdaqGS:ACAD Earnings Per Share Growth October 5th 2022 Underlying developments driving ACADIA Pharmaceuticals' growth isn’t the focus of this broad overview, however, take into account that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. For a more comprehensive look at ACADIA Pharmaceuticals, take a look at ACADIA Pharmaceuticals' company page on Simply Wall St. We've also compiled a list of pertinent factors you should look at: Valuation: What is ACADIA Pharmaceuticals worth today?"
+2022-10-04,17.239999771118164,18.059999465942383,0.6131477130901205,,
+2022-10-03,16.6200008392334,17.040000915527344,4.756378803426369,,
+2022-09-30,16.049999237060547,16.360000610351562,2.527076143717679,,
+2022-09-29,16.670000076293945,16.139999389648438,1.93147282259803,,
+2022-09-28,16.969999313354492,16.790000915527344,-3.17936823167272,,
+2022-09-27,16.450000762939453,16.729999542236328,-1.0606859464366578,,
+2022-09-26,16.75,16.280000686645508,1.70212015994364,,
+2022-09-23,16.84000015258789,16.75,-2.8059660498775654,SPDR S&P Biotech ETF Experiences Big Outflow,"Among the largest underlying components of XBI, in trading today CRISPR Therapeutics AG (Symbol: CRSP) is down about 2.5%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.8%, and ChemoCentryx, Inc. (Symbol: CCXI) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $329.5 million dollar outflow -- that's a 4.6% decrease week over week (from 91,620,000 to 87,400,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point — that compares with a last trade of $76.51."
+2022-09-22,16.950000762939453,16.989999771118164,-0.5344427064869108,,
+2022-09-21,18.25,17.06999969482422,0.23598233851509484,,
+2022-09-20,17.719999313354492,18.15999984741211,-6.465755096853595,,
+2022-09-19,17.770000457763672,17.8700008392334,2.483073087514261,,
+2022-09-16,17.969999313354492,18.020000457763672,0.5627483336728707,,
+2022-09-15,17.299999237060547,18.270000457763672,0.27824789270871647,,
+2022-09-14,16.93000030517578,17.43000030517578,5.606943719541681,,
+2022-09-13,17.6200008392334,16.899999618530273,2.953337217880272,,
+2022-09-12,17.360000610351562,17.90999984741211,-4.086272340577541,Acadia Says FDA Accepts For Filing NDA Of Trofinetide For Rett Syndrome Treatment,"(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said that the U.S. Food and Drug Administration has accepted for filing its New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The company noted that the FDA has granted a priority review and assigned a PDUFA or Prescription Drug User Fee Act action date of March 12, 2023. Rett syndrome is a complex, multisystem neurodevelopmental disorder that includes a period of normal development followed by significant developmental regression with loss of language and hand function skills, impaired gait and development of hand stereotypes."
+2022-09-09,17.459999084472656,17.3799991607666,3.1681982587753414,,
+2022-09-08,16.799999237060547,17.420000076293945,-0.4581897359731215,October 28th Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 85 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 28th expiration."
+2022-09-07,16.1200008392334,16.850000381469727,3.6904813535091474,Acadia (ACAD) Down 0.6% Since Last Earnings Report: Can It Rebound? | Add Up The Parts: IYY Could Be Worth $119,"Acadia's Q2 Earnings & Revenues Surpass Estimates Acadia reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents. VGM Scores Currently, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. A month has gone by since the last earnings report for Acadia Pharmaceuticals (ACAD). | Similarly, MSTR has 35.13% upside from the recent share price of $204.25 if the average analyst target price of $276.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $20.76/share, which is 28.73% above the recent price of $16.13. Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), MicroStrategy Inc. (Symbol: MSTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of BEAM, MSTR, and ACAD: Below is a summary table of the current analyst target prices discussed above:"
+2022-09-06,16.559999465942383,16.1299991607666,4.5285329046610885,,
+2022-09-02,16.8700008392334,16.729999542236328,-2.5966202840774737,,
+2022-09-01,16.3799991607666,16.8700008392334,-0.8298831655744731,Interesting ACAD Put And Call Options For October 14th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 5 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 14th expiration."
+2022-08-31,16.299999237060547,16.43000030517578,2.9914633917714086,,
+2022-08-30,16.540000915527344,16.1200008392334,0.7975526024544652,Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC | Wall Street Analysts Believe Acadia (ACAD) Could Rally 26%: Here's is How to Trade,"Some better-ranked stocks in this space are Bolt Pharmaceuticals BOLT, Acadia Pharmaceuticals ACAD and Dynavax DVAX. Loss estimates for ACAD have narrowed to $1.30 from $1.40 in the past 60 days. ACAD surpassed earnings in two of the trailing four quarters, the average being 6.83%. | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price target may not be a reliable indicator of how much ACAD could gain, the direction of price movement it implies does appear to be a good guide. Shares of Acadia Pharmaceuticals (ACAD) have gained 16.7% over the past four weeks to close the last trading session at $16.47, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. However, an impressive consensus price target is not the only factor that indicates a potential upside in ACAD."
+2022-08-29,16.31999969482422,16.469999313354492,-2.5392989906044057,,
+2022-08-26,16.969999313354492,16.530000686645508,0.9191153268087673,,
+2022-08-25,17.280000686645508,16.84000015258789,-2.5928028551110707,,
+2022-08-24,16.8799991607666,17.139999389648438,-2.546299285726664,,
+2022-08-23,16.81999969482422,16.8799991607666,1.5402857927039617,,
+2022-08-22,16.8799991607666,16.75,0.3567150239654618,,
+2022-08-19,17.219999313354492,16.90999984741211,-0.7701372466223374,,
+2022-08-18,17.139999389648438,17.3700008392334,-1.8002292584412087,,
+2022-08-17,16.809999465942383,17.059999465942383,1.3418988201590512,,
+2022-08-16,16.600000381469727,16.959999084472656,1.4872100413001696,,
+2022-08-15,16.329999923706055,16.600000381469727,2.1686668357236276,,
+2022-08-12,15.880000114440918,16.399999618530273,1.6534014637178023,,
+2022-08-11,16.110000610351562,15.739999771118164,3.2745560474932214,,
+2022-08-10,16.579999923706055,16.149999618530273,-2.296715240318815,,
+2022-08-09,16.600000381469727,16.219999313354492,-2.5934879804249427,Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates,"Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 17% year over year to $134.6 million in the second quarter, driven by Nuplazid demand growth. Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Acadia Pharmaceuticals Inc. ACAD reported a second-quarter 2022 loss of 21 cents per share, narrower than the Zacks Consensus Estimate of a loss of 25 cents."
+2022-08-08,16.030000686645508,16.6200008392334,-2.289163008329943,"Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $134.56 million for the quarter ended June 2022, surpassing the Zacks Consensus Estimate by 2.82%. Acadia shares have lost about 29.6% since the beginning of the year versus the S&P 500's decline of -13%."
+2022-08-05,15.210000038146973,16.440000534057617,3.680599671336359,,
+2022-08-04,15.260000228881836,15.619999885559082,8.086788250005124,,
+2022-08-03,15.380000114440918,14.970000267028809,2.3591064959218864,Moderna (MRNA) Q2 Earnings and Revenues Beat Estimates,"Acadia Pharmaceuticals (ACAD), another stock in the same industry, has yet to report results for the quarter ended June 2022. Acadia Pharmaceuticals' revenues are expected to be $130 million, up 12.8% from the year-ago quarter. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report"
+2022-08-02,14.079999923706056,15.010000228881836,-2.6657987279671316,,
+2022-08-01,14.5600004196167,14.109999656677246,6.605115839595759,Acadia Pharmaceuticals (ACAD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release,"Wall Street expects a year-over-year increase in earnings on higher revenues when Acadia Pharmaceuticals (ACAD) reports results for the quarter ended June 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects."
+2022-07-29,14.520000457763672,14.6899995803833,-3.0906644915556925,,
+2022-07-28,14.789999961853027,14.579999923706056,1.1707928185961758,Interesting ACAD Put And Call Options For September 9th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of 25 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 9th expiration."
+2022-07-27,14.210000038146973,14.770000457763672,-1.4198785577323296,,
+2022-07-26,14.270000457763672,14.15999984741211,3.9408896418956307,,
+2022-07-25,14.43000030517578,14.229999542236328,-0.7708521851638488,,
+2022-07-22,15.020000457763672,14.420000076293944,-1.3860066438648286,,
+2022-07-21,15.029999732971191,14.979999542236328,-3.9946761863086016,ACAD September 2nd Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 2nd expiration."
+2022-07-20,15.390000343322754,15.09000015258789,-0.33266927227668713,,
+2022-07-19,15.229999542236328,15.470000267028809,-1.949318934648524,Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate,"Acadia Pharmaceuticals Inc. ACAD announced that it has submitted a new drug application or NDA to the FDA seeking approval of its pipeline candidate, trofinetide, for the treatment of Rett syndrome in adults and pediatric patients aged two years and above. Shares of Acadia have lost 35.7% so far this year compared with the industry’s decrease of 20.5%. Image Source: Zacks Investment Research In December 2021, ACAD announced positive top-line data from the pivotal phase III Lavender study evaluating trofinetide for the treatment of Rett syndrome."
+2022-07-18,15.380000114440918,15.010000228881836,1.5758419698365893,,
+2022-07-15,15.800000190734863,15.279999732971191,-2.4057209545250515,,
+2022-07-14,15.899999618530272,15.739999771118164,-3.2911420980146615,,
+2022-07-13,15.279999732971191,15.989999771118164,-1.0062883726464977,,
+2022-07-12,15.829999923706056,15.529999732971191,4.646597189494279,,
+2022-07-11,15.710000038146973,15.920000076293944,-1.8951370320956402,,
+2022-07-08,15.539999961853027,15.739999771118164,1.336728438173453,Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why,Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Shares of Acadia Pharmaceuticals Inc. ACAD have plunged 33.5% in the past three months compared with the industry’s decrease of 7.6%. This might be a reason for ACAD’s shares to have remained down during this time frame.
+2022-07-07,15.050000190734863,15.710000038146973,1.2870000627804907,ACAD August 26th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the August 26th expiration."
+2022-07-06,15.170000076293944,15.119999885559082,4.385380990349893,,
+2022-07-05,14.289999961853027,15.270000457763672,-0.32959914623201925,,
+2022-07-01,14.0600004196167,14.369999885559082,6.857946105855447,,
+2022-06-30,14.029999732971191,14.09000015258789,2.204832551141801,,
+2022-06-29,14.039999961853027,14.220000267028809,0.427658023939197,,
+2022-06-28,14.619999885559082,14.0,1.2820534591513235,,
+2022-06-27,14.880000114440918,14.640000343322754,-4.2407653242972145,,
+2022-06-24,14.84000015258789,14.979999542236328,-1.6129016752173695,,
+2022-06-23,13.4399995803833,14.720000267028809,0.9433921038337965,August 5th Options Now Available For Acadia Pharmaceuticals,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $14.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $15.00 strike price has a current bid of $1.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $15.00 strike highlighted in red: Considering the fact that the $15.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 5th expiration."
+2022-06-22,12.75,13.43000030517578,9.523814930126678,,
+2022-06-21,13.199999809265137,13.010000228881836,5.333335726868858,"Health Care Sector Update for 06/21/2022: HOTH,CVNY,VALN,PFE,ACAD | ACADIA Stock: Deep Discount or Trap for Investors? Analysts Weigh In | Health Care Sector Update for 06/21/2022: CVNY, VALN, PFE, ACAD | Why Acadia Pharmaceuticals Stock Is Crashing Today","To the downside, Acadia (ACAD) plunged as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF (XLV) both rising 2.8%. Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing nearly 139%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price. | “However,” the 5-star analyst summed up, “with little else expected this year, we suspect it will be difficult for ACAD to outperform our broader coverage universe.” Accordingly, the analyst downgraded his rating for ACAD from Overweight (i.e., Buy) to Neutral, and lowered his price target from $34 to $19. (See ACAD stock forecast on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Case in point: ACADIA Pharmaceuticals (ACAD) shares are down 33% following a negative decision made last Friday by the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC). | Acadia (ACAD) dropped as much as 37% on Tuesday, sinking to its lowest share price since March 2013, after a US Food and Drug Administration advisory panel concluded the company's pimavanserin drug candidate did not effectively treat hallucinations and delusions in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.4% while the SPDR Health Care Select Sector ETF (XLV) was up 2.7%. In company news, Convey Health Solutions (CNVY) more than doubled in price on Tuesday, recently climbing over 138%, after agreeing to a $1.1 billion buyout offer from private-equity investors TPG, which will pay $10.50 per share in cash for the workflow-management company, or 143% above Friday's closing price. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) were crashing 35.4% as of 11 a.m. But the trading of Acadia stock was halted that day because of the FDA advisory committee's deliberations. Acadia still has a chance of winning approval."
+2022-06-17,19.51000022888184,19.51000022888184,-1.439390781278188,,
+2022-06-16,18.530000686645508,19.51000022888184,0.0,Acadia (ACAD) Up on FDA Briefing Document for Nuplazid sNDA | Acadia (ACAD) Surges 15.5%: Is This an Indication of Further Gains?,"Shares of ACADIA Pharmaceuticals Inc. ACAD gained 15.5% on Wednesday after the FDA issued briefing documents related to the resubmitted sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with Alzheimer's disease psychosis (“ADP”). Image Source: Zacks Investment Research In March 2022, Acadia received the action date from the FDA related to its resubmitted sNDA for pimavanserin to treat hallucinations and delusions associated with ADP. ACADIA Pharmaceuticals Inc. Price ACADIA Pharmaceuticals Inc. price | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). | You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Acadia belongs to the Zacks Medical - Biomedical and Genetics industry. Acadia Pharmaceuticals (ACAD) shares rallied 15.5% in the last trading session to close at $18.77. For Acadia, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days."
+2022-06-15,17.389999389648438,18.770000457763672,5.288718326614058,"Why Acadia Pharmaceuticals Spiked Today | Health Care Sector Update for 06/15/2022: ACAD,AMN,OSH,ATNF | Noteworthy Wednesday Option Activity: ACAD, VST, OLED","10 stocks we like better than Acadia Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. What happened Acadia Pharmaceuticals' (NASDAQ: ACAD) stock was up more than 14.3% as of 12:03 p.m. So what Nuplazid is Acadia's only approved drug, and it helped the company to bring in trailing-12-month revenue of more than $493 million. | In company news, ACADIA Pharmaceuticals (ACAD) streaked almost 16% higher after briefing documents prepared for an upcoming advisory panel meeting indicates the US Food and Drug Administration has ""no key safety issue"" with the company's pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were trading higher this afternoon, with the NYSE Health Care Index rising 1.5% and the SPDR Health Care Select Sector ETF (XLV) up 1.2%. 180 Life Sciences (ATNF) slumped over 34%, earlier sinking nearly 40% to a record low of $0.81 a share, after saying UK and US regulators were unlikely to accept the endpoints proposed by the company to evaluate its adalimumab drug candidate as a prospective treatment for early-stage Dupuytren's disease - a progressive condition that causes fingers to irreversibly curl into the palm and is currently only treatable through surgery. | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 34,497 contracts have traded so far, representing approximately 3.4 million underlying shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $16 strike highlighted in orange: Vistra Corp (Symbol: VST) saw options trading volume of 73,014 contracts, representing approximately 7.3 million underlying shares or approximately 135.6% of VST's average daily trading volume over the past month, of 5.4 million shares. That amounts to about 209% of ACAD's average daily trading volume over the past month of 1.7 million shares."
+2022-06-14,16.8700008392334,16.25,7.935601590283511,,
+2022-06-13,16.549999237060547,16.770000457763672,-3.6751678031426365,,
+2022-06-10,17.15999984741211,17.09000015258789,1.3293125730814204,,
+2022-06-09,17.90999984741211,17.43000030517578,-0.40792363313904906,,
+2022-06-08,18.06999969482422,18.1200008392334,-2.680064468597331,,
+2022-06-07,16.780000686645508,18.270000457763672,0.2767080534234956,,
+2022-06-06,18.020000457763672,16.93000030517578,8.87961686618995,"Notable Monday Option Activity: RWT, ORA, ACAD","Below is a chart showing ORA's trailing twelve month trading history, with the $70 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,422 contracts, representing approximately 842,200 underlying shares or approximately 49.3% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $30 strike call option expiring June 24, 2022, with 3,530 contracts trading so far today, representing approximately 353,000 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for RWT options, ORA options, or ACAD options, visit StockOptionsChannel.com."
+2022-06-03,16.15999984741211,17.899999618530273,-6.048835321301443,,
+2022-06-02,16.15999984741211,16.209999084472656,10.767325417993804,July 22nd Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $12.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 60 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 22nd expiration."
+2022-06-01,16.239999771118164,16.3700008392334,0.3094012223555425,,
+2022-05-31,16.93000030517578,16.149999618530273,0.8004991991836923,,
+2022-05-27,16.229999542236328,17.079999923706055,-4.607210115684692,"Noteworthy Friday Option Activity: LMND, WDC, ACAD | Biotech Stocks Facing FDA Decision In June 2022","Particularly high volume was seen for the $20 strike call option expiring June 24, 2022, with 3,171 contracts trading so far today, representing approximately 317,100 underlying shares of ACAD. Below is a chart showing WDC's trailing twelve month trading history, with the $62.50 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 7,695 contracts thus far today. That number of contracts represents approximately 769,500 underlying shares, working out to a sizeable 45.7% of ACAD's average daily trading volume over the past month, of 1.7 million shares. | (RTTNews) - As another month comes to a close, it's time to take a look back at some of the healthcare sector news that made headlines in May and look ahead to what's in store on the regulatory front in June. Hyundai Bioscience, as recently as May 25, announced that it is planning to submit a request for a fast track processing to the FDA for investigational drug CP-COV03, an oral antiviral medicine for the treatment of monkeypox, which it developed as a treatment for COVID-19. As of May 25, 2022, there were 219 confirmed cases of monkeypox reported from countries where the disease is not considered endemic, including 118 cases in the European Union, according to the European Centre for Disease Prevention and Control."
+2022-05-26,15.93000030517578,16.229999542236328,5.237217532001268,ACAD July 8th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $16.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $16.00 strike highlighted in red: Considering the fact that the $16.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 8th expiration."
+2022-05-25,16.020000457763672,15.960000038146973,1.8832343459722134,,
+2022-05-24,16.649999618530273,15.979999542236328,-0.37453444383406115,,
+2022-05-23,17.329999923706055,16.790000915527344,-4.024024574440726,,
+2022-05-20,17.010000228881836,17.110000610351562,-3.115978133618082,,
+2022-05-19,16.06999969482422,16.829999923706055,0.5878917114882376,,
+2022-05-18,16.559999465942383,16.040000915527344,4.7293107860270505,ACADIA Pharmaceuticals: No Upturn in Sight,"However, with analysts believing ACADIA's earnings will deteriorate this year, forecasting a 33% rise in net losses, the company is likely to delay its upbeat earnings report beyond 2022, undoing any optimistic findings from the regulator. Despite the increase in net sales, ACADIA's earnings for the first quarter of 2022 were still negative as the company posted a new net loss of $0.70, missing average estimates by $0.13. Looking ahead, ACADIA is forecasting revenue from the sale of Nuplazid to be between $510 million and $560 million, versus analysts' median forecast of $533.09 million."
+2022-05-17,17.030000686645508,17.049999237060547,-3.1400879660925,Analysts Predict 43% Gains Ahead For FBT,"Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioNTech SE (Symbol: BNTX), and FibroGen Inc (Symbol: FGEN). Although ACAD has traded at a recent price of $16.60/share, the average analyst target is 79.72% higher at $29.83/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BNTX, and FGEN: Combined, ACAD, BNTX, and FGEN represent 9.31% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2022-05-16,16.799999237060547,16.600000381469727,0.11743129541222752,,
+2022-05-13,16.360000610351562,16.850000381469727,-1.1904694325796505,,
+2022-05-12,15.229999542236328,16.030000686645508,2.995108513676482,,
+2022-05-11,16.639999389648438,15.289999961853027,5.252798217035993,,
+2022-05-10,17.31999969482422,16.84000015258789,-8.11297762808351,,
+2022-05-09,17.450000762939453,16.3799991607666,-2.7713599924587045,Acadia Pharmaceuticals is Now Oversold (ACAD),"In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $16.85 per share. A bullish investor could look at ACAD's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $28.055 as the 52 week high point — that compares with a last trade of $16.85."
+2022-05-06,18.540000915527344,17.8799991607666,-6.131814071007581,,
+2022-05-05,19.51000022888184,18.82999992370605,-3.559879839099616,"Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates | ABC Boosts EPS Outlook, ADPT Sees 20-26% Revenue Growth, ANAB To Report HARP Data In Q3","Acadia Pharmaceuticals Inc. ACAD reported first-quarter 2022 loss of 70 cents per share, wider than the Zacks Consensus Estimate of a loss of 49 cents. Total revenues, comprising net sales of Acadia's only marketed drug, Nuplazid (pimavanserin), increased 8% year over year to $115.5 million in the first quarter, driven by Nuplazid demand growth. Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). | Acadia Pharmaceuticals Inc. (ACAD) has a regulatory catalyst to watch next month. ACAD closed Wednesday's trading at $19.89, up 0.40%. Net loss attributable to the company widened to $62.7 million or $0.44 per share for the first quarter of 2022 from $40.6 million or $0.29 per share for the same period in 2021."
+2022-05-04,19.950000762939453,19.88999938964844,-3.4853936299249377,"Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.49. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $115.47 million for the quarter ended March 2022, missing the Zacks Consensus Estimate by 6.68%. Acadia shares have lost about 15.1% since the beginning of the year versus the S&P 500's decline of -12.4%."
+2022-05-03,19.56999969482422,19.809999465942383,-0.30075875186167866,,
+2022-05-02,18.18000030517578,19.540000915527344,1.2263657376634403,"Notable Monday Option Activity: MAT, MPWR, ACAD | Zymeworks Inc. (ZYME) Surges 23.2%: Is This an Indication of Further Gains?","That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 62.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing MPWR's trailing twelve month trading history, with the $340 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 10,649 contracts thus far today. Especially high volume was seen for the $22 strike call option expiring June 17, 2022, with 2,503 contracts trading so far today, representing approximately 250,300 underlying shares of ACAD. | One other stock in the same industry, Acadia Pharmaceuticals (ACAD), finished the last trading session 2.7% lower at $18.44. ACAD has returned -21.7% over the past month. Acadia's consensus EPS estimate for the upcoming report has changed +7.3% over the past month to -$0.49."
+2022-04-29,18.8799991607666,18.440000534057617,7.4807513065023175,,
+2022-04-28,19.43000030517578,18.959999084472656,-2.3305013043820426,,
+2022-04-27,19.0,18.989999771118164,-2.4189460284152733,Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for,"Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2022. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects."
+2022-04-26,20.049999237060547,18.940000534057617,-0.052632783588610205,,
+2022-04-25,20.1299991607666,20.26000022888184,-5.536153342845026,,
+2022-04-22,21.32999992370605,20.43000030517578,0.6458076181573331,,
+2022-04-21,22.709999084472656,21.34000015258789,-4.219407509373758,,
+2022-04-20,21.850000381469727,22.31999969482422,-6.032580304335921,"Notable Wednesday Option Activity: ACAD, W, SCCO","Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 8,563 contracts have traded so far, representing approximately 856,300 underlying shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: Wayfair Inc (Symbol: W) saw options trading volume of 13,372 contracts, representing approximately 1.3 million underlying shares or approximately 57.8% of W's average daily trading volume over the past month, of 2.3 million shares. That amounts to about 58.2% of ACAD's average daily trading volume over the past month of 1.5 million shares."
+2022-04-19,21.530000686645508,21.71999931335449,2.151026568187538,"Pre-market Movers: AXSM, SST, SAVA, ENSV, SMCI…","In the Green Axsome Therapeutics, Inc. (AXSM) is up over 34% at $43.89 Super Micro Computer, Inc. (SMCI) is up over 15% at $42.20 4D pharma plc (LBPS) is up over 13% at $5.27 BARK, Inc. (BARK) is up over 13% at $3.76 American Campus Communities, Inc. (ACC) is up over 12% at $65.00 Sharps Technology, Inc. (STSS) is up over 12% at $2.37 Zendesk, Inc. (ZEN) is up over 6% at $129.87 Banco Bradesco S.A. (BBD) is up over 5% at $4.41 ARC Document Solutions, Inc. (ARC) is up over 5% at $4.00 Fresh Vine Wine, Inc. (VINE) is up over 5% at $3.74 In the Red System1, Inc. (SST) is down over 27% at $14.75 Cassava Sciences, Inc. (SAVA) is down over 18% at $20.55 Enservco Corporation (ENSV) is down over 16% at $3.04 NETGEAR, Inc. (NTGR) is down over 12% at $20.31 Indonesia Energy Corporation Limited (INDO) is down over 9% at $23.40 Origin Agritech Limited (SEED) is down over 8% at $7.36 ACADIA Pharmaceuticals Inc. (ACAD) is down over 7% at $20.70 Ecopetrol S.A. (EC) is down over 6% at $18.08 IsoPlexis Corporation (ISO) is down over 6% at $2.30 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.50 A.M. ET)."
+2022-04-18,23.540000915527344,22.40999984741211,0.8824831428214118,,
+2022-04-14,24.229999542236328,23.46999931335449,-4.800344197819757,,
+2022-04-13,23.51000022888184,24.43000030517578,-3.136608515229442,"After Hours Most Active for Apr 13, 2022 : WBD, VALE, PBR, TMUS, ACAD, PM, BAC, AAPL, CMCSA, MTOR, PDBC, PG","ACADIA Pharmaceuticals Inc. (ACAD) is unchanged at $24.43, with 2,144,598 shares traded. ACAD's current last sale is 80.1% of the target price of $30.5. The consensus earnings per share forecast is 0.76 per share, which represents a 86 percent increase over the EPS one Year Ago"
+2022-04-12,23.780000686645508,23.39999961853028,3.913228699860791,We Did The Math IYY Can Go To $129,"Similarly, ACAD has 27.48% upside from the recent share price of $23.62 if the average analyst target price of $30.11/share is reached, and analysts on average are expecting CHGG to reach a target price of $44.70/share, which is 26.66% above the recent price of $35.29. Three of IYY's underlying holdings with notable upside to their analyst target prices are Blue Owl Capital Inc (Symbol: OWL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Chegg Inc (Symbol: CHGG). Below is a twelve month price history chart comparing the stock performance of OWL, ACAD, and CHGG: Below is a summary table of the current analyst target prices discussed above:"
+2022-04-11,25.61000061035156,23.6200008392334,-1.5979859425682448,,
+2022-04-08,27.049999237060547,26.0,-7.770401107736808,,
+2022-04-07,27.059999465942383,27.059999465942383,-3.8816978435325367,ACAD May 27th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the May 27th expiration."
+2022-04-06,25.81999969482422,27.21999931335449,0.0,,
+2022-04-05,26.21999931335449,25.75,5.422151956147809,,
+2022-04-04,25.81999969482422,26.21999931335449,-1.7925222183934477,,
+2022-04-01,24.270000457763672,25.559999465942383,1.549185217885391,,
+2022-03-31,24.5,24.21999931335449,5.3151997686347645,ACAD May 13th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 13th expiration."
+2022-03-30,25.34000015258789,24.40999984741211,-1.142859945491883,Why Is Acadia (ACAD) Up 1% Since Last Earnings Report?,"Acadia’s Q4 Earnings & Revenues Fall Shy of Estimates Acadia reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. VGM Scores At this time, Acadia has a strong Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD)."
+2022-03-29,24.700000762939453,25.31999969482422,-3.670088001482523,,
+2022-03-28,26.700000762939453,24.64999961853028,2.5101170556036125,,
+2022-03-25,27.239999771118164,26.88999938964844,-7.6779066885070915,,
+2022-03-24,26.06999969482422,27.14999961853028,-1.2848765947524674,,
+2022-03-23,26.170000076293945,25.68000030517578,4.142692506131784,,
+2022-03-22,25.56999969482422,26.38999938964844,-1.8723720660667083,,
+2022-03-21,25.270000457763672,25.549999237060547,3.2068819108754374,,
+2022-03-18,24.190000534057617,25.3799991607666,1.1080283902838288,,
+2022-03-17,23.61000061035156,23.86000061035156,4.91938239122219,,
+2022-03-16,24.36000061035156,23.600000381469727,1.0588733313729357,,
+2022-03-15,22.440000534057617,23.049999237060547,-3.1198694985207727,,
+2022-03-14,23.020000457763672,22.270000457763672,2.7183542267618175,"Notable Monday Option Activity: LVS, ACAD, SIRI","Below is a chart showing ACAD's trailing twelve month trading history, with the $25 strike highlighted in orange: And Sirius XM Holdings Inc (Symbol: SIRI) saw options trading volume of 201,617 contracts, representing approximately 20.2 million underlying shares or approximately 82.7% of SIRI's average daily trading volume over the past month, of 24.4 million shares. Below is a chart showing LVS's trailing twelve month trading history, with the $25 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 11,985 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 85.3% of ACAD's average daily trading volume over the past month, of 1.4 million shares."
+2022-03-11,24.59000015258789,23.18000030517578,-3.2580364252210807,,
+2022-03-10,25.299999237060547,24.559999465942383,-5.7340375708119655,Acadia (ACAD) Stock Up on FDA's Action Date for Nuplazid sNDA,"Acadia Pharmaceuticals Inc. ACAD announced that it has received the action date from the FDA related to its resubmitted supplemental New Drug Application (sNDA) for pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis (“ADP”). Shares of Acadia were up 10.2% on Wednesday following the announcement of the above news. Image Source: Zacks Investment Research Last month, Acadia resubmitted the sNDA to the FDA for pimavanserin for the treatment of hallucinations and delusions associated with ADP."
+2022-03-09,23.89999961853028,25.780000686645508,-2.924900369301909,"Health Care Sector Update for 03/09/2022: BLI,ACAD,BFLY,CYTO | Health Care Sector Update for 03/09/2022: ACAD,BFLY,CYTO","Acadia Pharmaceuticals (ACAD) rose over 10% after it said the US Food and Drug Administration set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks extended their Wednesday gains, with the NYSE Health Care Index rising 2.5% this afternoon and the SPDR Health Care Select Sector ETF (XLV) up 2.1%. In company news, Berkeley Lights (BLI) climbed 6.4% after it said it hired Siddhartha Kadia from privately held EAG Laboratories to be its new CEO, succeeding Eric Hobbs, who is becoming president of the digital cell biology company's antibody therapeutics business. | In company news, Acadia Pharmaceuticals (ACAD) rose over 10% after saying the US Food and Drug Administration has set an Aug. 4 deadline for the agency to complete its review of the company's supplemental new drug application for the pimavanserin drug candidate to treat psychosis in patients with Alzheimer's disease. Health care stocks were mostly higher this afternoon, with the NYSE Health Care Index rising 2.1% while the SPDR Health Care Select Sector ETF (XLV) was up 1.9%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2022-03-08,24.14999961853028,23.39999961853028,7.866113381263882,,
+2022-03-07,23.90999984741211,24.39999961853028,-3.1055901111672295,Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?,"Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Alternatives First Trust NYSE Arca Biotechnology ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors."
+2022-03-04,24.13999938964844,24.040000915527344,2.0493507914898883,Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?,"Looking at individual holdings, Acadia Pharmaceuticals Inc. (ACAD) accounts for about 3.97% of total assets, followed by Sarepta Therapeutics, Inc. (SRPT) and Neurocrine Biosciences, Inc. (NBIX). ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report A smart beta exchange traded fund, the First Trust NYSE Arca Biotechnology ETF (FBT) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market."
+2022-03-03,24.670000076293945,24.36000061035156,-0.4142438966422592,,
+2022-03-02,25.030000686645508,24.65999984741211,-1.2565847790177878,,
+2022-03-01,24.239999771118164,25.06999969482422,-1.4782294410036052,Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates,"Acadia Pharmaceuticals Inc. ACAD reported a fourth-quarter 2021 loss of 27 cents per share, wider than the Zacks Consensus Estimate of a loss of 24 cents. Total revenues, comprising net sales of Acadia's only marketed drug Nuplazid (pimavanserin), increased 8% year over year to $130.8 million for the fourth quarter, driven by Nuplazid volume growth. Acadia Pharmaceuticals Inc. Price, Consensus and EPS Surprise Acadia Pharmaceuticals Inc. price-consensus-eps-surprise-chart | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold)."
+2022-02-28,25.459999084472656,25.40999984741211,3.424092126828299,"Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.24. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $130.76 million for the quarter ended December 2021, missing the Zacks Consensus Estimate by 3.09%. Acadia shares have added about 9.9% since the beginning of the year versus the S&P 500's decline of -8%."
+2022-02-25,25.56999969482422,25.63999938964844,-0.1963834990514199,,
+2022-02-24,23.799999237060547,25.81999969482422,0.2737571202959043,Interesting ACAD Put And Call Options For April 8th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $2.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 8th expiration."
+2022-02-23,26.459999084472656,24.690000534057617,8.48739715343434,,
+2022-02-22,25.299999237060547,26.14999961853028,-6.689337156680838,,
+2022-02-18,26.75,25.86000061035156,3.359685403565609,,
+2022-02-17,27.32999992370605,26.6299991607666,-3.327100522050247,,
+2022-02-16,27.190000534057617,27.5,-2.561290760678959,"Noteworthy Wednesday Option Activity: PAG, MU, ACAD | Here's How Much a $1000 Investment in Acadia Pharmaceuticals Made 10 Years Ago Would Be Worth Today","Below is a chart showing MU's trailing twelve month trading history, with the $65 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 8,309 contracts, representing approximately 830,900 underlying shares or approximately 55.5% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $30 strike call option expiring June 17, 2022, with 2,407 contracts trading so far today, representing approximately 240,700 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $30 strike highlighted in orange: For the various different available expirations for PAG options, MU options, or ACAD options, visit StockOptionsChannel.com. | Acadia Pharmaceuticals' Business In-Depth With that in mind, let's take a look at Acadia Pharmaceuticals' main business drivers. ACADIA’s sole marketed drug, Nuplazid, has recorded strong sales since its launch. ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report"
+2022-02-15,26.32999992370605,27.280000686645508,1.1401230594095946,,
+2022-02-14,25.959999084472656,26.190000534057617,3.6080545601678087,,
+2022-02-11,26.32999992370605,25.950000762939453,0.8859840435145884,,
+2022-02-10,26.239999771118164,26.229999542236328,-1.4432174776592694,April 1st Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of $2.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 1st expiration."
+2022-02-09,26.34000015258789,26.850000381469727,-0.0381106286930802,"4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates","Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC price-eps-surprise | Jazz Pharmaceuticals PLC Quote ACADIA’s ACAD sole marketed drug, Nuplazid, has recorded strong sales since its launch, and the same is likely to have boosted the top line in the fourth quarter. ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report"
+2022-02-08,24.96999931335449,25.1299991607666,1.9362195365504913,,
+2022-02-07,23.600000381469727,25.309999465942383,0.6407683292427709,,
+2022-02-04,23.01000022888184,23.600000381469727,7.245758715391018,First Week of March 25th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 23% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 25th expiration."
+2022-02-03,23.11000061035156,23.1299991607666,2.564103201734552,,
+2022-02-02,23.799999237060547,23.40999984741211,0.08653634741179866,,
+2022-02-01,22.770000457763672,23.84000015258789,-1.6386529502116276,,
+2022-01-31,22.229999542236328,22.489999771118164,4.69916413400594,,
+2022-01-28,21.5,22.11000061035156,1.1695916969671698,,
+2022-01-27,22.06999969482422,21.530000686645508,2.8372121411700415,,
+2022-01-26,22.14999961853028,21.93000030517578,-2.44675584796383,,
+2022-01-25,22.0,21.93000030517578,-0.9932249080963953,,
+2022-01-24,20.920000076293945,22.450000762939453,-0.31818043101917615,,
+2022-01-21,21.38999938964844,21.18000030517578,7.313578781384751,,
+2022-01-20,22.309999465942383,21.489999771118164,-0.981762928774498,,
+2022-01-19,21.09000015258789,21.8700008392334,-3.6754805668014465,,
+2022-01-18,22.780000686645508,20.940000534057617,3.6984385064112777,,
+2022-01-14,21.86000061035156,23.049999237060547,-8.077261181412378,,
+2022-01-13,22.200000762939453,22.13999938964844,5.443726411176207,Acadia (ACAD) Up More Than 20% in Past 3 Months: Here's Why | Analysts See 12% Upside For The Holdings of RXL,"The partnership is looking to leverage Stoke’s RNA-based capabilities with Acadia’s expertise in neuroscience drug development for discovering multiple RNA-based treatments in severe and rare genetic neurodevelopmental diseases, including SYNGAP1 syndrome, Rett syndrome and an undisclosed neurodevelopmental target. Acadia Pharmaceuticals Inc. Price Acadia Pharmaceuticals Inc. price | Acadia Pharmaceuticals Inc. Quote Zacks Rank & Another Stock to Consider Acadia currently carries a Zacks Rank #2 (Buy). Shares of Acadia Pharmaceuticals Inc. ACAD have rallied 24.2% in the past three months against the industry’s decrease of 13%. | Similarly, BPMC has 42.19% upside from the recent share price of $81.50 if the average analyst target price of $115.89/share is reached, and analysts on average are expecting ACAD to reach a target price of $28.94/share, which is 30.73% above the recent price of $22.14. Three of RXL's underlying holdings with notable upside to their analyst target prices are Agios Pharmaceuticals Inc (Symbol: AGIO), Blueprint Medicines Corp (Symbol: BPMC), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of AGIO, BPMC, and ACAD: Below is a summary table of the current analyst target prices discussed above:"
+2022-01-12,22.68000030517578,22.13999938964844,-0.2702764469773262,,
+2022-01-11,22.64999961853028,22.75,-2.3809563856315608,,
+2022-01-10,22.6299991607666,22.709999084472656,0.4415027953815405,"Acadia, Stoke To Jointly Develop RNA Treatments For Genetic Neuro-developmental Diseases","For the Rett syndrome (MECP2) and the undisclosed neurodevelopmental program, Stoke will lead research and pre-clinical development activities, while Acadia will lead clinical development and commercialization activities. Acadia will fully fund the research and pre-clinical development activities related to these two targets and Stoke is eligible to receive potential development, regulatory, first commercial sales and sales milestones as well as tiered royalty payments on worldwide sales starting in the mid-single digit range and escalating to the mid-teens based on revenue levels. (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) and Stoke Therapeutics, Inc. (STOK), said on Monday that they have signed a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neuro-developmental diseases of the central nervous system."
+2022-01-07,23.049999237060547,22.59000015258789,0.3535127117669087,,
+2022-01-06,23.3799991607666,23.38999938964844,-1.9956576993419357,,
+2022-01-05,24.36000061035156,23.11000061035156,0.04277258015740491,,
+2022-01-04,24.38999938964844,23.6200008392334,-5.131362761414809,,
+2022-01-03,23.32999992370605,24.38999938964844,-3.157025705961453,,
+2021-12-31,23.65999984741211,23.34000015258789,4.543503940886449,,
+2021-12-30,23.920000076293945,23.540000915527344,-1.3524923790699845,Interesting ACAD Put And Call Options For February 2022,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration."
+2021-12-29,24.600000381469727,23.959999084472656,-1.588625248973983,,
+2021-12-28,24.34000015258789,24.670000076293945,-2.6016312482627426,,
+2021-12-27,24.170000076293945,24.31999969482422,1.3557926114925198,,
+2021-12-23,23.850000381469727,24.299999237060547,0.620602474376464,Interesting ACAD Put And Call Options For February 2022,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 2022 expiration."
+2021-12-22,21.51000022888184,23.920000076293945,1.8867876242905524,"Acadia Pharmaceuticals Inc Shares Close the Day 20.8% Lower - Daily Wrap | Why Acadia Pharmaceuticals Stock Climbed More Than 10% Wednesday | Health Care Sector Update for 12/22/2021: BVXV,ACAD,CODX,NVST","Acadia Pharmaceuticals Inc (ACAD) shares closed today 20.8% lower than it did at the end of yesterday. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -274.5% The company's stock price performance over the past 12 months lags the peer average by -293.4% This story was produced by the Kwhen Automated News Generator. | But in April, Acadia received a Complete Response Letter from the Food and Drug Administration declining Nuplazid's use for dementia, noting problems with the studies for the drug in dementia patients, including a lack of statistical significance in some of the subgroups of patients in the study and too few patients with less-common dementia subtypes in the study. What happened Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. The catalyst for the fall was the concern investors had over the decision Acadia announced after the market closed on Monday. | Acadia Pharmaceuticals (ACAD) rose more than 11% after Canaccord Genuity Wednesday raised its price target for the drug maker's shares by $4 to $30 apiece and reiterated its hold rating for the company's stock. Health care stocks were finishing just under their intra-day highs this afternoon, with the NYSE Health Care Index rising 1.0% while the SPDR Health Care Select Sector ETF (XLV) also was up 0.8%. In company news, BiondVax Pharmaceuticals (BVXV) raced 85% higher after the biopharmaceuticals firm said it was working with the Max Planck Society and the University Medical Center Gottingen in Germany to develop and commercialize nanosized antibodies to fight COVID-19 and part of a broader collaboration expected to be announced next month to commercialize nanosized antibodies for several other disease indications."
+2021-12-21,25.15999984741211,21.450000762939453,11.204090291808358,"Health Care Sector Update for 12/21/2021: AQST,ARDS,ACAD,ALDX | Health Care Sector Update for 12/21/2021: ARDS,ACAD,ALDX","Acadia Pharmaceuticals (ACAD) fell almost 21% after saying it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication as a treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV) adding about 0.1%. In company news, Aquestive Therapeutics (AQST) shed more than 29% after saying the US Food and Drug Administration has told the company it will not be able to issue a decision on the company's Libervant seizure medication by the Dec. 23 regulatory deadline. | Acadia Pharmaceuticals (ACAD) shares fell more than 22% after the company said it expects to resubmit a supplemental new drug application for its pimavanserin drug candidate early next year with a narrowed indication for the potential treatment of hallucinations and delusions associated with Alzheimer's disease. Health care stocks were edging higher Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR ETF (XLV) both up about 0.2%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2021-12-20,25.5,27.09000015258789,-14.74562443152899,,
+2021-12-17,24.729999542236328,25.76000022888184,6.2352947160309435,,
+2021-12-16,24.170000076293945,24.790000915527344,4.1649846571423295,,
+2021-12-15,23.1299991607666,24.3799991607666,2.565166889848289,,
+2021-12-14,22.549999237060547,23.0,5.404237117830362,,
+2021-12-13,22.299999237060547,22.89999961853028,1.9955688610396243,,
+2021-12-10,22.61000061035156,22.26000022888184,2.69058476231958,,
+2021-12-09,21.739999771118164,22.6200008392334,-1.5479892614840463,Interesting ACAD Put And Call Options For January 2022,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.55. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2022 expiration."
+2021-12-08,21.59000015258789,21.780000686645508,4.047843042226366,Is It Time to Buy the Nasdaq's 11 Worst-Performing Stocks of 2021?,"As of Monday, Editas Medicine (NASDAQ: EDIT), Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), and TG Therapeutics (NASDAQ: TGTX) are down by 60%, 65%, 65%, and 70% (respectively) since the end of 2020. As of Monday, Chindata (NASDAQ: CD), iQIYI (NASDAQ: IQ), Pinduoduo (NASDAQ: PDD), and Kingsoft Cloud (NASDAQ: KC) were all down by more than 60% since the end of 2020. Finally, while a slew of biotech stocks are well into the red this year, several non-biotech Nasdaq-listed healthcare stocks are also deep in the hole."
+2021-12-07,21.799999237060547,21.31999969482422,0.8800395216062227,"Acadia Rises 21.8% on Positive Lavender Study Results | Health Care Sector Update for 12/07/2021: HQY, ACAD, BHG, XLV, IBB | Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out | Pre-market Movers: BJDX, MDB, CELZ, ISIG, ACAD… | Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday","Official Comment The Senior Vice-President, Chief Scientific Officer and Head of Rare Disease at Acadia, Kathie Bishop (Ph.D.), said, “The consistent efficacy across primary and key secondary endpoints in the Lavender study demonstrates the potential of trofinetide to treat Rett syndrome… We look forward to continuing this important work and potentially delivering an FDA-approved treatment for this rare and devastating disease.” In the first quarter of 2022, Acadia plans to attend a pre-NDA meeting with the U.S. Food and Drug Administration, seeking to submit a New Drug Application around mid-year 2022. Hedge Fund Trading Activity TipRanks’ Hedge Fund Trading Activity tool shows that confidence in Acadia is currently Neutral, as the cumulative change in holdings across 2 hedge funds that were active in the last quarter was a decrease of 2.3 million shares. Shares of Acadia Pharmaceuticals Inc. (ACAD) rallied 21.8% in Monday’s extended trading session after the biopharmaceutical company revealed positive top-line results for the Phase 3 Lavender study of its drug, trofinetide, to treat Rett syndrome. | ACADIA Pharmaceuticals (ACAD) was gaining more than 16% in value after saying patients in its Phase 3 trial of trofinetide for the treatment of Rett syndrome showed improvements in core symptoms, including being able to respond to a choice or having more freedom from repetitive hand movements. HealthEquity (HQY) was shedding over 27% in value after it reported a non-GAAP EPS of $0.35 in Q3, down from $0.41 a year earlier, but meeting analyst estimates in a Capital IQ survey. Bright Health Group (BHG) was over 12% higher after it reiterated its 2021 revenue guidance of $4.1 billion to $4.2 billion and said it expects 2022 revenue to rise to $6.3 billion to $6.5 billion. | With all that said, could one of these health care stocks be worth watching in thestock market today Best Health Care Stocks For Your December 2021 Watchlist Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Novavax Inc. (NASDAQ: NVAX) Cellectis (NASDAQ: CLLS) Intellia Therapeutics Inc. (NASDAQ: NTLA) Acadia Pharmaceuticals Inc. First up, we have Acadia Pharmaceuticals, a biotech company with more than 25 years of experience in the industry. ACAD stock currently trades at $21.42 as of 2:26 p.m. Diving in, Acadia announced positive top-line results from its pivotal Phase 3 Lavender study. | In the Green Bluejay Diagnostics, Inc. (BJDX) is up over 25% at $3.22 MongoDB, Inc. (MDB) is up over 21% at $520.00 ACADIA Pharmaceuticals Inc. (ACAD) is up over 14% at $22.12 Palatin Technologies, Inc. (PTN) is up over 13% at $0.63 Vaxxinity, Inc. (VAXX) is up over 10% at $8.06 Eqonex Limited (EQOS) is up over 10% at $3.63 Moxian (BVI) Inc (MOXC) is up over 9% at $4.38 SuperCom Ltd. (SPCB) is up over 9% at $0.66 BIT Mining Limited (BTCM) is up over 8% at $6.99 VBI Vaccines Inc. (VBIV) is up over 8% at $2.39 monday.com Ltd. (MNDY) is up over 6% at $306.00 In the Red Creative Medical Technology Holdings, Inc. (CELZ) is down over 19% at $1.79 Insignia Systems, Inc. (ISIG) is down over 15% at $12.74 Coupa Software Incorporated (COUP) is down over 12% at $152.31 Imperial Petroleum Inc. (IMPP) is down over 9% at $6.80 Code Chain New Continent Limited (CCNC) is down over 9% at $1.21 Valneva SE (VALN) is down over 6% at $45.23 China Jo-Jo Drugstores, Inc. (CJJD) is down over 6% at $0.42 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.05 A.M. ET). | ACADIA Pharmaceuticals (NASDAQ:ACAD) stock is surging close to 14% on positive results from a Phase 3 clinical trial. Pre-Market Stock Movers: 10 Top Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock is soaring more than 24% as retail traders take interest in the company. China Jo-Jo Drugstores (NASDAQ:CJJD) shares are decreasing over 8% after shares of the penny stock ran higher yesterday."
+2021-12-06,18.81999969482422,19.39999961853028,-2.201832839609998,,
+2021-12-03,20.0,18.790000915527344,3.0818274873063385,,
+2021-12-02,18.89999961853028,19.940000534057617,-6.049995422363281,,
+2021-12-01,19.01000022888184,18.89999961853028,5.502650457768688,,
+2021-11-30,18.64999961853028,19.200000762939453,-0.578646023288497,,
+2021-11-29,19.06999969482422,18.84000015258789,2.9490678587612518,,
+2021-11-26,19.450000762939453,18.790000915527344,-1.206080471510192,,
+2021-11-24,19.31999969482422,19.780000686645508,-3.393315277754079,,
+2021-11-23,19.209999084472656,19.489999771118164,2.380957552212189,,
+2021-11-22,19.01000022888184,19.290000915527344,1.4575778239980808,,
+2021-11-19,18.93000030517578,19.14999961853028,1.4729125895543127,,
+2021-11-18,19.59000015258789,18.950000762939453,1.1621727934909107,,
+2021-11-17,20.270000457763672,19.479999542236328,-3.2669698043054476,,
+2021-11-16,19.82999992370605,20.459999084472656,-3.8973897271164746,,
+2021-11-15,20.90999984741211,19.770000457763672,3.1770003186609386,,
+2021-11-12,20.729999542236328,20.64999961853028,-5.451933993148869,,
+2021-11-11,20.309999465942383,20.68000030517578,-0.3859137745905482,"December 31st Options Now Available For Acadia Pharmaceuticals | LABU, ALXO, ABBV, ACAD: Large Outflows Detected at ETF","Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $22.50 strike price has a current bid of $1.15. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.50 strike highlighted in red: Considering the fact that the $22.50 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 31st expiration. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.5%, AbbVie Inc (Symbol: ABBV) is trading flat, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is higher by about 2.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $95.7 million dollar outflow -- that's a 12.8% decrease week over week (from 13,711,600 to 11,961,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $54.92."
+2021-11-10,21.559999465942383,20.34000015258789,1.8217668585065638,,
+2021-11-09,20.84000015258789,21.56999969482422,-5.658624042554754,Acadia Pharmaceuticals Inc (ACAD) Q3 2021 Earnings Call Transcript,"Operator [Operator Closing Remarks] Duration: 75 minutes Call participants: Mark Johnson -- Vice President, Investor Relations Stephen R. Davis -- Chief Executive Officer Brendan Teehan -- Executive Vice President, Chief Operating Officer, Head of Commercial Serge Stankovic -- President Mark Schneyer -- Senior Vice President, Business Development, Chief Business and Interim Chief Financial Officer Neena Bitritto-Garg -- Citi -- Analyst Gavin Scott -- JPMorgan -- Analyst Ritu Baral -- Cowen -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Yatin Suneja -- Guggenheim Partners -- Analyst Marc Goodman -- SVB Leerink -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Ami Fadia -- Needham -- Analyst Paul Matteis -- Stifel -- Analyst Jeffrey Hung -- Morgan Stanley -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q3 2021 Earnings Call Nov 8, 2021, 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good day, ladies and gentlemen, and welcome to the Acadia Pharmaceuticals Third Quarter 2021 Financial Results Conference Call."
+2021-11-08,20.18000030517578,19.56999969482422,3.502876856484464,,
+2021-11-05,20.0,20.020000457763672,-3.0227978252067174,,
+2021-11-04,20.239999771118164,20.020000457763672,0.10000228881835936,"Noteworthy ETF Outflows: LABU, ALXO, ACAD, XLRN","Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 8.7%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $92.3 million dollar outflow -- that's a 9.3% decrease week over week (from 15,061,600 to 13,661,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $65.52."
+2021-11-03,19.170000076293945,20.3700008392334,-1.0869531415134905,,
+2021-11-02,20.18000030517578,19.18000030517578,6.259784862616673,,
+2021-11-01,18.5,20.530000686645508,-4.955401312573416,,
+2021-10-29,18.200000762939453,17.950000762939453,10.972976684570312,,
+2021-10-28,17.420000076293945,18.11000061035156,-1.3736263160443016,,
+2021-10-27,17.600000381469727,17.559999465942383,3.960967457150604,,
+2021-10-26,17.350000381469727,17.559999465942383,-0.2272779242065186,,
+2021-10-25,18.450000762939453,17.360000610351562,1.21036933634273,,
+2021-10-22,18.100000381469727,18.540000915527344,-5.907859661325195,,
+2021-10-21,17.920000076293945,18.049999237060547,2.4309421258801596,ACAD December 3rd Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $20.00 strike price has a current bid of 55 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $20.00 strike highlighted in red: Considering the fact that the $20.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the December 3rd expiration."
+2021-10-20,17.65999984741211,17.979999542236328,0.7254417422607893,,
+2021-10-19,17.729999542236328,17.690000534057617,1.8120028176054113,How The Parts Add Up: IYY Headed For $124,"Similarly, ACAD has 43.94% upside from the recent share price of $17.60 if the average analyst target price of $25.33/share is reached, and analysts on average are expecting BMBL to reach a target price of $66.42/share, which is 30.30% above the recent price of $50.97. Three of IYY's underlying holdings with notable upside to their analyst target prices are Luminar Technologies Inc (Symbol: LAZR), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bumble Inc (Symbol: BMBL). Below is a twelve month price history chart comparing the stock performance of LAZR, ACAD, and BMBL: Below is a summary table of the current analyst target prices discussed above:"
+2021-10-18,17.40999984741211,17.600000381469727,-0.22560072877286586,,
+2021-10-15,17.979999542236328,17.510000228881836,1.0913299007630928,,
+2021-10-14,17.40999984741211,17.81999969482422,-2.6140118204699037,,
+2021-10-13,17.520000457763672,17.84000015258789,2.3549675531620027,,
+2021-10-12,17.309999465942383,17.6299991607666,1.8264822286714992,,
+2021-10-11,16.940000534057617,17.399999618530273,1.848640697267621,,
+2021-10-08,17.25,16.93000030517578,2.715460861691444,,
+2021-10-07,16.850000381469727,17.059999465942383,-1.855070694633152,November 26th Options Now Available For Acadia Pharmaceuticals,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $15.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.50 strike price has a current bid of 40 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.50 strike highlighted in red: Considering the fact that the $17.50 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 26th expiration."
+2021-10-06,16.739999771118164,16.8700008392334,1.2462853395754003,"LABU, ALXO, ACAD, XLRN: Large Inflows Detected at ETF","Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is off about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $115.2 million dollar inflow -- that's a 20.6% increase week over week in outstanding units (from 10,661,600 to 12,861,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $47.59 per share, with $185.61 as the 52 week high point — that compares with a last trade of $50.73."
+2021-10-05,16.739999771118164,16.920000076293945,0.7765894258823567,,
+2021-10-04,17.3799991607666,16.790000915527344,1.0752706549395488,,
+2021-10-01,16.56999969482422,17.479999542236328,-3.394696626747328,,
+2021-09-30,17.0,16.610000610351562,5.491851926203449,,
+2021-09-29,17.360000610351562,16.959999084472656,-2.294114056755515,Can These Former Biotech Growth Stocks Regain Their Form?,"Acadia Pharmaceuticals (NASDAQ: ACAD) and Clovis Oncology (NASDAQ: CLVS) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in the not-so-distant past. And although Acadia's management expects the drug to possibly achieve sales in excess of $500 million for Parkinson's disease psychosis in 2021, this second indication was widely believed to be the key to push it into blockbuster territory (sales topping $1 billion per year). Acadia: Patience will be key Acadia's shares are down by a jaw-dropping 68% so far this year, which is in stark contrast to its nearly 1,000% gain from Jan., 1, 2013 to March 1, 2021."
+2021-09-28,17.239999771118164,17.270000457763672,-2.304156174052149,,
+2021-09-27,16.920000076293945,17.40999984741211,0.17401790628656144,,
+2021-09-24,17.280000686645508,16.940000534057617,2.895979721682665,,
+2021-09-23,17.0,17.3700008392334,-1.96759339743923,November 5th Options Now Available For Acadia Pharmaceuticals,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 15 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 5th expiration."
+2021-09-22,17.010000228881836,17.040000915527344,2.1764755249023438,,
+2021-09-21,16.75,17.020000457763672,0.17637087737699536,,
+2021-09-20,16.389999389648438,16.709999084472656,1.6119430314249068,,
+2021-09-17,16.15999984741211,16.700000762939453,1.9524082168442516,,
+2021-09-16,15.920000076293944,16.1200008392334,3.341589855360181,Oversold Conditions For Acadia Pharmaceuticals,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $15.705 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $15.6792 per share, with $57.46 as the 52 week high point — that compares with a last trade of $15.78."
+2021-09-15,15.75,15.899999618530272,1.2562861933478933,,
+2021-09-14,16.329999923706055,15.779999732971191,0.9523785303509311,,
+2021-09-13,16.100000381469727,16.260000228881836,-3.3680354764511353,,
+2021-09-10,16.469999313354492,16.09000015258789,0.9937878485783205,,
+2021-09-09,16.43000030517578,16.450000762939453,-2.3072202587068964,ACAD October 29th Options Begin Trading | How Does Acadia Stock Performance In The Current Crisis Compare With That In 2008?,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of 55 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $17.00 strike highlighted in red: Considering the fact that the $17.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 29th expiration. | In contrast, here is how ACAD stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ACAD and S&P 500 Performance Over 2007-08 Financial Crisis ACAD stock plummeted from from levels of about $16 in October 2007 (pre-crisis peak for the broader markets) to levels of $3 in September 2008 before plunging to under $1 in March 2009 (as the markets bottomed out), implying ACAD stock lost 95% from its peak. Acadia Fundamentals Over Recent Years Have Been Robust Acadia’s revenues increased from $125 million in 2017 to $463 million for the last twelve-month period, led by increased sales of Nuplazid. We believe that Acadia Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time."
+2021-09-08,16.420000076293945,16.530000686645508,0.1217313292281031,,
+2021-09-07,16.68000030517578,16.280000686645508,0.6699184521343197,"LABU, ALXO, ACAD, XLRN: Large Outflows Detected at ETF","Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 2%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.5%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $190.4 million dollar outflow -- that's a 21.0% decrease week over week (from 13,311,600 to 10,511,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $42.2563 per share, with $185.61 as the 52 week high point — that compares with a last trade of $67.85."
+2021-09-03,17.170000076293945,16.780000686645508,-2.3980792039083725,,
+2021-09-02,17.549999237060547,17.170000076293945,-2.271400046100738,Interesting ACAD Put And Call Options For October 22nd,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 22nd expiration."
+2021-09-01,17.530000686645508,17.690000534057617,-2.1652374774134047,,
+2021-08-31,16.969999313354492,17.510000228881836,0.912720143439575,First Week of ACAD October 15th Options Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $16.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 95 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the October 15th expiration."
+2021-08-30,17.219999313354492,16.969999313354492,3.1820915579082647,,
+2021-08-27,16.68000030517578,17.110000610351562,-1.4518002901784057,,
+2021-08-26,17.15999984741211,16.68000030517578,2.5779394323053624,,
+2021-08-25,16.899999618530273,17.18000030517578,-2.7972001544552265,Relative Strength Alert For Acadia Pharmaceuticals,"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $16.77 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16 per share, with $57.46 as the 52 week high point — that compares with a last trade of $17.06."
+2021-08-24,17.049999237060547,17.0,1.656808834116757,,
+2021-08-23,16.850000381469727,17.0,-0.29325067036875035,,
+2021-08-20,16.09000015258789,16.68000030517578,0.8902054310647431,,
+2021-08-19,16.6200008392334,16.139999389648438,3.666874748245393,,
+2021-08-18,17.31999969482422,16.719999313354492,-2.8880952186949536,,
+2021-08-17,16.6299991607666,17.239999771118164,-3.4642054967762284,,
+2021-08-16,17.5,16.84000015258789,3.6680736087508192,,
+2021-08-13,18.09000015258789,17.579999923706055,-3.7714276994977682,,
+2021-08-12,18.299999237060547,18.040000915527344,-2.8192383890548345,Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021? | How The Pieces Add Up: FBT Targets $208,"One too many headwinds For the record, excluding always-volatile small caps and micro caps, the five biggest losers on the Nasdag this year are (with losses respectively ranging from -65% to -56%) Poshmark, Acadia Pharmaceuticals (NASDAQ: ACAD), AbCellera Biologics (NASDAQ: ABCL), Arrival, and Amicus Therapeutics (NASDAQ: FOLD). As veteran investors can attest, however, a stock that's been up-ended isn't inherently a stock that's ready for a recovery. See the 10 stocks *Stock Advisor returns as of August 9, 2021 James Brumley has no position in any of the stocks mentioned. | Similarly, SRPT has 58.24% upside from the recent share price of $80.89 if the average analyst target price of $128.00/share is reached, and analysts on average are expecting ACAD to reach a target price of $25.80/share, which is 40.75% above the recent price of $18.33. Three of FBT's underlying holdings with notable upside to their analyst target prices are bluebird bio Inc (Symbol: BLUE), Sarepta Therapeutics Inc (Symbol: SRPT), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of BLUE, SRPT, and ACAD: Combined, BLUE, SRPT, and ACAD represent 8.68% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2021-08-11,18.57999992370605,18.32999992370605,-1.4207559146049755,,
+2021-08-10,19.1200008392334,18.489999771118164,-1.3455328365261578,,
+2021-08-09,19.290000915527344,19.15999984741211,-3.294984521248032,,
+2021-08-06,19.239999771118164,19.18000030517578,-0.673929818274871,Acadia Pharmaceuticals Inc (ACAD) Q2 2021 Earnings Call Transcript,"Also in July, ACADIA hosted a disease awareness symposium to further discuss the high unmet need in DRP at this year's Alzheimer's Association International Conference. Operator [Operator Closing Remarks] Duration: 69 minutes Call participants: Mark Johnson -- Vice President, Investor Relations Stephen R. Davis -- Chief Executive Officer Amanda Morgan -- Senior Vice President, Chief Revenue and Customer Officer Charmaine Lykins -- Senior Vice President, Global Production Planning and Chief Marketing Officer Serge Stankovic -- President Elena Ridloff -- Executive Vice President, Chief Financial Officer Gavin Scott -- JPMorgan -- Analyst Neena Bitritto-Garg -- Citi -- Analyst Jeff Hung -- Morgan Stanley -- Analyst Lyla Youssef -- Cowen -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Tazeen Ahmad -- Bank of America -- Analyst Jason Butler -- JMP Securities -- Analyst Marc Goodman -- SVB Leerink -- Analyst Andrea Tan -- Goldman Sachs -- Analyst Joseph Stringer -- Needham and Company -- Analyst Jay Olson -- Oppenheimer -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Danielle Brill -- Raymond James -- Analyst Vamil Divan -- Mizuho Securities -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q2 2021 Earnings Call Aug 6, 2021, 8:30 p.m."
+2021-08-05,19.65999984741211,19.25,-0.3118475397928544,,
+2021-08-04,21.440000534057617,21.049999237060547,-2.085451935881264,,
+2021-08-03,21.01000022888184,21.6299991607666,-1.819035854861804,ACADIA: The Street’s Gaze Turns to FDA Meeting’s Outcome on DRP Treatment,"“In what was a surprising move to us, and the market, the FDA seemingly changed the goalposts on ACAD by focusing more on subgroups within DRP in its sNDA review vs. treating DRP as a whole.” Although Nuplazid is already approved to treat Parkinson's disease psychosis (PDP), and is generating more than $500 million in annual sales, Kulkarni believes the “intense investor focus” is down the fact the unmet need and market opportunity for the DRP indication is a much bigger one. Should the company manage to get the FDA to change its mind and instigate a more favourable outcome, the analyst thinks ACAD shares will look “significantly undervalued.” However, while Kulkarni remains “constructive on valuation,” he says it is “difficult to convince investors to buy the stock mainly on this basis.” It’s a Hold rating, then, backed by a $27 price target. (See ACAD stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights."
+2021-08-02,21.68000030517578,21.0,2.950970609854956,,
+2021-07-30,22.1299991607666,21.6299991607666,-3.1365327288000135,,
+2021-07-29,22.270000457763672,22.290000915527344,-2.259376497792328,"Interesting ACAD Put And Call Options For September 10th | Notable ETF Inflow Detected - LABU, ALXO, ACAD, XLRN","Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $19.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $24.00 strike price has a current bid of 15 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $24.00 strike highlighted in red: Considering the fact that the $24.00 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 10th expiration. | Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 1.6%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.1%, and Acceleron Pharma, Inc. (Symbol: XLRN) is higher by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $98.8 million dollar inflow -- that's a 12.8% increase week over week in outstanding units (from 12,911,600 to 14,561,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $40.145 per share, with $185.61 as the 52 week high point — that compares with a last trade of $60.89."
+2021-07-28,21.3700008392334,22.14999961853028,0.08980896880358798,,
+2021-07-27,21.209999084472656,21.14999961853028,3.649970747146039,,
+2021-07-26,21.6299991607666,21.290000915527344,-0.28288292565886963,,
+2021-07-23,22.170000076293945,21.459999084472656,-1.571882840642735,Acadia Pharmaceuticals is Now Oversold (ACAD),"In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $21.32 per share. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $19.20 per share, with $57.46 as the 52 week high point — that compares with a last trade of $21.46."
+2021-07-22,24.36000061035156,22.229999542236328,-3.2025303986375833,,
+2021-07-21,24.209999084472656,23.729999542236328,-8.74384653016021,,
+2021-07-20,23.11000061035156,24.26000022888184,-1.982649980950148,First Week of March 2022 Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $4.40. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the March 2022 expiration."
+2021-07-19,23.170000076293945,23.209999084472656,4.976198996789149,,
+2021-07-16,23.280000686645508,23.5,0.17263274944757273,,
+2021-07-15,23.420000076293945,23.15999984741211,0.9450142047491178,,
+2021-07-14,24.059999465942383,23.43000030517578,-1.1101632281590461,,
+2021-07-13,23.690000534057617,23.979999542236328,-2.61845043537255,,
+2021-07-12,23.68000030517578,23.739999771118164,1.2241409946859125,,
+2021-07-09,23.700000762939453,23.709999084472656,0.25337611980211255,Look Under The Hood: FBT Has 18% Upside,"Similarly, ACAD has 22.62% upside from the recent share price of $23.70 if the average analyst target price of $29.06/share is reached, and analysts on average are expecting INCY to reach a target price of $96.70/share, which is 18.75% above the recent price of $81.43. Three of FBT's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc (Symbol: BMRN), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Incyte Corporation (Symbol: INCY). Below is a twelve month price history chart comparing the stock performance of BMRN, ACAD, and INCY: Combined, BMRN, ACAD, and INCY represent 9.93% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2021-07-08,23.63999938964844,23.700000762939453,0.04218700933055606,,
+2021-07-07,24.200000762939453,23.96999931335449,0.25381292233571573,,
+2021-07-06,24.38999938964844,24.1299991607666,-0.9504191831976925,,
+2021-07-02,24.729999542236328,24.299999237060547,-1.0660116252081102,,
+2021-07-01,24.21999931335449,24.770000457763672,-1.7387800773768087,,
+2021-06-30,24.25,24.38999938964844,2.270855326184597,,
+2021-06-29,25.36000061035156,24.1299991607666,0.5773170707152209,,
+2021-06-28,26.14999961853028,25.32999992370605,-4.850163328004377,,
+2021-06-25,24.96999931335449,26.170000076293945,-3.1357541368496435,,
+2021-06-24,24.549999237060547,25.01000022888184,4.8057701078817034,,
+2021-06-23,25.020000457763672,24.520000457763672,1.8737311858115155,,
+2021-06-22,24.959999084472656,24.8799991607666,-1.998401242414249,,
+2021-06-21,26.0,25.01000022888184,-0.3205125266043049,,
+2021-06-18,25.790000915527344,26.030000686645508,-3.80769142737754,,
+2021-06-17,25.82999992370605,25.850000381469727,0.930592332680639,,
+2021-06-16,26.309999465942383,25.89999961853028,0.07743111816783076,Shareholders Will Most Likely Find ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation Acceptable,"At the time of writing, our data shows that ACADIA Pharmaceuticals Inc. has a market capitalization of US$4.2b, and reported total annual CEO compensation of US$7.8m for the year to December 2020. NasdaqGS:ACAD CEO Compensation June 16th 2021 ACADIA Pharmaceuticals Inc.'s Growth ACADIA Pharmaceuticals Inc.'s earnings per share (EPS) grew 9.3% per year over the last three years. Under the guidance of CEO Steve Davis, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has performed reasonably well recently."
+2021-06-15,27.06999969482422,26.270000457763672,-1.558342287094443,,
+2021-06-14,27.36000061035156,27.239999771118164,-2.955298286218698,,
+2021-06-11,27.09000015258789,27.420000076293945,-0.4385995488172358,,
+2021-06-10,25.950000762939453,27.299999237060547,1.218161394785116,,
+2021-06-09,26.729999542236328,26.1299991607666,5.202306105705773,,
+2021-06-08,25.39999961853028,26.56999969482422,-2.244670376898661,,
+2021-06-07,23.71999931335449,25.39999961853028,4.606299582147938,,
+2021-06-04,23.38999938964844,23.690000534057617,7.082632183003238,,
+2021-06-03,22.559999465942383,23.309999465942383,1.2826043276510117,ACAD July 23rd Options Begin Trading | Should You Buy ACADIA Pharmaceuticals Stock At $22?,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $21.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of 40 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 13% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 23rd expiration. | [Updated: 6/1/2021] ACAD Stock Update We believe that the stock price of ACADIA Pharmaceuticals (NASDAQ:ACAD), a biopharmaceutical company focused on neuroscience drugs, looks undervalued at current levels of around $22. Looking at the valuation, at the current levels of $22, ACAD stock is trading at under 7x its expected RPS of $3.31 in 2021, compared to levels of around 20x seen in 2019 and 2020, implying there is significant room for growth in ACAD stock. In contrast, here is how ACAD stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ACAD and S&P 500 Performance Over 2007-08 Financial Crisis ACAD stock plummeted from from levels of about $16 in October 2007 (pre-crisis peak for the broader markets) to levels of $3 in September 2008 before plunging to under $1 in March 2009 (as the markets bottomed out), implying ACAD stock lost 95%."
+2021-06-02,22.5,22.6200008392334,3.3244681638057423,The Implied Analyst 12-Month Target For JKH,"Similarly, ACAD has 30.05% upside from the recent share price of $22.35 if the average analyst target price of $29.07/share is reached, and analysts on average are expecting RGLD to reach a target price of $140.14/share, which is 13.05% above the recent price of $123.96. Three of JKH's underlying holdings with notable upside to their analyst target prices are Exelixis Inc (Symbol: EXEL), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Royal Gold Inc (Symbol: RGLD). Below is a twelve month price history chart comparing the stock performance of EXEL, ACAD, and RGLD: Below is a summary table of the current analyst target prices discussed above:"
+2021-06-01,22.51000022888184,22.350000381469727,0.5333370632595485,,
+2021-05-28,22.07999992370605,22.34000015258789,-0.7107945170379092,,
+2021-05-27,21.850000381469727,22.040000915527344,1.1775372725553857,,
+2021-05-26,21.26000022888184,21.709999084472656,0.8695676464095189,,
+2021-05-25,21.34000015258789,21.280000686645508,2.116645582061145,,
+2021-05-24,22.0,21.31999969482422,-0.28115963220884377,First Week of July 16th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $21.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $23.00 strike price has a current bid of $1.05. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red: Considering the fact that the $23.00 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the July 16th expiration."
+2021-05-21,21.59000015258789,21.940000534057617,-3.090910478071733,,
+2021-05-20,20.76000022888184,21.57999992370605,1.621122644724825,,
+2021-05-19,21.239999771118164,20.71999931335449,3.94990214731986,,
+2021-05-18,21.26000022888184,21.38999938964844,-2.4482131043653035,,
+2021-05-17,21.51000022888184,21.229999542236328,0.6114729979635509,,
+2021-05-14,21.270000457763672,21.770000457763672,-1.3017233085360442,,
+2021-05-13,21.850000381469727,21.21999931335449,2.3507286753136722,,
+2021-05-12,20.770000457763672,21.82999992370605,-2.8833000325689757,,
+2021-05-11,20.64999961853028,20.84000015258789,5.103512000868346,,
+2021-05-10,20.89999961853028,21.020000457763672,0.9200994555327404,,
+2021-05-07,20.88999938964844,21.06999969482422,0.5741667053763801,,
+2021-05-06,19.549999237060547,20.950000762939453,0.8616577809235013,Interesting ACAD Put And Call Options For December 17th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $21.00 strike price has a current bid of $3.40. Below is a chart showing ACAD's trailing twelve month trading history, with the $21.00 strike highlighted in red: Considering the fact that the $21.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the December 17th expiration."
+2021-05-05,19.420000076293945,19.39999961853028,7.161133404163776,,
+2021-05-04,20.1299991607666,19.520000457763672,-0.10298896851230908,Acadia Pharmaceuticals Becomes Oversold (ACAD),"In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $19.41 per share. A bullish investor could look at ACAD's 28.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $19.41 per share, with $58.72 as the 52 week high point — that compares with a last trade of $19.56."
+2021-05-03,20.540000915527344,20.25,-3.0302967135329943,,
+2021-04-30,20.32999992370605,20.559999465942383,-1.4118836543386701,,
+2021-04-29,20.940000534057617,20.59000015258789,1.1313307579904996,,
+2021-04-28,21.15999984741211,20.770000457763672,-1.6714439949534508,,
+2021-04-27,21.309999465942383,21.049999237060547,-1.843097317867584,,
+2021-04-26,20.64999961853028,21.350000381469727,-1.2200855720215666,,
+2021-04-23,20.850000381469727,20.5,3.3898342657173717,,
+2021-04-22,21.46999931335449,20.8700008392334,-1.6786588732189505,ACAD June 4th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $23.50 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.50 strike highlighted in red: Considering the fact that the $23.50 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the June 4th expiration."
+2021-04-21,20.81999969482422,21.46999931335449,-2.7945900945971944,,
+2021-04-20,20.700000762939453,20.799999237060547,3.1219962923047384,,
+2021-04-19,21.040000915527344,20.71999931335449,0.4830843982389,,
+2021-04-16,21.31999969482422,21.14999961853028,-1.5209200962377176,,
+2021-04-15,21.34000015258789,21.200000762939453,-0.7973737276141168,,
+2021-04-14,20.61000061035156,21.280000686645508,-0.6560421211218214,,
+2021-04-13,20.5,20.600000381469727,3.2508493762850024,,
+2021-04-12,20.39999961853028,20.43000030517578,0.48780673887671494,,
+2021-04-09,20.780000686645508,20.38999938964844,0.14706219218871786,,
+2021-04-08,21.59000015258789,20.68000030517578,-1.8768107993745415,,
+2021-04-07,20.38999938964844,21.229999542236328,-4.214913575639933,,
+2021-04-06,20.75,20.63999938964844,4.1196673748520904,Is Acadia a Buy Following the FDA’s CRL? J.P. Morgan Says ‘Yes’,"(See ACAD stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Accordingly, Acadia (ACAD) investors got the blues on Monday. The rejection was for Nuplazid, Acadia’s treatment for patients with dementia-related psychosis (DRP) and follows on from last month’s notification letter which cited deficiencies in the supplemental New Drug Application (sNDA)."
+2021-04-05,21.25,21.18000030517578,-0.5301234233810069,"Health Care Sector Update for 04/05/2021: NNOX,MTEM,ACAD,TAK | Health Care Sector Update for 04/05/2021: NVTA,NNOX,MTEM,ACAD,TAK | Acadia Pharma Receives CRL For SNDA Of Pimavanserin On Dementia-Related Psychosis; Stock Plunges | FDA Rejects Acadia’s Supplemental New Drug Application For NUPLAZID; Shares Plunge","ACADIA Pharmaceuticals (ACAD) slid over 17% after the US Food and Drug Administration rejected a supplemental new drug application for the company's dementia drug pimavanserin. Health care stocks were higher this afternoon, with the NYSE Health Care Index rising 0.7% while the SPDR Health Care Select Sector ETF also up 0.6%. Molecular Templates (MTEM) dropped nearly 24% after it said it will discontinue the development of its MT-3724 first-generation engineered toxin body and will instead focus on next-generation ETBs MT-5111, TAK-169, and MT-6402 in addition to assuming full rights to Takeda's (TAK) TAK-169 myeloma drug candidate. | On the losing side, ACADIA Pharmaceuticals (ACAD) slid 17% after the US Food and Drug Administration rejected a supplemental new drug application for the company's pimavanserin dementia drug. Health care stocks were moderately higher this afternoon, with the NYSE Health Care Index rising 0.5% while the SPDR Health Care Select Sector ETF also was up 0.5%. In company news, Invitae (NVTA) was 3.3% higher late in Monday trading after announcing its $200 million purchase of genomics firm Genosity, with the deal consisting of $120 million in cash and $80 million of Invitae shares. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) said Monday that it has received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its supplemental New Drug Application or sNDA for NUPLAZID or pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis or DRP. In Monday pre-market trade, ACAD was trading at $22.00 down $3.59 or 14.03 percent. The Division of Psychiatry cited a lack of statistical significance in some of the subgroups of dementia, and insufficient numbers of patients with certain less common dementia subtypes as lack of substantial evidence of effectiveness to support approval. | Shares of Acadia Pharmaceuticals plunged more than 15% in early trade on Monday after the biopharmaceutical company received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA), which rejected the supplemental New Drug Application (sNDA) for NUPLAZID (pimavanserin). The CRL indicated that the application cannot be approved in its present form as it lacks substantial evidence of effectiveness to support approval, despite prior agreements with the Division of Psychiatry regarding the pivotal Phase 3 HARMONY study design targeting a broad DRP patient population analyzed as a single group, Acadia (ACAD) said. Acadia CEO Steve Davis said, “We will immediately request a Type A meeting to work with the FDA to address the CRL and determine an expeditious path forward for the approval of pimavanserin in DRP.” On March 10, Merrill Lynch analyst Tazeen Ahmad downgraded the stock to Hold from Buy."
+2021-04-01,25.86000061035156,25.59000015258789,-0.3294103285845588,,
+2021-03-31,25.940000534057617,25.799999237060547,-1.0440852722006095,,
+2021-03-30,25.1200008392334,25.709999084472656,-0.5397120050682237,,
+2021-03-29,25.799999237060547,25.299999237060547,2.3487190506688815,,
+2021-03-26,25.950000762939453,25.86000061035156,-1.9379845534327471,"Noteworthy ETF Inflows: LABU, ALXO, ACAD, XLRN","Among the largest underlying components of LABU, in trading today ALX Oncology Holdings Inc (Symbol: ALXO) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 0.3%, and Acceleron Pharma, Inc. (Symbol: XLRN) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Daily S&P Biotech Bull 3X Shares (Symbol: LABU) where we have detected an approximate $145.7 million dollar inflow -- that's a 29.8% increase week over week in outstanding units (from 6,211,600 to 8,061,600). For a complete list of holdings, visit the LABU Holdings page » The chart below shows the one year price performance of LABU, versus its 200 day moving average: Looking at the chart above, LABU's low point in its 52 week range is $18.28 per share, with $185.61 as the 52 week high point — that compares with a last trade of $77.36."
+2021-03-25,25.09000015258789,26.020000457763672,-0.34682138705917914,,
+2021-03-24,25.86000061035156,25.34000015258789,3.7066572320441256,,
+2021-03-23,26.940000534057617,25.8799991607666,-2.010829255570536,,
+2021-03-22,27.86000061035156,27.0,-3.934674655818805,,
+2021-03-19,27.309999465942383,27.75,-3.0868650090123126,First Week of May 21st Options Trading For Acadia Pharmaceuticals,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $3.70. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the May 21st expiration."
+2021-03-18,27.36000061035156,27.049999237060547,1.611133440725002,,
+2021-03-17,27.38999938964844,27.549999237060547,-1.1330459297348268,ACADIA Pharmaceuticals Stock Now Looks Oversold At $27 Levels,"After the recent development many analysts cut their price targets for ACAD stock, but still the average price estimate stands at $44, implying a potential 60% premium to the current stock price of $27. In contrast, here is how ACAD stock and the broader market fared during the 2007-08 crisis Timeline of 2007-08 Crisis 10/1/2007: Approximate pre-crisis peak in S&P 500 index 9/1/2008 – 10/1/2008: Accelerated market decline corresponding to Lehman bankruptcy filing (9/15/08) 3/1/2009: Approximate bottoming out of S&P 500 index 12/31/2009: Initial recovery to levels before accelerated decline (around 9/1/2008) ACAD and S&P 500 Performance Over 2007-08 Financial Crisis ACAD stock plummeted from from levels of about $16 in October 2007 (pre-crisis peak for the broader markets) to levels of $3 in September 2008 before plunging to under $1 in March 2009 (as the markets bottomed out), implying ACAD stock lost 95%. We believe that ACADIA Pharmaceuticals stock (NASDAQ: ACAD), a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time."
+2021-03-16,30.1200008392334,27.34000015258789,0.5841542569459673,,
+2021-03-15,27.07999992370605,29.989999771118164,-9.22974969849391,,
+2021-03-12,26.549999237060547,27.040000915527344,10.745937428399605,,
+2021-03-11,27.18000030517578,26.75,1.845580762890624,ACAD April 30th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $27.00 strike price has a current bid of $3.90. Below is a chart showing ACAD's trailing twelve month trading history, with the $27.00 strike highlighted in red: Considering the fact that the $27.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 30th expiration."
+2021-03-10,25.61000061035156,26.88999938964844,-1.5820467268129426,,
+2021-03-09,25.950000762939453,25.020000457763672,4.998042752015816,"Why Acadia Pharmaceuticals Stock Is Crashing Today | Is ACADIA Still a Buy Following FDA Setback? Analyst Weighs In | Notable Tuesday Option Activity: ACAD, Z, TUP | News Flash: 19 Analysts Think ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Earnings Are Under Threat | ACAD Stock: The Bad News That Has Acadia Pharmaceuticals Plunging Today | Tuesday's ETF with Unusual Volume: OMFL | These 2 Nasdaq Stocks Were Surprise Losers in Tuesday's Market Rally","10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of the mid-cap biopharma Acadia Pharmaceuticals (NASDAQ: ACAD) fell by as much as 44% in pre-market trading Tuesday morning. Acadia has been trialing the drug for several years across a variety of broadly similar indications in the hope of expanding its commercial footprint. | After the close on Monday, the company announced that the FDA has said it found deficiencies in ACADIA’s supplemental New Drug Application (sNDA) for Pimavanserin - which goes under the brand name of Nuplazidin - for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). (See ACAD stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Unfortunately, for ACADIA Pharmaceuticals (ACAD), the latter case currently holds true. | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 25,688 contracts has been traded thus far today, a contract volume which is representative of approximately 2.6 million underlying shares (given that every 1 contract represents 100 underlying shares). Below is a chart showing ACAD's trailing twelve month trading history, with the $40 strike highlighted in orange: Zillow Group Inc (Symbol: Z) saw options trading volume of 46,401 contracts, representing approximately 4.6 million underlying shares or approximately 90.9% of Z's average daily trading volume over the past month, of 5.1 million shares. That number works out to 253.3% of ACAD's average daily trading volume over the past month, of 1.0 million shares. | NasdaqGS:ACAD Earnings and Revenue Growth March 10th 2021 The consensus price target fell 28% to US$45.06, implicitly signalling that lower earnings per share are a leading indicator for ACADIA Pharmaceuticals' valuation. It's pretty clear that there is an expectation that ACADIA Pharmaceuticals' revenue growth will slow down substantially, with revenues to the end of 2021 expected to display 26% growth on an annualised basis. Market forces rained on the parade of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders today, when the analysts downgraded their forecasts for this year. | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals (NASDAQ:ACAD) stock is taking a beating on Tuesday after revealing an update from the U.S. Food and Drug Administration (FDA). 7 of the Top Transportation Stocks to Buy Right Now The news has also resulted in heavy trading of ACAD stock today. The post ACAD Stock: The Bad News That Has Acadia Pharmaceuticals Plunging Today appeared first on InvestorPlace. | Peloton Interactive is the component faring the best Tuesday, up by about 12.1% on the day, while Acadia Pharmaceuticals is lagging other components of the Invesco Russell 1000—Dynamic Multifactor ETF, trading lower by about 47.8%. The Invesco Russell 1000—Dynamic Multifactor ETF is seeing unusually high volume in afternoon trading Tuesday, with over 881,000 shares traded versus three month average volume of about 134,000. Components of that ETF with the highest volume on Tuesday were General Electric, trading up about 1% with over 60.8 million shares changing hands so far this session, and Apple, up about 3.3% on volume of over 59.7 million shares. | Both Acadia Pharmaceuticals (NASDAQ: ACAD) and Stitch Fix (NASDAQ: SFIX) were down sharply, as unexpected bad news surprised investors who'd been hoping for better things. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them!"
+2021-03-08,49.08000183105469,45.77999877929688,-3.5838160995508064,,
+2021-03-05,46.02999877929688,48.97999954223633,-6.723722348497906,,
+2021-03-04,47.52000045776367,45.81999969482422,6.408865611932802,,
+2021-03-03,47.06999969482422,47.43999862670898,-3.5774426484916253,,
+2021-03-02,49.220001220703125,46.93999862670898,0.7860610458543159,,
+2021-03-01,49.34000015258789,49.560001373291016,-4.632268462917314,,
+2021-02-26,47.34000015258789,48.970001220703125,0.44588816380776986,,
+2021-02-25,48.290000915527344,47.310001373291016,3.4431792624870297,,
+2021-02-24,49.709999084472656,48.68999862670898,-2.029404687630096,,
+2021-02-23,48.77999877929688,49.7400016784668,-2.051901984609541,,
+2021-02-22,50.630001068115234,50.18000030517578,1.9680256728037422,,
+2021-02-19,50.68999862670898,51.72999954223633,-0.8888025942050508,,
+2021-02-18,49.86000061035156,50.41999816894531,2.051688584933924,,
+2021-02-17,49.0,50.06999969482422,1.1231398951838107,,
+2021-02-16,50.5,49.119998931884766,2.1836728465800386,,
+2021-02-12,51.0099983215332,50.130001068115234,-2.7326753824064047,,
+2021-02-11,51.91999816894531,51.2400016784668,-1.7251466033600897,Interesting ACAD Put And Call Options For April 1st,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $52.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $53.00 strike price has a current bid of $2.40. Below is a chart showing ACAD's trailing twelve month trading history, with the $53.00 strike highlighted in red: Considering the fact that the $53.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 1st expiration."
+2021-02-10,50.45000076293945,51.630001068115234,-1.3097005286206636,,
+2021-02-09,51.06999969482422,50.45000076293945,2.338950024442039,"Trade Alert: The CEO & Director Of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Stephen Davis, Has Sold Some Shares Recently","ACADIA Pharmaceuticals Insider Transactions Over The Last Year In fact, the recent sale by Stephen Davis was the biggest sale of ACADIA Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. In the last year ACADIA Pharmaceuticals insiders didn't buy any company stock. NasdaqGS:ACAD Insider Trading Volume February 10th 2021 If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies."
+2021-02-08,52.2400016784668,51.27999877929688,-1.2140178883682284,,
+2021-02-05,50.61000061035156,51.70000076293945,-1.837677772444685,,
+2021-02-04,49.630001068115234,51.06999969482422,2.153724835887369,ACAD March 26th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $48.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $50.00 strike price has a current bid of $2.20. Below is a chart showing ACAD's trailing twelve month trading history, with the $50.00 strike highlighted in red: Considering the fact that the $50.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 26th expiration."
+2021-02-03,49.45000076293945,49.31999969482422,2.901468055043244,,
+2021-02-02,46.970001220703125,49.43000030517578,-0.2628939658433015,,
+2021-02-01,48.4900016784668,46.58000183105469,5.237383479965409,,
+2021-01-29,49.72999954223633,48.04999923706055,-3.938956034848505,,
+2021-01-28,48.22999954223633,49.540000915527344,-3.3782431543135956,ACAD Makes Notable Cross Below Critical Moving Average,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $47.65, changing hands as low as $47.58 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $30.22 per share, with $58.72 as the 52 week high point — that compares with a last trade of $47.74. Acadia Pharmaceuticals Inc shares are currently trading down about 1.9% on the day."
+2021-01-27,51.33000183105469,48.61000061035156,2.7161546459145445,,
+2021-01-26,54.16999816894531,51.61000061035156,-5.299047581676731,,
+2021-01-25,53.20000076293945,53.95000076293945,-4.725858676623236,,
+2021-01-22,51.9900016784668,52.83000183105469,1.409774415872697,Analysts Expect FBT To Hit $207,"Similarly, REGN has 18.72% upside from the recent share price of $535.48 if the average analyst target price of $635.72/share is reached, and analysts on average are expecting ACAD to reach a target price of $61.73/share, which is 18.69% above the recent price of $52.01. Three of FBT's underlying holdings with notable upside to their analyst target prices are Exelixis Inc (Symbol: EXEL), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of EXEL, REGN, and ACAD: Combined, EXEL, REGN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2021-01-21,53.650001525878906,52.0099983215332,1.6156955673571398,,
+2021-01-20,53.5,53.34000015258789,-3.0568558391459173,,
+2021-01-19,54.4900016784668,53.369998931884766,-0.29906513534973717,,
+2021-01-15,54.369998931884766,53.65999984741211,-2.055427990608102,First Week of September 17th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $50.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $55.00 strike price has a current bid of $9.60. Below is a chart showing ACAD's trailing twelve month trading history, with the $55.00 strike highlighted in red: Considering the fact that the $55.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the September 17th expiration."
+2021-01-14,53.41999816894531,54.459999084472656,-1.3058655479507175,,
+2021-01-13,53.77000045776367,53.310001373291016,1.9468381714245888,,
+2021-01-12,54.36000061035156,53.56999969482422,-0.8554939195769311,,
+2021-01-11,53.20000076293945,54.41999816894531,-1.4532761343952358,,
+2021-01-08,55.22999954223633,53.130001068115234,2.293228173890821,,
+2021-01-07,53.34000015258789,54.9900016784668,-3.8022786375639037,,
+2021-01-06,51.720001220703125,53.790000915527344,3.0933661814000826,Interesting ACAD Put And Call Options For April 16th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $50.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $55.00 strike price has a current bid of $3.50. Below is a chart showing ACAD's trailing twelve month trading history, with the $55.00 strike highlighted in red: Considering the fact that the $55.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 16th expiration."
+2021-01-05,52.900001525878906,52.02999877929688,4.002319501097795,,
+2021-01-04,54.11000061035156,52.810001373291016,-1.6446176209586973,,
+2020-12-31,53.869998931884766,53.459999084472656,-2.4025119615538304,,
+2020-12-30,53.880001068115234,53.68999862670898,-0.761091248452647,,
+2020-12-29,52.65999984741211,53.77999877929688,-0.3526400104670665,,
+2020-12-28,55.560001373291016,53.16999816894531,2.1268494780290306,,
+2020-12-24,55.560001373291016,55.0099983215332,-4.301661528566184,,
+2020-12-23,55.720001220703125,55.09000015258789,-0.9899262745918717,,
+2020-12-22,57.06999969482422,55.59000015258789,-1.1306551584947802,,
+2020-12-21,55.16999816894531,56.68999862670898,-2.5933056775021357,,
+2020-12-18,55.540000915527344,55.25,2.7551214576970193,,
+2020-12-17,53.45000076293945,55.209999084472656,-0.5221478407398947,,
+2020-12-16,53.16999816894531,53.08000183105469,3.292793819291263,,
+2020-12-15,52.45000076293945,52.56999969482422,-0.16926150270809795,,
+2020-12-14,51.790000915527344,52.130001068115234,0.22878728339229207,,
+2020-12-11,52.45000076293945,51.2599983215332,0.6564976763419095,,
+2020-12-10,52.209999084472656,52.56999969482422,-2.2688320764469685,,
+2020-12-09,53.93999862670898,52.33000183105469,0.6895242609928092,,
+2020-12-08,53.209999084472656,54.060001373291016,-2.984792059036283,,
+2020-12-07,54.68999862670898,53.380001068115234,1.5974484184240487,,
+2020-12-04,53.4900016784668,54.2400016784668,-2.395314667193974,,
+2020-12-03,54.880001068115234,53.27999877929688,1.402131195486434,,
+2020-12-02,56.5,54.72999954223633,-2.9154560088883428,,
+2020-12-01,57.25,56.790000915527344,-3.132744173033047,,
+2020-11-30,56.70000076293945,56.65999984741211,-0.8034918506072599,,
+2020-11-27,56.18999862670898,56.0,-0.07054835095079814,,
+2020-11-25,54.88999938964844,55.86000061035156,-0.33813602305137735,,
+2020-11-24,54.06999969482422,54.720001220703125,1.7671729486046506,,
+2020-11-23,54.119998931884766,53.84000015258789,1.2021481959452032,,
+2020-11-20,53.5,53.56999969482422,-0.5173665647134998,,
+2020-11-19,53.77999877929688,53.61000061035156,0.13084055107330608,,
+2020-11-18,55.540000915527344,53.81999969482422,-0.3160992428485551,,
+2020-11-17,54.16999816894531,55.290000915527344,-3.0968692696262874,,
+2020-11-16,53.540000915527344,54.630001068115234,2.0675702131075733,,
+2020-11-13,51.0,51.56999969482422,2.035861288660859,,
+2020-11-12,49.31999969482422,50.61000061035156,1.1176464604396448,,
+2020-11-11,49.52000045776367,49.06999969482422,2.6155736486403915,,
+2020-11-10,50.150001525878906,49.0099983215332,-0.9087252802496747,,
+2020-11-09,51.369998931884766,50.02999877929688,-2.2731867789823044,,
+2020-11-06,48.09000015258789,50.18999862670898,-2.6085267285379694,QQQJ's Underlying Holdings Could Mean 11% Gain Potential,"Similarly, OTEX has 31.70% upside from the recent share price of $39.20 if the average analyst target price of $51.62/share is reached, and analysts on average are expecting ACAD to reach a target price of $59.80/share, which is 23.15% above the recent price of $48.56. Three of QQQJ's underlying holdings with notable upside to their analyst target prices are Vodafone Group plc (Symbol: VOD), Open Text Corp (Symbol: OTEX), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of VOD, OTEX, and ACAD: Below is a summary table of the current analyst target prices discussed above:"
+2020-11-05,46.400001525878906,48.560001373291016,4.366809040253409,What's Behind Acadia Pharmaceuticals' Mixed Q3 Results,"Looking ahead Acadia expects that Nuplazid sales for full-year 2020 will be between $430 million and $450 million. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Acadia Pharmaceuticals (NASDAQ: ACAD) has taken investors on something of a wild ride so far in 2020."
+2020-11-04,46.79999923706055,49.130001068115234,4.655171931853067,,
+2020-11-03,45.36000061035156,46.59999847412109,4.978636472304849,,
+2020-11-02,46.5,45.63999938964844,2.733681320732931,,
+2020-10-30,46.79999923706055,46.45000076293945,-1.849463678175403,,
+2020-10-29,46.68999862670898,47.34999847412109,-0.7478599996299418,,
+2020-10-28,45.900001525878906,46.41999816894531,1.4135786395901861,,
+2020-10-27,45.0,46.36000061035156,1.1328902522437319,,
+2020-10-26,42.900001525878906,44.869998931884766,3.0222235785590277,,
+2020-10-23,42.369998931884766,43.16999816894531,4.5920683821362624,,
+2020-10-22,41.02000045776367,42.22999954223633,1.8881266396693772,,
+2020-10-21,41.34000015258789,41.040000915527344,2.94977833000888,,
+2020-10-20,41.4900016784668,41.209999084472656,-0.7256875567325485,,
+2020-10-19,42.93000030517578,41.4900016784668,-0.674867637181758,,
+2020-10-16,42.560001373291016,42.61000061035156,-3.3542944711681573,,
+2020-10-15,42.45000076293945,42.709999084472656,0.1174794065958946,,
+2020-10-14,43.790000915527344,42.91999816894531,0.6124813118029248,,
+2020-10-13,43.25,43.2599983215332,-1.9867611975169883,,
+2020-10-12,43.18999862670898,43.119998931884766,0.023117506435151734,,
+2020-10-09,43.16999816894531,42.72999954223633,-0.16207385285935938,,
+2020-10-08,43.209999084472656,43.18000030517578,-1.0192231766771327,,
+2020-10-07,41.95000076293945,42.88999938964844,-0.06942554948503793,,
+2020-10-06,42.20000076293945,41.68000030517578,2.2407594984823507,,
+2020-10-05,41.81999969482422,42.13999938964844,-1.2322285506220714,,
+2020-10-02,41.38999938964844,41.36000061035156,0.7651833982768369,,
+2020-10-01,41.25,42.13999938964844,-0.07247832746858567,,
+2020-09-30,41.11000061035156,41.25,2.157574277935606,,
+2020-09-29,40.09999847412109,40.40999984741211,0.34054825485258067,,
+2020-09-28,40.58000183105469,40.22999954223633,0.7730707857534834,Clovis Oncology Stock Tanked 14% Yesterday: Time To Buy?,"Despite an almost 60% rise since the March 23 lows of this year, at the current price of around $6 per share, we believe Clovis Oncology stock (NASDAQ:CLVS) has more room for growth. That said, investors willing to invest in Clovis should weigh the threat from AstraZeneca and Merck’s Lynparza, which is expected to see stronger growth over the coming years for similar settings in prostate cancer treatment. However, over the coming weeks, we expect continued improvement in demand and subdued growth in the number of new COVID-19 cases in the U.S. to buoy market expectations. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently."
+2020-09-25,38.72999954223633,40.18000030517578,-0.8624994406740338,,
+2020-09-24,40.040000915527344,38.61000061035156,3.743869816879755,,
+2020-09-23,41.0,40.45000076293945,-3.5714292519439805,,
+2020-09-22,41.52999877929688,40.970001220703125,-1.3414615538062118,,
+2020-09-21,41.790000915527344,41.31999969482422,-1.3484169878495673,,
+2020-09-18,41.13999938964844,42.41999816894531,-1.1246738703192827,,
+2020-09-17,38.75,40.7599983215332,3.1113242544649764,,
+2020-09-16,38.959999084472656,39.20000076293945,5.187092442666331,,
+2020-09-15,39.0,38.790000915527344,0.6160207497603575,,
+2020-09-14,37.25,38.61000061035156,-0.5384591909555289,,
+2020-09-11,36.58000183105469,36.619998931884766,3.6510083499370807,,
+2020-09-10,37.9900016784668,36.41999816894531,0.10934144020769972,,
+2020-09-09,38.5099983215332,37.900001525878906,-4.132675546606732,,
+2020-09-08,37.86000061035156,38.20000076293945,-1.5839959029892035,,
+2020-09-04,38.2599983215332,38.27000045776367,0.898045819087834,,
+2020-09-03,39.06999969482422,38.38999938964844,0.026142542261533307,"3 Cheap Stocks to Buy for Under $5 Now | We Did The Math FBT Can Go To $198 | ACADIA, NovoCure & Alexion: How Are Out Of Favor Health Care Stocks Performing?","Acadia Pharmaceuticals (NASDAQ:ACAD) once traded at 72 cents before hitting $49.81. Vuzix Corporation (NASDAQ:VUZI) New Gold (NYSEAMERICAN:NGD) Identiv (NASDAQ:INVE) Cheap Stocks to Buy: Vuzix Corporation (VUZI) Source: zixia / Shutterstock.com Augmented reality is changing just about everything, which should create a sizable boon for AR stocks like Vuzix. Facebook (NASDAQ:FB), Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ:GOOGL, NASDAQ:GOOG), and Qualcomm (NASDAQ:QCOM) are just a few of the multi-billion-dollar businesses investing in AR, as well. | Similarly, ACAD has 52.19% upside from the recent share price of $39.22 if the average analyst target price of $59.69/share is reached, and analysts on average are expecting FGEN to reach a target price of $63.80/share, which is 40.62% above the recent price of $45.37. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), Acadia Pharmaceuticals Inc (Symbol: ACAD), and FibroGen Inc (Symbol: FGEN). Below is a twelve month price history chart comparing the stock performance of ICPT, ACAD, and FGEN: Combined, ICPT, ACAD, and FGEN represent 9.72% of the First Trust NYSE Arca Biotechnology Index Fund ETF. | (related: Alexion Pharmaceuticals: Good Growth But Out Of Favor) ACADIA Pharmaceuticals (ACAD) a pharma company best known for Parkinson’s disease psychosis drug is down by about -1% over the last week. Below is a bit more on the companies in our Out Of Favor Healthcare Stocks, their strengths, and relative performance NovoCure Limited (NVCR), an oncology company that uses electric fields to cure tumors, gained about 4% over the last week. BioMarin Pharmaceutical (BMRN) a biotech company focused on enzyme replacement therapies (ERTs) is up about 2% over the last week, although it remains down by about -10% year-to-date."
+2020-09-02,38.52999877929688,39.220001220703125,-1.7404666252553462,,
+2020-09-01,39.560001373291016,38.08000183105469,1.79081874712386,,
+2020-08-31,38.5,39.59000015258789,-3.7411513924657034,,
+2020-08-28,38.04999923706055,37.97999954223633,2.8311692275010145,,
+2020-08-27,37.84000015258789,37.97999954223633,-0.1839676641991607,ACAD October 9th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $37.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $38.00 strike price has a current bid of 50 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $38.00 strike highlighted in red: Considering the fact that the $38.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 9th expiration."
+2020-08-26,38.369998931884766,37.66999816894531,0.3699772438792205,,
+2020-08-25,38.290000915527344,38.369998931884766,-1.8243439729620774,,
+2020-08-24,39.02999877929688,38.0,0.20892665041692676,,
+2020-08-21,39.04999923706055,38.31999969482422,-2.6389925993111634,,
+2020-08-20,39.33000183105469,39.27000045776367,-1.8693970716996053,,
+2020-08-19,39.47999954223633,38.90999984741211,-0.15255878590790956,Acadia Pharmaceuticals Enters Oversold Territory (ACAD),"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.0, after changing hands as low as $37.87 per share. A bullish investor could look at ACAD's 28.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $23.77 per share, with $58.72 as the 52 week high point — that compares with a last trade of $38.65."
+2020-08-18,39.75,39.65999984741211,-1.4437682407124246,,
+2020-08-17,39.66999816894531,39.459999084472656,-0.2264154782085299,,
+2020-08-14,39.84999847412109,39.34999847412109,-0.5293649966362965,,
+2020-08-13,39.630001068115234,39.90999984741211,-1.2547051923344592,,
+2020-08-12,40.619998931884766,39.86000061035156,0.7065323536469728,,
+2020-08-11,41.119998931884766,40.22999954223633,-1.870995424710956,,
+2020-08-10,42.77999877929688,41.290000915527344,-2.1643954590629257,,
+2020-08-07,43.9900016784668,42.72999954223633,-3.4829310572365277,,
+2020-08-06,43.0,43.630001068115234,-2.8642920849153835,,
+2020-08-05,43.619998931884766,42.869998931884766,1.4651187630586846,,
+2020-08-04,43.060001373291016,43.52000045776367,-1.7193948151424072,,
+2020-08-03,42.08000183105469,43.27000045776367,1.0682746628010598,We Did The Math FBT Can Go To $196,"Similarly, FGEN has 54.85% upside from the recent share price of $40.47 if the average analyst target price of $62.67/share is reached, and analysts on average are expecting ACAD to reach a target price of $59.14/share, which is 42.27% above the recent price of $41.57. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intercept Pharmaceuticals Inc (Symbol: ICPT), FibroGen Inc (Symbol: FGEN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of ICPT, FGEN, and ACAD: Combined, ICPT, FGEN, and ACAD represent 9.22% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2020-07-31,42.43000030517578,41.56999969482422,2.8279433814824015,,
+2020-07-30,42.27000045776367,42.4900016784668,-2.026869206141995,September 11th Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $42.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $42.50 strike price has a current bid of $1.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $42.50 strike highlighted in red: Considering the fact that the $42.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the September 11th expiration."
+2020-07-29,43.52999877929688,42.52999877929688,0.5204665680639179,,
+2020-07-28,44.2400016784668,43.150001525878906,-2.297266317580523,,
+2020-07-27,43.66999816894531,44.33000183105469,-2.4638338861511233,,
+2020-07-24,43.20000076293945,43.459999084472656,1.5113434618339827,,
+2020-07-23,42.95000076293945,43.75,0.6018479558830269,,
+2020-07-22,44.880001068115234,42.91999816894531,1.8626291568098117,,
+2020-07-21,47.5,44.68999862670898,-4.367207781914238,"Tuesday's ETF Movers: XOP, FBT | Tuesday Sector Laggards: Biotechnology, Drugs | ACAD Crosses Below Key Moving Average Level | BUZZ-U.S. STOCKS ON THE MOVE-Tailored Brands, Philip Morris, JanOne Inc | BUZZ-U.S. STOCKS ON THE MOVE-Coca-Cola Co, Lockheed Martin, Acadia Pharma | BUZZ-U.S. STOCKS ON THE MOVE-Ebay Inc, Chevron Corp, Novavax | AZN's COVID-19 Vaccine Shows Strong Responses, ACAD Fails CLARITY Study, BTAI Hits New High","Among components of that ETF with the weakest showing on Tuesday were shares of Acadia Pharmaceuticals, lower by about 18.8%, and shares of Alnylam Pharmaceuticals, lower by about 4.3% on the day. In trading on Tuesday, the SPDR— S&P— Oil & Gas Exploration & Production ETF is outperforming other ETFs, up about 7.9% on the day. And underperforming other ETFs today is the First Trust NYSE Arca Biotechnology Index Fund ETF, down about 2% in Tuesday afternoon trading. | Also lagging the market Tuesday are drugs shares, down on the day by about 0.7% as a group, led down by Acadia Pharmaceuticals, trading lower by about 18.8% and Dynavax Technologies, trading lower by about 14.4%. In trading on Tuesday, biotechnology shares were relative laggards, down on the day by about 1.2%. VIDEO: Tuesday Sector Laggards: Biotechnology, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $44.98, changing hands as low as $44.60 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $21.56 per share, with $58.72 as the 52 week high point — that compares with a last trade of $45.03. Acadia Pharmaceuticals Inc shares are currently trading down about 18.7% on the day. | The top three S&P 500 .PG.INX percentage gainers: ** Occidental Petroleum Corp , up 13.3% ** Devon Energy Corp , up 12.2% ** Apache Corp , up 10.7% The top three S&P 500 .PL.INX percentage losers: ** FirstEnergy Corp , down 6.7% ** EBay Inc , down 3.3% ** Vertex Pharmaceuticals Inc , down 3.3% The top three NYSE .PG.N percentage gainers: ** Owens & Minor Inc , up 66.4% ** Arlo Tchnologies Inc , up 33.1% ** Northern Dynasty Minerals Ltd , up 18.1% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality AHT.N, down 17.5% ** Protalix BioTherapeutics Inc , down 9.8% ** Aim ImmunoTech Inc , down 9.8% The top three Nasdaq .PG.O percentage gainers: ** Midatech Pharma PLC , up 250% ** Immuron Ltd Ads IMRN.O, up 56.1% ** New Age Beverages Corp , up 48.2% The top three Nasdaq .PL.O percentage losers: ** Acadia Pharmaceuticals Inc , down 18.6% ** Heat Biologics Inc , down 17.7% ** PDS Biotechnology Corp , down 16% ** Prologis Inc PLD.N: up 4.2% BUZZ-Rises after lifting 2020 profit forecast ** Chevron Corp CVX.N: up 6.6% BUZZ-Street View: Chevron gets a steal with Noble deal ** Novavax Inc NVAX.O: up 2.5% BUZZ-Rises ahead of update on COVID-19 vaccine candidate ** International Business Machines Corp IBM.N: up 0.7% BUZZ-Street View: Digital transformation to lead the way for IBM ** Signature Bank SBNY.O: up 3.3% BUZZ-Signature Bank set to snap 3-day losing streak ** Halliburton Co HAL.N: up 9.8% BUZZ-Street View: Halliburton's cost control, digitalization likely to support margins ** Owens & Minor Inc OMI.N: up 66.4% BUZZ-Jumps after raising FY profit forecast on strong demand ** Lexicon Pharma LXRX.O: up 4.8% BUZZ-Surges as diabetes drug meets main goals in late-stage trials ** Lockheed Martin Corp LMT.N: up 2.4% BUZZ-Jumps after lifting 2020 profit forecast ** Acadia Pharmaceuticals Inc ACAD.O: down 18.6% BUZZ-Down after antipsychotic drug fails depression study ** Coca-Cola Co KO.N: up 2.3% BUZZ-Rises on profit beat, recovering demand ** Tapestry Inc TPR.N: up 3.0% BUZZ-Rises as investors look past CEO exit to upbeat Q4 comments ** Albertsons Companies Inc ACI.N: up 1.2% BUZZ-Climbs above IPO price amid wave of bullish initiations ** Moleculin Biotech MBRX.O: up 16.8% BUZZ-Rises as potential COVID-19 drug shows promise in lab test ** Philip Morris International Inc PM.N: up 4.8% BUZZ-Rises after upbeat Q2 earnings ** Zions Bancorporation ZION.O: up 3.7% BUZZ-Shares climb after quarterly report ** BioNTech BNTX.O: up 4.9% BUZZ-Rises on proposed public offerings ** Tesla Inc TSLA.O: down 1.3% BUZZ-JMP downgrades Tesla on challenging additional returns from stock ** Tailored Brands Inc TLRD.N: up 5.8% BUZZ-Rises on plan to cut jobs, shut stores ** Gilead Sciences Inc GILD.O: down 1.4% BUZZ-Dips as Jefferies expects COVID-19 hit to Q2 results ** First Choice Bancorp FCBP.O: up 1.5% BUZZ-Rises on Q2 profit jump, decline in bad loans ** Tractor Supply Co TSCO.O: down 1.1% BUZZ-Dips as Oppenheimer says shares 'priced for perfection', downgrades ** JanOne Inc JAN.O: up 6.9% BUZZ-Up as FDA nod paves way for trials on artery disease drug The 11 major S&P 500 sectors: Communication Services up 0.15% Consumer Discretionary down 0.23% Consumer Staples | The top three S&P 500 .PG.INX percentage gainers: ** Devon Energy Corp DVN.N, up 6.2% ** Halliburton Co HAL.N, up 6% ** Diamondback Energy Inc FANG.OQ, up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Tractor Supply Co TSCO.OQ, down 2.4% ** Regeneron Pharmaceuticals Inc REGN.OQ, down 2.3% ** ServiceNow Inc NOW.N, down 2.3% The top three NYSE .PG.N percentage gainers: ** Endeavour Silver Corp EXK.N, up 12% ** Americas Gold and Silver Corporation USAS.N, up 11.7% ** Guess Inc GES.N, up 11.6% The top three NYSE .PL.N percentage losers: ** Ashford Hospitality Trust Inc AHT.N, down 14.9% ** Amira Nature Foods Ltd RYCE.K, down 10.3% ** Emergent Biosolutions Inc EBS.N, down 7.6% The top three Nasdaq .PG.O percentage gainers: ** Midatech Pharma MTP.O, up 145.3% ** Immuron Ltd IMRN.O, up 80.1% ** New Age Beverages Corp NBEV.O, up 51.7% The top three Nasdaq .PL.O percentage losers: ** Acadia Pharmaceuticals Inc ACAD.O, down 16.2% ** Cytosorbents Corp CTSO.O, down 15.8% ** Biofrontera AG BFRA.O, down 14.6% ** Ebay Inc EBAY.O: up 0.8% BUZZ-Shares rise after $9.2 bln deal with Adevinta ** Chevron Corp CVX.N: up 2.2% BUZZ-Street View: Chevron gets a steal with Noble deal ** Novavax Inc NVAX.O: up 0.5% BUZZ-Rises ahead of update on COVID-19 vaccine candidate ** International Business Machines Corp IBM.N: up 2.9% BUZZ-Street View: Digital transformation to lead the way for IBM ** Signature Bank SBNY.O: up 6.7% BUZZ-Signature Bank set to snap 3-day losing streak ** Halliburton Co HAL.N: up 5.9% BUZZ-Street View: Halliburton's cost control, digitalization likely to support margins ** Owens & Minor Inc OMI.N: up 29.7% BUZZ-Jumps after raising FY profit forecast on strong demand ** Lexicon Pharma LXRX.O: up 24.2% BUZZ-Surges as diabetes drug meets main goals in late-stage trials ** Lockheed Martin Corp LMT.N: up 2.3% BUZZ-Jumps after lifting 2020 profit forecast ** Acadia Pharmaceuticals Inc ACAD.O: down 16.2% BUZZ-Down after antipsychotic drug fails depression study ** Coca-Cola Co KO.N: up 3.6% BUZZ-Rises on profit beat, recovering demand ** Tapestry Inc TPR.N: up 3.4% BUZZ-Rises as investors look past CEO exit to upbeat Q4 comments ** Albertsons Companies Inc ACI.N: up 2.6% BUZZ-Climbs above IPO price amid wave of bullish initiations ** Moleculin Biotech MBRX.O: up 27.3% BUZZ-Rises as potential COVID-19 drug shows promise in lab test The 11 major S&P 500 sectors: Communication Services ET, the Dow Jones Industrial Average .DJI was up 0.89% at 26,919.02. up 0.28% Consumer Discretionary | The top three NYSE percentage gainers premarket .PRPG.NQ: ** Qudian Inc , up 7.1% ** Endeavour Silver Corp , up 7.0% ** Sasol Ltd , up 6.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Just Energy Group Inc , down 7.4% ** Party City Holdco Inc , down 11.5% ** Denbury Resources Inc , down 7.9% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Immuron Ltd , up 106.3% ** Midatech Pharma PLC , up 93.5% ** New Age Beverages Corp , up 81.1% The top three Nasdaq percentage losers premarket .PRPL.O: ** Bio-Key International Inc , down 28% ** Cytosorbents Corp , down 14.2% ** Acadia Pharmaceuticals Inc , down 12.3% ** Ebay Inc EBAY.O: up 2.4% premarket BUZZ-Shares rise after $9.2 bln deal with Adevinta ** Chevron Corp CVX.N: up 1.4% premarket BUZZ-Street View: Chevron gets a steal with Noble deal ** Novavax Inc NVAX.O: up 5.4% premarket BUZZ-Rises ahead of update on COVID-19 vaccine candidate (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rose on Tuesday after a better-than-expected quarterly profit from IBM and on hopes for more domestic stimulus to prop up an economy reeling from the COVID-19 pandemic. S&P 500 e-minis ESc1 were up 0.72% at 3,268.5, while Nasdaq 100 e-minis NQc1 were up 0.84% at 11,042.5. | (RTTNews) - Today's Daily Dose brings you news about disappointing results from ACADIA's major depressive disorder drug trial, AstraZeneca's promising results of COVID-19 vaccine candidate, BioXcel Therapeutics' SERENITY program, Immuron's update on its new therapeutic against campylobacter and ETEC (E-Coli) and very encouraging results of Synairgen's SNG001 in hospitalized COVID-19 patients. ACADIA Fails CLARITY Study Shares of ACADIA Pharmaceuticals Inc. (ACAD) fell more than 12% to $48.57 in after-hours on Monday, following disappointing results from a phase III program of Pimavanserin, dubbed CLARITY. ACAD closed Monday's trading at $55.42, up 0.82%."
+2020-07-20,55.29999923706055,55.41999816894531,-5.915792364823206,U.S. FDA accepts Acadia's application for dementia drug | Acadia's Pimavanserin Misses Primary Endpoint In Phase 3 Trial,"July 20 (Reuters) - The U.S. Food and Drug Administration on Monday accepted Acadia Pharmaceuticals Inc's ACAD.O application for an antipsychotic drug to treat dementia patients with hallucinations and delusions. In June, Acadia submitted a supplemental new drug application (sNDA) for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis, which affects about 30% of all patients with dementia in the United States, the company said. Separately, Acadia said top-line results from a late-stage study of the same drug as an adjunctive treatment for major depressive disorder (MDD) did not achieve statistical significance on its main goal, adding that it would not pursue additional studies. | (RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) Monday said a late stage study evaluating treatment of depressive disorder didn't achieve primary endpoint. Separately, Acadia announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application for Nuplazid for the treatment of hallucinations and delusions associated with dementia-related psychosis. ""We observed a consistent improvement of depressive symptoms over time with pimavanserin but, unfortunately, the robust positive results from our CLARITY-1 study were not replicated,"" said Serge Stankovic, ACADIA's President."
+2020-07-17,54.93000030517578,54.970001220703125,0.21699626318321105,,
+2020-07-16,54.84999847412109,54.58000183105469,0.07282161897890006,,
+2020-07-15,54.5,55.130001068115234,-0.4922454887465256,,
+2020-07-14,52.400001525878906,53.720001220703125,1.1559652625967602,,
+2020-07-13,56.08000183105469,52.31999969482422,2.5190833137138506,First Week of August 21st Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $45.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $60.00 strike price has a current bid of $2.65. Below is a chart showing ACAD's trailing twelve month trading history, with the $60.00 strike highlighted in red: Considering the fact that the $60.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the August 21st expiration."
+2020-07-10,56.02000045776367,55.45000076293945,-6.704711150969224,,
+2020-07-09,56.5,56.06999969482422,-1.0174931991547742,,
+2020-07-08,57.34000015258789,56.400001525878906,-0.761062487036781,,
+2020-07-07,55.54999923706055,57.0,-1.6393418629360783,,
+2020-07-06,52.77000045776367,53.68999862670898,2.610262435381053,,
+2020-07-02,50.90999984741211,51.61000061035156,1.7434113340242592,August 14th Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $50.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $55.00 strike price has a current bid of $2.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $55.00 strike highlighted in red: Considering the fact that the $55.00 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the August 14th expiration."
+2020-07-01,48.77000045776367,50.290000915527344,1.374976949592421,,
+2020-06-30,48.5,48.470001220703125,3.1166709934317907,,
+2020-06-29,48.93999862670898,48.15999984741211,-0.061853153189432984,,
+2020-06-26,51.470001220703125,47.93000030517578,-1.593785862656694,,
+2020-06-25,51.41999816894531,50.18999862670898,-6.877794504701557,,
+2020-06-24,52.77000045776367,52.02000045776367,-2.3920645391605313,2 Biotech Stocks With Major Incoming Catalysts,"Acadia Pharmaceuticals: Nuplazid expansion Unlike Y-mAbs, Acadia Pharmaceuticals already has a drug approved for sale. Acadia's operations are already close to generating positive cash flows with Nuplazid as a treatment for the limited Parkinson's disease population, and it looks like the market hasn't priced in an unreasonable amount of success as a treatment for the much larger population of people with DRP. Luckily, companies such as Acadia Pharmaceuticals (NASDAQ: ACAD) Y-mAbs (NASDAQ: YMAB) have major catalysts unrelated to COVID-19 in their near term future."
+2020-06-23,52.56999969482422,52.72999954223633,-1.4212620683986708,,
+2020-06-22,51.790000915527344,52.31999969482422,0.3043558081432939,,
+2020-06-19,49.90999984741211,52.02999877929688,1.0233612085879964,,
+2020-06-18,46.93000030517578,49.31999969482422,4.247643635275821,,
+2020-06-17,47.84000015258789,47.11999893188477,5.092689908601708,3 “Strong Buy” Healthcare Stocks That Should Remain Healthy,"(See LH stock analysis on TipRanks) ACADIA Pharmaceuticals (ACAD) Last on our list is ACADIA, a biopharmaceutical company that designs medications for central nervous system disorders. ACADIA has developed the only approved therapy for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, NUPLAZID. (See ACADIA stock-price forecast on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights."
+2020-06-16,47.5099983215332,47.34000015258789,-1.5050192692446502,,
+2020-06-15,44.900001525878906,46.4900016784668,-0.3578155650413133,,
+2020-06-12,46.0,45.84999847412109,3.541202892101164,,
+2020-06-11,46.34999847412109,45.18999862670898,-0.32609027364981163,,
+2020-06-10,47.91999816894531,47.02000045776367,-2.5026966248117137,,
+2020-06-09,46.81999969482422,47.4900016784668,-1.878125512460655,,
+2020-06-08,45.45000076293945,46.81000137329102,1.431016633937835,,
+2020-06-05,45.77999877929688,45.61000061035156,2.9923005226009427,,
+2020-06-04,46.54999923706055,45.75,-0.37133720724824043,Interesting ACAD Put And Call Options For July 24th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $45.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $47.50 strike price has a current bid of $2.00. Below is a chart showing ACAD's trailing twelve month trading history, with the $47.50 strike highlighted in red: Considering the fact that the $47.50 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 24th expiration."
+2020-06-03,48.27000045776367,46.9000015258789,-1.7185805589092933,,
+2020-06-02,49.0099983215332,48.02000045776367,-2.8381995419360395,Is Acadia Pharmaceuticals a Buy?,"In its first-quarter earnings report, released May 7, Acadia reported revenue of $90.1 million, a 43% increase year over year, and posted a net loss of $88 million, or $0.57 per share. CEO Steve Davis noted that Acadia sees ""continued growth in Nuplazid this year, and we remain confident in driving the long-term market opportunity in PDP."" 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
+2020-06-01,49.47000122070313,48.88999938964844,-2.0199916296152214,,
+2020-05-29,51.0099983215332,49.68000030517578,-1.1724314063933448,Now’s the Time to Buy These 3 Stocks,"Acadia Pharmaceuticals Among the ranks of specialty drug developers, Acadia Pharmaceuticals (NASDAQ: ACAD) continues to shine. This week Acadia updated investors following discussions with the Food and Drug Administration that it will stop enrollment early from two parallel pivotal trials for Nuplazid as a treatment for major depressive disorder (MDD). If positive, Acadia plans to submit those data along, with prior clinical trial results, to support an FDA submission for approval in treating MDD."
+2020-05-28,51.09999847412109,50.68999862670898,-2.6073280927672187,ACAD July 10th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $50.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $52.00 strike price has a current bid of $1.90. Below is a chart showing ACAD's trailing twelve month trading history, with the $52.00 strike highlighted in red: Considering the fact that the $52.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 10th expiration."
+2020-05-27,51.58000183105469,50.63000106811523,-0.8023480619471023,,
+2020-05-26,51.93999862670898,51.16999816894531,-1.8418005607116803,,
+2020-05-22,51.59000015258789,51.2400016784668,-1.4824807048949542,,
+2020-05-21,52.58000183105469,51.56999969482422,-0.6784230918509445,Interesting ACAD Put And Call Options For July 2nd,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $51.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $52.50 strike price has a current bid of $2.20. Below is a chart showing ACAD's trailing twelve month trading history, with the $52.50 strike highlighted in red: Considering the fact that the $52.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 2nd expiration."
+2020-05-20,51.45000076293945,52.54999923706055,-1.9208864607417024,,
+2020-05-19,51.93000030517578,51.040000915527344,2.1379950589105654,Is Amarin Stock a Buy?,"With a price-to-book-value ratio of 5, Amarin is undervalued compared with its peers, including Acadia Pharmaceuticals (12.4) and Sarepta Therapeutics (9.6). Amarin's P/S is 5.3, much lower than Acadia's at 20.8 and Sarepta's at 25.9. Increased sales and prescriptions As mentioned, Amarin's first quarter was a success, with increased revenue and gross margins from sales of Vascepa in the U.S."
+2020-05-18,51.45000076293945,52.06000137329102,-1.713844375925668,,
+2020-05-15,47.45000076293945,50.83000183105469,1.1856182727036346,,
+2020-05-14,45.33000183105469,47.36000061035156,7.123289807732025,,
+2020-05-13,49.88999938964844,46.02000045776367,4.4782675872432085,,
+2020-05-12,51.27000045776367,49.36999893188477,-7.7570634981561915,,
+2020-05-11,50.209999084472656,50.88999938964844,-3.705873822732114,,
+2020-05-08,49.75,50.72000122070313,1.3543125225550343,Acadia Pharmaceuticals (ACAD) Q1 2020 Earnings Call Transcript,"Operator [Operator signoff] Duration: 73 minutes Call participants: Mark Johnson -- Vice President of Investor Relations Steve Davis -- Chief Executive Officer Michael Yang -- Commercial Performance and Highlights Serge Stankovic -- President Elena Ridloff -- Chief Financial Officer Cory Kasimov -- J.P. Morgan -- Analyst Neena Bitritto -- Citi -- Analyst Joey Stringer -- Needham and Company -- Analyst Tazeen Ahmad -- Bank of America Merrill Lynch -- Analyst Marc Goodman -- SVB Leerink -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Ritu Baral -- Cowen and Company -- Analyst Salveen Richter -- Goldman Sachs -- Analyst Chris Howerton -- Jefferies -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals (NASDAQ: ACAD) Q1 2020 Earnings Call May 07, 2020, 4:30 p.m. Operator Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals' first-quarter 2020 financial results conference call."
+2020-05-07,49.59000015258789,49.34000015258789,1.9497511973932304,,
+2020-05-06,47.959999084472656,48.18000030517578,-0.5041338964120845,,
+2020-05-05,46.86999893188477,47.38000106811523,0.45871815033948105,,
+2020-05-04,44.52000045776367,46.59000015258789,1.0881206482885362,,
+2020-05-01,47.36999893188477,44.93000030517578,4.649594954043266,,
+2020-04-30,49.209999084472656,48.31000137329102,-5.150936630202512,,
+2020-04-29,51.5,50.7599983215332,-1.8288919486397874,,
+2020-04-28,51.88999938964844,50.63999938964844,-1.4368964630423242,10 Stocks to Buy for an Aging Population,"Teladoc Health (NYSE:TDOC) Biogen (NASDAQ:BIIB) Acadia Pharmaceuticals (NASDAQ:ACAD) Hillrom (NYSE:HRC) Ventas (NYSE:VTR) Amedisys (NASDAQ:AMED) UnitedHealth (NYSE:UNH) Boyd Gaming (NYSE:BYD) Thor Industries (NYSE:THO) Royal Caribbean (NYSE:RCL) Good or bad, these 10 stocks to buy have a big part to play in an aging population. Acadia Pharmaceuticals (ACAD) ACAD)"" width=""300"" height=""169""> Source: Shutterstock In April 2016, Acadia Pharmaceuticals’ drug Nuplazid, which is used to treat patients with Parkinson’s who are suffering from hallucinations and delusions, was approved for commercial use by the FDA. In December, Acadia reported positive results from its Stage III clinical trial that showed patients in the trial on Nuplazid were three times less likely to see a relapse in their psychosis than those on the placebo."
+2020-04-27,51.91999816894531,51.88999938964844,-2.408942021011785,,
+2020-04-24,49.75,50.93000030517578,-0.057778852763554295,,
+2020-04-23,49.65999984741211,49.13999938964844,2.371859909901068,,
+2020-04-22,49.0,49.40999984741211,-1.0471213438611604,,
+2020-04-21,48.9900016784668,47.84000015258789,0.8367343824736926,,
+2020-04-20,49.0,49.72999954223633,-2.3474208746238543,,
+2020-04-17,47.52000045776367,48.9000015258789,1.4897949841557716,,
+2020-04-16,46.08000183105469,46.54999923706055,2.9040426237827757,,
+2020-04-15,44.560001373291016,45.18999862670898,1.0199596079206623,,
+2020-04-14,43.5,44.93000030517578,1.4138178500945426,,
+2020-04-13,42.959999084472656,42.84999847412109,3.287357023392601,,
+2020-04-09,43.22000122070313,43.79999923706055,-0.256053567727677,,
+2020-04-08,42.2400016784668,42.79999923706055,1.3419666820360607,,
+2020-04-07,44.0,41.709999084472656,1.325751743232593,,
+2020-04-06,42.0,43.290000915527344,-5.204547535289417,,
+2020-04-03,40.93999862670898,40.7599983215332,3.0714307512555803,,
+2020-04-02,38.810001373291016,41.68000030517578,-0.4396685667164218,,
+2020-04-01,40.95000076293945,39.2599983215332,7.3949982744909,,
+2020-03-31,43.52000045776367,42.25,-4.1269900120142,Implied RXL Analyst Target Price: $112,"Similarly, XRAY has 37.12% upside from the recent share price of $39.20 if the average analyst target price of $53.75/share is reached, and analysts on average are expecting ACAD to reach a target price of $55.36/share, which is 33.97% above the recent price of $41.32. Three of RXL's underlying holdings with notable upside to their analyst target prices are Globus Medical Inc (Symbol: GMED), DENTSPLY SIRONA Inc (Symbol: XRAY), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of GMED, XRAY, and ACAD: Below is a summary table of the current analyst target prices discussed above:"
+2020-03-30,39.02999877929688,41.31999969482422,-2.918199550563452,,
+2020-03-27,38.61000061035156,38.83000183105469,5.867284107480033,,
+2020-03-26,38.31999969482422,39.52000045776367,0.5698037224172988,,
+2020-03-25,37.88999938964844,38.060001373291016,3.1315260242591654,,
+2020-03-24,36.25,38.060001373291016,0.4486724370046381,,
+2020-03-23,33.79999923706055,35.0,4.99310723666487,,
+2020-03-20,34.77000045776367,33.369998931884766,3.5502981953434287,,
+2020-03-19,33.540000915527344,34.7599983215332,-4.026463927084317,,
+2020-03-18,33.439998626708984,33.209999084472656,3.637439990173231,,
+2020-03-17,32.040000915527344,34.380001068115234,-0.6877977023977039,,
+2020-03-16,31.38999938964844,31.64999961853028,7.303371054068451,,
+2020-03-13,37.130001068115234,35.630001068115234,0.828290009357504,Interesting ACAD Put And Call Options For May 1st,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $33.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $36.00 strike price has a current bid of $3.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $36.00 strike highlighted in red: Considering the fact that the $36.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the May 1st expiration."
+2020-03-12,34.2599983215332,35.38999938964844,-4.039859835307411,This 1 Stock Is a Good Buy During the Coronavirus Sell-Off,"Primary: Significantly reduced the risk of relapse of psychosis by 2.8-fold Secondary: Significantly reduced the risk of discontinuing the drug by 2.2-fold If the drug application is approved by the U.S. Food and Drug Administration (FDA) later this year, Nuplazid for treatment of DRP will generate more profit for Acadia -- and likely stock-price growth for investors. Biopharma company Acadia Pharmaceuticals (NASDAQ: ACAD) saw its stock price rise by more than 164% in 2019, outperforming both the Virtus LifeSci Biotech Clinical Trials ETF (up 64%) and the S&P 500 (up 29%). To understand whether this stock is a great long-term investment at this price, let's briefly review the company's recent earnings, Nuplazid's growth prospects, and Acadia's strategic goals for 2020."
+2020-03-11,39.790000915527344,36.869998931884766,3.298310342896318,,
+2020-03-10,40.27000045776367,41.0099983215332,-7.3385320845848465,,
+2020-03-09,39.0,39.31999969482422,1.837590899820481,,
+2020-03-06,43.43999862670898,41.90999984741211,0.8205120380108174,6 Quality Biotech Stocks on Sale Now,"See the 10 stocks *Stock Advisor returns as of December 1, 2019 David Haen owns shares of Acadia Pharmaceuticals, Amarin, Exact Sciences, Exelixis, and Seattle Genetics. Acadia Pharmaceuticals Acadia Pharmaceuticals (NASDAQ: ACAD) markets Nuplazid, a treatment for hallucinations and delusions associated with Parkinson's disease psychosis. Acadia reported $339.1 million in revenues for Nuplazid in 2019, a 52% increase over the prior year."
+2020-03-05,43.5,44.38999938964844,-3.522096748769582,,
+2020-03-04,42.7599983215332,44.52999877929688,2.045975608387213,,
+2020-03-03,43.540000915527344,41.97999954223633,4.139383833587143,First Week of April 9th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $40.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $43.50 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $43.50 strike highlighted in red: Considering the fact that the $43.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 9th expiration."
+2020-03-02,42.709999084472656,43.7599983215332,-3.5829153433358885,,
+2020-02-28,37.83000183105469,42.7400016784668,2.458438912592431,,
+2020-02-27,39.5,39.09999847412109,12.979116071259309,Acadia Pharmaceuticals (ACAD) Q4 2019 Earnings Call Transcript,"In closing, we expect 2020 to be another great year for Acadia, as we drive continued growth in the net sales of Nuplazid in PDP, deliver the DRP opportunity to the market with a potential approval around year-end and develop new and innovative treatments with our ongoing and planned pivotal studies. Operator [Operator signoff] Duration: 65 minutes Call participants: Mark Johnson -- Vice President of Investor Relations Steve Davis -- Chief Executive Officer Michael Yang -- Chief Commercial Officer Serge Stankovic -- President Elena Ridloff -- Chief Financial Officer Ritu Baral -- Cowen and Company -- Analyst Tazeen Ahmad -- Bank of America Merrill Lynch -- Analyst Marc Goodman -- SVB Leerink -- Analyst Unknown speaker Charles Duncan -- Cantor Fitzgerald -- Analyst Jason Butler -- JMP Securities -- Analyst Gregory Renza -- RBC Capital Markets -- Analyst Jay Olson -- Oppenheimer and Company -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals (NASDAQ: ACAD) Q4 2019 Earnings Call Feb 26, 2020, 5:00 p.m."
+2020-02-26,40.93000030517578,40.220001220703125,-1.012662090832692,,
+2020-02-25,42.47999954223633,40.66999816894531,-1.734666697236437,"Notable Tuesday Option Activity: ACAD, KNX, EXPE","Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 10,220 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (given that every 1 contract represents 100 underlying shares). Below is a chart showing ACAD's trailing twelve month trading history, with the $36 strike highlighted in orange: Knight-Swift Transportation Holdings Inc (Symbol: KNX) saw options trading volume of 15,004 contracts, representing approximately 1.5 million underlying shares or approximately 90.2% of KNX's average daily trading volume over the past month, of 1.7 million shares. That number works out to 94.1% of ACAD's average daily trading volume over the past month, of 1.1 million shares."
+2020-02-24,43.93000030517578,42.25,-4.260831903944341,,
+2020-02-21,44.77000045776367,45.130001068115234,-3.8242665456522786,,
+2020-02-20,45.52000045776367,44.83000183105469,0.8041112501019283,,
+2020-02-19,45.560001373291016,45.84000015258789,-1.5158141910591778,,
+2020-02-18,46.08000183105469,45.43999862670898,0.6145714900285776,,
+2020-02-14,46.43000030517578,46.09000015258789,-1.3888957875743682,,
+2020-02-13,44.959999084472656,46.869998931884766,-0.732285484284154,"Noteworthy Thursday Option Activity: AVGO, ACAD, GDDY","Below is a chart showing AVGO's trailing twelve month trading history, with the $330 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 4,767 contracts, representing approximately 476,700 underlying shares or approximately 42.5% of ACAD's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing ACAD's trailing twelve month trading history, with the $47 strike highlighted in orange: And GoDaddy Inc (Symbol: GDDY) saw options trading volume of 4,719 contracts, representing approximately 471,900 underlying shares or approximately 42.1% of GDDY's average daily trading volume over the past month, of 1.1 million shares. Especially high volume was seen for the $47 strike call option expiring February 21, 2020, with 609 contracts trading so far today, representing approximately 60,900 underlying shares of ACAD."
+2020-02-12,44.06999969482422,45.220001220703125,4.248220387690678,,
+2020-02-11,44.0,43.880001068115234,2.6094883908382864,,
+2020-02-10,41.66999816894531,43.4900016784668,-0.2727248451926491,,
+2020-02-07,41.91999816894531,41.66999816894531,4.367659202053547,,
+2020-02-06,43.09999847412109,41.93999862670898,-0.5963740718509909,,
+2020-02-05,42.06999969482422,42.75,-2.6914150544775963,,
+2020-02-04,41.09999847412109,41.66999816894531,1.616354433345623,,
+2020-02-03,40.38999938964844,40.900001525878906,1.3868606228370794,,
+2020-01-31,39.880001068115234,39.93999862670898,1.262694092442045,,
+2020-01-30,39.84999847412109,39.97999954223633,0.1504452281514907,3 Top Biotech Stocks to Buy Right Now,"Acadia's annual revenue has climbed since the product was approved in 2016, and in the most recent quarter, the company said net sales of Nuplazid soared $94.6 million, up 62% from the same quarter last year. Acadia Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), and Seattle Genetics (NASDAQ: SGEN) are three companies that fit the bill. Acadia Acadia's Nuplazid is the only U.S. Food and Drug Administration-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis."
+2020-01-29,41.45000076293945,40.2400016784668,0.3262260303464384,,
+2020-01-28,40.54999923706055,41.54999923706055,-2.9191774721377555,,
+2020-01-27,38.79999923706055,40.43000030517578,2.4660912917750513,,
+2020-01-24,40.88999938964844,39.34000015258789,4.201033763315923,,
+2020-01-23,42.0,40.790000915527344,-3.790656053306127,Interesting ACAD Put And Call Options For March 6th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $37.50 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $46.50 strike price has a current bid of 70 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $46.50 strike highlighted in red: Considering the fact that the $46.50 strike represents an approximate 13% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 6th expiration."
+2020-01-22,43.5099983215332,42.15999984741211,-2.8809502011253723,,
+2020-01-21,43.0099983215332,43.369998931884766,-3.102731616178841,,
+2020-01-17,44.93000030517578,43.43000030517578,0.837016099513136,Acadia Pharmaceuticals Larger Than S&P 500 Component Flowserve Corp | 2 Biotech Stocks to Watch In 2020,"In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Flowserve Corp (Symbol: FLS), according to The Online Investor. Below is a three month price history chart comparing the stock performance of ACAD vs. FLS: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers — much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $6.69B, versus Flowserve Corp (Symbol: FLS) at $6.61B. | It's hard to tell, but if you are interested in investing in biotech stocks, here are two companies you should keep an eye on: Acadia Pharmaceuticals (NASDAQ: ACAD) and CRISPR Therapeutics (NASDAQ: CRSP). Acadia only has one drug on the market, a medicine called Nuplazid, which treats hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Second, Acadia is looking to add a new indication to Nuplazid."
+2020-01-16,45.5,44.560001373291016,-3.338526574252449,,
+2020-01-15,44.02999877929688,45.400001525878906,-2.0659310477120534,,
+2020-01-14,41.77000045776367,44.04999923706055,3.111521200464366,AstraZeneca’s Loss is Amarin’s Big Gain This Year,"By comparison, Acadia Pharmaceuticals (NASDAQ:) more than doubled in 2019. The question is whether the news is enough to push its stock to $30 in 2020. Here are the arguments for and against AMRN hitting the $30 target by Christmas. Amarin Stock Will Hit $30 In December, I discussed how could be willing to pay as much as $56 a share, or $20 billion, for Amarin’s stock. In the meantime, with sales growing at 75%-100% a year, it will take Amarin three or four years to hit an estimated peak of $4 billion in sales. In four years, this growth rate could make $56 look like a rounding error."
+2020-01-13,45.38999938964844,41.79999923706055,5.458460029470979,,
+2020-01-10,45.65999984741211,45.2400016784668,-7.909231550698411,,
+2020-01-09,44.40999984741211,45.58000183105469,-0.9198383056260936,ACAD February 28th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $42.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $51.50 strike price has a current bid of $1.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $51.50 strike highlighted in red: Considering the fact that the $51.50 strike represents an approximate 13% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the February 28th expiration."
+2020-01-08,42.27999877929688,44.40999984741211,2.634546245581123,,
+2020-01-07,42.619998931884766,42.18000030517578,5.037845623491878,The 10 Best Healthcare Stocks of the Decade | Where Will GW Pharmaceuticals Be in 5 Years?,"Neurocrine Biosciences $2.77 $109.78 3,863% ACADIA Pharmaceuticals $1.32 $40.35 2,956% Exact Sciences $3.50 $94.94 2,612% DexCom $8.21 $218.70 2,563% Repligen $4.17 $92.74 2,123% Simulations Plus $1.37 $28.79 2,001% Accelerate Diagnostics $0.89 $17.03 1,813% NeoGenomics $1.55 $29.31 1,790% Abiomed $8.86 $166.82 1,782% Jazz Pharmaceuticals $8.06 $145.10 1,700% It's been a pretty amazing decade for healthcare stocks. ACADIA Pharmaceuticals (up 2,956%) ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biotech that is focused on disorders of the central nervous system. The company provides simulation software and services to drug companies to help with drug discovery and development. | If GW's Board felt it needed a sizable merger to bolster its prospects, then perhaps CNS-focused biotechs like Acadia Pharmaceuticals (NASDAQ: ACAD), Neurocrine Therapeutics (NASDAQ: NBIX), or Sage Therapeutics (NASDAQ: SAGE) could fit the bill. See the 10 stocks *Stock Advisor returns as of December 1, 2019 David Haen owns shares of Acadia Pharmaceuticals. Epidiolex, GW's first drug to attain U.S. Food and Drug Administration (FDA) approval, launched into the market in November 2018 as a treatment for two rare forms of childhood-onset epilepsy."
+2020-01-06,39.97999954223633,42.810001373291016,-1.0323759684090787,,
+2020-01-03,40.7400016784668,40.34999847412109,7.07854393060953,,
+2020-01-02,42.869998931884766,41.11000061035156,-0.9572979584628912,,
+2019-12-31,43.0,42.77999877929688,-4.105431223195566,,
+2019-12-30,44.02999877929688,43.15999984741211,-0.5116307458212044,,
+2019-12-27,45.36000061035156,43.970001220703125,-1.9759231342378563,,
+2019-12-26,45.45000076293945,45.04999923706055,-3.0643725109016575,,
+2019-12-24,44.630001068115234,45.45000076293945,-0.8800913512966823,2 Biotech Stocks Poised to Soar in 2020,"10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Acadia Pharmaceuticals (NASDAQ: ACAD) and Axsome Therapeutics (NASDAQ: AXSM) both check this all-important box. The case for Acadia Acadia's shares have nearly quadrupled in value in 2019."
+2019-12-23,45.27999877929688,44.56999969482422,1.8373284230325655,,
+2019-12-20,43.709999084472656,45.18999862670898,-1.5680192217613138,,
+2019-12-19,43.459999084472656,43.630001068115234,3.385951894842454,,
+2019-12-18,46.18999862670898,43.43999862670898,0.3911688615366682,,
+2019-12-17,46.20000076293945,46.119998931884766,-5.953669802470692,,
+2019-12-16,45.2400016784668,46.060001373291016,-0.17316413362240263,,
+2019-12-13,44.75,44.34000015258789,1.812554519012142,,
+2019-12-12,45.06999969482422,44.52000045776367,-0.9162007763399092,Analysts Expect FBT Will Reach $179,"Similarly, NKTR has 28.70% upside from the recent share price of $21.60 if the average analyst target price of $27.80/share is reached, and analysts on average are expecting ACAD to reach a target price of $54.42/share, which is 20.90% above the recent price of $45.01. Three of FBT's underlying holdings with notable upside to their analyst target prices are Sarepta Therapeutics Inc (Symbol: SRPT), Nektar Therapeutics (Symbol: NKTR), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of SRPT, NKTR, and ACAD: Combined, SRPT, NKTR, and ACAD represent 10.36% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2019-12-11,46.15999984741211,45.0099983215332,-1.2203222560121474,,
+2019-12-10,47.88999938964844,46.2599983215332,-2.4913378026004898,,
+2019-12-09,51.130001068115234,47.93000030517578,-3.4036356001031063,,
+2019-12-06,50.5099983215332,51.400001525878906,-6.2585579817931585,Save Yourself the Migraine and Buy This 1 Pharma Stock Now,"Acadia Pharmaceuticals (NASDAQ: ACAD) added over $1 billion in valuation following positive results on a drug to treat dementia-related psychosis. See the 10 stocks *Stock Advisor returns as of December 1, 2019 David Haen owns shares of Acadia Pharmaceuticals. Biohaven takes aim at migraines One of Biohaven's key research and development efforts centers on the development of drugs that interact with the calcitonin gene-related peptide (CGRP) receptor, which is found in a pathway that sends pain signals to the brain."
+2019-12-05,52.97999954223633,50.47999954223633,1.7620337238583532,"Health Care Sector Update for 12/05/2019: AUPH, ACAD, SAGE, JNJ, PFE, ABT, MRK, AMGN | Why Acadia Pharmaceuticals Stock Is on Fire Today","(+) ACADIA Pharmaceuticals (ACAD) was rallying nearly 20% after saying its pivotal phase 3 trial of pimavanserin in patients with dementia-related psychosis met its primary endpoint of significantly reducing the risk of relapse of psychosis by 2.8 fold. Stocks moving on news include: (+) Aurinia Pharmaceuticals (AUPH), which was surging by more than 103% amid positive results from the late-stage trial of Voclosporin, in combination with mycophenolate and low-dose corticosteroids, in the treatment of lupus nephritis. (-) Sage Therapeutics (SAGE) was plunging more than 62% as the late-stage study evaluating its drug SAGE-217 to treat major depressive disorder did not meet its primary endpoint. | 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of mid-cap drugmaker Acadia Pharmaceuticals (NASDAQ: ACAD) rose by as much as 13% in pre-market trading today. So what Earlier this year, Acadia announced that Harmony had been halted early because patients on placebo were more than twice as likely to show worsening symptoms compared to those on Nuplazid."
+2019-12-04,45.06999969482422,44.27999877929688,-4.718761837676062,"AUPH Soars On Lupus Trial Results, ACAD On Watch, ALNA Trims Workforce","Read on… ACADIA Pharmaceuticals Inc. (ACAD) is planning to meet with the FDA in the first half of 2020 regarding a supplemental NDA submission for Pimavanserin for the treatment of dementia-related psychosis. ACAD closed Wednesday's trading at $44.28, down 1.47%. (RTTNews) - Today's Daily Dose brings you news about the layoff in Allena Pharma; the positive phase III trial results of Aurinia Pharma's lupus drug; stock offerings of Millendo Therapeutics and Relmada Therapeutics."
+2019-12-03,45.66999816894531,44.93999862670898,-1.7528309759852503,,
+2019-12-02,45.54999923706055,45.77999877929688,-1.5984225344960061,7 Exciting Biotech Stocks to Buy Now,"Acadia Pharmaceuticals (ACAD) Source: Shutterstock Acadia Pharmaceuticals (NASDAQ:) focuses on central nervous system disorders. ACAD stock is up 182% year-to-date and with a $7 billion market cap, it’s still the early days. China Biologic Products (CBPO) Source: Shutterstock China Biologic Products (NASDAQ:) is one of China’s leading biotech companies."
+2019-11-29,47.02999877929688,45.290000915527344,0.5049386302715944,,
+2019-11-27,47.7599983215332,47.0,-3.699761660498925,,
+2019-11-26,47.84999847412109,47.400001525878906,-1.5912863237906527,,
+2019-11-25,47.81999969482422,47.7599983215332,-0.940432523703327,,
+2019-11-22,47.77999877929688,47.08000183105469,-0.1254733870220201,,
+2019-11-21,45.459999084472656,47.52999877929688,-1.4650417876224473,,
+2019-11-20,46.40999984741211,46.18999862670898,4.553453005966417,"Notable Wednesday Option Activity: ACAD, SPWR, ZS","Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 7,402 contracts have traded so far, representing approximately 740,200 underlying shares. That amounts to about 59.4% of ACAD's average daily trading volume over the past month of 1.2 million shares. Particularly high volume was seen for the $50 strike call option expiring December 20, 2019, with 2,032 contracts trading so far today, representing approximately 203,200 underlying shares of ACAD."
+2019-11-19,45.25,46.810001373291016,-0.4740383999708195,,
+2019-11-18,46.060001373291016,45.06999969482422,3.447516847051968,,
+2019-11-15,45.869998931884766,46.09999847412109,-2.1493739664560083,,
+2019-11-14,46.43999862670898,45.470001220703125,0.5014160618967132,,
+2019-11-13,46.040000915527344,46.40999984741211,-2.0887110996768614,,
+2019-11-12,45.52999877929688,46.33000183105469,0.80364666491564,,
+2019-11-11,42.75,45.2400016784668,1.7570899916684775,,
+2019-11-08,41.04999923706055,42.61000061035156,5.824565329746894,IYH's Holdings Imply 12% Gain Potential,"Similarly, ACAD has 28.08% upside from the recent share price of $41.20 if the average analyst target price of $52.77/share is reached, and analysts on average are expecting LIVN to reach a target price of $92.60/share, which is 26.23% above the recent price of $73.36. Below is a twelve month price history chart comparing the stock performance of AVNS, ACAD, and LIVN: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Avanos Medical Inc (Symbol: AVNS), Acadia Pharmaceuticals Inc (Symbol: ACAD), and LivaNova PLC (Symbol: LIVN)."
+2019-11-07,40.900001525878906,41.20000076293945,3.8002470213997555,,
+2019-11-06,41.7400016784668,40.9900016784668,0.733494439775819,,
+2019-11-05,42.70000076293945,41.619998931884766,-1.7968374936288434,,
+2019-11-04,43.15999984741211,42.45000076293945,-2.529278247676407,,
+2019-11-01,42.869998931884766,43.0,-1.645039589858173,,
+2019-10-31,42.790000915527344,42.40999984741211,0.30324485970198023,"Acadia Pharmaceuticals Delivers Record Q3 Revenue, Fueled by Antipsychotic Drug Nuplazid | Acadia Pharmaceuticals (ACAD) Q3 2019 Earnings Call Transcript | Is Acadia Pharmaceuticals Stock Now a Buy?","Looking ahead After its strong performance in Q3, Acadia now anticipates full-year 2019 revenue will be between $330 million and $340 million. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Acadia Pharmaceuticals (NASDAQ: ACAD) has been a huge winner so far in 2019. | Joining me on the call today from ACADIA are Steve Davis, our chief executive officer, who will review our achievement this quarter; Michael Yang, our chief commercial officer, who will provide updates on our commercial initiatives and plans; Serge Stankovic, our president, will discuss our pipeline progress; and Elena Ridloff, our chief financial officer, who will discuss our financial results, before turning it back over to Steve for his final remarks and the lead the call up for questions. Operator [Operator signoff] Duration: 68 minutes Call participants: Mark Johnson -- Vice President of Investor Relations Steve Davis -- Chief Executive Officer Michael Yang -- Chief Commercial Officer Serge Stankovic -- President Elena Ridloff -- Chief Financial Officer Ritu Baral -- Cowen and Company -- Analyst Cory Kasimov -- J.P. Morgan -- Analyst Marc Goodman -- SVB Leerink -- Analyst Tazeen Ahmad -- Bank of America Merrill Lynch -- Analyst Andrea Tan -- Goldman Sachs -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Unknown speaker Roy Buchanan -- JMP Securities -- Analyst Danielle Brill -- Piper Jaffray -- Analyst Alan Carr -- Needham and Company -- Analyst Beau Miller -- RBC Capital Markets -- Analyst Sumant Kulkarni -- Canaccord Genuity -- Analyst Jay Olson -- Oppenheimer and Company -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals (NASDAQ: ACAD) Q3 2019 Earnings Call Oct 30, 2019, 4:30 p.m. | Should investors change their tune toward Acadia's stock after this standout quarter, or is yesterday's muted reaction appropriate in light of the company's near-term outlook? The high and low lights from Acadia's Q3 report On the positive side of the ledger, there's now no doubt about the tremendous commercial potential in regards to the company's Parkinson's disease psychosis (PDP) medicine Nuplazid. Although the company raised its annual revenue guidance to $330 million to $340 million in yesterday's earnings release -- up from the previous range of $320 million to $330 million, Acadia's shares are still trading at an astronomical 19.2 times its 2019 high-end revenue estimate."
+2019-10-30,42.310001373291016,43.04999923706055,-0.8880604346454738,,
+2019-10-29,42.20000076293945,42.2599983215332,1.7489904035707944,,
+2019-10-28,41.16999816894531,42.150001525878906,0.14217430689347424,,
+2019-10-25,41.06999969482422,41.58000183105469,2.380382318483594,,
+2019-10-24,41.709999084472656,41.130001068115234,1.2417875335283748,,
+2019-10-23,42.540000915527344,41.810001373291016,-1.3905490987491709,,
+2019-10-22,43.18000030517578,42.5099983215332,-1.716030856900791,,
+2019-10-21,40.66999816894531,43.2400016784668,-1.551648862684858,,
+2019-10-18,39.7400016784668,39.95000076293945,6.319163081457625,,
+2019-10-17,40.22999954223633,39.97999954223633,0.5284325002594167,,
+2019-10-16,39.650001525878906,39.900001525878906,-0.6214268029944473,,
+2019-10-15,39.56999969482422,40.15999984741211,0.6305169996950166,,
+2019-10-14,40.209999084472656,39.47999954223633,1.4910289541019708,,
+2019-10-11,40.65999984741211,40.52000045776367,-1.8154676917618284,,
+2019-10-10,39.93000030517578,40.47999954223633,-0.34431724095874056,,
+2019-10-09,39.11000061035156,39.880001068115234,1.3774085470999988,,
+2019-10-08,38.209999084472656,39.06999969482422,1.9688070717131863,,
+2019-10-07,37.790000915527344,38.70000076293945,2.250721358172028,,
+2019-10-04,38.43999862670898,38.15999984741211,2.4080439940878757,3 Mid-Cap Biotech Stocks To Consider Buying Now | Here's Why Acadia Pharmaceuticals Jumped 30.1% in September,"Acadia Pharmaceuticals (NASDAQ: ACAD), Amarin (NASDAQ: AMRN) and Exelixis (NASDAQ: EXEL) check the boxes for what investors should look for in a promising biotech company: compelling drugs, increasing sales, near-term catalysts, and the possibility of being acquired. See the 10 stocks *Stock Advisor returns as of June 1, 2019 David Haen owns shares of Acadia Pharmaceuticals, Amarin, and Exelixis. Acadia's Nuplazid is approved to treat hallucinations and delusions associated with Parkinson's disease psychosis. | What happened Acadia Pharmaceuticals (NASDAQ: ACAD) jumped 30.1% in September, according to data provided by S&P Global Market Intelligence, after the company reported positive results for the phase 3 Harmony clinical trial testing its antipsychotic Nuplazid in patients with dementia. Acadia Pharmaceuticals didn't release the actual difference, but since it was an interim analysis, the statistical threshold is more demanding, requiring the P value to be less than 0.0033 instead of the usual less than 0.05. Now what After a biotech skyrockets higher, it'll often take the opportunity to raise additional capital through a secondary offering, and Acadia was no exception."
+2019-10-03,37.209999084472656,38.29999923706055,-0.7284047588449143,,
+2019-10-02,35.9900016784668,37.400001525878906,2.9293205573948438,,
+2019-10-01,38.0,36.209999084472656,3.9177543252400775,,
+2019-09-30,36.68999862670898,35.9900016784668,-4.710528725071957,,
+2019-09-27,37.560001373291016,36.77999877929688,-1.907868559397024,,
+2019-09-26,39.060001373291016,37.47999954223633,-2.0766841466326325,"FBT, ACAD, UTHR, NBIX: ETF Outflow Alert","Among the largest underlying components of FBT, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1.6%, United Therapeutics Corp (Symbol: UTHR) is off about 2.1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust NYSE Arca Biotechnology Index Fund (Symbol: FBT) where we have detected an approximate $381.9 million dollar outflow -- that's a 17.6% decrease week over week (from 17,050,002 to 14,050,002). For a complete list of holdings, visit the FBT Holdings page » The chart below shows the one year price performance of FBT, versus its 200 day moving average: Looking at the chart above, FBT's low point in its 52 week range is $113.43 per share, with $159.85 as the 52 week high point — that compares with a last trade of $126.77."
+2019-09-25,39.22999954223633,39.209999084472656,-4.0450634293502175,,
+2019-09-24,41.56999969482422,38.66999816894531,-0.05098255925835205,,
+2019-09-23,42.20000076293945,41.61000061035156,-6.976188470455963,"Health Care Sector Update for 09/23/2019: ACAD,AKCA,PSTV,CMD","Among health care stocks moving on news: (+) Acadia Pharmaceuticals (ACAD) rose 2.5% after Monday presenting positive data from phase II testing of its pimavanserin drug candidate in patients with Parkinson's disease and depressive symptoms, showing significant improvement in symptoms as soon as two weeks after treatment began. Health care stocks still were falling this afternoon, including a nearly 0.4% decline for the NYSE Health Care Index while the shares of health care companies in the S&P 500 also were down just over 0.4% as a group. (-) Plus Therapeutics (PSTV) fell 50% after the specialty drugmaker priced a $15 million public offering of 3 million units comprised of one share of common stock and a five-year warrant to buy another common share also at $5 apiece."
+2019-09-20,41.61000061035156,40.7400016784668,-1.3981046017090024,,
+2019-09-19,41.97999954223633,41.68000030517578,-2.0908409495873235,,
+2019-09-18,40.650001525878906,42.15999984741211,-0.714624202791417,,
+2019-09-17,44.0,42.59999847412109,3.7146328778656916,"How Doctors Treat Dementia and Lung Cancer Could Be About to Change | 5 Top Stock Trades for Wednesday: BA, ACB, PINS","In this episode of The Motley Fool's Industry Focus: Healthcare, host Shannon Jones and Motley Fool contributor Todd Campbell discuss Acadia's latest trial results and why an eventual approval could cause sales to soar. Acadia Pharmaceuticals' (NASDAQ: ACAD) Nuplazid is already helping thousands of Parkinson's disease patients who are suffering from hallucinations and delusions, and soon it may also win use in Alzheimer's disease and other indications associated with dementia. I want to start with Acadia Pharmaceuticals, ticker ACAD. | Top Stock Trades for Tomorrow #5: Acadia Pharmaceuticals Acadia Pharmaceuticals (NASDAQ:) has been a beast lately, gapping from $23.77 to almost $39 in a single move. ACAD stock consolidated that move beautifully in a narrowing range, before resolving higher on Monday. Over $44 puts the $44.85 highs on the table and over that, ACAD can regain upside momentum."
+2019-09-16,40.20000076293945,44.0099983215332,-3.181821649724803,,
+2019-09-13,40.119998931884766,40.45000076293945,9.477605687277007,,
+2019-09-12,41.16999816894531,39.13999938964844,0.8225369886349212,,
+2019-09-11,41.290000915527344,41.38999938964844,-4.930772090313355,Does Acadia Pharmaceuticals Have More Room to Run?,"The bull case Not surprisingly, Acadia's stock was immediately blessed with several analyst upgrades following Nuplazid's positive late-stage readout for dementia-related psychosis. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Acadia Pharmaceuticals (NASDAQ: ACAD) stock has been on absolute fire in 2019."
+2019-09-10,39.04999923706055,41.220001220703125,0.2421856912177707,Is Acadia Pharmaceuticals a Good Biotech Stock to Buy Now?,"From the day the FDA gave Nuplazid a green light to treat Parkinson's disease-associated psychosis in 2016 until the day before Acadia announced success with dementia-driven psychosis, the stock had fallen 26%. After years of dismay, Acadia Pharmaceuticals' (NASDAQ: ACAD) long-term shareholders have a new reason to cheer for the company's only drug, Nuplazid. Can Nuplazid perform well enough to drive Acadia's recent $5.6 billion market cap even higher?"
+2019-09-09,41.75,38.84999847412109,5.556983421354666,"Health Care Sector Update for 09/09/2019: ACAD, AXNX, AMGN, JNJ, PFE, ABT, MRK | What Happened in the Stock Market Today | Why Acadia Pharmaceuticals Stock Skyrocketed Today | Health Care Sector Update for 09/09/2019: ACHC,ACAD,RGEN | Health Care Sector Update for 09/09/2019: TLRY,ACHC,ACAD,RGEN","Stocks moving on news include: (+) ACADIA Pharmaceuticals (ACAD), which was jumping more than 77% after the company said its phase 3 study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint and would be stopped earlier than expected. Top health care stocks were mixed in Monday's pre-bell trading. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA's perfect reason to end a drug study early Shares of ACADIA Pharmaceuticals popped 63.2% today after the biopharmaceuticals leader announced it has stopped a key late-stage drug study early after the drug demonstrated its efficacy. As for individual stocks, AT&T (NYSE: T) climbed after a notable activist investor took a large stake in the telecommunications giant, while ACADIA Pharmaceuticals (NASDAQ: ACAD) skyrocketed on good news regarding a key new drug study. At the recommendation of the study's independent data-monitoring committee, ACADIA said it decided to stop the phase 3 Harmony trial of its pimavanserin treatment for dementia-related psychosis after the drug met the study's endpoint of ""demonstrating a highly statistically significant longer time to relapse"" compared with a placebo. | Now what With these exceptionally strong late-stage results in hand, Acadia now plans to approach the Food and Drug Administration (FDA) regarding pimavanserin's regulatory pathway for dementia-related psychosis. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of the mid-cap biotech Acadia Pharmaceuticals (NASDAQ: ACAD) gained an astounding 63.2% today on nearly 17 times the average daily volume. | Among health care stocks moving on news: (+) Acadia Healthcare Co (ACHC) was 4% higher in Monday trade after a new regulatory filing showed CEO Debra Osteen last Thursday bought another 20,000 shares of the inpatient psychiatric services company's common stock last Thursday at an average price of $26.53 a share. In other sector news: (+) Acadia Pharmaceuticals (ACAD) raced as much as 85% higher to $43.98 a share after the company Monday said its pimavanserin drug candidate met its primary endpoint during phase III testing, with patients with dementia-related psychosis who were treated with the drug demonstrating a ""highly statistically significant"" longer time to relapse compared with patients treated with a placebo. Following her $530,660 purchase last week, Osteen now directly owns 117,178 Acadia shares. | (+) Acadia Healthcare Co (ACHC) was 6% higher in Monday trade after a new regulatory filing showed CEO Debra Osteen last Thursday bought another 20,000 shares of the inpatient psychiatric services company's common stock last Thursday at an average price of $26.53 a share. In other sector news: (+) Acadia Pharmaceuticals (ACAD) raced as much as 85% higher to $43.98 a share after the company Monday said its pimavanserin drug candidate met its primary endpoint during phase III testing, with patients with dementia-related psychosis who were treated with the drug demonstrating a ""highly statistically significant"" longer time to relapse compared with patients treated with a placebo. Following her $530,660 purchase last week, Osteen now directly owns 117,178 Acadia shares."
+2019-09-06,24.600000381469727,23.799999237060547,-6.94611143923093,Acadia Pharmaceuticals (ACAD) Shares Cross Below 200 DMA | October 25th Options Now Available For Acadia Pharmaceuticals (ACAD),"In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $24.11, changing hands as low as $23.77 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $13.17 per share, with $30.38 as the 52 week high point — that compares with a last trade of $23.80. Acadia Pharmaceuticals Inc shares are currently trading off about 2.9% on the day. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $1.75. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the October 25th expiration."
+2019-09-05,25.1299991607666,24.520000457763672,-3.2520371219660267,,
+2019-09-04,25.57999992370605,24.84000015258789,-2.427372556204739,,
+2019-09-03,27.31999969482422,25.26000022888184,-2.8928841803176546,October 11th Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 11th expiration."
+2019-08-30,28.65999984741211,27.65999984741211,-7.540261672596749,,
+2019-08-29,28.100000381469727,28.440000534057617,-3.4891835496303965,,
+2019-08-28,27.64999961853028,27.96999931335449,1.2099649394029917,,
+2019-08-27,28.420000076293945,27.76000022888184,1.1573226012261966,,
+2019-08-26,28.31999969482422,27.81999969482422,-2.3223076905007938,ACAD October 4th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $29.00 strike price has a current bid of $1.35. Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red: Considering the fact that the $29.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the October 4th expiration."
+2019-08-23,29.309999465942383,28.049999237060547,-1.765536742189232,,
+2019-08-22,29.96999931335449,29.209999084472656,-4.298874963631202,First Week of October 18th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $29.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of 95 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 12% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the October 18th expiration."
+2019-08-21,29.6299991607666,29.82999992370605,-2.535870024338572,,
+2019-08-20,29.31999969482422,29.280000686645508,0.674994156612305,,
+2019-08-19,29.670000076293945,29.239999771118164,-0.13642226669522053,First Week of March 2020 Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $29.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $30.00 strike price has a current bid of $4.40. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the March 2020 expiration."
+2019-08-16,29.31999969482422,29.61000061035156,-1.449276387158986,,
+2019-08-15,29.26000022888184,29.020000457763672,0.9890890809884056,,
+2019-08-14,29.040000915527344,29.1200008392334,-0.8202316105290718,,
+2019-08-13,29.540000915527344,29.450000762939453,0.27548182225875784,,
+2019-08-12,29.670000076293945,29.71999931335449,-0.30467213878989124,,
+2019-08-09,29.3700008392334,29.8700008392334,0.16851781911686697,,
+2019-08-08,29.209999084472656,29.3799991607666,1.7024173841087664,,
+2019-08-07,28.46999931335449,29.01000022888184,0.5819927477653135,,
+2019-08-06,28.89999961853028,28.86000061035156,1.8967366650902988,,
+2019-08-05,28.100000381469727,28.59000015258789,-0.13840487441762728,,
+2019-08-02,28.6299991607666,28.729999542236328,1.7437714037943204,,
+2019-08-01,26.09000015258789,28.670000076293945,0.3492853105170994,"Health Care Sector Update for 08/01/2019: SYRS,MYGN,ACAD,ABMD | Health Care Sector Update for 08/01/2019: MYGN,ACAD,ABMD | Why Acadia Pharmaceuticals Stock Is Crushing It Today | Acadia Pharmaceuticals (ACAD) Q2 2019 Earnings Call Transcript","(+) Acadia Pharmaceuticals (ACAD) climbed 16% after reporting improved Q2 financial results and also raised its FY19 sales outlook. Health care stocks were hanging on for a narrow rise late Thursday with the NYSE Health Care Index climbing nearly 0.2% while the shares of health care companies in the S&P 500 also were up almost 0.2% as a group. Among health care stocks moving on news: (+) Syros Pharmaceuticals (SYRS) rose 13% on Thursday after the specialty drugmaker said its Q2 revenue rose to $462,000 compared with $375,00 during the same quarter last year, climbing 18.8% to beat the Capital IQ consensus expecting $430,000 in revenue for the three months ended June 30. | In other sector news: (+) Acadia Pharmaceuticals (ACAD) climbed 11.5% after reporting improved Q2 financial results and also raised its FY19 sales outlook. Health care stocks were rising, including a 0.9% gain for the NYSE Health Care Index while the shares of health care companies in the S&P 500 also were up 1% as a group. Among health care stocks moving on news: (+) Myriad Genetics (MYGN) was trading 52% higher after Thursday saying UnitedHealthcare (UNH) will cover the cost of the company's GeneSight multi-gene diagnostic test to determine what psychotropic drugs will likely best treat certain mental conditions. | While Acadia announced a net loss of $54.9 million, or $0.38 per share, its bottom line in Q2 was much better than the net loss of $63 million, or $0.51 per share, in the prior-year period. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) are soaring today, up 17.8% as of 11:27 a.m. EDT, after the drugmaker announced strong second-quarter financial results. | Operator [Operator signoff] Duration: 54 minutes Call participants: Mark Johnson -- Vice President of Investor Relations Steve Davis -- Chief Executive Officer Michael Yang -- Chief Commercial Officer Serge Stankovic -- President Elena Ridloff -- Chief Financial Officer Unknown speaker Tazeen Ahmad -- Bank of America Merrill Lynch -- Analyst Jason Butler -- JMP Securities -- Analyst Ritu Baral -- Cowen and Company -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Alan Carr -- Needham and Company -- Analyst Ben Burnett -- Stifel Financial Corp. -- Analyst Danielle Brill -- Piper Jaffray -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals (NASDAQ: ACAD) Q2 2019 Earnings Call Jul 31, 2019, 4:30 p.m. Operator Good day, ladies and gentlemen and welcome to ACADIA Pharmaceuticals' second-quarter 2019 financial results conference call."
+2019-07-31,25.229999542236328,24.57999992370605,9.88884595100373,,
+2019-07-30,23.989999771118164,25.0,-2.5762965926421995,,
+2019-07-29,23.450000762939453,24.06999969482422,4.210088530712646,,
+2019-07-26,22.8799991607666,23.34000015258789,2.643918600056578,,
+2019-07-25,23.0,22.700000762939453,2.0104939191172444,,
+2019-07-24,22.15999984741211,23.01000022888184,-1.3043445089588994,,
+2019-07-23,22.5,22.21999931335449,3.835741820047869,Acadia Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ACAD | RSI Alert: Acadia Pharmaceuticals (ACAD) Now Oversold | Are These 2 Beaten-Down Biotech Stocks Worth Buying? | Why Acadia Pharmaceuticals Is Tanking Today,"In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $23.08, changing hands as low as $22.00 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.77 per share, with $28.67 as the 52 week high point — that compares with a last trade of $22.09. Acadia Pharmaceuticals Inc shares are currently trading off about 15.3% on the day. | In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $22 per share. A bullish investor could look at ACAD's 28.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $12.77 per share, with $28.67 as the 52 week high point — that compares with a last trade of $22.18. | Keeping with this theme, Acadia Pharmaceuticals (NASDAQ: ACAD) and Dynavax Technologies (NASDAQ: DVAX) both took a big step backwards this week. The case for and against Acadia Yesterday, Acadia announced that the late-stage trial dubbed ""Enhanced"" designed to evaluate pimavanserin (a.k.a. In 2018, Acadia reported a noteworthy $223.8 million in sales for the full year, representing a healthy 79% increase over the prior year. | 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biopharma focused on diseases of the central nervous system, had fallen 14% as of 11:01 a.m. EST on Tuesday."
+2019-07-22,25.600000381469727,25.96999931335449,-1.2444474962022727,,
+2019-07-19,26.100000381469727,25.700000762939453,1.4453083061380798,,
+2019-07-18,25.520000457763672,26.14999961853028,-1.5325655658390795,,
+2019-07-17,26.25,25.56999969482422,2.4686487048041994,,
+2019-07-16,26.61000061035156,26.270000457763672,-2.590477353050595,,
+2019-07-15,27.39999961853028,26.71999931335449,-1.2777156887986827,Interesting ACAD Put And Call Options For July 19th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 35 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the July 19th expiration."
+2019-07-12,27.15999984741211,27.229999542236328,-2.4817529731493724,,
+2019-07-11,27.26000022888184,27.25,0.25773083658867746,,
+2019-07-10,27.38999938964844,27.299999237060547,-0.036684625083914325,,
+2019-07-09,26.61000061035156,27.209999084472656,-0.32858763999063145,,
+2019-07-08,26.89999961853028,26.729999542236328,2.254785645843585,,
+2019-07-05,27.0,27.13999938964844,-0.6319705528056829,,
+2019-07-03,26.790000915527344,27.190000534057617,0.518516257957189,JKK's Holdings Imply 14% Gain Potential,"Similarly, HALO has 22.74% upside from the recent share price of $17.38 if the average analyst target price of $21.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $32.55/share, which is 21.89% above the recent price of $26.70. Below is a twelve month price history chart comparing the stock performance of TLRY, HALO, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of JKK's underlying holdings with notable upside to their analyst target prices are Tilray Inc (Symbol: TLRY), Halozyme Therapeutics Inc (Symbol: HALO), and Acadia Pharmaceuticals Inc (Symbol: ACAD)."
+2019-07-02,26.940000534057617,26.700000762939453,1.493092963272113,,
+2019-07-01,26.989999771118164,26.920000076293945,-0.8908677296229291,,
+2019-06-28,26.39999961853028,26.729999542236328,-0.2593541882839325,,
+2019-06-27,25.3799991607666,26.43000030517578,1.2499997290697653,,
+2019-06-26,25.84000015258789,25.239999771118164,4.137120485142934,,
+2019-06-25,25.88999938964844,25.780000686645508,-2.3219828867130876,,
+2019-06-24,26.01000022888184,25.790000915527344,-0.4248694692782181,,
+2019-06-21,25.549999237060547,26.0,-0.84582588011747,,
+2019-06-20,26.8799991607666,25.729999542236328,1.7612554848405717,,
+2019-06-19,26.059999465942383,26.6200008392334,-4.278272523939603,,
+2019-06-18,25.61000061035156,25.93000030517578,2.1488924971885637,,
+2019-06-17,24.6200008392334,25.420000076293945,1.2495106880039608,,
+2019-06-14,25.51000022888184,24.26000022888184,3.2493875296125165,,
+2019-06-13,25.690000534057617,25.6299991607666,-4.900039156349275,,
+2019-06-12,25.709999084472656,25.56999969482422,-0.2335592527974879,,
+2019-06-11,25.850000381469727,25.6200008392334,-0.5445328457167817,,
+2019-06-10,25.940000534057617,25.65999984741211,-0.8897467653470544,,
+2019-06-07,25.030000686645508,25.84000015258789,-1.0794166572120314,,
+2019-06-06,25.850000381469727,24.90999984741211,3.236114437561919,,
+2019-06-05,25.489999771118164,25.770000457763672,-3.636365648688523,,
+2019-06-04,24.76000022888184,25.350000381469727,1.0984726918780396,,
+2019-06-03,23.950000762939453,24.38999938964844,2.3828762000562045,,
+2019-05-31,24.5,23.989999771118164,1.8371549590505551,,
+2019-05-30,24.700000762939453,24.89999961853028,-2.0816335872728,,
+2019-05-29,25.850000381469727,24.59000015258789,0.8097119409441926,,
+2019-05-28,26.09000015258789,26.13999938964844,-4.874275475001743,,
+2019-05-24,25.450000762939453,25.959999084472656,0.19164138278316933,,
+2019-05-23,24.799999237060547,25.34000015258789,2.0039226178565297,Interesting ACAD Put And Call Options For July 5th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of 65 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the July 5th expiration."
+2019-05-22,25.420000076293945,25.13999938964844,2.1774231134667894,,
+2019-05-21,24.559999465942383,25.540000915527344,-1.1014975838124637,,
+2019-05-20,24.75,24.229999542236328,3.990234002015918,,
+2019-05-17,25.34000015258789,25.030000686645508,-2.10101195056029,,
+2019-05-16,25.96999931335449,25.65999984741211,-1.223360158151868,,
+2019-05-15,25.239999771118164,25.940000534057617,-1.1936829962986137,,
+2019-05-14,24.920000076293945,25.600000381469727,2.773378642183887,,
+2019-05-13,25.100000381469727,24.6299991607666,2.7287331584828376,,
+2019-05-10,25.790000915527344,25.84000015258789,-1.872514795059952,,
+2019-05-09,25.739999771118164,25.979999542236328,0.1938706292578839,,
+2019-05-08,25.780000686645508,26.14999961853028,0.9324000514850754,,
+2019-05-07,26.739999771118164,25.809999465942383,1.4352169202091551,,
+2019-05-06,25.6299991607666,26.790000915527344,-3.477936847928747,,
+2019-05-03,25.51000022888184,26.520000457763672,4.525953151556974,,
+2019-05-02,23.200000762939453,25.5,3.9592325355541678,"Health Care Sector Update for 05/02/2019: ABMD,ABC,ACAD,CGC,WEED.TO | Health Care Sector Update for 05/02/2019: ABC,ACAD,CGC | June 14th Options Now Available For Acadia Pharmaceuticals (ACAD) | Acadia Pharmaceuticals (ACAD) Q1 2019 Earnings Call Transcript","In other sector news: (+) ACADIA Pharmaceuticals (ACAD) climbed 6% on Thursday after the specialty drugmaker saw its revenue rise 28.8% over year-ago levels to $62.96 million, topping the $60.93 million analyst mean. Among health care stocks moving on news: (-) Abiomed (ABMD) fell nearly 6% on Thursday after the cardiac medical device company reported Q4 revenue lagging analyst projections, rising to $207.1 million during the three months ended March 31 from $174.4 million during the same quarter last year but missing the Capital IQ consensus by $11.8 million. The company also raised the bottom end of its expected sales range for its Nuplazid medication by $5 million, now looking for between $280 million and $300 million in sales for the Parkinson's treatment. | In other sector news: (+) ACADIA Pharmaceuticals (ACAD) climbed 6% on Thursday after the specialty drugmaker saw its revenue rise 28.8% over year-ago levels to $62.96 million, topping the $60.93 million analyst mean. Health care stocks were falling, including a 0.2% loss for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: (+) AmerisourceBergen (ABC) rose almost 5% after the pharmaceuticals distributor reported non-GAAP net income of $2.11 per share during its fiscal Q2 ended March 31, up from $1.94 per share during the same quarter last year and beating the Capital IQ by $0.15 per share. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of 85 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the June 14th expiration. | Joining me on the call today from ACADIA are Steve Davis, our chief executive officer, who will provide a brief overview of our strategy, recent achievements, pipeline opportunities, and financial performance; Michael Yang, our chief commercial officer, will provide updates on our commercial initiatives with Nuplazid; Serge Stankovic, our president, will discuss our pipeline progress; and Elena Ridloff, our chief financial officer, who will discuss our financial results before turning it back to Steve for his final remarks and opening the call for questions. Operator [Operator signoff] Duration: 63 minutes Call participants: Mark Johnson -- Vice President of Investor Relations Steve Davis -- Chief Executive Officer Michael Yang -- Chief Commercial Officer Serge Stankovic -- President Elena Ridloff -- Chief Financial Officer Ritu Baral -- Cowen and Company -- Analyst Cory Kasimov -- J.P. Morgan -- Analyst Jason Butler -- JMP Securities -- Analyst Salveen Richter -- Goldman Sachs -- Analyst Tazeen Ahmad -- Bank of America Merrill Lynch -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Alan Carr -- Needham and Company -- Analyst Danielle Brill -- Piper Jaffray -- Analyst Marc Goodman -- Leerink -- Analyst Ben Burnett -- Stifel Financial Corp. -- Analyst Sumant Kulkarni -- Canaccord Genuity -- Analyst More ACAD analysis All earnings call transcripts This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals (NASDAQ: ACAD) Q1 2019 Earnings Call May."
+2019-05-01,24.170000076293945,23.65999984741211,9.913789488897997,,
+2019-04-30,25.170000076293945,24.049999237060547,-2.110054725990864,,
+2019-04-29,25.1299991607666,25.1200008392334,-4.4497450768315945,,
+2019-04-26,24.5,25.170000076293945,-0.039786398197786975,,
+2019-04-25,24.0,24.450000762939453,2.734694188954879,,
+2019-04-24,24.40999984741211,24.040000915527344,1.875003178914388,,
+2019-04-23,23.739999771118164,24.3700008392334,-1.515767858245161,,
+2019-04-22,23.600000381469727,23.739999771118164,2.6537534717320725,,
+2019-04-18,23.270000457763672,23.57999992370605,0.5932177431588619,,
+2019-04-17,25.61000061035156,23.31999969482422,1.3321850444526002,,
+2019-04-16,25.790000915527344,25.51000022888184,-8.941822963493887,,
+2019-04-15,25.670000076293945,25.51000022888184,-1.0856947526392862,,
+2019-04-12,26.270000457763672,25.68000030517578,-0.6232950796126584,,
+2019-04-11,26.790000915527344,26.020000457763672,-2.245908421419634,,
+2019-04-10,26.82999992370605,26.780000686645508,-2.874208404066846,3 Biotech Stocks That Doubled After Hitting Bottom in 2018,"Acadia: An expensive drug launch This biotech launched Nuplazid in 2016 to treat psychosis caused by Parkinson's disease, and Acadia has big plans to expand its addressable patient population. Runaway expenses and a disappointing Nuplazid launch caused Acadia to lose $244 million last year and $802 million over the past three years. Acadia's also moving Nuplazid into a phase 3 trial for major depressive disorder, and the company acquired rights to develop a rare-disease drug that's about to enter another phase 3 study."
+2019-04-09,26.989999771118164,26.670000076293945,-0.18635571078166774,,
+2019-04-08,28.07999992370605,27.06999969482422,-1.185623184653186,,
+2019-04-05,26.89999961853028,28.1200008392334,-3.5968669217451,,
+2019-04-04,27.459999084472656,26.86000061035156,4.535320587375438,,
+2019-04-03,27.440000534057617,27.350000381469727,-2.184990874454793,,
+2019-04-02,26.950000762939453,27.31999969482422,-0.3279888878871756,,
+2019-04-01,27.1200008392334,26.979999542236328,1.3729087992961142,,
+2019-03-29,26.959999084472656,26.850000381469727,-0.5162289552533352,,
+2019-03-28,26.270000457763672,26.63999938964844,-0.4080070724716098,,
+2019-03-27,26.89999961853028,26.239999771118164,1.4084466137701266,,
+2019-03-26,26.479999542236328,26.950000762939453,-2.4535310660654073,"Notable ETF Inflow Detected - FBT, IONS, RARE, ACAD","Among the largest underlying components of FBT, in trading today Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 1.1%, Ultragenyx Pharmaceutical Inc (Symbol: RARE) is up about 1%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is up by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust NYSE Arca Biotechnology Index Fund (Symbol: FBT) where we have detected an approximate $87.6 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (from 19,950,002 to 20,550,002). For a complete list of holdings, visit the FBT Holdings page » The chart below shows the one year price performance of FBT, versus its 200 day moving average: Looking at the chart above, FBT's low point in its 52 week range is $113.43 per share, with $159.85 as the 52 week high point - that compares with a last trade of $147.79."
+2019-03-25,26.040000915527344,26.190000534057617,1.7749291118886166,,
+2019-03-22,27.049999237060547,26.100000381469727,0.576035381169401,,
+2019-03-21,25.86000061035156,27.21999931335449,-3.512010655768337,,
+2019-03-20,26.96999931335449,26.21999931335449,5.259082254075944,,
+2019-03-19,27.31999969482422,26.920000076293945,-2.780867701500568,,
+2019-03-18,26.799999237060547,27.100000381469727,-1.4641274633910537,,
+2019-03-15,26.84000015258789,26.850000381469727,1.1194072871252967,,
+2019-03-14,27.5,26.68000030517578,0.0372586766951703,,
+2019-03-13,26.38999938964844,27.3799991607666,-2.9818170720880683,,
+2019-03-12,26.1299991607666,26.200000762939453,3.751420212258478,,
+2019-03-11,25.190000534057617,26.06999969482422,0.26789745281720806,,
+2019-03-08,25.190000534057617,25.76000022888184,3.493446375980885,,
+2019-03-07,25.63999938964844,25.38999938964844,2.262801440014128,,
+2019-03-06,26.84000015258789,25.64999961853028,-0.9750390247705378,,
+2019-03-05,26.89999961853028,26.65999984741211,-4.433683037601888,,
+2019-03-04,26.920000076293945,26.850000381469727,-0.8921924703405772,,
+2019-03-01,26.559999465942383,26.600000381469727,-0.2600285833054706,,
+2019-02-28,25.59000015258789,26.5,0.15060585968247672,"Noteworthy Thursday Option Activity: FRO, ULTA, ACAD","Below is a chart showing ULTA's trailing twelve month trading history, with the $315 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 5,957 contracts thus far today. That number of contracts represents approximately 595,700 underlying shares, working out to a sizeable 40.7% of ACAD's average daily trading volume over the past month, of 1.5 million shares. Especially high volume was seen for the $28 strike call option expiring March 15, 2019 , with 2,610 contracts trading so far today, representing approximately 261,000 underlying shares of ACAD."
+2019-02-27,23.01000022888184,25.530000686645508,3.5560759749353963,"Wednesday's ETF Movers: FBT, IHF | Acadia Pharmaceuticals Inc (ACAD) Q4 2018 Earnings Conference Call Transcript","Components of that ETF showing particular strength include shares of Ionis Pharmaceuticals ( IONS ), up about 13.9% and shares of Acadia Pharmaceuticals ( ACAD ), up about 5.1% on the day. In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF ( FBT ) is outperforming other ETFs, up about 1.9% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Capital Senior Living ( CSU ), lower by about 5.5%, and shares of Wellcare Health Plans (WCG), lower by about 4.8% on the day. | Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer, who will provide a brief overview of our strategy, recent achievements, pipeline opportunities and financial performance; Michael Yang, our Chief Commercial Officer, who will provide updates on our commercial initiatives with NUPLAZID; and Dr. Serge Stankovic, our President, who will discuss our pipeline progress. Duration: 60 minutes Call participants: Elena Ridloff -- Senior Vice President, Investor Relations and Interim Chief Financial Officer Stephen R. Davis -- Chief Executive Officer Michael J. Yang -- Executive Vice President, Chief Commercial Officer Serge Stankovic -- President Matthew Holt -- JPMorgan -- Analyst Ritu Baral -- Cowen -- Analyst Tazeen Ahmad -- Bank of America -- Analyst Charles Duncan -- Cantor Fitzgerald -- Analyst Danielle Brill -- Piper Jaffray -- Analyst Andrea -- Goldman Sachs -- Analyst Unidentified Participant-- Analyst Alan Carr -- Needham -- Analyst Nate -- Stifel Nicolaus -- Analyst Roy Buchanan -- JMP Securities -- Analyst More ACAD analysis Transcript powered by AlphaStreet This article is a transcript of this conference call produced for The Motley Fool. Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Q4 2018 Earnings Conference Call Feb. 26, 2019 , 5:00 p.m."
+2019-02-26,23.479999542236328,23.559999465942383,10.951761984776507,"Earnings Reaction History: ACADIA PHARMA, 54.5% Follow-Through Indicator, 8.5% Sensitive","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 3.9% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.9%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 80% Average next regular session additional loss: 4.8% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 80.0% of the time (4 events) the stock dropped further, adding to the extended-hours losses by an average of 4.8% by the following regular session close. Extended-Hours Dollar Volume: $5,467,584 ACADIA PHARMA ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
+2019-02-25,23.31999969482422,23.75,0.3407151842662906,,
+2019-02-22,22.440000534057617,22.93000030517578,1.8439121389492046,,
+2019-02-21,22.84000015258789,22.26000022888184,2.183599641071675,,
+2019-02-20,23.020000457763672,22.81999969482422,-2.539404202413432,,
+2019-02-19,23.25,22.979999542236328,-0.8688130276383262,,
+2019-02-15,22.049999237060547,23.25,-1.1612922914566532,What's in the Cards for Bausch Health (BHC) Q4 Earnings?,"Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report Mallinckrodt public limited company (MNK): Free Stock Analysis Report Bausch Health Cos Inc. (BHC): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +12.95% and a Zacks Rank #3. Factors Likely to Impact Results Bausch conducts its business in four operating segments - the Bausch + Lomb/International segment, the Salix segment, the Ortho Dermatologics segment and the Diversified Products segment."
+2019-02-14,22.200000762939453,21.93000030517578,5.4421805190929495,5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings,"Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report To read this article on Zacks.com click here. Bet on These 5 Stocks for Robust Returns Acadia Pharmaceuticals Inc.ACAD has an Earnings ESP of +3.39% and a Zacks Rank #3. By means of the Zacks Stock Screener , we have zeroed in on five drug/ biotech stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) and a positive Earnings ESP ."
+2019-02-13,22.520000457763672,22.309999465942383,-1.2162182364174015,,
+2019-02-12,21.59000015258789,22.38999938964844,-0.9325088257220356,,
+2019-02-11,22.15999984741211,21.479999542236328,3.705415615593029,Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?,"Click to get this free report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.89% and a Zacks Rank #3. Earnings ESP: Zoetis has an Earnings ESP of +1.52% as the Zacks Consensus Estimate is pegged at 77 cents, while the Most Accurate Estimate is pegged at 78 cents."
+2019-02-08,22.239999771118164,21.989999771118164,-3.0685934560382817,Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?,"Click to get this free report Novartis AG (NVS): Get Free Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mallinckrodt public limited company (MNK): Get Free Report Tilray, Inc. (TLRY): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.89% and a Zacks Rank #3. In September 2018, Tilray announced that the U.S. Drug Enforcement Administration (DEA) has approved an import pharmaceutical-grade medical cannabis product produced by Tilray in the United States, for a clinical trial focused on Essential Tremor (ET), a neurological movement disorder."
+2019-02-07,22.71999931335449,22.34000015258789,-1.1241007309930864,The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You?,"Acadia Pharmaceuticals (NASDAQ: ACAD) , Vanguard FTSE Emerging Markets (NYSEMKT: VWO) , and Kraft Heinz (NASDAQ: KHC) are among those stocks attracting a name-brand following. A rebound in the making George Budwell (Acadia Pharmaceuticals): The Baker brothers -- Julian and Felix Baker -- are widely revered within biotech investing circles for their ability to pick outstanding growth stocks. Investors have long cited the Baker brothers' larger ownership stake in Acadia Pharmaceuticals as a key reason for their confidence in the company."
+2019-02-06,23.1200008392334,22.90999984741211,-1.6725315680059902,,
+2019-02-05,22.850000381469727,23.09000015258789,-0.9083087551836446,,
+2019-02-04,22.790000915527344,22.700000762939453,1.0503272083653556,,
+2019-02-01,22.81999969482422,22.739999771118164,-0.39491070194109335,,
+2019-01-31,22.96999931335449,22.780000686645508,-0.3505693460819782,Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?,"Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Get Free Report Vertex Pharmaceuticals Incorporated (VRTX): Get Free Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.89% and a Zacks Rank #3. Zacks Rank : Gilead currently carries a Zacks Rank #4 (Sell), which when combined with a negative ESP indicates very low chances of an earnings beat."
+2019-01-30,22.3799991607666,22.93000030517578,-0.8271599146218426,Is a Beat in Store for Vertex (VRTX) This Earnings Season?,"Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report CRISPR Therapeutics AG (CRSP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.89% and a Zacks Rank #2. Vertex's another CF medicine - Orkambi - is approved in the United States and Europe for treating CF in patients aged six years or above, having two copies of the F508del mutation."
+2019-01-29,22.14999961853028,22.309999465942383,2.457556590857084,,
+2019-01-28,22.209999084472656,22.100000381469727,0.7223469533527638,MacroGenics Up on Lifting of Partial Hold on Cancer Candidate,"Click to get this free report MacroGenics, Inc. (MGNX): Get Free Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Alder BioPharmaceuticals, Inc. (ALDR): Free Stock Analysis Report Five Prime Therapeutics, Inc. (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks fromthe pharma sector include Alder BioPharmaceuticals, Inc. ALDR , ACADIA Pharmaceuticals Inc. ACAD and Five Prime Therapeutics, Inc. FPRX . ACADIA Pharma's loss estimates have narrowed from $2.00 to $1.99 for 2018 and from $1.77 to $1.72 for 2019 over the past 30 days."
+2019-01-25,21.729999542236328,22.61000061035156,-0.4952665805368332,,
+2019-01-24,20.799999237060547,21.63999938964844,4.049705875072771,Will ACADIA Pharmaceuticals Continue to Surge Higher?,"From this look, the company's future is quite favorable; as ACAD has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. As of late, it has definitely been a great time to be an investor in ACADIA Pharmaceuticals Inc.ACAD ."
+2019-01-23,20.440000534057617,20.809999465942383,4.038462420187102,,
+2019-01-22,20.8700008392334,20.31999969482422,1.8101708523356668,,
+2019-01-18,21.690000534057617,21.06999969482422,-2.635367140835163,,
+2019-01-17,21.770000457763672,21.57999992370605,-2.8584639187070273,Amgen's Postmenopausal Osteoporosis Drug Gets FDA Panel Nod,"Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report Amgen Inc. (AMGN): Get Free Report To read this article on Zacks.com click here. Better-ranked stocks in the biotech sector are ACADIA Pharmaceuticals Inc. ACAD , Vanda Pharmaceuticals Inc. VNDA and Exelixis, Inc. EXEL , all sporting a Zacks Rank #1. ACADIA's stock has soared 23.8% in the past six months."
+2019-01-16,21.36000061035156,21.770000457763672,-0.8727631146643466,,
+2019-01-15,20.8799991607666,21.32999992370605,1.9194748862198878,,
+2019-01-14,20.76000022888184,20.65999984741211,2.155176154341033,,
+2019-01-11,20.64999961853028,21.07999992370605,-0.4816974006127757,,
+2019-01-10,19.670000076293945,20.709999084472656,2.0823259715216156,"Thursday's ETF Movers: FBT, GDXJ","Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals ( ACAD ), up about 6% and shares of Alnylam Pharmaceuticals ( ALNY ), up about 5.5% on the day. In trading on Thursday, the First Trust NYSE Arca Biotechnology Index Fund ETF ( FBT ) is outperforming other ETFs, up about 1.4% on the day. Among components of that ETF with the weakest showing on Thursday were shares of Golden Star Resources ( GSS ), lower by about 6.6%, and shares of New Gold (NGD), lower by about 6.6% on the day."
+2019-01-09,18.64999961853028,19.739999771118164,5.287234388128477,,
+2019-01-08,18.40999984741211,18.540000915527344,5.844504959157642,Here's Why ACADIA Pharmaceuticals Dropped 15.2% in December,"10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) fell over 15% last month, according to data provided by S&P Global Market Intelligence . Unfortunately for investors, ACADIA Pharmaceuticals was an easy target after struggling mightily throughout the year."
+2019-01-07,17.8799991607666,18.229999542236328,0.7061437761690617,,
+2019-01-04,16.440000534057617,17.56999969482422,1.957496632537428,,
+2019-01-03,16.799999237060547,16.170000076293945,6.8734739906222035,,
+2019-01-02,15.84000015258789,16.649999618530273,-3.7499951748618705,,
+2018-12-31,15.699999809265137,16.170000076293945,5.113632942800494,,
+2018-12-28,15.359999656677246,15.649999618530272,2.9936323104376377,,
+2018-12-27,15.649999618530272,15.449999809265137,1.8880206271811848,,
+2018-12-26,14.34000015258789,15.84000015258789,-1.2779540839625745,,
+2018-12-24,14.010000228881836,14.31999969482422,10.460250934720529,,
+2018-12-21,15.300000190734863,14.329999923706056,2.212701362440493,,
+2018-12-20,15.729999542236328,15.270000457763672,-6.339870947297141,Acadia Pharmaceuticals Becomes Oversold (ACAD),"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $15.34 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $12.77 per share, with $32.99 as the 52 week high point - that compares with a last trade of $15.38. A bullish investor could look at ACAD's 29.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
+2018-12-19,17.06999969482422,15.779999732971191,-2.9243426437332136,,
+2018-12-18,17.729999542236328,17.040000915527344,-7.557117662071003,,
+2018-12-17,17.639999389648438,17.559999465942383,-3.891701322751152,Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD,"In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $18.43, changing hands as high as $18.59 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.77 per share, with $32.99 as the 52 week high point - that compares with a last trade of $18.47. Acadia Pharmaceuticals Inc shares are currently trading up about 4.4% on the day."
+2018-12-14,17.790000915527344,17.670000076293945,-0.45351432241545603,,
+2018-12-13,18.61000061035156,17.93000030517578,-0.6745409390544783,,
+2018-12-12,18.780000686645508,18.479999542236328,-3.6539510095316,,
+2018-12-11,19.059999465942383,18.56999969482422,-1.5974501248155495,,
+2018-12-10,18.030000686645508,18.780000686645508,-2.570827832360262,,
+2018-12-07,18.739999771118164,18.209999084472656,4.159733618621054,,
+2018-12-06,18.65999984741211,18.90999984741211,-2.828178725286527,,
+2018-12-04,20.21999931335449,18.81999969482422,1.339764212456152,,
+2018-12-03,19.71999931335449,20.299999237060547,-6.923836132900495,,
+2018-11-30,20.020000457763672,19.059999465942383,2.9411761861131467,,
+2018-11-29,20.3700008392334,20.1299991607666,-4.795209639713094,ACAD January 2019 Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $22.00 strike price has a current bid of 10 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.00 strike highlighted in red: Considering the fact that the $22.00 strike represents an approximate 10% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2019 expiration."
+2018-11-28,19.15999984741211,20.530000686645508,-1.1782114314131225,Here's Why Acadia Pharmaceuticals Is Soaring,"What happened In response to the release of the pricing details of its just-announced secondary common stock offering , shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma, jumped as much as 16% in early-morning trading on Wednesday. So what Acadia stated that it is selling 16.2 million shares to the public at a price of $17 per share. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
+2018-11-27,18.209999084472656,17.0,7.150317589477647,"XBI, ACAD, TSRO, IONS: ETF Outflow Alert | Health Care Sector Update for 11/27/2018: DVA,VRTX,ACAD,GTHX | Why Acadia Pharmaceuticals Is Plummeting | Health Care Sector Update for 11/27/2018: VRTX,HALO,GTHX,ACAD","Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 10%, Tesaro Inc (Symbol: TSRO) is off about 0.3%, and Ionis Pharmaceuticals Inc (Symbol: IONS) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $236.2 million dollar outflow -- that's a 5.3% decrease week over week (from 55,650,000 to 52,700,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $73.97 per share, with $101.55 as the 52 week high point - that compares with a last trade of $78.33. | (-) ACADIA Pharmaceuticals ( ACAD ) was down by double digits in late Tuesday trading, dropping almost 12% after earlier announcing plans for a $200 million public offering of its common stock. Among health care stocks moving on news: (+) DaVita ( DVA ) was nearly 4% higher in late Tuesday trading after the kidney dialysis chain said lenders, led by JPMorgan Chase Bank, agreed to a revised senior secured credit facility increasing the company's maximum leverage ratio from 4.50-to-1.00 to 5.00-to-1.00 through June 29, 2019. In other sector news: (+) Vertex Pharmaceuticals ( VRTX ) rose over 5% on Tuesday after saying a combination of its VX-659 drug candidate with two previously approved chemotherapy medications, tezacaftor and ivacaftor, produced statistically significant improvements in lung function in patients with cystic fibrosis during a pair of Phase III studies compared with tezacaftor and ivacaftor alone. | What happened After management announced its intention to raise capital through a common stock offering, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell 12% as of 3:07 p.m. EST on Tuesday. Now what Earlier in November, Acadia told investors that it planned on ending the year with at least $160 million in cash on its books, so the company isn't in dire need of a cash injection just yet. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | Among health care stocks moving on news: (+) Vertex Pharmaceuticals ( VRTX ) rose 5% on Tuesday after saying a triple combination of its VX-659 drug candidate with two previously approved chemotherapy medications, tezacaftor and ivacaftor, produced statistically significant improvements in lung function in patients with cystic fibrosis during a pair of Phase III studies In other sector news: (-) ACADIA Pharmaceuticals ( ACAD ) was down 12% after announcing plans for a $200 million public offering of its common stock. (-) Halozyme Therapeutics ( HALO ) declined 7.5% after the biotech company late Monday said the US Food and Drug Administration agreed to allow the company to change the primary endpoint of a late-stage clinical study of its PEGPH20 drug candidate as a first-line treatment in patients with metastatic pancreas cancer to a single primary endpoint of overall survival. (-) G1 Therapeutics ( GTHX ) dropped 16% this afternoon after late Monday saying there was no statistically significant difference in the overall response rate and progression-free survival for patients with small cell lung cancer treated with a combination of its trilaciclib drug candidate and traditional chemotherapy and patients treated with chemotherapy alone during Phase II testing."
+2018-11-26,18.68000030517578,19.459999084472656,-6.6446960203551075,,
+2018-11-23,18.6299991607666,18.51000022888184,4.17558226206643,,
+2018-11-21,18.440000534057617,18.780000686645508,-0.6441166789608394,,
+2018-11-20,17.360000610351562,18.239999771118164,1.8438185615012859,,
+2018-11-19,18.850000381469727,18.1200008392334,5.069119411446729,,
+2018-11-16,18.479999542236328,18.93000030517578,-3.872676538266523,"Noteworthy ETF Outflows: XBI, ACAD, IONS, ARRY","Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.4%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 1.3%, and Array BioPharma Inc. (Symbol: ARRY) is higher by about 1.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $275.9 million dollar outflow -- that's a 6.3% decrease week over week (from 56,150,000 to 52,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $73.97 per share, with $101.55 as the 52 week high point - that compares with a last trade of $78.95."
+2018-11-15,17.399999618530273,18.6299991607666,2.4350691238436957,,
+2018-11-14,18.1299991607666,17.530000686645508,7.068963041392426,,
+2018-11-13,18.89999961853028,17.809999465942383,-3.3094236177323886,,
+2018-11-12,18.920000076293945,18.86000061035156,-5.767196690941835,,
+2018-11-09,19.15999984741211,18.86000061035156,-0.31712191173594895,,
+2018-11-08,20.0,19.25,-1.5657580347061983,December 28th Options Now Available For Acadia Pharmaceuticals (ACAD),"At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new December 28th contracts and identified the following put contract of particular interest. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $19.00 strike is located relative to that history: The implied volatility in the put contract example above is 124%. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the December 28th expiration."
+2018-11-07,23.0,20.0,-3.75,,
+2018-11-06,21.51000022888184,21.8799991607666,-13.043478260869565,"Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 60.0% Follow-Through Indicator, 8.5% Sensitive","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.58. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $58.31 million for the quarter ended September 2018, surpassing the Zacks Consensus Estimate by 0.70%. Acadia shares have lost about 28.1% since the beginning of the year versus the S&P 500's gain of 2.4%. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.9% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.9%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 80% Average next regular session additional loss: 4.8% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 80.0% of the time (4 events) the stock dropped further, adding to the extended-hours losses by an average of 4.8% by the following regular session close. Extended-Hours Dollar Volume: $5,260,497 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
+2018-11-05,22.63999938964844,21.65999984741211,1.7201251880414128,,
+2018-11-02,22.5,22.729999542236328,-4.3286200028981066,,
+2018-11-01,19.690000534057617,22.36000061035156,1.0222201877170138,,
+2018-10-31,22.51000022888184,19.479999542236328,13.560182853604633,ACAD Makes Notable Cross Below Critical Moving Average,"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $20.03, changing hands as low as $19.50 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.77 per share, with $38 as the 52 week high point - that compares with a last trade of $19.98. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day."
+2018-10-30,21.06999969482422,21.09000015258789,-13.460687053915784,Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline,"Acadia Pharmaceuticals (ACAD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2018. How Have the Numbers Shaped Up for Acadia? For Acadia, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects."
+2018-10-29,22.36000061035156,21.100000381469727,0.0949238635660015,,
+2018-10-26,20.790000915527344,21.739999771118164,-5.63506348161062,,
+2018-10-25,19.51000022888184,21.270000457763672,4.569498863664304,,
+2018-10-24,21.950000762939453,19.239999771118164,9.021015931493414,,
+2018-10-23,21.229999542236328,22.0,-12.34624554727522,,
+2018-10-22,22.170000076293945,21.76000022888184,3.626945239597313,,
+2018-10-19,22.57999992370605,22.209999084472656,-1.8493452683859601,,
+2018-10-18,22.84000015258789,22.729999542236328,-1.6386219684834558,,
+2018-10-17,22.88999938964844,22.8700008392334,-0.4816138774810772,,
+2018-10-16,21.520000457763672,22.920000076293945,-0.08736806879989072,,
+2018-10-15,21.670000076293945,21.280000686645508,6.505574297165974,,
+2018-10-12,21.3799991607666,21.71999931335449,-1.799720296609875,,
+2018-10-11,20.21999931335449,20.989999771118164,1.590272057689342,,
+2018-10-10,21.020000457763672,20.239999771118164,3.808113174638544,Here's Why ACADIA Pharmaceuticals Jumped 46% in September,"Considering the drug comprises four of five clinical programs under development by ACADIA Pharmaceuticals, this may not be the last time investors are confronted with uncertainty or hesitation concerning the drug's safety. What happened Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD) soared 46% last month, according to data provided by S&P Global Market Intelligence . Considering the drug posted revenue of roughly $106 million in the first half of 2018 and is the only commercial product of ACADIA Pharmaceuticals, the results of the postmarketing review were about as good as investors could have hoped for."
+2018-10-09,21.030000686645508,21.15999984741211,-3.7107548508992396,,
+2018-10-08,21.200000762939453,21.11000061035156,0.6181605160343802,,
+2018-10-05,21.56999969482422,21.440000534057617,-0.42452900636318347,,
+2018-10-04,20.950000762939453,21.46999931335449,-0.6026850375792784,"Noteworthy Thursday Option Activity: ACAD, CL, INGN","Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 15,250 contracts has been traded thus far today, a contract volume which is representative of approximately 1.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42% of ACAD's average daily trading volume over the past month, of 3.6 million shares. Particularly high volume was seen for the $23 strike call option expiring December 21, 2018 , with 5,420 contracts trading so far today, representing approximately 542,000 underlying shares of ACAD."
+2018-10-03,20.36000061035156,21.15999984741211,2.4820932290127304,,
+2018-10-02,20.57999992370605,20.15999984741211,3.929269219441034,5 Top Healthcare Mutual Funds to Buy in October,"Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Amarin Corporation PLC (AMRN): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report Get Your Free (PRHSX): Fund Analysis Report Get Your Free (FACDX): Fund Analysis Report Get Your Free (DLHAX): Fund Analysis Report Get Your Free (FBDIX): Fund Analysis Report Get Your Free (FSMEX): Fund Analysis Report To read this article on Zacks.com click here. The FDA issued a clear statement reaffirming the positive benefit-risk profile of ACADIA Pharmaceuticals Inc's ACAD Nuplazid for patients with Parkinson's disease psychosis. These funds boast a Zacks Mutual Fund Rank #1 (Strong Buy) or 2 (Buy), require a minimum initial investment within $5,000 and carry a low expense ratio."
+2018-10-01,20.81999969482422,20.790000915527344,-2.040816704815167,5 Best Biotech Stocks to Buy In October,"Click to get this free report Allergan plc (AGN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Amarin Corporation PLC (AMRN): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Infinity Pharmaceuticals, Inc. (INFI): Free Stock Analysis Report Champions Oncology, Inc. (CSBR): Free Stock Analysis Report CytoDyn Inc. (CYDY): Free Stock Analysis Report Nektar Therapeutics (NKTR): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report Madrigal Pharmaceuticals, Inc. (MDGL): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA issued a clear statement reaffirming the positive benefit-risk profile of ACADIA Pharmaceuticals Inc's ACAD Nuplazid for patients with Parkinson's disease psychosis. Biotech Stocks on Strong Ground The Zacks Medical - Drugs industry, part of the broader Zacks Medical Sector, has outperformed its own sector over the past year."
+2018-09-28,21.75,20.76000022888184,-0.14408635800476305,,
+2018-09-27,21.059999465942383,21.809999465942383,-4.551723085600738,Interesting ACAD Put And Call Options For November 9th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $21.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $22.00 strike price has a current bid of 30 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $22.00 strike highlighted in red: Considering the fact that the $22.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the November 9th expiration."
+2018-09-26,21.51000022888184,21.100000381469727,3.5612536515628985,,
+2018-09-25,20.09000015258789,21.40999984741211,-1.906089460945701,Bullish Two Hundred Day Moving Average Cross - ACAD,"In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $21.05, changing hands as high as $21.85 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $12.77 per share, with $41.20 as the 52 week high point - that compares with a last trade of $21.41. Acadia Pharmaceuticals Inc shares are currently trading up about 7.9% on the day."
+2018-09-24,20.21999931335449,19.850000381469727,6.570431482322229,,
+2018-09-21,20.100000381469727,20.170000076293945,-1.8298661941120482,FDA Confirms Positive Safety Profile of Acadia's Nuplazid,"Shares of ACADIA Pharmaceuticals Inc.ACAD soared 26.6% after the FDAissued a clear statement reaffirming the positive benefit-risk profile of Nuplazid (pimavanserin) for patients with Parkinson's disease psychosis. ACADIA Pharmaceuticals Inc. Price ACADIA Pharmaceuticals Inc. Price | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Stocks to Consider Acadia is a Zacks Rank #4 (Sell) stock. Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here."
+2018-09-20,15.199999809265137,19.11000061035156,0.34825718157076135,Here's Why Acadia Pharmaceuticals Inc. Spiked Over 26% Today,"What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) spiked 26.6% on Thursday after the U.S. Food and Drug Administration said it hadn't identified ""any new or unexpected safety findings with Nuplazid, or findings that are inconsistent with the established safety profile currently described in the drug label."" 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. When the FDA looked further into the reports, the agency determined that the postmarketing data was consistent with what was seen in the clinical trials Acadia Pharmaceuticals used to get the drug approved."
+2018-09-19,14.279999732971191,15.100000381469728,25.72368980362149,,
+2018-09-18,14.020000457763672,14.279999732971191,5.7423015674519355,,
+2018-09-17,13.90999984741211,14.050000190734863,1.854488350344833,,
+2018-09-14,13.760000228881836,13.880000114440918,1.0064726445615333,"Noteworthy Friday Option Activity: FDX, WYNN, ACAD","Below is a chart showing WYNN's trailing twelve month trading history, with the $135 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) saw options trading volume of 13,340 contracts, representing approximately 1.3 million underlying shares or approximately 84.4% of ACAD's average daily trading volume over the past month, of 1.6 million shares. Especially high volume was seen for the $14 strike call option expiring December 21, 2018 , with 7,016 contracts trading so far today, representing approximately 701,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $14 strike highlighted in orange: For the various different available expirations for FDX options , WYNN options , or ACAD options , visit StockOptionsChannel.com."
+2018-09-13,13.770000457763672,13.760000228881836,0.8720921770568419,,
+2018-09-12,13.529999732971191,13.770000457763672,-0.07262330101229374,,
+2018-09-11,13.890000343322754,13.489999771118164,1.7738413121149135,,
+2018-09-10,14.050000190734863,13.949999809265137,-2.8797736667938922,"Health Care Sector Update for 09/10/2018: ACAD,MRK,FOLD | Health Care Sector Update for 09/10/2018: MYOK, ACAD, MRK, FOLD, LLY","Among health care stocks moving on news: (-) ACADIA Pharmaceuticals ( ACAD ) was edging lower Monday afternoon, recovering from a nearly 2% decline earlier in the session that followed the company saying additional data from phase II testing of its pimavanserin drug candidate may demonstrate it has the dementia-related psychosis in patients with Alzheimer's disease. Health care stocks were trending lower Monday, including a 0.2% decline for the NYSE Health Care Index in recent trading. (-) Amicus Therapeutics ( FOLD ) was down almost 2% Monday afternoon, giving back a more than 1% gain that followed the company saying it has received written minutes from a recent meeting with US Food and Drug Administration officials detailing the regulatory path for its AT-GAA drug candidate after ruling Amicus' current clinical package is not sufficient to support accelerated approval of the prospective treatment for Pompe disease. | (-) ACADIA Pharmaceuticals ( ACAD ) was edging lower Monday afternoon, recovering from a nearly 2% decline earlier in the session after the company said additional data from Phase II testing of its pimavanserin drug candidate may demonstrate it has the dementia-related psychosis in patients with Alzheimer's disease. Health care stocks trended lower, including a slightly more than 0.2% decline for the NYSE Health Care Index in recent trade. Among health care stocks moving on news: (+) MyoKardia ( MYOK ) jumped to a new record high on Monday, rising more than 5% to a best-ever $61.15 a share after analysts at Morgan Stanley began coverage of the biotech company with an Overweight investment rating and a $72 price target."
+2018-09-07,13.899999618530272,14.039999961853027,-0.7117464776667466,,
+2018-09-06,14.449999809265137,14.029999732971191,1.007196742193571,,
+2018-09-05,14.140000343322754,14.380000114440918,-2.9065749608152047,,
+2018-09-04,14.1899995803833,14.239999771118164,1.697310928507139,,
+2018-08-31,14.479999542236328,14.220000267028809,0.3523621720467498,,
+2018-08-30,14.390000343322754,14.420000076293944,-1.7955751617887452,,
+2018-08-29,14.699999809265137,14.420000076293944,0.20847624916916768,,
+2018-08-28,14.520000457763672,14.600000381469728,-1.9047601129539782,,
+2018-08-27,14.449999809265137,14.539999961853027,0.550963644517528,,
+2018-08-24,14.31999969482422,14.390000343322754,0.6228384344350218,,
+2018-08-23,14.550000190734863,14.260000228881836,0.4888313546810634,,
+2018-08-22,14.06999969482422,14.18000030517578,-1.9931268594600655,,
+2018-08-21,13.630000114440918,14.109999656677246,0.7818096143386818,,
+2018-08-20,13.100000381469728,13.56999969482422,3.521640045532876,,
+2018-08-17,13.300000190734863,13.029999732971191,3.5877809134976646,,
+2018-08-16,13.81999969482422,13.300000190734863,-2.030078600688754,,
+2018-08-15,14.3100004196167,13.789999961853027,-3.7626593022581916,,
+2018-08-14,14.510000228881836,14.329999923706056,-3.633825594098762,,
+2018-08-13,14.81999969482422,14.289999961853027,-1.24052586034763,,
+2018-08-10,13.829999923706056,14.920000076293944,-3.5762465849192413,,
+2018-08-09,12.800000190734863,13.90999984741211,7.881418355755112,"Why Acadia Pharmaceuticals Stock Is Tanking Today | After Hours Most Active for Aug 9, 2018 : ABEV, QQQ, VER, BRK/B, F, DBX, KMI, WFC, ACAD, GRPN, EA, OSTK","So what During the accompanying conference call, Acadia's CEO Stephen Davis laid the blame for the lowered guidance on ""reduced patient starts"" during the second quarter resulting from a pair CNN articles questioning Nuplazid's risk-to-reward ratio. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them! | ACADIA Pharmaceuticals Inc. ( ACAD ) is +0.12 at $14.03, with 811,041 shares traded. As reported by Zacks, the current mean recommendation for ACAD is in the ""buy range"". Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2018."
+2018-08-08,14.1899995803833,14.020000457763672,8.671872188570019,"Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Lags Revenue Estimates","Acadia Pharmaceuticals (ACAD) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $57.06 million for the quarter ended June 2018, missing the Zacks Consensus Estimate by 1.58%. Acadia shares have lost about 52.9% since the beginning of the year versus the S&P 500's gain of 6.9%."
+2018-08-07,14.119999885559082,14.1899995803833,-1.1980206317598558,,
+2018-08-06,14.649999618530272,13.90999984741211,0.49574855093171344,,
+2018-08-03,15.609999656677246,15.220000267028809,-5.0511931084432415,,
+2018-08-02,15.1899995803833,15.489999771118164,-2.4983946074695367,,
+2018-08-01,14.989999771118164,15.359999656677246,1.9749848520225777,,
+2018-07-31,14.880000114440918,15.09000015258789,2.4683114823789105,Will ACADIA (ACAD) Disappoint Investors in Q2 Earnings?,"Earnings ESP: ACADIA has an Earnings ESP of -7.30%, which decreases the odds of an earnings surprise. Click to get this free report Dicerna Pharmaceuticals, Inc. (DRNA): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc ."
+2018-07-30,15.329999923706056,14.8100004196167,1.4112905680905832,,
+2018-07-27,16.190000534057617,15.4399995803833,-3.3920385301844567,,
+2018-07-26,16.049999237060547,16.229999542236328,-4.632494928561608,,
+2018-07-25,15.859999656677246,16.049999237060547,1.1214972818201026,,
+2018-07-24,16.540000915527344,15.989999771118164,1.197979725701373,,
+2018-07-23,16.709999084472656,16.469999313354492,-3.325278802692521,,
+2018-07-20,17.110000610351562,16.84000015258789,-1.4362644181182378,,
+2018-07-19,17.450000762939453,17.079999923706055,-1.5780271661727554,,
+2018-07-18,18.200000762939453,17.579999923706055,-2.120348556197265,,
+2018-07-17,16.8700008392334,18.15999984741211,-3.406597874962194,,
+2018-07-16,17.520000457763672,16.8700008392334,7.646703876733954,,
+2018-07-13,17.700000762939453,17.459999084472656,-3.710043387825586,5 Big Pharma Stocks Investors Love Right Now | Better Buy: Acadia Pharmaceuticals vs. Eli Lilly,"Big Pharma Stocks Investors Love: Acadia Pharmaceuticals (ACAD) Source: Shutterstock Investors changed their mind on Acadia Pharmaceuticals (NASDAQ: ACAD ) on Monday, July 9 after Southern Investigative Reporting Foundation (SIRF) wrote a negative piece on it. Acadia is described as a biotechnology company that makes drugs targeting disorders in the central nervous system. But the Foundation believes that Acadia is not a biotech company at all, but instead a ""ruthless marketing entity."" | The case for Eli Lilly Eli Lilly doesn't have nearly as much drama as Acadia. Acadia Pharmaceuticals (NASDAQ: ACAD) aspires to become a big player in the neuroscience market. Investors considering buying shares of Acadia or Lilly have a stark contrast -- beaten-down biotech, or relatively boring big pharma."
+2018-07-12,16.979999542236328,17.760000228881836,-1.355941627806685,"Dopamine and the Weather, Part 2","Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report bluebird bio, Inc. (BLUE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report CRISPR THERAPTC (CRSP): Free Stock Analysis Report To read this article on Zacks.com click here. Followers of my portfolios at Zacks know that I have been a frequent investor in Acadia Pharmaceuticals (ACAD), maker of NUPLAZID (pimavanserin), the first and only medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. (0: 45 ) - The Century of Biology (8: 00 ) - Wonderful Dopamine: The Attention Drug (21: 30 ) - Memory, Emotion and Learning Complete the Loop (33: 00 ) - Dopamine in the Noisy Concert of Consciousness (39: 05 ) - The Cerebral Symphony: Arouse, Orient, Detect, Execute (43: 10 ) - Find Your Flow: 5 Ways To Learn More, Better, Faster Welcome back to Mind Over Money."
+2018-07-11,16.5,16.81999969482422,4.593643743660424,,
+2018-07-10,16.559999465942383,16.68000030517578,1.93939208984375,,
+2018-07-09,17.959999084472656,16.6299991607666,0.7246427723635771,Why ACADIA Pharmaceuticals Stock Is Falling Today,"InvestorPlace - Stock Market News, Stock Advice & Trading Tips ACADIA Pharmaceuticals (NASDAQ: ACAD ) stock fell more than 6% on Monday as one of the company's drugs is being investigated for its efficacy. His report was published Monday morning and it was titled ""Acadia Pharmaceuticals: This Is Not a Pharmaceuticals Company."" More From InvestorPlace 20 Red-Hot Tech Stocks to Consider The ABSOLUTE Best Way to Invest in the Marijuana Boom The Best Shot You'll Ever Have at Making 50 TIMES Your Money 4 Developments That Will Fuel the Mega Marijuana Market Compare Brokers The post Why ACADIA Pharmaceuticals Stock Is Falling Today appeared first on InvestorPlace ."
+2018-07-06,16.770000457763672,17.84000015258789,-7.40534516427625,,
+2018-07-05,16.489999771118164,16.639999389648438,6.380439270225913,,
+2018-07-03,16.719999313354492,16.399999618530273,0.9096399066844995,,
+2018-07-02,15.15999984741211,16.709999084472656,-1.9138738514697822,,
+2018-06-29,16.549999237060547,15.270000457763672,10.224269476659261,Why Acadia Pharmaceuticals Is Soaring Today,"What happened After reporting the regulatory approval of two new dosing formulations for the company's one and only drug Nuplazid , shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, rose as much as 13% in early morning trading on Friday. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. So what Acadia announced today that the FDA has approved two new dosing formulation of its Parkinson's disease psychosis drug Nuplazid."
+2018-06-28,15.84000015258789,15.06999969482422,-7.734131953496187,,
+2018-06-27,16.360000610351562,15.869999885559082,-4.861113954205801,,
+2018-06-26,16.0,16.299999237060547,-2.995114342981377,,
+2018-06-25,16.280000686645508,16.06999969482422,1.874995231628418,,
+2018-06-22,16.010000228881836,16.329999923706055,-1.2899323277888617,,
+2018-06-21,17.049999237060547,15.949999809265137,1.9987488460302665,,
+2018-06-20,16.329999923706055,17.049999237060547,-6.451609835878516,,
+2018-06-19,16.149999618530273,16.329999923706055,4.409058889885714,,
+2018-06-18,15.5600004196167,15.829999923706056,1.1145529995508578,,
+2018-06-15,15.1899995803833,15.729999542236328,1.735215275116351,,
+2018-06-14,16.399999618530273,15.350000381469728,3.5549702223191315,"Noteworthy Thursday Option Activity: ACAD, ETSY, INSY","Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total of 24,816 contracts have traded so far, representing approximately 2.5 million underlying shares. Particularly high volume was seen for the $20 strike call option expiring September 21, 2018 , with 10,053 contracts trading so far today, representing approximately 1.0 million underlying shares of ACAD. That amounts to about 125% of ACAD's average daily trading volume over the past month of 2.0 million shares."
+2018-06-13,17.700000762939453,16.18000030517578,-6.40243452124326,,
+2018-06-12,17.940000534057617,17.670000076293945,-8.587572837546274,,
+2018-06-11,17.56999969482422,17.8700008392334,-1.5050192292419289,,
+2018-06-08,17.5,17.600000381469727,1.7074624338072937,,
+2018-06-07,17.6299991607666,17.5,0.5714307512555803,July 27th Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $17.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of 20 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $18.00 strike highlighted in red: Considering the fact that the $18.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the July 27th expiration."
+2018-06-06,17.510000228881836,17.520000457763672,-0.7373747416613537,,
+2018-06-05,17.40999984741211,17.43000030517578,0.05711152913259863,,
+2018-06-04,18.350000381469727,17.440000534057617,0.11487913807560902,,
+2018-06-01,18.1299991607666,18.34000015258789,-4.95912713076044,,
+2018-05-31,18.09000015258789,18.100000381469727,1.1583066825272235,,
+2018-05-30,17.829999923706055,18.11000061035156,0.05528042453004259,,
+2018-05-29,17.549999237060547,17.760000228881836,1.5703908460101927,,
+2018-05-25,17.420000076293945,17.690000534057617,1.1965869000029778,,
+2018-05-24,16.969999313354492,17.469999313354492,1.5499452157356919,,
+2018-05-23,17.229999542236328,17.0,2.9463760767893867,Is Acadia Pharmaceuticals (ACAD) a Buy?,"One major reason behind Acadia stock's big drop this year stems from reports of safety problems for the biotech's Parkinson's disease psychosis drug, Nuplazid. Assuming nothing bad happens as a result of the FDA's evaluation of Nuplazid, the question for Acadia would then primarily concern the commercial success of the drug. As for Nuplazid's sales momentum, it seems likely that the drug will continue to generate higher sales -- assuming, of course, Acadia moves past the current safety questions."
+2018-05-22,17.84000015258789,17.25,-1.3348784001562188,,
+2018-05-21,18.020000457763672,17.670000076293945,-3.3071757149189516,,
+2018-05-18,18.040000915527344,18.0,-1.9422884160856593,Better Buy: Acadia Pharmaceuticals vs. Biogen,"The case for Acadia The reason to consider buying Acadia stock can be summed up in one word: Nuplazid. Given that its market cap stands close to $2.3 billion, Acadia stock could have a huge ramp ahead of it if the drug gets anywhere close to that sales target. But 2018 has been horrible for Acadia Pharmaceuticals (NASDAQ: ACAD) , which has seen its share price plunge nearly 40%."
+2018-05-17,18.56999969482422,18.1299991607666,-0.22173455375445278,,
+2018-05-16,18.600000381469727,18.5,-2.369415946626283,,
+2018-05-15,19.06999969482422,18.57999992370605,-0.5376364484882058,,
+2018-05-14,18.64999961853028,19.13999938964844,-2.569479700889341,,
+2018-05-11,18.14999961853028,18.549999237060547,2.6273446709956296,,
+2018-05-10,18.59000015258789,18.26000022888184,2.203854693869447,,
+2018-05-09,18.13999938964844,18.57999992370605,-1.7751475040203926,,
+2018-05-08,18.39999961853028,18.11000061035156,2.4255818570131575,,
+2018-05-07,17.770000457763672,18.540000915527344,-1.576081598864107,Are These 2 Biotech Laggards Ready to Rebound?,"First off, the company's valuation at the start of the year seemed to reflect an unwarranted optimism surrounding the commercial potential of Nuplazid, Acadia's FDA-approved drug for Parkinson's disease psychosis (PDP). Acadia Pharmaceuticals (NASDAQ: ACAD) and Celgene Corporation (NASDAQ: CELG) , for instance, are both trading near their 52-week lows right now. That's a surprising turn of events given that Acadia and Celgene were two of the absolute best-performing growth stocks since about the start of 2010."
+2018-05-04,17.5,17.799999237060547,4.33314821568989,"ACADIA Posts Narrower than Expected Loss in Q1, Sales Beat | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 66.7% Follow-Through Indicator, 9.2% Sensitive | Why Acadia Pharmaceuticals Jumped 11% Higher Today | Health Care Sector Update for 05/04/2018: SRPT, ACAD, PTLA, CELG | Health Care Sector Update for 05/04/2018: ACAD,PTLA,CELG","For the second quarter of 2018, ACADIA expects Nuplazid net sales to be between $57 million and $61 million. ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote Today's Stocks from Zacks' Hottest Strategies It's hard to believe, even for us at Zacks. ACADIA Pharmaceuticals, Inc .ACAD focuses on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.8% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (4 events) the stock dropped further, adding to the extended-hours losses by an average of 4.8% by the following regular session close. Extended-Hours Dollar Volume: $4,834,451 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) closed up 11% on Friday after announcing solid enough first-quarter revenue from its Parkinson's disease drug Nuplazid before the bell this morning. As a much larger potential market, MDD could give Acadia a major revenue boost, although sales for that indication would still be years away since the company would still need to run a phase 3 confirmatory program. | + ACADIA Pharmaceuticals ( ACAD ) still was about 12% higher this afternoon, staying within close range of its intra-day high, after Friday reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Among health care stocks moving on news: + Sarepta Therapeutics ( SRPT ) jumped out to its best share price in more than 18 years on Friday, climbing over 16% to $90.99 a share, after more than halving its adjusted Q1 net loss compared with year-ago levels and racing to a nearly four-fold year-over-year increase in quarterly revenue. | Among health care stocks moving on news: + ACADIA Pharmaceuticals ( ACAD ) was almost 12% higher Friday afternoon, staying within close range of its intra-day high, after reporting a narrower-than-expected Q1 net loss on above-consensus sales. ACADIA reiterated it FY18 forecast expecting between $255 million to $270 million in revenue compared with the Street view at $263.4 million. Net loss for the three months ended March 31 was $0.44 per share, trimming a $0.72 per share net loss from the same quarter last year and beating the Capital IQ consensus expecting a $0.56 per share net loss."
+2018-05-03,16.729999542236328,16.040000915527344,1.7142813546316964,,
+2018-05-02,16.399999618530273,16.8799991607666,-4.124319459585299,,
+2018-05-01,15.84000015258789,16.479999542236328,2.9268265451297886,Will ACADIA (ACAD) Disappoint Investors This Earnings Season?,"ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks That Warrant a Look Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to release first-quarter 2018 results on May 8."
+2018-04-30,16.3799991607666,15.8100004196167,4.040400148253006,,
+2018-04-27,15.68000030517578,16.280000686645508,-3.4798459728567273,,
+2018-04-26,15.5,15.119999885559082,3.826532970612733,Implied IWF Analyst Target Price: $157,"Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and LB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWF's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and L Brands, Inc (Symbol: LB). Although ACAD has traded at a recent price of $15.20/share, the average analyst target is 238.82% higher at $51.50/share."
+2018-04-25,19.39999961853028,15.199999809265137,-2.4516136415543093,RSI Alert: Acadia Pharmaceuticals (ACAD) Now Oversold | This Explains Why Acadia Pharmaceuticals Is Selling Off Today,"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $14.51 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $14.51 per share, with $41.20 as the 52 week high point - that compares with a last trade of $15.20. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | What happened Shares of Acadia Pharmaceuticals (NASDAQ: ACAD) dropped 19% as of 3:00 p.m. EDT on Wednesday after a news report was published on CNN stating that the Food and Drug Administration (FDA) will re-examine the safety profile of its Parkinson's Disease Psychosis (PDP) drug Nuplazid. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. If that happens, then the bull case for owning Acadia will be obliterated."
+2018-04-24,20.0,19.46999931335449,-21.649483978615308,,
+2018-04-23,19.950000762939453,19.920000076293945,-2.650003433227557,,
+2018-04-20,19.76000022888184,19.89999961853028,-0.15037937593084824,,
+2018-04-19,19.729999542236328,19.65999984741211,0.7084989272612129,Diamond Stocks Aren't Forever -- Your Shot At An Easy 35.8% Gain,"It's this rising trend of online, direct jewelers -- along with tighter wallets in general -- that could spell more pain for diamond and jewelry giant Signet (NYSE: SIG ) , a company already experiencing problems. Diamonds Aren't This Stock's Best Friend If you're not familiar, Signet Jewelers is the world's largest retailer of diamond jewelry and the largest specialty jewelry retailer in the United States, the U.K. and Canada. While the rest of the crowd is simply buying stocks and hoping for the best, my subscribers and I have spent years ""raiding"" the market with our simple options trades, taking more than our fair share of gains."
+2018-04-18,19.850000381469727,19.979999542236328,-0.35478812188702424,,
+2018-04-17,19.170000076293945,19.8799991607666,0.654907598329105,,
+2018-04-16,18.89999961853028,18.979999542236328,3.7036989131296725,,
+2018-04-13,19.3700008392334,18.89999961853028,0.423280028152025,,
+2018-04-12,19.09000015258789,19.290000915527344,-2.4264388246754405,,
+2018-04-11,17.600000381469727,19.100000381469727,1.047672924781724,Close Update: U.S. Equities Post First Slide in Three Days as Global Political Worries Dent Sentiment,"(+) EYEG (+26.6%) Granted patent for iontophoretic contact lens (+) ACAD (+7.67%) FDA approves risk disclosure for Nuplazid (+) MAT (+6.58%) Jefferies raises to hold from underperform, lifts PT to $13 vs $12 (+) HLT (+6.13%) Prices senior notes and secondary offering (+) NFLX (+1.88%) Cowen boosts PT to $325 from $275 Wall Street retreated for the first time in three days in a choppy mid-week session that saw the major equity indexes reclaim some losses but still end lower as heightened geopolitical tensions dented investor sentiment heading into earnings season. Markets slightly extended the selling tone after minutes from the Federal Open Market Committee's meeting last month that showed all members viewed economic data as positive and said they expect further rate hikes, while a strong majority of Fed officials saw the trade war as a downside risk."
+2018-04-10,16.68000030517578,17.739999771118164,8.522727088002139,Don't Try to Catch This Falling Knife,"Acadia Pharmaceuticals ' (NASDAQ: ACAD) stock got walloped yesterday after a CNN report suggested that Nuplazid, the company's Parkinson's disease psychosis medication (PDP), may be tied to an increased rate of mortality among patients, and that the drug may not even be all that effective at treating hallucinations, as advertised. But this falling knife still isn't a buy That being said, I don't think Acadia's shares are a compelling buy here, even after yesterday's bloodbath. But that doesn't mean Acadia is now a screaming buy."
+2018-04-09,17.600000381469727,16.5,6.354912749093095,Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher | Mid-Afternoon Market Update: Crude Oil Up Over 2%; Therapix Biosciences Shares Spike Higher | Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide,"Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The eurozone's STOXX 600 climbed 0.13 percent, the Spanish Ibex Index climbed 0.62 percent, while Italy's FTSE MIB Index gained 0.53 percent. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 24 percent to $16.31. Toward the end of trading Monday, the Dow traded up 1.59 percent to 24,313.96 while the NASDAQ climbed 2.05 percent to 7,056.84. The eurozone's STOXX 600 climbed 0.13 percent, the Spanish Ibex Index climbed 0.62 percent, while Italy's FTSE MIB Index gained 0.53 percent. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) were down 23 percent to $16.68. Midway through trading Monday, the Dow traded up 1.06 percent to 24,186.09 while the NASDAQ climbed 1.51 percent to 7,019.36. The eurozone's STOXX 600 slipped 0.03 percent, the Spanish Ibex Index climbed 0.73 percent, while Italy's FTSE MIB Index gained 0.53 percent."
+2018-04-06,21.88999938964844,21.530000686645508,-6.250002031976483,,
+2018-04-05,22.450000762939453,22.1299991607666,-1.6445806899984337,,
+2018-04-04,20.76000022888184,22.34000015258789,-1.4253968431979362,,
+2018-04-03,21.059999465942383,21.200000762939453,7.6107895293176115,Better Buy: Acadia Pharmaceuticals vs. Eli Lilly,"In one corner is Acadia Pharmaceuticals (NASDAQ: ACAD) , a one-drug company that it is currently in hyper-growth mode. The case for Acadia Pharmaceuticals Once upon a time, Acadia Pharmaceuticals was as red-hot as biotech stocks can be. What's more, Acadia priced Nuplazid at $24,000 per year, so it's understandable why Wall Street expected the drug to eventually reach blockbuster status."
+2018-04-02,22.170000076293945,20.8799991607666,0.6647735068724779,,
+2018-03-29,23.100000381469727,22.46999931335449,-5.818677993180175,ACAD May 11th Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $22.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $23.00 strike price has a current bid of 10 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $23.00 strike highlighted in red: Considering the fact that the $23.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the May 11th expiration."
+2018-03-28,22.71999931335449,23.11000061035156,-2.7272773061103925,,
+2018-03-27,23.690000534057617,22.68000030517578,1.7165550562663667,,
+2018-03-26,23.020000457763672,23.540000915527344,-4.263403149484199,,
+2018-03-23,23.6299991607666,22.56999969482422,2.258907243367572,,
+2018-03-22,24.450000762939453,23.850000381469727,-4.4858210054544685,,
+2018-03-21,24.530000686645508,24.65999984741211,-2.453989213690285,,
+2018-03-20,24.739999771118164,24.51000022888184,0.5299598741445409,Is Acadia Pharmaceuticals a Buy?,"Acadia Pharmaceuticals (NASDAQ: ACAD) , a company developing treatments for diseases of the central nervous system, has had an exceedingly rough go of it this year, with the company's stock falling by a whopping 14.5% year to date. So, as you can see, the Street's price targets for Acadia's stock don't match up with the company's near-term growth prospects. Wall Street, however, clearly thinks that Acadia's sizable downturn presents an outsize buying opportunity."
+2018-03-19,25.700000762939453,24.57999992370605,-0.9296667112536896,,
+2018-03-16,25.170000076293945,25.75,-4.35797978982356,,
+2018-03-15,25.26000022888184,25.209999084472656,2.3043302421453724,,
+2018-03-14,25.020000457763672,25.049999237060547,-0.19794593806857064,,
+2018-03-13,26.01000022888184,24.979999542236328,0.1198991956355717,,
+2018-03-12,25.459999084472656,25.88999938964844,-3.9600179837821963,Is Acadia Pharmaceuticals Stock Now a Strong Buy?,"So what Acadia's stock has shed more than a third of its value since Nuplazid's approval by the Food and Drug Administration roughly two years ago. 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acadia Pharmaceuticals wasn't one of them!"
+2018-03-09,25.309999465942383,25.32999992370605,1.6889250614232347,,
+2018-03-08,25.32999992370605,25.25,0.07902196043339044,Interesting ACAD Put And Call Options For April 27th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $23.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $26.00 strike price has a current bid of 20 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $26.00 strike highlighted in red: Considering the fact that the $26.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 27th expiration."
+2018-03-07,24.690000534057617,25.39999961853028,-0.31583073015006263,,
+2018-03-06,24.850000381469727,25.11000061035156,2.8756543909072985,,
+2018-03-05,24.26000022888184,24.82999992370605,1.0462785709883153,,
+2018-03-02,22.68000030517578,23.68000030517578,2.3495452986254293,,
+2018-03-01,25.40999984741211,22.979999542236328,4.409171016509162,,
+2018-02-28,27.770000457763672,24.920000076293945,-9.563165367052395,Mid-Morning Market Update: Markets Open Higher; Lowe's Profit Misses Views,"ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) was down, falling around 15 percent to $26.53 after the company reported results for its fourth quarter. Meanwhile, top gainers in the sector included TiVo Corp (NASDAQ: TIVO ), up 15 percent, and Agilysys, Inc. (NASDAQ: AGYS ), up 6 percent. The eurozone's STOXX 600 fell 0.33 percent, the Spanish Ibex Index fell 0.52 percent, while Italy's FTSE MIB Index declined 0.12 percent."
+2018-02-27,32.130001068115234,31.15999984741211,-10.262874809110603,"Earnings Reaction History: ACADIA Pharmaceuticals Inc, 62.5% Follow-Through Indicator, 8.3% Sensitive","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,965,797 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
+2018-02-26,31.68000030517578,32.33000183105469,-3.0189890708273976,,
+2018-02-23,30.3799991607666,31.520000457763672,2.0517724735397525,,
+2018-02-22,30.75,30.239999771118164,3.7524731023340285,Interesting ACAD Put And Call Options For April 6th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $32.00 strike price has a current bid of $1.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $32.00 strike highlighted in red: Considering the fact that the $32.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the April 6th expiration."
+2018-02-21,31.030000686645508,30.43000030517578,-1.6585373296970276,,
+2018-02-20,30.700000762939453,31.049999237060547,-1.9336138195058143,George Soros Just Dumped These 2 Healthcare Stocks. Should You? | Will ACADIA (ACAD) Disappoint Investors in Q4 Earnings?,"In the high-flying healthcare sector, the fund reportedly dumped its entire holdings of Acadia Pharmaceuticals (NASDAQ: ACAD) and Shire plc (NASDAQ: SHPG) in the fourth quarter of 2017, according to the latest 13F filings. Too high, too fast Acadia's stock has been steadily reverting to the mean ever since the FDA approval of its Parkinson's disease psychosis medicine, Nuplazid, in mid-2016. The key issue is that Nuplazid's sales are doing well, but arguably not well enough to justify Acadia's present market cap of $3.84 billion. | ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks That Warrant a Look Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to deliver an earnings beat this quarter. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Gemphire Therapeutics Inc. (GEMP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to release fourth-quarter 2017 results on Feb 27."
+2018-02-16,31.0,30.920000076293945,1.140060147958062,,
+2018-02-15,31.0,31.059999465942383,-0.25806427001953125,,
+2018-02-14,29.13999938964844,30.600000381469727,0.19354666433026713,Interesting ACAD Put And Call Options For April 20th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $1.80. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 20th expiration."
+2018-02-13,28.8799991607666,29.51000022888184,5.010298635558412,,
+2018-02-12,28.57999992370605,28.8700008392334,2.181444205064565,,
+2018-02-09,28.6200008392334,28.270000457763672,1.014698797416029,,
+2018-02-08,29.51000022888184,28.350000381469727,-1.222922331259797,Interesting ACAD Put And Call Options For March 29th,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $29.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $30.00 strike price has a current bid of $1.60. Below is a chart showing ACAD's trailing twelve month trading history, with the $30.00 strike highlighted in red: Considering the fact that the $30.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the March 29th expiration."
+2018-02-07,28.530000686645508,29.31999969482422,-3.930870343663384,,
+2018-02-06,26.729999542236328,28.799999237060547,2.7690115287957155,,
+2018-02-05,28.549999237060547,26.90999984741211,7.744106735031522,,
+2018-02-02,30.0,28.959999084472656,-5.74430624684419,,
+2018-02-01,29.61000061035156,30.26000022888184,-3.466669718424479,March 23rd Options Now Available For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $1.45. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 23rd expiration."
+2018-01-31,30.68000030517578,29.90999984741211,2.1952029893003204,,
+2018-01-30,30.979999542236328,30.64999961853028,-2.50977982432996,,
+2018-01-29,32.20000076293945,31.739999771118164,-1.0652031264756634,,
+2018-01-26,30.89999961853028,32.130001068115234,-1.4285744749134497,,
+2018-01-25,31.0,30.68000030517578,3.9805872646268248,,
+2018-01-24,30.75,30.56999969482422,-1.032257080078125,,
+2018-01-23,29.0,30.31999969482422,-0.5853668461001016,,
+2018-01-22,27.350000381469727,28.93000030517578,4.551723085600754,FBT's Holdings Imply 17% Gain Potential,"Three of FBT's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Ultragenyx Pharmaceutical Inc (Symbol: RARE), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $26.92/share, the average analyst target is 85.74% higher at $50.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, RARE, and BMRN: Combined, ACAD, RARE, and BMRN represent 8.57% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2018-01-19,27.81999969482422,26.920000076293945,5.776964905552769,,
+2018-01-18,28.25,27.780000686645508,-3.2350813386159536,,
+2018-01-17,28.43000030517578,28.25,-1.6637143835557244,,
+2018-01-16,28.57999992370605,28.14999961853028,-0.6331350799986153,,
+2018-01-12,27.799999237060547,28.3700008392334,-1.5045497072206122,"Noteworthy Friday Option Activity: MYL, MCD, ACAD","Below is a chart showing MCD's trailing twelve month trading history, with the $175 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 8,804 contracts thus far today. That number of contracts represents approximately 880,400 underlying shares, working out to a sizeable 52.8% of ACAD's average daily trading volume over the past month, of 1.7 million shares. Especially high volume was seen for the $31 strike call option expiring June 15, 2018 , with 2,501 contracts trading so far today, representing approximately 250,100 underlying shares of ACAD."
+2018-01-11,28.600000381469727,27.89999961853028,2.0503655317118676,Interesting ACAD Put And Call Options For March 2nd,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of $1.10. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the March 2nd expiration."
+2018-01-10,28.170000076293945,28.6299991607666,-2.447555082527148,3 Keys for Acadia Pharmaceuticals to Succeed in 2018,"Increase patient awareness of Nuplazid Although Nuplazid enjoyed solid momentum in 2017, Davis acknowledged one challenge for Acadia. Acadia's game plan, therefore, is to do all it can to increase patient and caregiver awareness of Nuplazid. Achieve positive results in clinical studies The third key for Acadia's success is to achieve positive results in clinical studies evaluating Nuplazid in treating other indications."
+2018-01-09,27.11000061035156,28.290000915527344,1.6329395925694787,,
+2018-01-08,28.96999931335449,27.11000061035156,4.35263843087196,,
+2018-01-05,28.8799991607666,28.89999961853028,-6.420430607830611,,
+2018-01-04,29.63999938964844,28.780000686645508,0.06925366462908193,"Noteworthy Thursday Option Activity: ACAD, V, NXPI","Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Acadia Pharmaceuticals Inc (Symbol: ACAD), where a total volume of 6,964 contracts has been traded thus far today, a contract volume which is representative of approximately 696,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.9% of ACAD's average daily trading volume over the past month, of 1.4 million shares. Particularly high volume was seen for the $30 strike put option expiring January 19, 2018 , with 4,336 contracts trading so far today, representing approximately 433,600 underlying shares of ACAD."
+2018-01-03,30.520000457763672,29.51000022888184,-2.9014801643460277,,
+2018-01-02,30.38999938964844,30.43000030517578,-3.309306073830378,,
+2017-12-29,31.18000030517578,30.11000061035156,0.13162525939689707,"TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise","Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 in the last 30 days."
+2017-12-28,30.71999931335449,31.18000030517578,-3.4316859664898907,,
+2017-12-27,30.5,30.700000762939453,1.4973990953877483,4 Biotech Stocks Ready to Crush the Market in 2018,"Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report SINO PHARMACEUT (SBMFF): Free Stock Analysis Report AnaptysBio, Inc. (ANAB): Free Stock Analysis Report To read this article on Zacks.com click here. Here we list a few biotech companies which should outperform the market in 2018: ACADIA Pharmaceuticals Inc . ACAD 's lead drug Nuplazid is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis."
+2017-12-26,29.100000381469727,30.459999084472656,0.6557402063588627,Why the Earnings Streak Will Continue for ACADIA Pharmaceuticals (ACAD),"ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Thanks in part to this history, recent estimates have been moving higher for ACADIA Pharmaceuticals. When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ACAD could see another beat at its next report, especially if recent trends are any guide. Consider ACADIA Pharmaceuticals Inc.ACAD , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat."
+2017-12-22,28.65999984741211,29.26000022888184,4.673535000600716,,
+2017-12-21,28.299999237060547,28.75,2.0935114607961447,,
+2017-12-20,28.299999237060547,28.299999237060547,1.5901087458339933,Minerva Initiates Phase III Study on Schizophrenia Candidate | First Week of ACAD February 2018 Options Trading | TherapeuticsMD Falls Despite Acceptance of NDA: Here's Why,"Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days. | Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $28.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $29.00 strike price has a current bid of $1.50. Below is a chart showing ACAD's trailing twelve month trading history, with the $29.00 strike highlighted in red: Considering the fact that the $29.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the February 2018 expiration. | Click to get this free report AMAG Pharmaceuticals, Inc. (AMAG): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report TherapeuticsMD, Inc. (TXMD): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days."
+2017-12-19,28.39999961853028,28.1200008392334,0.0,,
+2017-12-18,29.059999465942383,28.420000076293945,-0.9859112079501227,,
+2017-12-15,29.18000030517578,28.979999542236328,-2.2023379263943257,,
+2017-12-14,30.030000686645508,28.96999931335449,-0.6854035669902928,Shire's New Formulation of Oncaspar Gets Approval in Europe,"Click to get this free report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.42 to $2.41 for 2017 and from $1.62 to $1.59 over the last 30 days."
+2017-12-13,29.32999992370605,29.940000534057617,-3.5298080221570127,Glaxo's Nucala Label Expansion Application Gets FDA Approval,"Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Celldex Therapeutics, Inc. CLDX , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days."
+2017-12-12,30.64999961853028,29.18000030517578,2.0797838797760497,,
+2017-12-11,30.5,29.96999931335449,-4.796082648124314,Lilly Reports Mixed Results from Late-Stage Cyramza Study,"Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include Johnson & Johnson JNJ , ACADIA Pharmaceuticals Inc. ACAD and Corcept Therapeutics Inc. CORT . ACADIA's loss estimates narrowed from $2.44 to $2.41 for 2017 and from $1.67 to $1.59 over the last 30 days."
+2017-12-08,30.40999984741211,30.489999771118164,-1.7377071693295454,5 Cheap Biotech Stocks to Snag on the Bounce,"If so, here are five cheap biotech stocks ready to surge: Biotech Stocks to Buy: Acadia Pharmaceuticals (ACAD) Shares of Acadia Pharmacueticals Inc. (NASDAQ: ACAD ) are rising off of support from a multi-year pennant pattern, setting up another run at overhead resistance near the $40-a-share level. When the company last reported on Nov. 3, a loss of 61 cents per share missed estimates by 40 cents on a 10.4% Riss in revenues Biotech Stocks to Buy: Viking Therapeutics (VKTX) Viking Therapeutics Inc (NASDAQ: VKTX ) shares have more than quadrupled from their summertime low, rising above the $4-a-share threshold returning to levels not seen since January 2016. 7 'Strong Buy' Disruptive Stocks You Should Track Now When the company last reported on Nov. 9, a loss of 91 cents per share missed estimates by 91 cents on a 6.8% drop in revenues."
+2017-12-07,29.790000915527344,30.09000015258789,0.26307110854149734,,
+2017-12-06,29.950000762939453,29.709999084472656,1.0070467534097298,,
+2017-12-05,28.8799991607666,29.950000762939453,-0.8013411430819671,,
+2017-12-04,30.530000686645508,28.920000076293945,3.70499180493899,Here's How Acadia Pharmaceuticals Crushed It in 2017,"However, Acadia Pharmaceuticals (NASDAQ: ACAD) changed all of that in 2016 when the Food and Drug Administration approved its PDP drug Nuplazid for sale. Here's a quick review of the first three quarters: In the first quarter, Acadia reported total Nuplazid sales of $15.3 million . In October, Acadia kicked off a phase 3 study designed to test Nuplazid as a treatment for hallucinations and delusions associated with dementia-related psychosis (which can be associated with diseases such as Alzheimer's, Lewy bodies, Parkinson's, and more)."
+2017-12-01,30.14999961853028,30.15999984741211,-5.273503354540742,,
+2017-11-30,28.979999542236328,30.25,0.033168255417431784,Medicines Company to Sell Infectious Disease Unit to Melinta,"Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Cempra, Inc. (MLNT): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Inc. LGND and ACADIA Pharmaceuticals Inc. ACAD . ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days."
+2017-11-29,27.690000534057617,29.020000457763672,4.382334292009683,,
+2017-11-28,27.850000381469727,27.700000762939453,4.803177674446799,,
+2017-11-27,28.0,27.600000381469727,-0.5385982638265139,Spectrum Doubles in 3 Months: What's Driving the Rally?,"Some better-ranked stocks in the pharma sector include Ligand Pharmaceuticals Incorporated LGND , ACADIA Pharmaceuticals Inc. ACAD and ANI Pharmaceuticals, Inc. ANIP . Click to get this free report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss estimates narrowed from $2.53 to $2.42 for 2017 and from $1.82 to $1.62 over the last 30 days."
+2017-11-24,28.3799991607666,28.0,-1.428570066179548,,
+2017-11-22,27.82999992370605,28.25,-1.3389681888783291,ACAD January 2018 Options Begin Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $28.00 strike price has a current bid of 65 cents. Below is a chart showing ACAD's trailing twelve month trading history, with the $28.00 strike highlighted in red: Considering the fact that the $28.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading today, for the January 2018 expiration."
+2017-11-21,27.8799991607666,27.88999938964844,1.5091630522649981,,
+2017-11-20,27.75,27.700000762939453,0.03586882777210428,Analysts Anticipate 21% Upside For The Holdings of BBH,"Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Tesaro Inc (Symbol: TSRO), and BioMarin Pharmaceutical Inc. (Symbol: BMRN). Although ACAD has traded at a recent price of $27.86/share, the average analyst target is 75.43% higher at $48.88/share. Below is a twelve month price history chart comparing the stock performance of ACAD, TSRO, and BMRN: Combined, ACAD, TSRO, and BMRN represent 6.73% of the Biotech ETF."
+2017-11-17,27.64999961853028,27.86000061035156,-0.18017743084881757,,
+2017-11-16,27.11000061035156,27.63999938964844,0.7594972684214485,,
+2017-11-15,27.0,26.84000015258789,1.9549936088695985,,
+2017-11-14,27.299999237060547,27.0,-0.5925920274522569,,
+2017-11-13,28.489999771118164,27.309999465942383,-1.09889833496145,,
+2017-11-10,29.200000762939453,28.600000381469727,-4.141805246246476,,
+2017-11-09,29.450000762939453,29.15999984741211,-2.054795773263284,,
+2017-11-08,33.52000045776367,29.40999984741211,-0.9847229474176702,Acadia Pharmaceuticals is Now Oversold (ACAD) | How to Invest in Biotech Stocks,"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 24.9, after changing hands as low as $28.985 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $21.93 per share, with $41.20 as the 52 week high point - that compares with a last trade of $29.97. A bullish investor could look at ACAD's 24.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | That's how much a $10,000 investment in Acadia Pharmaceuticals five years ago would be worth today. If you choose wisely, you may wind up with the next Acadia Pharmaceuticals on your hands. My favorite biotech ETF is the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) , which has 159 different biotech stocks."
+2017-11-07,32.599998474121094,32.459999084472656,-12.261338168924853,"Nektar, Acadia Pop On Street-Crushing Quarters, But Tesaro Dips | Earnings Reaction History: ACADIA Pharmaceuticals Inc, 62.5% Follow-Through Indicator, 7.0% Sensitive","Acadia Beats And Raises For its third quarter, Acadia reported losses of 53 cents per share, narrowing from a 61-cent loss in the year-ago period, and beating the consensus view for a 63-cent loss. Acadia also boosted its 2017 sales guidance to between $124 million and $127 million, crushing views for $112 million. Nektar Therapeutics ( NKTR ) and Acadia Pharmaceuticals ( ACAD ) stocks jumped late Tuesday after beating third-quarter expectations, but Tesaro ( TSRO ) dove despite posting its own analyst-besting quarter. | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 75% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 75% Average next regular session additional loss: 2.7% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 75.0% of the time (3 events) the stock dropped further, adding to the extended-hours losses by an average of 2.7% by the following regular session close. Extended-Hours Dollar Volume: $4,510,007 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
+2017-11-06,35.2599983215332,32.54999923706055,-0.4294460006173725,Acadia Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ACAD,"In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $33.07, changing hands as low as $32.15 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $41.20 as the 52 week high point - that compares with a last trade of $32.55. Acadia Pharmaceuticals Inc shares are currently trading down about 9.2% on the day."
+2017-11-03,35.209999084472656,35.849998474121094,-7.685760673498574,Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings? | What's in the Cards for Adverum (ADVM) This Earnings Season?,"Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Earnings Whispers Our proven model shows that Perrigo is likely to beat on earnings because it has the right combination of the two key ingredients - a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. | Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Zacks ESP: Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -3.33%."
+2017-11-02,34.470001220703125,35.11000061035156,1.8176637497575865,Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised) | Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?,Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .. Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell). | Click to get this free report Horizon Pharma PLC (HZNP): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter .. Zacks Rank: Horizon Pharma currently carries a Zacks Rank #4 (Sell).
+2017-11-01,35.060001373291016,34.36000061035156,1.8566851377540585,,
+2017-10-31,35.2400016784668,34.83000183105469,-1.9965793939549563,Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3? | Will Endocyte (ECYT) Disappoint This Earnings Season? | Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store? | Is a Beat in the Cards for Mylan (MYL) This Earnings Season? | What's in the Cards for Prothena (PRTA) in Q3 Earnings?,"ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Other Stocks That Warrant a Look Here are some health care stocks that you may also want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter. Click to get this free report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. We expect ACADIA Pharmaceuticals Inc.ACAD to beat expectations when it reports its third-quarter 2017 results expectedly on Nov 6. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endocyte, Inc. (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.20% and a Zacks Rank #3. Zacks ESP: Endocyte's has an Earnings ESP of - 45.71% as the Most Accurate estimate is 51 cents while Zacks Consensus Estimate is pegged at a loss of 35 cents. | Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Jazz Pharmaceuticals PLC Price and EPS Surprise Jazz Pharmaceuticals PLC Price and EPS Surprise | Jazz Pharmaceuticals PLC Quote Let's see, how things have shaped up for this quarter: Factors at Play At the third-quarter conference call, investors' focus will be on the performance of Jazz's lead product, Xyrem, for cataplexy and excessive daytime sleepiness (""EDS""). | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Zacks ESP : The Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +3.92%. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Prothena Corporation PLC (PRTA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. Prothena Corporation PLC Price and EPS Surprise Prothena Corporation PLC Price and EPS Surprise | Prothena Corporation PLC Quote Earnings Whispers Our proven model doesn't conclusively show that Prothena is likely to beat estimates this quarter."
+2017-10-30,34.81999969482422,35.18000030517578,-1.16345013587964,Is a Beat in Store for Zoetis (ZTS) This Earnings Season? | What's in the Cards for Arena (ARNA) This Earnings Season? | Ball Corporation (BLL) to Post Q3 Earnings: What to Expect?,"Click to get this free report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Zoetis Inc. (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +3.2% and currently carries a Zacks Rank #3. The combination of Zoetis' Zacks Rank #2 and a positive ESP makes us confident of an earnings beat in the upcoming release. | Click to get this free report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is expected to release results on Nov 6. Arena Pharmaceuticals, Inc. Price and EPS Surprise Arena Pharmaceuticals, Inc. Price and EPS Surprise | Arena Pharmaceuticals, Inc. Quote Last quarter, the company missed expectations with a negative earnings surprise of 13.24%. | Click to get this free report Axcelis Technologies, Inc. (ACLS): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Ball Corporation (BLL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD also has a Zacks Rank of 3 and its Earnings ESP is +3.20%. Ball Corporation Price and EPS Surprise Ball Corporation Price and EPS Surprise | Ball Corporation Quote Factors to Consider Ball Corporation anticipates its food and aerosol business to improve in the third quarter due to incremental progress in the Canton metal service center, improving manufacturing metrics, as well as the ramping-up of its new aluminum aerosol capacity in Europe and India."
+2017-10-27,34.529998779296875,35.040000915527344,1.0338903317252883,,
+2017-10-26,34.52000045776367,34.650001525878906,1.4769827809442333,,
+2017-10-25,35.650001525878906,34.88999938964844,0.37659636845687433,,
+2017-10-24,35.81999969482422,35.63999938964844,-2.1318432081377923,,
+2017-10-23,36.4900016784668,35.779998779296875,-0.5025134190656909,,
+2017-10-20,35.849998474121094,36.31999969482422,-1.9457464141167835,,
+2017-10-19,36.06999969482422,35.83000183105469,1.3110215919322927,Implied FXH Analyst Target Price: $74,"Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and NBIX: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FXH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Neurocrine Biosciences, Inc. (Symbol: NBIX). Although ACAD has traded at a recent price of $36.73/share, the average analyst target is 31.36% higher at $48.25/share."
+2017-10-18,37.150001525878906,36.72999954223633,-0.6653669692266984,,
+2017-10-17,36.060001373291016,36.9900016784668,-1.1305571100717247,,
+2017-10-16,35.599998474121094,36.09999847412109,2.5790356898450244,,
+2017-10-13,35.81999969482422,35.400001525878906,1.4044944422215655,Lilly's Verzenio Gets Priority Review in First-Line Setting,"Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector includes ACADIA Pharmaceuticals Inc. ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018."
+2017-10-12,35.380001068115234,35.5,-1.172524211400258,Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017,"Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corporation CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-10-11,36.72999954223633,35.7599983215332,0.339171645737766,Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA,"(AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the health care sector is ACADIA Pharmaceuticals Inc ACAD carrying a Zacks Rank #2 (Buy). Over the last 60 days, ACADIA's loss per share estimates narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018."
+2017-10-10,37.63999938964844,36.90999984741211,-2.6408963593579884,Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel,"Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Celgene Corp. CELG and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-10-09,38.540000915527344,37.59000015258789,-1.9394249576876692,AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation | Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit | Roche (RHHBY) Receives FDA Approval For Cobas Zika Test,"Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Astrazeneca PLC (AZN): Free Stock Analysis Report To read this article on Zacks.com click here. Another better-ranked stocks in health care sector includes ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. | Click to get this free report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.63 to $2.52 for 2017 and from $1.92 to $1.85 for 2018 in the last 60 days. | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are include ACADIA Pharmaceuticals Inc. ACAD and Aduro Biotech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-10-06,38.130001068115234,38.540000915527344,-2.4649733792733466,,
+2017-10-05,40.59999847412109,38.29999923706055,1.0752683869053343,This Biotech Rockets — Then Dips — After FDA Breakthrough Win | ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status | Ligand (LGND) Signs Deal to Acquire Crystal Bioscience,"Acadia plans to see whether Nuplazid has a benefit in reducing hallucinations and delusions in patients with various forms of dementia, including Alzheimer's disease, Parkinson's disease, dementia related to blocked or reduced blood flow to the brain and frontotemporal dementia. Meanwhile, Acadia will discontinue enrolling a Phase 2 trial of Nuplazid in treating agitation in Alzheimer's due to overlap with the just-announced Phase 3 trial in dementia-related psychosis. Acadia Pharma Stock Rockets On Drug Breakthrough Nod Why These Biotechs Are Leading The Group Near A 21-Month High CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ACADIA Pharmaceuticals Inc. Price and Consensus ACADIA Pharmaceuticals Inc. Price and Consensus | ACADIA Pharmaceuticals Inc. Quote Zacks Rank & Other Stocks to Consider ACADIA carries a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis. | Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). ACADIA's loss per share estimates have narrowed from $2.82 to $2.53 for 2017 and from $2.07 to $1.87 for 2018 over the last 60 days."
+2017-10-04,38.7400016784668,39.13999938964844,-5.66502296429047,"Emergent Completes Acquisition of Anthrax Drug Raxibacumab | Celsion's Immunotherapy Candidate Impresses, Stock Surges | Acadia Pharma Stock Rockets On Drug Breakthrough Nod | 2 Stocks Move in After-Hours Trading","Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Both ACADIA and , Biogen carry Zacks Rank #2 (Buy). | Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Celsion Corporation (CLSN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . ACADIA's loss per share estimates have narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Acadia Pharmaceuticals ( ACAD ) rallied after the Food and Drug Administration late Wednesday granted its dementia drug breakthrough designation just as the drug begins a Phase 3 trial. [ibd-display-video id=2326965 width=50 float=left autostart=true]In premarket trading on the stock market today , Acadia jumped 5.3% to 41.20. There is no treatment approved by the FDA for the condition, Acadia said in a news release. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. On the other hand, AcadiaPharmaceuticalsInc. ( ACAD ) gained 0.72% and is also trading higher after market close."
+2017-10-03,38.59000015258789,38.86000061035156,1.0325185695693322,,
+2017-10-02,37.5,38.43000030517578,0.6996643086189915,,
+2017-09-29,38.43999862670898,37.66999816894531,2.4800008138020835,"Noteworthy Friday Option Activity: GRA, DDD, ACAD","Below is a chart showing DDD's trailing twelve month trading history, with the $15 strike highlighted in orange: And Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,894 contracts thus far today. That number of contracts represents approximately 689,400 underlying shares, working out to a sizeable 55.4% of ACAD's average daily trading volume over the past month, of 1.2 million shares. Especially high volume was seen for the $30 strike put option expiring December 15, 2017 , with 5,076 contracts trading so far today, representing approximately 507,600 underlying shares of ACAD."
+2017-09-28,38.0,38.369998931884766,-2.003123010594103,,
+2017-09-27,37.630001068115234,37.900001525878906,0.9736813996967516,,
+2017-09-26,37.66999816894531,37.43000030517578,0.7175138190268335,"Allergan Authorizes New $2B Share Buyback Plan, Stock Up","Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-09-25,37.40999984741211,37.66999816894531,-0.6371061200830707,,
+2017-09-22,37.65999984741211,37.59000015258789,0.6949968526962956,,
+2017-09-21,36.77999877929688,37.630001068115234,-0.18587279635644752,"Commit To Buy Acadia Pharmaceuticals At $25, Earn 8.2% Using Options | Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You?","Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $25 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2019 put at the $25 strike for the 6.2% annualized rate of return represents good reward for the risks. Investors eyeing a purchase of Acadia Pharmaceuticals Inc (Symbol: ACAD) stock, but cautious about paying the going market price of $37.17/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. | Acadia Pharmaceuticals (NASDAQ: ACAD) , for example, has proven to be an outstanding growth vehicle since the fund first bought it in 2010 (up over 9,600%), even though Acadia's Parkinson's disease psychosis drug, Nuplazid, initially missed the mark in late-stage testing. Even so, the Acadia Pharmaceuticals example clearly shows that even drugs with a problematic clinical history can make remarkable comebacks when the appropriate changes are made in future trials. There's no question that if Novavax can somehow change the trajectory of its RSV program, its stock could mimic even the jaw-dropping gains of Acadia Pharmaceuticals."
+2017-09-20,36.66999816894531,36.84999847412109,2.311044907638253,,
+2017-09-19,37.16999816894531,36.54999923706055,0.49086532359909096,Supernus Drops SPN-810's Lower Dose Test in Phase III Trials | Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD,"Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Supernus Pharmaceuticals, Inc. (SUPN): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days. | Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Innoviva, Inc. (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-09-18,36.790000915527344,36.97999954223633,-1.6680090460772758,BioMarin Says FDA Not Planning an AdCom for Pegvaliase BLA,"Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-09-15,36.290000915527344,36.83000183105469,0.5164409404208381,The Math Shows FBT Can Go To $140,"Similarly, BMRN has 24.89% upside from the recent share price of $91.23 if the average analyst target price of $113.94/share is reached, and analysts on average are expecting ACAD to reach a target price of $44.60/share, which is 22.70% above the recent price of $36.35. Three of FBT's underlying holdings with notable upside to their analyst target prices are Intrexon Corp (Symbol: XON), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of XON, BMRN, and ACAD: Combined, XON, BMRN, and ACAD represent 9.77% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2017-09-14,36.33000183105469,36.34999847412109,1.4880157120533288,"Alexion (ALXN) Reports Interim Results for Soliris Study | GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down","Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , ACADIA Pharmaceuticals Inc. ACAD and Aduro BioTech, Inc. ADRO . While Regeneron carries the same bullish rank as Alexion, ACADIA and Aduro hold a Zacks Rank #2 (Buy). | Notably, enobosarm has already been assessed in 24 completed or ongoing clinical trials for SUI enrolling over 1,700 subjects, of which, approximately 1,200 were treated with enobosarm at doses, ranging from 0.1-100 mg. GTx, Inc. Price GTx, Inc. Price | GTx, Inc. Quote Stocks to Consider Some stocks worth considering in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates lessened from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-09-13,37.18999862670898,36.459999084472656,0.05504167921430195,,
+2017-09-12,37.02999877929688,37.16999816894531,-1.9628920924779292,Marinus Stock Surges on Successful Phase II Epilepsy Study | Ultragenyx's Burosumab Positive in Phase II for XLH and TIO,"The promising data for ganaxolone in the study and a potential late stage study bode well for the company.. Stocks worth considering in the healthcare sector include Adverum Biotechnologies, Inc. ADVM , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD . Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharma's loss estimates have narrowed 8.9% to $2.59 for 2017 and 8.2% to $1.92 for 2018 over the last 60 days. | Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.57 for 2017 and from $2.07 to $1.90 for 2018 over the last 60 days."
+2017-09-11,37.04999923706055,37.08000183105469,0.37807019784916307,,
+2017-09-08,36.09999847412109,36.93000030517578,0.08097866292026665,,
+2017-09-07,35.290000915527344,35.79999923706055,2.299174144424676,Merck (MRK) Opts for Buying German Immuno-Oncology Biotech | BioMarin Presents Interim Data on BMN 250 from Phase I/II,"Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days. | Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.80 to $2.57 for 2017 and from $2.06 to $1.90 for 2018 over the last 30 days."
+2017-09-06,35.189998626708984,35.689998626708984,1.4451638093010295,"Notable ETF Inflow Detected - XBI, JUNO, EXEL, ACAD","Among the largest underlying components of XBI, in trading today Juno Therapeutics Inc (Symbol: JUNO) is off about 2.5%, Exelixis Inc (Symbol: EXEL) is up about 0.8%, and Acadia Pharmaceuticals Inc (Symbol: ACAD) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $121.7 million dollar inflow -- that's a 3.0% increase week over week in outstanding units (from 49,000,000 to 50,450,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $53.15 per share, with $84.90 as the 52 week high point - that compares with a last trade of $83.68."
+2017-09-05,36.0,35.20000076293945,1.420858253800849,,
+2017-09-01,35.689998626708984,36.15999984741211,-2.222220102945964,,
+2017-08-31,34.91999816894531,35.61000061035156,1.3168989598990757,The Medicines Company's Infection Drug Vabomere Gets FDA Nod,"Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days."
+2017-08-30,33.900001525878906,34.720001220703125,1.975952112219398,FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down,"Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Akebia Therapeutics, Inc. AKBA , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days."
+2017-08-29,32.0,33.90999984741211,2.418878046947106,The Medicines Co's Inclisiran Positive in Extension Study,"Click to get this free report The Medicines Company (MDCO): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days."
+2017-08-28,32.939998626708984,33.439998626708984,5.968749523162842,J&J's (JNJ) Xarelto/Aspirin Regimen Positive in Phase III | Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval,"Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , each carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Some other stocks worth considering in the pharma sector are Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , both carrying a Zacks Rank #2. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days."
+2017-08-25,32.869998931884766,32.45000076293945,1.5179114172596877,"Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars | Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate","Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report Recro Pharma, Inc. (REPH): Free Stock Analysis Report Adamas Pharmaceuticals, Inc. (ADMS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharmaceutical sector are Corcept Therapeutics Incorporated CORT , Recro Pharma, Inc. REPH and ACADIA Pharmaceuticals Inc. ACAD . ACADIA Pharma's loss estimates have narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days. | Some better-ranked stocks in the pharma sector are Aerie Pharmaceuticals, Inc. AERI , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 (Buy). Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Aerie Pharmaceuticals, Inc. (AERI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days."
+2017-08-24,31.989999771118164,32.81999969482422,-1.2777553471043872,Kite Pharma at New 52-Week High: What's Driving the Stock?,"Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss per share estimates narrowed from $2.82 to $2.59 for 2017 and from $2.07 to $1.92 for 2018 over the last 30 days."
+2017-08-23,31.280000686645508,31.90999984741211,2.5945605803205143,,
+2017-08-22,31.040000915527344,31.440000534057617,2.0140637689805727,,
+2017-08-21,31.07999992370605,30.940000534057617,1.2886585268435962,,
+2017-08-18,31.040000915527344,31.07999992370605,-0.4504484877480659,Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer,"Click to get this free report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Summit Therapeutics PLC (SMMT): Free Stock Analysis Report To read this article on Zacks.com click here. Some other stocks worth considering in the pharma sector are Summit Therapeutics PLC SMMT , Aduro Biotech, Inc. ADRO and ACADIA Pharmaceuticals Inc. ACAD , all three carrying a Zacks Rank #2 as well. ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days."
+2017-08-17,31.32999992370605,31.030000686645508,0.12886278028006892,FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa,"Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. A better-ranked stock in the pharma sector is ACADIA Pharmaceuticals Inc. ACAD , carrying a Zacks Rank #2 (Buy). ACADIA's loss estimates narrowed from $2.82 to $2.65 for 2017 and from $2.07 to $1.98 for 2018 over the last 30 days."
+2017-08-16,32.18000030517578,31.38999938964844,-0.9575462425505686,,
+2017-08-15,32.0099983215332,32.11000061035156,-2.454943778854712,"What You See, and What You Get: The Neurology of Perception","Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD). ( (1: 00 ) - Neuroscience: The 4 Theaters Of The Brain (5: 00 ) - Investors Train Their Brains to Trade: Assumption and Perception (10: 00 ) - Neurology Is The New Oncology: The Boom In Brain Sciences (14: 00 ) - Biotech Companies With Breakthrough Research (21: 00 ) - Appreciating Differences: The Story Of A Misdiagnosis (34: 00 ) - Episode Roundup: Podcast@Zacks.com Welcome back to Mind Over Money."
+2017-08-14,31.5,31.88999938964844,0.31240954096235485,"Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern | Analysts Forecast 10% Gains Ahead For VXF","Click to get this free report Geron Corporation (GERN): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the pharma sector include ACADIA Pharmaceuticals Inc. ACAD , Aduro Biotech, Inc. ADRO and Enzo Biochem, Inc. ENZ . ACADIA Pharma's loss estimates narrowed from $2.82 to $2.69 for 2017 and $2.07 to $1.99 for 2018 over the last 30 days. | Similarly, BMRN has 40.70% upside from the recent share price of $82.40 if the average analyst target price of $115.93/share is reached, and analysts on average are expecting ACAD to reach a target price of $43.80/share, which is 40.34% above the recent price of $31.21. Below is a twelve month price history chart comparing the stock performance of HALO, BMRN, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VXF's underlying holdings with notable upside to their analyst target prices are Halozyme Therapeutics Inc (Symbol: HALO), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Acadia Pharmaceuticals Inc (Symbol: ACAD)."
+2017-08-11,30.46999931335449,31.209999084472656,1.2380933004712416,,
+2017-08-10,33.02000045776367,30.229999542236328,2.428617616652975,,
+2017-08-09,32.75,33.209999084472656,-8.449427246665461,Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today,"What happened In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous system, were trading 13.9% higher as of 1:35 p.m. EDT on Wednesday. Acadia also shared a few non-financial highlights from the quarter with investors: The company held an end-of-phase-2 meeting with the FDA related to its Alzheimer's disease psychosis program. Acadia's cash balance at quarter end was $417 million."
+2017-08-08,30.530000686645508,29.540000915527344,1.4045773571684161,,
+2017-08-07,30.5,30.56999969482422,-3.2427112638461604,"Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More","Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Endo International PLC (ENDP): Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to report after the closing bell. ACADIA has missed estimates in two of the trailing four quarters, beat once and reported in-line results in the remaining quarter, resulting in an average negative surprise of 10.2%Currently, the company has a Zacks Rank #3 (Hold) and a 0.00% Earnings ESP ."
+2017-08-04,29.600000381469727,30.690000534057617,0.2295071961449795,,
+2017-08-03,29.549999237060547,29.59000015258789,3.6824329004747427,,
+2017-08-02,29.51000022888184,29.489999771118164,0.13536689191238976,,
+2017-08-01,29.940000534057617,29.549999237060547,-0.06777518674534169,,
+2017-07-31,30.13999938964844,29.770000457763672,-1.3026095191729625,,
+2017-07-28,29.280000686645508,30.1299991607666,-1.2276009932894856,,
+2017-07-27,30.229999542236328,29.46999931335449,2.903000185067532,,
+2017-07-26,30.100000381469727,30.1299991607666,-2.5140596771097963,,
+2017-07-25,30.600000381469727,30.030000686645508,0.09966371733118966,,
+2017-07-24,30.40999984741211,30.46999931335449,-1.8627440775111568,,
+2017-07-21,29.979999542236328,30.43000030517578,0.19730176337861843,,
+2017-07-20,29.030000686645508,30.09000015258789,1.501003234858241,,
+2017-07-19,29.14999961853028,29.0,3.6513931824672943,,
+2017-07-18,28.89999961853028,28.959999084472656,-0.5145784579528012,These 2 Companies Have No Competition,"While Acadia will face plenty of competition in many of these disease states, the company could enjoy the same virtual monopoly it has in PDP in Alzheimer's disease psychosis, since there are currently no FDA-approved treatments for it on the market. Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . Thankfully, that all changed last year when the FDA approved Acadia Pharmaceutical's drug Nuplazid."
+2017-07-17,28.64999961853028,28.850000381469727,0.207610611537534,,
+2017-07-14,28.15999984741211,28.59000015258789,0.6980829514918712,,
+2017-07-13,27.989999771118164,28.170000076293945,1.5269897283586031,,
+2017-07-12,26.850000381469727,27.950000762939453,0.6430879122818602,The Math Shows BBH Can Go To $140,"Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). Although ACAD has traded at a recent price of $26.76/share, the average analyst target is 62.18% higher at $43.40/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB: Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF."
+2017-07-11,28.200000762939453,26.76000022888184,4.09683562697035,,
+2017-07-10,29.200000762939453,27.600000381469727,-5.106384734393581,,
+2017-07-07,28.81999969482422,29.190000534057617,-5.4794532180301925,,
+2017-07-06,29.46999931335449,28.690000534057617,1.2838335987208456,,
+2017-07-05,28.39999961853028,29.63999938964844,-2.6467553358354197,,
+2017-07-03,28.100000381469727,28.46999931335449,4.366196435823514,,
+2017-06-30,28.6299991607666,27.88999938964844,1.3167221596507674,,
+2017-06-29,28.14999961853028,28.68000030517578,-2.584700638525433,,
+2017-06-28,27.770000457763672,28.26000022888184,1.882773335089559,,
+2017-06-27,29.030000686645508,27.63999938964844,1.764493205044864,,
+2017-06-26,29.38999938964844,29.01000022888184,-4.788154543986974,Minerva On Track to Initiate Phase III Schizophrenia Study,"Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Minerva Neurosciences, Inc (NERV): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, ACADIA Pharmaceuticals Inc. ACAD and Alkermes plc ALKS are also developing treatments for schizophrenia. The company said that it has completed a bridging study to select a new and safer formulation of MIN-101, while using the same dose strengths used in phase IIb study for use in the scheduled phase III study."
+2017-06-23,28.68000030517578,29.239999771118164,-1.2929539593676973,3 Biotech Stocks for Enterprising Investors,"They recommended Kite Pharma (NASDAQ: KITE) , Celgene (NASDAQ: CELG) , and Acadia Pharmaceuticals (NASDAQ: ACAD) . No competition in sight Brian Feroldi ( Acadia Pharmaceuticals ): Launching a new drug to market is always easier when you have an entire market to yourself. That's a big reason Acadia Pharmaceuticals' Nuplazid is off to a fast start ."
+2017-06-22,29.530000686645508,28.68000030517578,1.9525783123556022,,
+2017-06-21,28.13999938964844,29.270000457763672,-2.8784299414328367,,
+2017-06-20,28.06999969482422,28.21999931335449,4.015639988005516,,
+2017-06-19,27.34000015258789,27.989999771118164,0.5343769866799395,3 Value Stocks You Haven't Thought Of,"Right now, our contributors believe that Baidu (NASDAQ: BIDU) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Dycom Industries (NYSE: DY) look compelling after their recent price drops and deserve your attention right away. Sometimes fundamentals are misleading George Budwell (Acadia Pharmaceuticals): With its shares trading at 15.4 times the company's projected 2018 revenue, Acadia may not look like a particularly attractive value play.But there are some good reasons to think otherwise. In the first quarter of this year, for instance, Acadia reported that Nuplazid sales jumped by a healthy 28% to $15.3 million compared to the fourth quarter of 2016."
+2017-06-16,26.40999984741211,27.100000381469727,2.37746750147237,"Baker Bros. Advisors Lp Buys Incyte Corp, AveXis Inc, La Jolla Pharmaceutical Co, Sells AbbVie ...","Shares added by 0.01% ACADIA Pharmaceuticals Inc ( ACAD ) - 25,819,768 shares, 7.39% of the total portfolio. Baker Bros. Advisors Lp New Purchases: ANAB , JNCE , TNXP , BPMX, WINT, Added Positions:INCY, AVXS, LJPC, ASND, AQXP, HRTX, BCRX, CBAY, DERM, SGMO, Reduced Positions:ARRY, EXEL, ZGNX, VSAR, AGLE, CRBP, JUNO, NTRA, PRTO, Sold Out:ABBV, DSCI, ADHD, ENTA, NERV, IONS, SCYX, CNCE, QURE, ALDX, For the details of BAKER BROS. ADVISORS LP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BAKER+BROS.+ADVISORS+LP These are the top 5 holdings of BAKER BROS. ADVISORS LP Incyte Corp ( INCY ) - 34,110,011 shares, 37.97% of the total portfolio. The purchase prices were between $16.62 and $28.78, with an estimated average price of $23.3."
+2017-06-15,27.13999938964844,26.280000686645508,2.6126487620000107,,
+2017-06-14,27.25,27.3799991607666,-3.168749898096712,,
+2017-06-13,27.299999237060547,27.25,0.47706114042789566,,
+2017-06-12,27.39999961853028,27.07999992370605,-0.18314739361850035,,
+2017-06-09,26.14999961853028,27.39999961853028,-1.1678821141581972,,
+2017-06-08,25.420000076293945,26.13999938964844,4.780114792484476,,
+2017-06-07,26.270000457763672,25.450000762939453,2.832412711225556,,
+2017-06-06,26.420000076293945,26.15999984741211,-3.1214300743640875,Sum Up The Pieces: BBH Could Be Worth $138,"Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Tesaro Inc (Symbol: TSRO). Although ACAD has traded at a recent price of $26.51/share, the average analyst target is 62.20% higher at $43.00/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and TSRO: Combined, ACAD, BMRN, and TSRO represent 6.94% of the Biotech ETF."
+2017-06-05,27.040000915527344,26.51000022888184,-0.9841038157873744,,
+2017-06-02,26.950000762939453,26.93000030517578,-1.9600616446028254,,
+2017-06-01,25.850000381469727,26.81999969482422,-0.07421319924849759,,
+2017-05-31,25.850000381469727,25.709999084472656,3.7524150833275227,,
+2017-05-30,25.989999771118164,25.64999961853028,-0.5415910829054712,,
+2017-05-26,26.280000686645508,26.020000457763672,-1.3081960584151853,,
+2017-05-25,27.5,26.270000457763672,-0.9893463549791994,,
+2017-05-24,27.350000381469727,27.36000061035156,-4.472725608132102,,
+2017-05-23,28.09000015258789,27.549999237060547,0.03656390765028207,,
+2017-05-22,27.989999771118164,28.01000022888184,-1.9223955592524062,,
+2017-05-19,27.39999961853028,27.850000381469727,0.07145572678536836,,
+2017-05-18,27.15999984741211,27.309999465942383,1.6423385737389429,,
+2017-05-17,27.799999237060547,27.059999465942383,0.5522813673526802,,
+2017-05-16,28.520000457763672,28.39999961853028,-2.6618697533331606,,
+2017-05-15,29.25,28.530000686645508,-0.4207602991139675,,
+2017-05-12,28.86000061035156,29.01000022888184,-2.4615361140324516,,
+2017-05-11,28.770000457763672,28.799999237060547,0.519749186964599,,
+2017-05-10,30.0,29.059999465942383,0.10427104212568665,Oversold Conditions For Acadia Pharmaceuticals (ACAD) | Mid-Day Market Update: Crude Oil Down 3%; Proteon Therapeutics Shares Spike Higher | Is This Why Acadia Pharmaceuticals Inc. Is Plunging Today?,"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 26.6, after changing hands as low as $28.01 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $28.51. A bullish investor could look at ACAD's 26.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | Meanwhile, top losers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ), down 12 percent, and HMS Holdings Corp (NASDAQ: HMSY ), down 10 percent. Midway through trading Wednesday, the Dow traded down 0.08 percent to 20,959.85 while the NASDAQ declined 0.12 percent to 6,113.15. Meanwhile the German DAX slipped 0.06 percent, and the French CAC 40 declined 0.09 percent while U.K. shares rose 0.60 percent. | 10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened In response to the company reporting first-quarter earnings, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a commercial-stage biopharma focused on diseases of the central nervous system, fell by 11% as of 11:00 a.m. EDT. Acadia's cash balance at quarter-end was $469.5 million."
+2017-05-09,32.0099983215332,32.2599983215332,-3.1333351135253906,,
+2017-05-08,32.560001373291016,31.790000915527344,0.781005976597707,,
+2017-05-05,32.25,32.7400016784668,-2.364866171029414,,
+2017-05-04,32.61000061035156,32.349998474121094,1.5193850495094476,Analysts Forecast 12% Upside For BBH,"Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Alkermes plc (Symbol: ALKS). Although ACAD has traded at a recent price of $32.45/share, the average analyst target is 34.56% higher at $43.67/share. Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and ALKS: Combined, ACAD, BMRN, and ALKS represent 7.20% of the Biotech ETF."
+2017-05-03,32.7599983215332,32.45000076293945,-0.7973079771974457,,
+2017-05-02,34.34000015258789,32.77000045776367,-0.9462685423582213,What's in the Cards for ACADIA (ACAD) this Earnings Season?,"ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Stocks to Consider Here are some health care stocks that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat this quarter. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report FibroGen, Inc (FGEN): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report first-quarter 2017 results on May 4."
+2017-05-01,34.31999969482422,34.40999984741211,-4.571926872009353,,
+2017-04-28,33.869998931884766,34.33000183105469,0.2622382091730132,,
+2017-04-27,33.68000030517578,33.83000183105469,1.3581426444536475,,
+2017-04-26,34.77000045776367,33.65999984741211,0.4453726975051563,,
+2017-04-25,33.97999954223633,34.709999084472656,-3.1924089609947486,Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market,"Aside from Alzheimer's disease psychosis, Acadia is also in the process of advancing Nuplazid in mid-stage trials as a treatment for Alzheimer's disease agitation as well as adjunctive therapy for both schizophrenia and major depressive disorder. Investor confidence in a potential acquisition of Acadia Pharmaceuticals(NASDAQ: ACAD) seems to have waned, and the stock's price has suffered as a result. However, with share prices at their current depressed level, Acadia could be a bargain should its key drug Nuplazid succeed in Alzheimer's disease psychosis."
+2017-04-24,32.65999984741211,33.720001220703125,2.1483212244572165,,
+2017-04-21,32.52000045776367,32.209999084472656,3.245564538405861,,
+2017-04-20,32.45000076293945,32.59000015258789,-0.9532637420889315,,
+2017-04-19,32.470001220703125,32.349998474121094,0.43143108276388153,,
+2017-04-18,33.0099983215332,32.439998626708984,-0.3695803574701333,,
+2017-04-17,33.459999084472656,33.369998931884766,-1.726748633163045,,
+2017-04-13,33.0099983215332,33.47999954223633,-0.2689783474311445,,
+2017-04-12,33.060001373291016,33.09000015258789,1.4238147367506289,,
+2017-04-11,33.0,32.900001525878906,0.09074040547714811,,
+2017-04-10,32.560001373291016,33.06999969482422,-0.30302567915482953,,
+2017-04-07,32.400001525878906,32.36000061035156,1.566333845279119,,
+2017-04-06,32.650001525878906,32.40999984741211,-0.12345961001080125,,
+2017-04-05,33.650001525878906,32.66999816894531,-0.7350740191438208,Acadia Pharmaceuticals Becomes Oversold (ACAD),"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $32.48 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $20.68 per share, with $42.49 as the 52 week high point - that compares with a last trade of $32.67. A bullish investor could look at ACAD's 27.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
+2017-04-04,34.04999923706055,33.529998779296875,-2.9123426820052636,,
+2017-04-03,34.43000030517578,34.04999923706055,-1.527167311057368,,
+2017-03-31,34.099998474121094,34.380001068115234,-1.1036917361226677,,
+2017-03-30,35.630001068115234,34.099998474121094,0.8211220132653028,,
+2017-03-29,35.84000015258789,35.86000061035156,-4.294141308245195,,
+2017-03-28,35.70000076293945,35.709999084472656,0.055804848433371745,,
+2017-03-27,34.400001525878906,35.650001525878906,0.028006502295603558,,
+2017-03-24,34.58000183105469,34.83000183105469,3.633720769051806,,
+2017-03-23,34.959999084472656,34.45000076293945,0.7229612109953293,,
+2017-03-22,34.91999816894531,34.93000030517578,-1.4588053057464663,,
+2017-03-21,37.34000015258789,35.0099983215332,0.028643003307382026,,
+2017-03-20,37.11000061035156,37.18999862670898,-6.2399620287446735,,
+2017-03-17,37.33000183105469,37.130001068115234,0.21556996777601753,,
+2017-03-16,38.36000061035156,37.5,-0.5357641391088099,,
+2017-03-15,37.68000030517578,38.20000076293945,-2.2419202207194147,,
+2017-03-14,37.400001525878906,37.52999877929688,1.3800436665395777,,
+2017-03-13,36.83000183105469,37.470001220703125,0.34758622490436086,,
+2017-03-10,36.540000915527344,36.83000183105469,1.7377120766494139,,
+2017-03-09,36.52999877929688,36.470001220703125,0.7936532793137138,,
+2017-03-08,36.209999084472656,36.540000915527344,-0.1642418850223458,,
+2017-03-07,36.209999084472656,36.209999084472656,0.9113555354830063,,
+2017-03-06,36.88999938964844,36.790000915527344,0.0,,
+2017-03-03,35.689998626708984,36.88999938964844,-0.2710720405952458,,
+2017-03-02,36.81999969482422,35.79999923706055,3.362288621780501,Analysts Expect BBH Will Reach $134,"Similarly, REGN has 12.99% upside from the recent share price of $379.05 if the average analyst target price of $428.29/share is reached, and analysts on average are expecting ACAD to reach a target price of $41.38/share, which is 12.95% above the recent price of $36.63. Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc. (Symbol: BMRN), Regeneron Pharmaceuticals, Inc. (Symbol: REGN), and Acadia Pharmaceuticals Inc (Symbol: ACAD). Below is a twelve month price history chart comparing the stock performance of BMRN, REGN, and ACAD: Combined, BMRN, REGN, and ACAD represent 9.92% of the Biotech ETF."
+2017-03-01,38.09999847412109,36.630001068115234,-2.7702348349205805,,
+2017-02-28,40.0,38.11000061035156,-3.858261062672557,"Earnings Reaction History: ACADIA Pharmaceuticals Inc, 50.0% Follow-Through Indicator, 5.9% Sensitive | After-Hours Earnings Report for February 28, 2017 : CRM, ROST, PANW, UHS, TSRO, JAZZ, AR, DXCM, EPR, LOGM, ACAD, BUFF","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 3.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $2,686,645 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2016. Zacks Investment Research reports that the 2016 Price to Earnings ratio for ACAD is -17.25 vs. an industry ratio of -3.10. Zacks Investment Research reports that the 2016 Price to Earnings ratio for JAZZ is 22.38 vs. an industry ratio of 6.60, implying that they will have a higher earnings growth than their competitors in the same industry."
+2017-02-27,38.77999877929688,39.84999847412109,-4.724998474121094,,
+2017-02-24,39.08000183105469,38.880001068115234,2.7591535031079872,3 Earnings Reports That Should Be on Your Radar,"Earnings Reports: Acadia Pharmaceuticals (ACAD) Earnings Date: Feb. 28 One thing that hasn't been driving ACAD stock? Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Priceline Group Inc (NASDAQ: PCLN ) and 3D Systems Corporation (NYSE: DDD ) are all blowing away the broader market with double-digit gains just two months into 2017. And when it reports on Tuesday, Acadia is expected to lose 65 cents per share - wider than the 45-cent-per-share loss of a year ago."
+2017-02-23,39.2599983215332,39.560001373291016,-0.511772654986223,ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?,"ACADIA Pharmaceuticals Inc. Price and EPS Surprise ACADIA Pharmaceuticals Inc. Price and EPS Surprise | ACADIA Pharmaceuticals Inc. Quote Earnings Whispers Our proven model does not conclusively show that ACADIA is likely to beat estimates this quarter. Zacks Rank : ACADIA has a Zacks Rank #3, which increases the predictive power of ESP. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report Pacira Pharmaceuticals, Inc. (PCRX): Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX): Free Stock Analysis Report To read this article on Zacks.com click here."
+2017-02-22,39.0,39.13999938964844,0.7641443315937886,First Week of April 21st Options Trading For Acadia Pharmaceuticals,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $39.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $3.20. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options begin trading this week, for the April 21st expiration."
+2017-02-21,39.540000915527344,39.20000076293945,0.35897279397035253,,
+2017-02-17,39.02999877929688,39.27999877929688,-0.8598890862806549,,
+2017-02-16,39.400001525878906,39.220001220703125,0.6405329434255844,,
+2017-02-15,39.58000183105469,39.470001220703125,-0.4568535487430186,,
+2017-02-14,36.959999084472656,39.68999862670898,-0.2779196696884825,Caution: Acadia Pharmaceuticals Is Overvalued,"Nuplazid Acadia only has one drug product, Nuplazid, which is approved solely for the treatment of Parkinson's disease psychosis (PDP). The Alzheimer's disease controversy Toward the end of last year, Acadia released topline data from a phase 2 study of Nuplazid in Alzheimer's disease psychosis. Shareholders of Acadia Pharmaceuticals (NASDAQ: ACAD) must be riding high after the stock's meteoric run -- up a massive 29% in the past 3 months."
+2017-02-13,37.09000015258789,37.2400016784668,7.38636258079137,,
+2017-02-10,37.95000076293945,37.09000015258789,0.40442578932812473,,
+2017-02-09,38.84000015258789,37.95000076293945,-2.266141220190453,,
+2017-02-08,37.88999938964844,38.540000915527344,-2.2914505307723005,,
+2017-02-07,37.970001220703125,38.18999862670898,1.7154962690669426,,
+2017-02-06,36.31999969482422,37.84999847412109,0.579397942936854,,
+2017-02-03,35.54999923706055,36.61000061035156,4.212551740508138,,
+2017-02-02,34.56999969482422,35.22999954223633,2.9817198200836357,"Notable ETF Inflow Detected - XBI, CLVS, ACAD, UTHR | Forget GW Pharmaceuticals -- These 2 Stocks Are Better Buys","Among the largest underlying components of XBI, in trading today Clovis Oncology Inc (Symbol: CLVS) is up about 0.1%, Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 0.2%, and United Therapeutics Corp (Symbol: UTHR) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the XBI: SPDR S&P Biotech ETF, US Equities (Symbol: XBI) where we have detected an approximate $136.6 million dollar inflow -- that's a 5.3% increase week over week in outstanding units (from 39,550,000 to 41,650,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $69.21 as the 52 week high point - that compares with a last trade of $64.78. | This battleground stock has momentum on its side Since the launch of its Parkinson's disease psychosis (PDP) drug Nuplazid last May, Acadia has gotten a lot of attention from bulls and bears alike. So, if you're on the hunt for biopharma growth stocks with more attractive valuations than GW, I think Acadia Pharmaceuticals (NASDAQ: ACAD) and Sarepta Therapeutics (NASDAQ: SRPT) are definitely worth checking out. If true, Acadia's shares are currently trading at a sharp discount relative to Nuplazid's value proposition."
+2017-02-01,34.650001525878906,34.4900016784668,1.9091693758705002,Forget Anavex Life Sciences Corp.: These 2 Biotech Stocks Are Better Buys | 3 Big Mergers & Acquisitions That We Could See in 2017,"Acadia's recent market cap of around $3.85 billion suggests a great deal of success for the drug is already priced in, but a possible expansion to the much larger Alzheimer's disease (AD) indication could send the stock higher still. If you'd like to stay within the Alzheimer's disease space, ACADIA Pharmaceuticals (NASDAQ: ACAD) also has a compelling opportunity to expand its lead drug into this underserved space and beyond. Both Geron and Acadia present risks, but both stocks have a better chance of providing market-beating gains over the long term than Anavex. | Possible Mergers & Acquisitions: Acadia Pharmaceuticals (ACAD) Source: Shutterstock The biotech space is prime takeover territory, as the sector has been beaten down over the past year, making consolidation within the industry much more likely. Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is one such company that is likely to see some takeover action sometime over the course of the year. One of the reasons Acadia looks so enticing to big pharma firms is the company's drug Nuplazid, which has already been approved to treat psychosis experienced by those affected by Parkinson's disease."
+2017-01-31,32.369998931884766,34.59000015258789,-0.46176000105688575,,
+2017-01-30,31.459999084472656,32.599998474121094,6.858206036319643,How Risky Is Acadia Pharmaceuticals Stock?,Acadia is also advancing to a late-stage clinical trial evaluating Nuplazid in treating Alzheimer's disease psychosis. Great potential Acadia definitely faces considerable risks with the commercial launch of Nuplazid and the possibilities for clinical study disappointments. Acadia Pharmaceuticals (NASDAQ: ACAD) is probably in better shape now than it's ever been.
+2017-01-27,31.38999938964844,31.93000030517578,3.623647243559818,,
+2017-01-26,31.280000686645508,31.3700008392334,1.7202960370410765,,
+2017-01-25,30.13999938964844,31.1299991607666,0.28772426666318696,,
+2017-01-24,30.18000030517578,30.13999938964844,3.284670839967486,,
+2017-01-23,31.020000457763672,30.3700008392334,-0.13254113692132785,,
+2017-01-20,31.459999084472656,31.020000457763672,-2.0954210475119184,,
+2017-01-19,32.209999084472656,31.43000030517578,-1.3985970741052862,Surprising Analyst 12-Month Target For FBT,"Similarly, ACAD has 28.06% upside from the recent share price of $32.31 if the average analyst target price of $41.38/share is reached, and analysts on average are expecting TECH to reach a target price of $124.00/share, which is 25.25% above the recent price of $99.00. Three of FBT's underlying holdings with notable upside to their analyst target prices are Juno Therapeutics Inc (Symbol: JUNO), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Bio-Techne Corp (Symbol: TECH). Below is a twelve month price history chart comparing the stock performance of JUNO, ACAD, and TECH: Combined, JUNO, ACAD, and TECH represent 9.15% of the First Trust NYSE Arca Biotechnology Index Fund ETF."
+2017-01-18,31.3799991607666,32.310001373291016,-2.421604475216784,,
+2017-01-17,31.350000381469727,31.350000381469727,2.9636782581153343,,
+2017-01-13,31.799999237060547,31.770000457763672,0.0,Why Acadia Pharmaceuticals Inc. Stock Slipped 19% in 2016,"10 stocks we like better than Acadia Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating central nervous system disorders, fell 19.1% last year, according to data from S&P Global Market Intelligence . ACAD data by YCharts So what Nuplazid recently earned approval from the Food and Drug Administration as a treatment for the roughly 400,000 U.S. patients with Parkinson's disease-related psychosis."
+2017-01-12,29.559999465942383,31.780000686645508,-0.09433578621572306,,
+2017-01-11,31.450000762939453,29.8700008392334,7.510153115059776,,
+2017-01-10,32.560001373291016,31.46999931335449,-5.023847012327961,,
+2017-01-09,32.97999954223633,32.689998626708984,-3.3476720330566576,,
+2017-01-06,31.700000762939453,32.63999938964844,-0.8793235886979007,Acadia Pharmaceuticals' Alzheimer's Data Raises Some Questions,"In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors' minds as Acadia Pharmaceuticals preps for phase 3 studies. Acadia Pharmaceuticals (NASDAQ: ACAD) recently reported intriguing mid-stage study data for Nuplazid in Alzheimer's disease psychosis, which sent shares surging higher. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease?"
+2017-01-05,32.099998474121094,31.68000030517578,2.965295281027056,First Week of ACAD February 17th Options Trading,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $31.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of $2.25. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the February 17th expiration."
+2017-01-04,28.90999984741211,31.940000534057617,-1.30840557292834,"Wednesday's ETF Movers: XBI, XLE | Acadia Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ACAD | Why Encana, Acadia Pharmaceuticals, and Tenet Healthcare Jumped Today | Here's Why Acadia Pharmaceuticals Inc. Stock Is Up Today | Exploring an Apple Inc. (AAPL) Takeover of Sirius and Pandora | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout","Components of that ETF showing particular strength include shares of Acadia Pharmaceuticals, up about 10.1% and shares of Exact Sciences, up about 10% on the day. And underperforming other ETFs today is the Energy Select Sector SPDR Fund ETF, off about 0.1% in Wednesday afternoon trading. Among components of that ETF with the weakest showing on Wednesday were shares of Valero Energy, lower by about 3.2%, and shares of Marathon Petroleum, lower by about 3% on the day. | In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $30.88, changing hands as high as $31.60 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $31.24. Acadia Pharmaceuticals Inc shares are currently trading up about 8.3% on the day. | Investors continued to look forward to potential gains in economic growth ahead, and Encana (NYSE: ECA) , Acadia Pharmaceuticals (NASDAQ: ACAD) , and Tenet Healthcare (NYSE: THC) were among the best performers on the day. Could Acadia find a partner? Acadia jumped 11% after rumors surfaced that drug-maker Pfizer (NYSE: PFE) might be interested in buying the biopharmaceutical company. | 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and ACADIA Pharmaceuticals wasn't one of them! What happened Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) popped just ahead of lunch on Wednesday, and have risen about 12.6% as of 3:31 p.m. EST. | Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout Most importantly, this buyout cannot happen without John Malone of Liberty Media Group (NASDAQ: LMCA ) giving the go-ahead. By buying Sirius and Pandora, Apple would increase its revenue from services, boost its position in connected car services and strengthen Apple Music against Spotify . Buying Sirius/Pandora Will Help Apple Increase Services Revenue and Growth Services already makes up a substantial chunk of Apple's revenue, at 13%. | InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) is having a Happy New Year, as ACAD stock sets the second trading day of the year ablaze with 12%-plus gains. Regardless of whether PFE actually does buy Acadia, ACAD stock bulls are cheering right now because shares finally cracked through the 200-day moving average. More From InvestorPlace Mobileye NV (MBLY) Stock Soars on Autonomous Vehicle Test 7 Beaten-Down Tech Stocks to Buy With 50% Upside in 2017 The 10 Best Fidelity Funds for 2017 The post Acadia Pharmaceuticals Inc. (ACAD) Flirts With a Pfizer Inc. (PFE) Buyout appeared first on InvestorPlace ."
+2017-01-03,29.1299991607666,28.770000457763672,10.480804920919914,,
+2016-12-30,28.920000076293945,28.84000015258789,-1.2358349240455515,,
+2016-12-29,28.46999931335449,28.790000915527344,-0.2766249083506453,,
+2016-12-28,28.8799991607666,28.520000457763672,1.123995819777738,,
+2016-12-27,30.40999984741211,28.950000762939453,-1.2465329413582078,,
+2016-12-23,27.6299991607666,29.75,-4.8010492989098195,,
+2016-12-22,27.440000534057617,27.670000076293945,7.672822669657216,,
+2016-12-21,28.459999084472656,27.459999084472656,0.8381907352766277,ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint,"ACADIA Pharmaceuticals Inc.ACAD announced that a phase II exploratory study (-019 Study) evaluating pimavanserin for the treatment of Alzheimer's disease psychosis (AD Psychosis) met the primary endpoint. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote Zacks' Best Private Investment Ideas In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here."
+2016-12-20,29.26000022888184,28.56999969482422,-3.513703556461408,"Wall Street Sees Higher Open, Uncertainty Looms After Terror Attacks in Berlin, Zurich, Ankara | Health Care Sector Update for 12/20/2016: BMY, ACAD, JNJ, PFE, ABT, MRK, AMGN | Pre-Market Most Active for Dec 20, 2016 : AZN, ACAD, RAD, CNAT, ABB, BAC, GFI, MO, TVIX, BBRY, NVDA, XIV | US Futures Point North, Uncertainty Looms After Terror Attacks in Berlin, Zurich, Ankara | Why ACADIA Pharmaceuticals Inc. Is Soaring Today","In equities, Acadia Pharmaceutical ( ACAD ) shares were 18.8% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. Nikkei up 0.53% Hang Seng down 0.47% Shanghai Composite down 1.49% FTSE-100 up 0.33% DAX-30 up 0.24% (+) Large cap tech: unchanged to higher (+) Chip stocks: unchanged to higher (+) Software stocks: unchanged to higher (+) Hardware stocks: unchanged to higher (+) Internet stocks: unchanged to higher (+) Oil stocks: unchanged to higher (+/-) Biotech stocks: mixed (+) Drug stocks: unchanged to higher (+) Financial stocks: higher (+) Retail stocks: unchanged to higher (+/-) Industrial stocks: mixed (+/-) Airlines: unchanged (+) Autos: unchanged to higher | In health care stocks news, ACADIA Pharmaceuticals ( ACAD ) was up 23.9% after the company said top-line results were positive from its Phase II exploratory study (-019 Study) of pimavanserin in patients with Alzheimer's disease psychosis. And, Bristol-Myers Squibb Company ( BMY ) was up 0.5% after the company said PsiOxus Therapeutics, Ltd granted the company exclusive worldwide rights to NG-348, a pre-clinical stage, ""armed"" oncolytic virus with the goal of addressing solid tumors. Bristol-Myers Squibb will grant PsiOxus a $50 million upfront payment and will be solely responsible for global clinical development and commercialization activities related to NG-348. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.37 at $30.80, with 1,780,851 shares traded. As reported in the last short interest update the days to cover for ACAD is 12.826531; this calculation is based on the average trading volume of the stock. The consensus earnings per share forecast is 0.05 per share, which represents a 6 percent increase over the EPS one Year Ago Conatus Pharmaceuticals Inc. ( CNAT ) is +2.78 at $4.74, with 1,310,128 shares traded. | In equities, Acadia Pharmaceutical ( ACAD ) shares were 30.2% higher pre-bell after the company reported positive top-line results from its phase 2 exploratory trial of pimavanserin in patients with Alzheimer's disease psychosis. U.S. stock futures point north on Tuesday in a typically quiet trading period before the holiday season and as uncertainty reigned on investors after separate terror attacks in Berlin, Zurich and Ankara on Monday. Oil prices nudged higher with global benchmark Brent Crude up 0.80% recently, and U.S. benchmark West Texas Intermediate up 0.40% ahead of a weekly supply update on U.S. crude stock inventories. | 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened After releasing encouraging data from an important Phase II clinical trial, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) rose by 14% as of 10:10 a.m. EST on Tuesday. So what Acadia released top-line results from its Phase II -019 Study today."
+2016-12-19,26.14999961853028,25.43000030517578,-2.358169954409426,ACADIA Pharmaceuticals Inc.'s Stock Has Fallen 27% in 2016 -- Have We Hit Bottom?,"Why it's been a rough year Acadia's investors got the big news they were looking for in April when the FDA approved the company's first drug, Nuplazid, as a treatment for Parkinson's disease psychosis. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. 2016 was suppose to be a breakout year for ACADIA Pharmaceuticals (NASDAQ: ACAD) , but it's turned out to be a bust instead."
+2016-12-16,25.71999931335449,25.979999542236328,-2.7533434946756064,,
+2016-12-15,24.959999084472656,26.01000022888184,1.0108873865593015,,
+2016-12-14,24.790000915527344,24.940000534057617,4.206735508505598,,
+2016-12-13,25.299999237060547,24.8700008392334,0.6050811334836234,,
+2016-12-12,26.600000381469727,25.280000686645508,-1.6995984616365836,,
+2016-12-09,27.21999931335449,26.76000022888184,-4.962404796594536,,
+2016-12-08,26.8799991607666,27.239999771118164,-1.689930551346368,,
+2016-12-07,27.61000061035156,27.07999992370605,1.3392880267534037,,
+2016-12-06,27.770000457763672,28.25,-1.9195967943832628,,
+2016-12-05,27.68000030517578,27.790000915527344,1.7284822986098816,,
+2016-12-02,26.6299991607666,27.14999961853028,0.3974010445765562,,
+2016-12-01,27.09000015258789,26.479999542236328,1.9526867223104698,,
+2016-11-30,27.739999771118164,26.989999771118164,-2.251755654911982,,
+2016-11-29,27.40999984741211,27.64999961853028,-2.7036770230289315,3 Biotechs With Save-the-Date Catalysts on Tap,"Major blockbuster opportunity for ACADIA Pharmaceuticals Another stock with a save-the-date catalyst rapidly approaching is ACADIA Pharmaceuticals. The coming catalyst for ACADIA Pharmaceuticals' investors is top-line results for Nuplazid's phase 2 study for Alzheimer's disease psychosis (ADP). 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen."
+2016-11-28,27.920000076293945,27.32999992370605,0.8755920191689841,,
+2016-11-25,28.309999465942383,28.040000915527344,-2.113181056503098,,
+2016-11-23,25.96999931335449,28.21999931335449,-0.9537214959677194,,
+2016-11-22,28.75,26.71999931335449,8.663843124720408,5 Biotech Stocks George Soros Is Buying,"But Acadia and Biogen still have some serious work to do to lower their risk profiles moving forward. The fly in Biogen's ointment, though, is that numerous companies are attempting to cut into the biotech's overwhelming share of the MS drug market at the moment, and its clinical efforts to defend its territory have run into multiple setbacks over the past year. BioMarin isn't cheap -- but for good reason When it comes to biotechs with rich valuations, the orphan drug specialist BioMarin is nearly always close to the top of the list."
+2016-11-21,29.600000381469727,28.6299991607666,-7.060871953549605,,
+2016-11-18,29.299999237060547,29.530000686645508,-3.277031108791363,,
+2016-11-17,28.71999931335449,29.100000381469727,0.7849879029827419,,
+2016-11-16,28.76000022888184,28.549999237060547,1.3231235278565676,ACADIA Starts Phase II Schizophrenia Study on Pimavanserin,"Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase II study; ADVANCE, to evaluate pimavanserin for treating patients with negative symptoms of schizophrenia. ACADIA PHARMA Price ACADIA PHARMA Price | ACADIA PHARMA Quote ACADIA currently carries a Zacks Rank #3 (Hold)."
+2016-11-15,28.8799991607666,28.46999931335449,-0.7301842494785586,,
+2016-11-14,29.0,29.059999465942383,-1.4196671029308636,,
+2016-11-11,29.0,28.809999465942383,0.20689471014614763,,
+2016-11-10,29.709999084472656,29.739999771118164,-0.6551742553710938,ACAD Crosses Above Key Moving Average Level,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $29.44, changing hands as high as $30.23 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $42.49 as the 52 week high point - that compares with a last trade of $29.33. Acadia Pharmaceuticals Inc shares are currently trading up about 1.4% on the day."
+2016-11-09,28.09000015258789,28.8700008392334,0.10097841659371534,,
+2016-11-08,25.959999084472656,26.84000015258789,2.7767913222088305,Why Acadia Pharmaceuticals Stock Is Surging Today | Here's What Caused ACADIA Pharmaceuticals to Drop 27% in October,"So what Acadia's stock has been getting crushed over the past few weeks due to the headwinds emanating from the U.S. presidential election toward biotechs in general, and the Street's widely divided views on Nuplazid's commercial potential in particular. 10 stocks we like better than ACADIA Pharmaceuticals When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. What happened As of 11:35 a.m. EST, shares of Acadia Pharmaceuticals (NASDAQ: ACAD) , a mid-cap biopharma, were up by nearly 18%. | The company reported sales of $5.3 million in Q3, and as a result, ACADIA Pharmaceuticals lost $71.6 million in the period. Now what ACADIA Pharmaceuticals' management says Nuplazid demand is building, and the potential addressable market for Nuplazid is huge, so there are reasons investors ought to keep tabs on this company's stock. What happened In the wake of launching its Parkinson's disease drug -- Nuplazid -- on its own, and ahead of third-quarter financial results, ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) shares tumbled 26.7% last month, according to S&P Global Market Intelligence ."
+2016-11-07,22.32999992370605,22.989999771118164,3.3898347424888224,"Earnings Reaction History: ACADIA Pharmaceuticals Inc, 42.9% Follow-Through Indicator, 5.0% Sensitive","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,924,505 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
+2016-11-04,20.93000030517578,21.690000534057617,2.955664351397698,"Drug Stocks Earnings Roster for Nov 7: HZNP, ACAD & More | What to Expect from Repros (RPRX) This Earnings Season","ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Nuplazid, a new drug launched in May, generated revenues of $0.1 million in the second quarter and sales are expected to pick up in the third quarter. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report CATALENT INC (CTLT): Free Stock Analysis Report ULTRAGENYX PHAR (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD ACADIA Pharmaceuticals is expected to report third-quarter 2016 results after market close. | Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD is scheduled to release results on Nov 7. Stocks that Warrant a Look Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 - to post an earnings beat this quarter."
+2016-11-03,22.18000030517578,20.8700008392334,3.6311524978520686,Will Juno Therapeutics (JUNO) Disappoint in Q3 Earnings? | What to Expect from Repros (RPRX) This Earnings Season | Puma Biotechnology (PBYI) Q3 Earnings: What's in Store?,"Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and a Zacks Rank #3. JUNO THERAPEUTC Price and EPS Surprise JUNO THERAPEUTC Price and EPS Surprise | JUNO THERAPEUTC Quote Factors at Play With no approved products in its portfolio, Juno does not generate any product revenue yet. | Click to get this free report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. (ACAD) is scheduled to release results on Nov 7. Stocks that Warrant a Look Here are some companies in the health care sector you may want to consider as our model shows that they have the right combination of elements - a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 - to post an earnings beat this quarter. | Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ACAD has an Earnings ESP of +5.46% and carries a Zacks Rank #3. Zacks Rank: Although Puma Biotech's carries a favorable Zacks Rank #2, its 0.00% ESP makes surprise prediction difficult."
+2016-11-02,22.790000915527344,22.0,-5.906219332362632,,
+2016-11-01,23.36000061035156,22.93000030517578,-3.46643652387525,,
+2016-10-31,22.82999992370605,23.309999465942383,-1.8407546829653374,ACADIA Pharma (ACAD): Will It Disappoint in Q3 Earnings?,Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD is expected to report third-quarter 2016 results on Nov 3. ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Let's see how things are shaping up for this announcement.
+2016-10-28,22.540000915527344,22.56999969482422,2.1024947167779584,,
+2016-10-27,23.39999961853028,22.559999465942383,0.13309129582248358,Acadia Pharmaceuticals Becomes Oversold,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $22.42 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $22.56. A bullish investor could look at ACAD's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
+2016-10-26,23.600000381469727,23.18000030517578,-3.589744300349082,,
+2016-10-25,23.6200008392334,23.61000061035156,-1.779661311462187,,
+2016-10-24,25.670000076293945,23.71999931335449,-0.04233797005302754,,
+2016-10-21,23.8700008392334,25.34000015258789,-7.596418999391698,,
+2016-10-20,23.350000381469727,23.950000762939453,6.158354678137926,,
+2016-10-19,24.18000030517578,23.40999984741211,2.5695947394753773,"Commit To Purchase Acadia Pharmaceuticals At $20, Earn 45.1% Annualized Using Options","Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares decline 14.5% and the contract is exercised (resulting in a cost basis of $17.70 per share before broker commissions, subtracting the $2.30 from $20), the only upside to the put seller is from collecting that premium for the 45.1% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $20 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $20 strike for the 45.1% annualized rate of return represents good reward for the risks."
+2016-10-18,24.71999931335449,24.32999992370605,-3.1844518116025484,,
+2016-10-17,23.770000457763672,24.32999992370605,-1.577667477675649,,
+2016-10-14,25.51000022888184,23.670000076293945,2.355908519805999,,
+2016-10-13,25.07999992370605,25.190000534057617,-7.212858236295459,,
+2016-10-12,26.790000915527344,25.780000686645508,0.4385989261809828,,
+2016-10-11,27.040000915527344,26.8799991607666,-3.770064182030114,,
+2016-10-10,27.030000686645508,27.209999084472656,-0.5917224457964548,The Implied Analyst 12-Month Target For IWR,"Below is a twelve month price history chart comparing the stock performance of ACAD, SAVE, and GPOR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWR's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Spirit Airlines Inc (Symbol: SAVE), and Gulfport Energy Corp. (Symbol: GPOR). Although ACAD has traded at a recent price of $26.86/share, the average analyst target is 66.60% higher at $44.75/share."
+2016-10-07,27.940000534057617,26.86000061035156,0.6659208037537298,,
+2016-10-06,28.51000022888184,27.38999938964844,-3.8654255657210403,These 2 Biotechs Could Vanish by 2018,"ACAD data by YCharts . The overarching concern seems to be Acadia's lack of experience in terms of handling a commercial launch. So, if Nuplazid gets off to a slower than expected start and Acadia's valuation continues to trend lower as a result, this mid-cap biotech might prove to be a particularly compelling buyout target."
+2016-10-05,28.979999542236328,28.809999465942383,-3.928449071350024,Acadia Pharmaceuticals Enters Oversold Territory (ACAD),"In trading on Wednesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $28.62 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $28.82. A bullish investor could look at ACAD's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
+2016-10-04,30.690000534057617,29.100000381469727,-0.5866117287068348,Notable Two Hundred Day Moving Average Cross - ACAD,"In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $30.16, changing hands as low as $28.83 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $16.64 per share, with $43.30 as the 52 week high point - that compares with a last trade of $29.22. Acadia Pharmaceuticals Inc shares are currently trading down about 4.7% on the day."
+2016-10-03,31.600000381469727,30.709999084472656,-5.180841071747196,10 Biotech Stocks to Put on Your Radar This Quarter,"Biotech Stocks to Watch: Acadia Pharmaceuticals Inc. (ACAD) Despite all the time, not to mention the hundreds of millions of dollars, spent developing a therapy to treat Alzheimer's disease, the industry still only has a better idea of what doesn't work than what actually works. Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) may be close to turning that tide. For the record, Acadia Pharmaceuticals isn't taking broad aim at Alzheimer's."
+2016-09-30,32.709999084472656,31.809999465942383,-2.816459766623826,,
+2016-09-29,33.5,32.70000076293945,-2.751451066097708,,
+2016-09-28,34.95000076293945,33.68000030517578,-2.388057424061334,,
+2016-09-27,34.150001525878906,35.22999954223633,-3.633763748326909,,
+2016-09-26,34.18000030517578,34.29999923706055,3.162512351687593,,
+2016-09-23,34.790000915527344,34.97999954223633,0.35107937628249386,,
+2016-09-22,35.810001373291016,34.97999954223633,0.54612998479165,A Critical Couple of Months for Acadia Pharmaceuticals,"ACADIA Pharmaceuticals also plans to release data from a mid-stage trial evaluating Nuplazid in Alzeimer's disease psychosis soon, and if that trial is a success, it could significantly expand Nuplazid's addressable target market. Targeting Alzheimer's disease ACADIA Pharmaceuticals is scheduled to update investors on Nuplazid's potential to treat patients suffering from Alzheimer's disease psychosis soon, and if results are solid, it could significantly expand Nuplazid's addressable target market. ACADIA Pharmaceuticals '(NASDAQ: ACAD) investors have a lot of news to look forward to over the coming months."
+2016-09-21,36.20000076293945,35.619998931884766,-2.317793351646578,,
+2016-09-20,35.0,35.97999954223633,-1.6022149691457388,,
+2016-09-19,34.29999923706055,34.81999969482422,2.7999986921037943,,
+2016-09-16,33.72999954223633,34.150001525878906,1.516036353732103,,
+2016-09-15,33.43000030517578,34.16999816894531,1.245188228113245,,
+2016-09-14,31.809999465942383,33.40999984741211,2.213574205845764,,
+2016-09-13,32.0,32.06999969482422,5.029866106042469,,
+2016-09-12,30.559999465942383,32.470001220703125,0.2187490463256836,,
+2016-09-09,32.54999923706055,30.8700008392334,6.250005851241408,,
+2016-09-08,31.770000457763672,33.09000015258789,-5.161285521365997,,
+2016-09-07,31.38999938964844,32.0,4.154862057931286,,
+2016-09-06,31.790000915527344,31.43000030517578,1.9432960248884883,,
+2016-09-02,32.20000076293945,31.59000015258789,-1.1324334695936598,,
+2016-09-01,32.189998626708984,32.099998474121094,-1.894411788504185,,
+2016-08-31,32.45000076293945,32.130001068115234,-0.2795904207128946,3 Stocks That Could Make You Rich,"Acadia Pharmaceuticals (NASDAQ: ACAD) recently launched its first drug for sale after winning Food and Drug Administration approval earlier this year. Acadia knows it's in a great position with Nuplazid and has priced the drug accordingly. All in all, the growth ahead of Acadia could be extreme if Nuplazid can live up to its full potential."
+2016-08-30,32.70000076293945,32.540000915527344,-0.9861315479218248,,
+2016-08-29,32.86000061035156,32.619998931884766,-0.4892961580399876,,
+2016-08-26,32.369998931884766,32.86000061035156,-0.7303763664301075,,
+2016-08-25,32.7400016784668,32.29999923706055,1.513752532083467,,
+2016-08-24,34.36000061035156,32.459999084472656,-1.343929196239599,,
+2016-08-23,34.599998474121094,34.36000061035156,-5.5296900236564515,,
+2016-08-22,34.31999969482422,34.31999969482422,-0.693635475010314,,
+2016-08-19,33.13999938964844,33.63999938964844,0.0,The 10 Best Small- and Mid-Cap Stocks to Buy Now,"Best Small- and Mid-Cap Stocks to Buy Now: Acadia Pharmaceuticals (ACAD) Market Cap: $4.1 billion Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ) stock is trading right in the middle of its 52-week range, despite recently launching a drug that could very well be a top-selling drug for the next decade to come. Problem is that Acadia is going to have some growing pains. Instead, Acadia must go through the trial-and-error period that happens when a developmental stage biotech becomes a commercial company."
+2016-08-18,32.63999938964844,33.27000045776367,1.508750782162595,Director takes a bigger stake in ACADIA Pharmaceuticals,"Baker Brothers, holder of a Director seat at ACADIA Pharmaceuticals ( ACAD ), bought 1,303,030 shares of the company's common stock on August 10. InvestorsKeyhole Trade Alert IK-> The technicals for ACAD ($33.26 up $0.69) are bearish with a neutral trend. [InvestorsKeyhole, Various news and data services] The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2016-08-17,32.4900016784668,32.560001373291016,1.9301503673282392,,
+2016-08-16,32.81999969482422,32.369998931884766,0.21544995754990073,,
+2016-08-15,31.75,32.81999969482422,-1.371117511041352,,
+2016-08-12,31.709999084472656,31.3700008392334,3.370077778973917,,
+2016-08-11,31.299999237060547,31.8700008392334,-1.072211463436288,5 Can't-Miss Quotes From ACADIA Pharmaceuticals Inc.'s Q2 Investor Call,"There's no doubt that the growth opportunity in front of Nuplazid is huge, so if management can successfully execute on its commercialization plan then it wouldn't surprise me one bit to see the stock continue its winning ways from today's price. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2016-08-10,34.08000183105469,31.07999992370605,1.821091425133152,,
+2016-08-09,33.70000076293945,33.34000015258789,-8.80282202512955,,
+2016-08-08,36.38999938964844,35.22999954223633,-1.0682510451081717,,
+2016-08-05,35.54999923706055,36.4900016784668,-3.1876885596818254,,
+2016-08-04,37.119998931884766,36.47999954223633,2.6441700747669947,"Earnings Reaction History: ACADIA Pharmaceuticals Inc, 37.5% Follow-Through Indicator, 4.8% Sensitive","Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 40% Average next regular session additional gain: 1.4% Over the prior three fiscal years (12 quarters), when shares of ACAD rose in the extended-hours session in reaction to its earnings announcement, history shows that 40.0% of the time (2 events) the stock posted additional gains in the following regular session by an average of 1.4%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 66.7% Average next regular session additional loss: 3.2% Over that same historical period, when shares of ACAD dropped in the extended-hours in reaction to its earnings announcement, history shows that 66.7% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.2% by the following regular session close. Extended-Hours Dollar Volume: $1,620,961 ACADIA Pharmaceuticals Inc ( ACAD ) is due to issue its quarterly earnings report in the upcoming extended-hours session."
+2016-08-03,36.43999862670898,37.16999816894531,-1.72413633637985,5 Drug Stocks to Watch for Earnings on Aug 4: BMRN & More,"ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Biopharma stock, Alnylam Pharmaceuticals, Inc.ALNY , is scheduled to report second-quarter results after the market closes. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. TEVA PHARM ADR Price and EPS Surprise TEVA PHARM ADR Price and EPS Surprise | TEVA PHARM ADR Quote San Diego, CA-based ACADIA Pharmaceuticals Inc.ACAD will be reporting second-quarter 2016 results after the market closes."
+2016-08-02,37.0,36.59000015258789,2.0032919038072534,ACADIA (ACAD) Q2 Earnings: What's in Store for the Stock?,"ACADIA PHARMA Price and EPS Surprise ACADIA PHARMA Price and EPS Surprise | ACADIA PHARMA Quote Earnings Whispers? Zacks ESP : The Earnings ESP for ACADIA is 0.00% since the Most Accurate estimate stands at a loss of 48 cents per share, in line with the Zacks Consensus Estimate. Click to get this free report BIO-TECHNE CP (TECH): Free Stock Analysis Report RAPTOR PHARMACT (RPTP): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here."
+2016-08-01,36.9900016784668,37.22999954223633,-1.1081076957084037,,
+2016-07-29,36.619998931884766,37.040000915527344,0.6488182018906006,,
+2016-07-28,37.40999984741211,36.7400016784668,1.1469197047870077,,
+2016-07-27,36.91999816894531,37.43999862670898,-1.7909600953704912,,
+2016-07-26,36.130001068115234,36.790000915527344,1.4084520139577232,,
+2016-07-25,36.630001068115234,36.310001373291016,1.8267363075019665,,
+2016-07-22,36.34999847412109,36.54999923706055,-0.8736000149963525,,
+2016-07-21,35.599998474121094,36.060001373291016,0.5502084493396835,,
+2016-07-20,33.18000030517578,34.650001525878906,1.2921430305799433,,
+2016-07-19,33.15999984741211,32.7400016784668,4.430383385119554,"Commit To Buy Acadia Pharmaceuticals At $18, Earn 11.4% Using Options","Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares decline 45.3% and the contract is exercised (resulting in a cost basis of $15.95 per share before broker commissions, subtracting the $2.05 from $18), the only upside to the put seller is from collecting that premium for the 7.6% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $18 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2018 put at the $18 strike for the 7.6% annualized rate of return represents good reward for the risks."
+2016-07-18,33.0,33.25,-1.2665807324425853,This Could Be the Next Big Pharma Buyout,"Poised for growth Brian Feroldi : One company that's likely to be on Big Pharma's watch list is Acadia Pharmaceuticals (NASDAQ: ACAD) . Acadia recently won FDA approval for its first drug, called Nuplazid, which has been approved to treat Parkinson's disease psychosis, or PDP. Since there aren't currently any good treatment options for PDP, Acadia should have this market all to itself."
+2016-07-15,32.720001220703125,33.0,0.7575757575757576,,
+2016-07-14,33.310001373291016,32.619998931884766,0.8557419585904833,,
+2016-07-13,35.02000045776367,32.91999816894531,-2.0714572589586115,,
+2016-07-12,34.369998931884766,34.68000030517578,-5.996579843998273,3 Risky Biotech Stocks That Could Make You Rich,"For investors brave enough to continue down this rabbit hole, I think Acadia Pharmaceuticals (NASDAQ: ACAD) , Amarin Corp. (NASDAQ: AMRN) , and Sarepta Therapeutics (NASDAQ: SRPT) are all worth a deeper dive. Acadia's flagship drug could be a megablockbuster Last April, the FDA gave the green light for Acadia's Parkinson's disease psychosis drug Nuplazid, despite some serious concerns within the agency that it may increase the risk of death . The particularly intriguing part of the story is that Acadia priced its new drug at $23,400 for a year's supply, giving it the potential to generate upwards of $4 billion in peak sales within the U.S. alone."
+2016-07-11,34.9900016784668,33.91999816894531,0.9019533980940275,,
+2016-07-08,33.59000015258789,34.619998931884766,-3.0580264595413706,,
+2016-07-07,33.720001220703125,33.5099983215332,3.066385158136179,,
+2016-07-06,32.31999969482422,33.61000061035156,-0.6227843759417958,,
+2016-07-05,33.900001525878906,32.63999938964844,3.9913395040468607,Acadia Pharmaceuticals Inc.: Why ACAD Stock Will Be Volatile Over the Next Year | These 3 Biotech Stocks Are Ridiculously Cheap Now,"Why ACAD stock will be more volatile Acadia Pharmaceuticals' drug Nuplazid was FDA approved earlier this year, and is now in the midst of a commercial launch. 3 Consumer Stocks With Strong Dividends AND Growth Acadia has never launched a drug before, but is targeting a very large Parkinson's disease psychosis, or PDP, market where efficient manufacturing of Nuplazid, sales and marketing, and maintaining a controlled balance of supply and demand will all be very crucial to a successful launch. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time commercial drug company, then the market will likely be harsh on ACAD stock. | As for Acadia and Trevena, I think these two picks are best suited for investors with a fairly high risk tolerance, given that neither company is producing much in the way of revenue at the moment, and the investing thesis for each company could fold like a house of cards. All told, my view is that Gilead's highly compressed PE ratio -- relative to its peers -- and the company's strong position from which to pursue deals make this stock a great buy for patient investors right now. Trevena's stock has been getting pummeled, but that may soon change Trevena's stock hasn't had a good 2016, to put it mildly: TRVN data by YCharts ."
+2016-07-01,32.31999969482422,34.25,-3.716820293558383,,
+2016-06-30,31.209999084472656,32.459999084472656,5.971535654082493,,
+2016-06-29,32.040000915527344,32.380001068115234,4.005126679487439,,
+2016-06-28,30.979999542236328,31.65999984741211,1.0611739790029735,ACADIA Pharmaceuticals Inc.'s Shareholders Are Having a Crazy Year. Here's Why,"Here's a review of the key developments that have taken place this year: In January, Acadia raised $300 million through a common share offering, selling just over 10 million shares for $29 each. Now what: AstraZeneca is facing some big revenue challenges over the next few years (which is a big reason it has become one of the highest-yielding big pharma stocks out there), so it's not out of the question that a bid may ultimately surface for Acadia. ACAD data by YCharts ."
+2016-06-27,31.030000686645508,30.299999237060547,2.194965510728005,,
+2016-06-24,30.8799991607666,31.43000030517578,-2.352566656239664,,
+2016-06-23,33.5,33.5,1.781091837295004,,
+2016-06-22,33.88999938964844,33.5,0.0,,
+2016-06-21,37.5,34.9900016784668,-1.1507801613226385,,
+2016-06-20,38.27999877929688,37.400001525878906,-6.693328857421875,,
+2016-06-17,38.52999877929688,37.40999984741211,-2.2988434730408303,,
+2016-06-16,37.900001525878906,38.34999847412109,-2.9068231699155302,,
+2016-06-15,39.29999923706055,38.16999816894531,1.18732699241427,"Noteworthy ETF Inflows: XBI, ACAD, ANAC, MDVN","Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is trading flat, and Medivation Inc (Symbol: MDVN) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $90.0 million dollar inflow -- that's a 4.7% increase week over week in outstanding units (from 34,950,000 to 36,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.94."
+2016-06-14,37.84000015258789,39.209999084472656,-2.8753208398274595,,
+2016-06-13,39.130001068115234,38.09999847412109,3.6205045622629863,,
+2016-06-10,39.4900016784668,39.59999847412109,-2.6322580267789384,,
+2016-06-09,41.33000183105469,40.209999084472656,0.27854340587245174,,
+2016-06-08,40.79999923706055,41.54999923706055,-2.7099024847864377,Acadia Pharmaceuticals Inc.: 7 Companies That Could Buy ACAD,"InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acadia Pharmaceuticals Inc. ( ACAD ) surged over $40 for the first time since last November on a report that AstraZeneca plc (ADR) ( AZN ) may be interested in acquiring the company . Big Pharma Could Battle for ACAD Stock I have a feeling that Acadia Pharmaceuticals' management knows it has a gem with Nuplazid. The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does."
+2016-06-07,40.68000030517578,40.58000183105469,1.8382353284917219,,
+2016-06-06,36.93999862670898,40.68000030517578,-0.2458172895057004,"Notable ETF Inflow Detected - XBI, ACAD, ANAC, MDVN | Why Shares of ACADIA Pharmaceuticals Inc. Jumped Today | Noteworthy Monday Option Activity: EAT, ACAD, LNKD","Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 4.4%, Anacor Pharmaceuticals Inc (Symbol: ANAC) is up about 0.2%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $116.0 million dollar inflow -- that's a 6.1% increase week over week in outstanding units (from 33,050,000 to 35,050,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $58.23. | Regardless, while the idea of a buyout is always exciting, ACADIA's investors should do their best to stay focused on how well the company's new Parkinson's psychosis drug, Nuplazid, performs on the market. ACAD Short Interest data by YCharts . I think that ACADIA bulls have plenty of reasons to believe that Nuplazid has a real shot at being a winner. | Especially high volume was seen for the $40 strike call option expiring June 17, 2016 , with 2,236 contracts trading so far today, representing approximately 223,600 underlying shares of ACAD. Below is a chart showing ACAD's trailing twelve month trading history, with the $40 strike highlighted in orange: And LinkedIn Corp (Symbol: LNKD) saw options trading volume of 10,177 contracts, representing approximately 1.0 million underlying shares or approximately 53.6% of LNKD's average daily trading volume over the past month, of 1.9 million shares. Below is a chart showing EAT's trailing twelve month trading history, with the $45 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 15,957 contracts thus far today."
+2016-06-03,36.77000045776367,36.06999969482422,10.124531178955284,,
+2016-06-02,35.400001525878906,36.810001373291016,-1.9037279146719563,,
+2016-06-01,35.83000183105469,35.5099983215332,3.983050244733293,,
+2016-05-31,36.209999084472656,35.43000030517578,-0.8931160847559041,How The Parts Add Up: IYY Headed For $115,"Similarly, ABCO has 30.90% upside from the recent share price of $32.34 if the average analyst target price of $42.33/share is reached, and analysts on average are expecting ACAD to reach a target price of $46.44/share, which is 30.42% above the recent price of $35.61. Below is a twelve month price history chart comparing the stock performance of RARE, ABCO, and ACAD: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYY's underlying holdings with notable upside to their analyst target prices are Ultragenyx Pharmaceutical Inc (Symbol: RARE), Advisory Board Company (Symbol: ABCO), and Acadia Pharmaceuticals Inc (Symbol: ACAD)."
+2016-05-27,34.900001525878906,35.61000061035156,-2.154097760337556,,
+2016-05-26,35.04999923706055,34.900001525878906,2.0343812419210945,"XBI, ACAD, MDVN, ANAC: Large Inflows Detected at ETF","Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 1.3%, Medivation Inc (Symbol: MDVN) is down about 0.8%, and Anacor Pharmaceuticals Inc (Symbol: ANAC) is up by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $39.2 million dollar inflow -- that's a 2.1% increase week over week in outstanding units (from 32,900,000 to 33,600,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $56.14."
+2016-05-25,35.279998779296875,35.27000045776367,-0.4279535362244422,,
+2016-05-24,34.529998779296875,34.900001525878906,-0.0283399146234392,The 10 Best Healthcare Stocks to Buy Now,"10 Best Healthcare Stocks to Buy: Acadia Pharmaceuticals (ACAD) After years of waiting, Acadia Pharmaceuticals Inc. ( ACAD ) Nuplazid is finally FDA-approved and will begin marketing distribution next month. With more than 1 million who suffer from Parkinson's disease, and with Acadia offering a breakthrough-designated anti-psychotic that is effective without the harsh side effects, the stage is set for Nuplazid sales to be quite remarkable. Plus, Acadia is pricing Nuplazid twice as high as shareholders expected, so ACAD stock has set the stake for big gains."
+2016-05-23,33.97999954223633,34.25,1.0715399932300997,,
+2016-05-20,32.97999954223633,34.040000915527344,0.7945864078899346,,
+2016-05-19,32.27000045776367,32.84000015258789,3.214073341430794,,
+2016-05-18,31.440000534057617,32.5099983215332,1.766345481061453,,
+2016-05-17,29.93000030517578,31.709999084472656,3.4033007929389276,,
+2016-05-16,28.15999984741211,30.030000686645508,5.947206017866497,,
+2016-05-13,27.6299991607666,28.11000061035156,6.640628016215174,,
+2016-05-12,28.700000762939453,27.809999465942383,1.7372474273055303,,
+2016-05-11,29.549999237060547,28.489999771118164,-3.1010497328848032,"Notable ETF Outflow Detected - VTI, VIS, ACAD, CPHD","Among the largest underlying components of VTI, in trading today Vanguard Sector Index Funds - Vanguard Industrials ETF (Symbol: VIS) is trading flat, Acadia Pharmaceuticals Inc (Symbol: ACAD) is down about 1%, and Cepheid (Symbol: CPHD) is up by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Total Stock Market ETF (Symbol: VTI) where we have detected an approximate $82.4 million dollar outflow -- that's a 0.1% decrease week over week (from 562,998,249 to 562,223,660). For a complete list of holdings, visit the VTI Holdings page » The chart below shows the one year price performance of VTI, versus its 200 day moving average: Looking at the chart above, VTI's low point in its 52 week range is $91.58 per share, with $110.90 as the 52 week high point - that compares with a last trade of $106.15."
+2016-05-10,29.559999465942383,29.809999465942383,-3.587138725245616,,
+2016-05-09,27.65999984741211,29.25,0.8457374983651067,,
+2016-05-06,28.030000686645508,27.64999961853028,5.748373685318918,,
+2016-05-05,27.88999938964844,27.049999237060547,-1.3556941091916324,,
+2016-05-04,29.030000686645508,27.530000686645508,-3.0118328109381953,Why ACADIA Pharmaceuticals Inc Jumped 12.7% in April,"Receiving regulatory approval for their lead compound was a transformative step for Acadia. Acadia also has about $490 million in cash on its balance sheet, so it has ample liquidity to launch the drug successfully. Will Acadia be able to successfully transition from a clinical-stage company into a commercial enterprise?"
+2016-05-03,31.809999465942383,30.0,-5.167068427559617,,
+2016-05-02,34.15999984741211,33.0,-5.69003299695202,"SPDR S&P Biotech ETF Experiences Big Outflow | Pre-Market Most Active for May 2, 2016 : TLK, TVIX, ACAD, OPWR, FCX, BIDU, ABX, BCRX, AUY, QQQ, SDRL, AAPL | 3 Stocks to Watch on Monday: Acadia Pharmaceuticals Inc. (ACAD), Caterpillar Inc. (CAT) and Tesla Motors Inc (TSLA)","Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 0.3%, Neurocrine Biosciences, Inc. (Symbol: NBIX) is off about 0.6%, and Medivation Inc (Symbol: MDVN) is lower by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $43.1 million dollar outflow -- that's a 2.4% decrease week over week (from 33,900,000 to 33,100,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $53.93. | ACADIA Pharmaceuticals Inc. ( ACAD ) is +2.16 at $34.46, with 288,750 shares traded.ACAD is scheduled to provide an earnings report on 5/5/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.4 per share, which represents a -40 percent increase over the EPS one Year Ago Opower, Inc. ( OPWR ) is +2.4 at $10.30, with 277,427 shares traded.OPWR is scheduled to provide an earnings report on 5/9/2016, for the fiscal quarter ending Mar2016. The consensus earnings per share forecast is -0.27 per share, which represents a -22 percent increase over the EPS one Year Ago Freeport-McMoran, Inc. ( FCX ) is +0.18 at $14.18, with 267,491 shares traded. | Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), Caterpillar Inc. (NYSE: CAT ) and Tesla Motors Inc (NASDAQ: TSLA ) are all stocks worth watching as the calendar turns to May. More From InvestorPlace 7 Wealth-Building REITs You Should Buy Now The 10 Best Growth Stocks to Buy for Retirement Berkshire Hathaway: A Great Buy for All Seasons (BRK.A, BRK.B) The post 3 Stocks to Watch on Monday: Acadia Pharmaceuticals Inc. (ACAD), Caterpillar Inc. (CAT) and Tesla Motors Inc (TSLA) appeared first on InvestorPlace . Here's what could have these three companies on the move today: Acadia Pharmaceuticals Inc. (ACAD) Acadia on Friday received a green light on a treatment for psychosis associated with Parkinson's disease."
+2016-04-29,33.040000915527344,32.29999923706055,-3.395784111808152,,
+2016-04-28,32.47999954223633,32.400001525878906,-2.2397144611428526,,
+2016-04-27,32.18000030517578,32.630001068115234,-0.24629931491653528,,
+2016-04-26,34.16999816894531,32.619998931884766,1.3983864470848861,,
+2016-04-25,33.939998626708984,34.18000030517578,-4.536140825635838,,
+2016-04-22,33.599998474121094,34.02000045776367,0.7071352038238689,,
+2016-04-21,33.349998474121094,33.689998626708984,1.2500059604647482,,
+2016-04-20,33.70000076293945,33.349998474121094,1.019490759052729,,
+2016-04-19,33.5,33.65999984741211,-1.0385824358890332,,
+2016-04-18,33.41999816894531,33.470001220703125,0.47761148481226684,3 Stocks That Could Double Your Money,"ACAD data by YCharts The long and short of it is that Nuplazid offers a jaw-dropping long-term value proposition for shareholders. But barring any unforeseen even events on the regulatory front, I'm cautiously optimistic that Acadia's shares could surge higher due to the need for new treatment options for PDP and Nuplazid's potential to gobble up a nice chunk of this already large and growing market. I think both Acadia and Celator easily have more room to run in light of the commercial potential of their lead product candidates relative to their respective market caps."
+2016-04-15,33.68000030517578,33.52000045776367,0.14962015109945928,,
+2016-04-14,33.34000015258789,33.790000915527344,-0.47505892506634384,,
+2016-04-13,32.560001373291016,33.220001220703125,1.3497323361725404,SPDR S&P Biotech ETF Experiences Big Inflow,"Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2%, Intercept Pharmaceuticals Inc (Symbol: ICPT) is down about 1%, and Neurocrine Biosciences, Inc. (Symbol: NBIX) is higher by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $76.9 million dollar inflow -- that's a 3.9% increase week over week in outstanding units (from 35,750,000 to 37,150,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $55.64."
+2016-04-12,31.06999969482422,32.2400016784668,2.0270264728966123,,
+2016-04-11,32.18000030517578,31.11000061035156,3.765696797987038,,
+2016-04-08,32.900001525878906,31.780000686645508,-3.3250456329303555,Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March,"Now what: Even though Acadia's stock was able to roar higher during the month, it still hasn't fully recovered from the drubbing that it took to start the year. With analysts predicting peak sales as high as $3 billion for Nuplazid, even after March's monster move there still could be plenty of room left for Acadia's stock to run -- assuming, of course, that everything goes according to plan. The article Why ACADIA Pharmaceuticals Inc Skyrocketed 46% Higher in March originally appeared on Fool.com."
+2016-04-07,32.70000076293945,32.2599983215332,-3.4042577121232465,,
+2016-04-06,30.38999938964844,32.86000061035156,-1.3455731839154168,Here's Why Sarepta Therapeutics Jumped Today,"The thesis rests in part on the fact that ACADIA Pharmaceuticals drug Nuplazid also did not have perfect data but the FDA's advisory committee still recommended approving the drug in a 12 to two vote . I understand their confidence as ACADIA Pharmaceutical's drug didn't have anywhere near that kind of support from the medical community as Sarepta does and yet it still managed to come out of its FDA panel meeting looking good. What: Shares of Sarepta Therapeutics , a clinical-stage biopharmaceutical company, jumped by more than 15% as of 3:00 p.m. EST Wednesday after an analyst raised his price target and issued a bullish forecast for the company."
+2016-04-05,29.950000762939453,29.89999961853028,8.127677756862552,SPDR S&P Biotech ETF Experiences Big Outflow,"Among the largest underlying components of XBI, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is up about 2.8%, Novavax, Inc. (Symbol: NVAX) is up about 2.7%, and Intercept Pharmaceuticals Inc (Symbol: ICPT) is up by about 18.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $83.5 million dollar outflow -- that's a 4.2% decrease week over week (from 37,300,000 to 35,750,000). For a complete list of holdings, visit the XBI Holdings page » The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $44.16 per share, with $91.11 as the 52 week high point - that compares with a last trade of $54.74."
+2016-04-04,29.549999237060547,30.059999465942383,-0.1669487249931716,,
+2016-04-01,27.8700008392334,28.65999984741211,1.7258891439909478,,
+2016-03-31,25.96999931335449,27.959999084472656,2.8345855198777272,10 Biotech Stocks With Big Catalysts Coming This Quarter,"Biotech Stocks to Watch in Q2: Acadia Pharmaceuticals Inc. (ACAD) Despite the dire need, there just aren't any game-changing drugs that treat Parkinson's disease. That's why the FDA has given priority review to Nuplazid (pimavanserin), from Acadia Pharmaceuticals Inc. ( ACAD ), for Parkinson's disease psychosis. Nuplazid met all of its targeted endpoints in Phase 3 of its trial, and Acadia Pharmaceuticals says those results were statistically significant."
+2016-03-30,28.56999969482422,26.01000022888184,7.662687037865476,"Midday Update: Wall Street Still Building on Post-Yellen Gains; Dow Hits New High for 2016 | Mid-Day Market Update: ACADIA Pharmaceuticals Rises Following FDA Panel Vote; Verint Systems Shares Slide | Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today | US Stocks Eye Higher Open on Yellen Remarks; ADP Report Shows 200,000 Jobs Added in March | Pre-Market Most Active for Mar 30, 2016 : STOR, ETE, FCAU, BAC, NOK, RIG, ACAD, TVIX, AAPL, YHOO, VOD, FB | US Futures Continue Higher After Yellen Suggests Caution on Rate Increase","(+) VICL (+10.36%) Gets FDA fast track status for invasive aspergillosis drug (+) ACAD (+9.45%) FDA rules that treatment with pimavanserin for psychosis associated with Parkinson's outweighed the risks (+) ATNM (+3.45%) FDA granted orphan drug status to Iomab-B for acute myloid leukemia (+) SYMX (+4.76%) Yima joint venture plant received performance test certificate, exceeding performance targets Compounding the bullish tone across global financial markets is today's rebound in oil, fueled by a weaker dollar as well as increase in stockpiles and falling production following the Energy Information Administration report that showed a seventh straight weekly increase in crude oil supply. NYSE Energy Sector Index up 0.86% NYSE Financial Sector Index up 0.77% NYSE Healthcare Sector Index up 0.12% | ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) shares were also up, gaining 10 percent to $26.22. A U.S. Food and Drug Administration panel voted 12-2 on Tuesday that Acadia's drug pimavanserin, a treatment for psychosis associated with Parkinson's disease, outweighed the risks of treatment. Midway through trading Wednesday, the Dow traded up 0.55 percent to 17,729.78 while the NASDAQ gained 0.54 percent to 4,872.85. | ACAD data by YCharts . Acadia's stock appears primed for a huge short squeeze after this positive regulatory development. The article Why Acadia Pharmaceuticals' Stock Is Rocketing Higher Today originally appeared on Fool.com. | In equities, Acadia Pharmaceuticals ( ACAD ) was higher 21% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. stocks were set to extend gains Wednesday in the wake of Federal Reserve Chair Janet Yellen's remarks Tuesday while the ADP employment report showed a solid increase in private payrolls ahead of the Bureau of Labor Statistics' report on Friday. (+) Large cap tech: unchanged to higher (+/-) Chip stocks: unchanged (+) Software stocks: unchanged to higher (+) Hardware stocks: unchanged to higher (+) Internet stocks: higher (+) Oil stocks: unchanged to higher (+/-) Biotech: unchanged (+/-) Drug stocks: mixed (+) Financial stocks: unchanged to higher (+/-) Retail stocks: unchanged (+) Industrial stocks: unchanged to higher (+) Airlines: unchanged to higher (+) Autos: unchanged to higher | ACADIA Pharmaceuticals Inc. ( ACAD ) is +5.12 at $28.93, with 646,845 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. The following are the most active stocks for the pre-market session : STORE Capital Corporation ( STOR ) is -0.7 at $25.28, with 1,439,251 shares traded. | In equities, Acadia Pharmaceuticals ( ACAD ) surged nearly 25% in recent pre-market trade after saying the U.S. Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease outweigh the risks of treatment. U.S. equities futures pointed to a higher open Wednesday, building on gains made Tuesday after Federal Reserve Chair Janet Yellen called for caution in raising rates further in the current economic environment. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2016-03-29,23.809999465942383,23.809999465942383,-8.96044624881866,,
+2016-03-28,24.479999542236328,23.809999465942383,0.0,"Midday Update: Stocks Inching Higher After Mixed Data, Sliding Oil Price Encourages Caution | Here's Why Acadia Pharmaceuticals' Stock Is Soaring Today | Pre-Market Most Active for Mar 28, 2016 : ACAD, SPIL, TVIX, FCX, XIV, FB, BAC, VRX, YHOO, TWTR, PBR, CHK | Why did Acadia Pharma (ACAD) Gained 17% on the Day? | Mid-Afternoon Market Update: Dow Jumps 50 Points; Pandora Shares Slide","(+) ALDR (+47.08%) Phase 2 trial of migraine meets primary and secondary endpoints (+) ACAD (+22.01%) Meeting with FDA on Tuesday regarding UPLAZID treatment for Parkinson's disease-related psychosis (+) LEU (+8.41%) Signed a $2.3 million contract for uranium centrifuge work at Oak Ridge National Lab Nikkei 225 Index up 0.77% Hang Seng Index down 1.31% Shanghai China Composite Index down 0.73% FTSE 100 Index down 1.49% CAC 40 down 2.13% DAX down 1.71% NYSE Energy Sector Index down 0.51% NYSE Financial Sector Index up 0.34% NYSE Healthcare Sector Index down 0.15% | Specifically, the agency noted in its internal review: So what : Short-sellers have been piling into Acadia ahead of Nuplazid's regulatory review, presumably because the drug has failed to meet its primary endpoint in three of its clinical trials and only hit the mark in a single late-stage study. What : Shares of Acadia Pharmaceuticals gained more than 20% in early morning trading today on exceptionally high volume. ACAD data by YCharts . | The following are the most active stocks for the pre-market session : ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.12 at $23.43, with 476,906 shares traded. As reported in the last short interest update the days to cover for ACAD is 8.197547; this calculation is based on the average trading volume of the stock. The total Pre-Market volume is currently 1,246,613 shares traded. | Acadia Pharmaceuticals Inc. (ACAD) Stock Price | FindTheCompany The primary reason for this active and positive trading day is that the Food and Drug Administration (FDA) briefed the upcoming Psychopharmacologic Drugs Advisory Committee (PDAC), meeting tomorrow, about a priority review of Nuplazid, an Acadia Pharmaceutical product. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals Inc. (ACAD) closed on the day 17% up, even reaching highs of over 22% during afternoon trading. | Shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) got a boost, shooting up 22 percent to $24.75 after the FDA released briefing documents for the company's drug called Nuplazid (pimavanserin). According to Fierce Biotech, Acadia Pharmaceuticals will face ""some tough questions"" on Tuesday when the U.S. Food and Drug Administration's advisory committee will review the company's antipshotic drug pimavanserin. Fierce Biotech noted that while the FDA recognized that Acadia Pharmaceuticals' 34-mg dose of pimavanserin significantly improved symptoms of Parkinson's, there was also a ""distinct"" increase in the numbers of deaths and adverse events among patients."
+2016-03-24,20.280000686645508,20.309999465942383,-2.736928467412621,,
+2016-03-23,22.61000061035156,20.25,0.1479229698282474,,
+2016-03-22,21.229999542236328,22.63999938964844,-10.43786177197659,,
+2016-03-21,19.729999542236328,21.530000686645508,6.641544407982527,Mid-Afternoon Market Update: US Stocks Gain; Markit Shares Surge,"Top gainers in the sector included Sarepta Therapeutics Inc (NASDAQ: SRPT ), Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ). Toward the end of trading Monday, the Dow traded up 0.24 percent to 17,643.73 while the NASDAQ climbed 0.35 percent to 4,812.29. The eurozone's STOXX 600 dropped 0.26 percent, the Spanish Ibex Index fell 0.33 percent, while Italy's FTSE MIB Index surged 0.46 percent."
+2016-03-18,19.56999969482422,19.790000915527344,9.12316870842236,,
+2016-03-17,19.229999542236328,19.530000686645508,1.1241759025745406,,
+2016-03-16,19.5,19.38999938964844,1.5600683907987833,,
+2016-03-15,20.13999938964844,19.64999961853028,-0.5641056941105587,,
+2016-03-14,20.18000030517578,20.31999969482422,-2.4329681527697096,,
+2016-03-11,19.479999542236328,20.190000534057617,0.6937531592233444,,
+2016-03-10,19.61000061035156,19.26000022888184,3.644769037503684,,
+2016-03-09,19.790000915527344,19.350000381469727,-1.7848055613265215,,
+2016-03-08,21.530000686645508,19.600000381469727,-2.2233477195667555,,
+2016-03-07,21.040000915527344,21.76000022888184,-8.964237081389921,Surprising Analyst 12-Month Target For IYH,"Below is a twelve month price history chart comparing the stock performance of ACAD, ANAC, and RDUS: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), Anacor Pharmaceuticals Inc (Symbol: ANAC), and Radius Health Inc (Symbol: RDUS). Although ACAD has traded at a recent price of $21.20/share, the average analyst target is 115.41% higher at $45.67/share."
+2016-03-04,21.530000686645508,21.200000762939453,3.4220498195090014,,
+2016-03-03,20.479999542236328,21.459999084472656,-1.5327446037228645,,
+2016-03-02,19.209999084472656,20.36000061035156,4.78515412178235,,
+2016-03-01,17.5,19.14999961853028,5.986473611070825,,
+2016-02-29,18.709999084472656,17.260000228881836,9.428569248744461,,
+2016-02-26,18.71999931335449,18.729999542236328,-7.749860644269982,"Pre-Market Earnings Report for February 29, 2016 : VRX, ENDP, IEP, NRG, HZNP, TRCO, VGR, ACAD, GRFS, BCPC, FI, SJI","ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ACAD is -12.08 vs. an industry ratio of -30.30, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2015 Price to Earnings ratio for VRX is 8.22 vs. an industry ratio of -10.10, implying that they will have a higher earnings growth than their competitors in the same industry."
+2016-02-25,19.13999938964844,18.479999542236328,0.05342002803763737,,
+2016-02-24,18.93000030517578,19.1200008392334,-3.448275174810419,,
+2016-02-23,19.920000076293945,19.190000534057617,1.0037006391683356,,
+2016-02-22,20.350000381469727,20.1200008392334,-3.664656322492054,,
+2016-02-19,19.1299991607666,19.76000022888184,-1.1302188595817462,,
+2016-02-18,20.809999465942383,19.21999931335449,3.293262392856225,,
+2016-02-17,18.93000030517578,20.6200008392334,-7.640558353641894,,
+2016-02-16,18.700000762939453,18.81999969482422,8.927630780838088,,
+2016-02-12,18.100000381469727,18.26000022888184,0.641705491919472,,
+2016-02-11,17.850000381469727,17.549999237060547,0.8839770388950726,,
+2016-02-10,18.600000381469727,18.229999542236328,-1.6806786442459354,,
+2016-02-09,17.3799991607666,18.479999542236328,-1.9892517830376617,,
+2016-02-08,19.09000015258789,17.760000228881836,6.32911642454422,,
+2016-02-05,19.89999961853028,19.36000061035156,-6.966997973154843,,
+2016-02-04,18.799999237060547,20.290000915527344,-2.7135629071866454,How The Pieces Add Up: IYH Targets $175,"Similarly, ACAD has 154.76% upside from the recent share price of $18.89 if the average analyst target price of $48.12/share is reached, and analysts on average are expecting HALO to reach a target price of $20.00/share, which is 146.61% above the recent price of $8.11. Below is a twelve month price history chart comparing the stock performance of NVAX, ACAD, and HALO: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Novavax, Inc. (Symbol: NVAX), Acadia Pharmaceuticals Inc (Symbol: ACAD), and Halozyme Therapeutics Inc (Symbol: HALO)."
+2016-02-03,19.21999931335449,18.88999938964844,7.925541164541901,,
+2016-02-02,20.420000076293945,19.040000915527344,-1.7169611628277022,,
+2016-02-01,21.46999931335449,20.86000061035156,-6.758076178308514,,
+2016-01-29,20.3799991607666,20.690000534057617,-2.8411677806785316,,
+2016-01-28,22.3799991607666,20.520000457763672,1.5211059178441833,,
+2016-01-27,23.6200008392334,21.950000762939453,-8.310986473420483,,
+2016-01-26,24.25,23.71999931335449,-7.0702794960110005,,
+2016-01-25,24.11000061035156,24.15999984741211,-2.18556984183716,April 15th Options Now Available For Acadia Pharmaceuticals ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $24.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $25.00 strike price has a current bid of $3.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $25.00 strike highlighted in red: Considering the fact that the $25.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the April 15th expiration."
+2016-01-22,24.100000381469727,24.520000457763672,0.2073796590410844,,
+2016-01-21,23.81999969482422,22.65999984741211,1.7427388781988553,,
+2016-01-20,22.21999931335449,23.780000686645508,-4.8698566846084494,,
+2016-01-19,24.489999771118164,22.65999984741211,7.020708467589554,,
+2016-01-15,22.8799991607666,23.780000686645508,-7.472437487991453,,
+2016-01-14,23.239999771118164,23.940000534057617,3.9335732469002043,,
+2016-01-13,27.43000030517578,23.1299991607666,3.0120515053076247,,
+2016-01-12,27.5,27.040000915527344,-15.676270858800576,Baker Brothers Advisors buys ACADIA shares,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2016-01-11,28.459999084472656,27.11000061035156,-1.6727239435369319,,
+2016-01-08,29.0,28.040000915527344,-4.743494439736774,,
+2016-01-07,28.350000381469727,28.729999542236328,-3.3103416705953665,Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff,"What: Investors in ACADIA Pharmaceuticals , a biopharmaceutical company focused on neurological and central nervous system disorders, are having a rough day as the stock fell by more than 12% earlier this morning (although shares have since recovered to down about 2.5% at the time of publication) after news broke that it will be raising capital via a common stock offering. If the FDA gives Nuplazid the green light, then ACADIA's stock price could increase, so why would it want to raise capital ahead of that potential catalyst? The article Why Shares of ACADIA Pharmaceuticals Inc. Fell off a Cliff originally appeared on Fool.com."
+2016-01-06,32.5,29.239999771118164,1.340385028759924,,
+2016-01-05,34.689998626708984,34.459999084472656,-10.030769935021034,,
+2016-01-04,34.84000015258789,34.619998931884766,-0.6630139848412788,,
+2015-12-31,35.61000061035156,35.650001525878906,-0.6314615951193774,,
+2015-12-30,36.0,35.869998931884766,0.11233056681194152,,
+2015-12-29,35.459999084472656,36.04999923706055,-0.36111407809787327,,
+2015-12-28,35.0,35.099998474121094,1.6638470609725478,,
+2015-12-24,34.88999938964844,35.060001373291016,0.28570992606026785,,
+2015-12-23,34.5099983215332,34.90999984741211,0.4872513230625515,,
+2015-12-22,33.70000076293945,34.27000045776367,1.1590888013150593,,
+2015-12-21,34.040000915527344,33.68000030517578,1.6913937148958718,,
+2015-12-18,34.34000015258789,33.70000076293945,-1.057581083046764,,
+2015-12-17,36.08000183105469,34.47999954223633,-1.8637139976838544,,
+2015-12-16,35.040000915527344,35.970001220703125,-4.434595919119964,,
+2015-12-15,34.81999969482422,34.599998474121094,2.6541103906297803,,
+2015-12-14,32.459999084472656,33.47999954223633,-0.6318243039382532,,
+2015-12-11,33.91999816894531,32.5,3.142330519200761,,
+2015-12-10,34.279998779296875,34.650001525878906,-4.18631558254434,,
+2015-12-09,35.02000045776367,34.290000915527344,1.0793546083948269,,
+2015-12-08,34.029998779296875,35.279998779296875,-2.0845217952431314,,
+2015-12-07,36.0,34.43000030517578,3.6732296351431946,,
+2015-12-04,35.290000915527344,36.150001525878906,-4.361110263400607,,
+2015-12-03,37.63999938964844,35.2400016784668,2.4369526439234757,,
+2015-12-02,37.5,37.47999954223633,-6.376189559242331,,
+2015-12-01,38.29999923706055,37.5099983215332,-0.053334554036458336,,
+2015-11-30,39.25,37.95000076293945,-2.062665616877894,,
+2015-11-27,38.5099983215332,39.20000076293945,-3.3120999670332405,,
+2015-11-25,37.5099983215332,38.27999877929688,1.7917488223322748,,
+2015-11-24,36.90999984741211,37.619998931884766,2.0527872359878194,,
+2015-11-23,35.779998779296875,37.06999969482422,1.9235954684579517,,
+2015-11-20,36.04999923706055,36.0,3.6053688081000375,,
+2015-11-19,36.38999938964844,35.869998931884766,-0.138694141799443,,
+2015-11-18,34.63999938964844,36.310001373291016,-1.428965283004627,,
+2015-11-17,35.09000015258789,34.56999969482422,4.821021977678294,,
+2015-11-16,34.790000915527344,34.88999938964844,-1.48190497435869,Interesting ACAD Put And Call Options For January 2018,"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $33.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $40.00 strike price has a current bid of $10.50. Below is a chart showing ACAD's trailing twelve month trading history, with the $40.00 strike highlighted in red: Considering the fact that the $40.00 strike represents an approximate 17% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available today, for the January 2018 expiration."
+2015-11-13,34.880001068115234,35.04999923706055,0.28743452569575184,,
+2015-11-12,35.220001220703125,34.970001220703125,0.4873800565926946,,
+2015-11-11,36.220001220703125,35.65999984741211,-0.7098239390549602,,
+2015-11-10,35.0,35.970001220703125,-1.5461108625554723,,
+2015-11-09,36.540000915527344,35.209999084472656,2.7714320591517856,,
+2015-11-06,41.150001525878906,36.75,-3.6398516631933506,,
+2015-11-05,42.06999969482422,41.540000915527344,-10.692591403943887,,
+2015-11-04,42.25,42.290000915527344,-1.2598021942987547,,
+2015-11-03,40.119998931884766,42.27999877929688,0.09467672314164202,,
+2015-11-02,37.09000015258789,40.18000030517578,5.383848217641623,"Health Care Sector Update for 11/02/2015: TTPH, ACAD, CTMX | Why Acadia Pharmaceuticals Is Up Today | Noteworthy Monday Option Activity: LPLA, ACAD, ECOM","ACADIA Pharmaceuticals ( ACAD ) were up by 7.7% to $37.50 in recent pre-market trade after the company announced that the Food and Drug Administration granted priority review status to its New Drug Application for NUPLAZID to treat psychosis associated with Parkinson's disease. In health-care stocks news, Tetraphase Pharmaceuticals ( TTPH ), a clinical-stage biopharmaceutical company, reported a Q3 net loss of $18 million, or $0.49 per share, compared to a net loss of $14.2 million, or $0.55 per share, for the same period in 2014. Shares in the company have traded between $26.57 and $51.99 over the past 52 weeks. | What: Shares of Acadia Pharmaceuticals , a clinical-stage biopharmaceutical company focused on disorders of the central nervous system, were up more than 16% in late afternoon trading today on heavy volume after the company released good news related to its pending New Drug Application, or NDA, with the FDA. The article Why Acadia Pharmaceuticals Is Up Today originally appeared on Fool.com. So what: The company announced that its NDA filing for its drug Nuplazid, which was submitted earlier this year as a potential treatment for Parkinson's disease psychosis, has been accepted for priority review by the FDA. | Below is a chart showing ACAD's trailing twelve month trading history, with the $38 strike highlighted in orange: And ChannelAdvisor Corp (Symbol: ECOM) saw options trading volume of 1,000 contracts, representing approximately 100,000 underlying shares or approximately 62.2% of ECOM's average daily trading volume over the past month, of 160,670 shares. Below is a chart showing LPLA's trailing twelve month trading history, with the $42 strike highlighted in orange: Acadia Pharmaceuticals Inc (Symbol: ACAD) options are showing a volume of 6,978 contracts thus far today. That number of contracts represents approximately 697,800 underlying shares, working out to a sizeable 63.9% of ACAD's average daily trading volume over the past month, of 1.1 million shares."
+2015-10-30,35.93000030517578,34.81999969482422,8.331086923363875,,
+2015-10-29,36.47999954223633,35.970001220703125,-3.0893420565645386,,
+2015-10-28,34.16999816894531,36.43999862670898,-1.398021732272036,,
+2015-10-27,33.220001220703125,34.09000015258789,6.643256012307039,,
+2015-10-26,33.65999984741211,33.459999084472656,2.6189009630215523,,
+2015-10-23,32.95000076293945,33.79999923706055,-0.5941793340644648,,
+2015-10-22,32.47999954223633,32.54999923706055,2.5796614702271277,,
+2015-10-21,32.869998931884766,32.220001220703125,0.21551630483612716,,
+2015-10-20,33.790000915527344,32.349998474121094,-1.97748017129117,,
+2015-10-19,33.63999938964844,33.970001220703125,-4.261622972447252,,
+2015-10-16,34.47999954223633,33.689998626708984,0.9809804906127148,,
+2015-10-15,31.96999931335449,34.349998474121094,-2.291185980323552,,
+2015-10-14,32.0,32.08000183105469,7.4444767340749785,,
+2015-10-13,32.459999084472656,31.82999992370605,0.25000572204589844,,
+2015-10-12,32.7400016784668,32.810001373291016,-1.9408477465668421,,
+2015-10-09,32.209999084472656,32.43000030517578,0.21380479913126504,,
+2015-10-08,32.52000045776367,32.08000183105469,0.6830215056081144,,
+2015-10-07,32.56999969482422,32.779998779296875,-1.3530092881777347,,
+2015-10-06,34.130001068115234,32.36000061035156,0.644762316365719,,
+2015-10-05,35.54999923706055,34.470001220703125,-5.1860545044554165,,
+2015-10-02,32.689998626708984,35.119998931884766,-3.0379691688756325,,
+2015-10-01,32.86000061035156,33.20000076293945,7.433467137531104,,
+2015-09-30,31.25,33.06999969482422,1.0346930805618542,,
+2015-09-29,31.950000762939453,30.61000061035156,5.8239990234375,,
+2015-09-28,33.970001220703125,31.82999992370605,-4.194053585570594,Oversold Conditions For Acadia Pharmaceuticals (ACAD),"In trading on Monday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.1, after changing hands as low as $30.41 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $22.04 per share, with $51.99 as the 52 week high point - that compares with a last trade of $31.83. A bullish investor could look at ACAD's 29.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side."
+2015-09-25,37.68999862670898,34.150001525878906,-6.299679776557804,5 Sell-Ranked Biotechs That Fell More Than 5% Today,"Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report To read this article on Zacks.com click here. Acadia Pharmaceuticals(ACAD) Focuses on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders is Acadia Pharmaceuticals. ACAD is currently a Zacks Rank #4 (Sell)."
+2015-09-24,37.5099983215332,36.959999084472656,-9.39240443039299,,
+2015-09-23,38.369998931884766,37.84999847412109,-1.4662736914728445,,
+2015-09-22,38.540000915527344,38.119998931884766,-1.3552266672897095,,
+2015-09-21,43.88999938964844,39.09000015258789,-1.0897819762981997,,
+2015-09-18,42.68000030517578,43.33000183105469,-10.93643040285081,,
+2015-09-17,42.47999954223633,43.15999984741211,1.5229651387797223,,
+2015-09-16,42.45000076293945,42.65999984741211,1.6007540313169766,,
+2015-09-15,42.59000015258789,42.209999084472656,0.49469748103277733,,
+2015-09-14,41.90999984741211,42.33000183105469,-0.8922307272923181,,
+2015-09-11,41.060001373291016,41.68999862670898,1.0021521955899333,,
+2015-09-10,40.310001373291016,41.16999816894531,1.5343332497493933,"The Zacks Analyst Blog Highlights: Amgen, Tetraphase, Geron, Alexion and ACADIA","Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report TETRAPHASE PHAR (TTPH): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Amgen ( AMGN ), Tetraphase ( TTPH ), Geron ( GERN ), Alexion ( ALXN ) and ACADIA ( ACAD ). ACADIA ( ACAD ) submitted a NDA seeking approval for its lead pipeline candidate, Nuplazid (pimavanserin)."
+2015-09-09,42.560001373291016,40.22999954223633,2.1334576193394073,,
+2015-09-08,40.38999938964844,41.790000915527344,-5.474628185789733,,
+2015-09-04,38.77000045776367,39.459999084472656,3.4662083363084,,
+2015-09-03,42.18000030517578,39.130001068115234,1.779723029564248,Why Parkinson's Disease-Focused ACADIA Pharmaceuticals is Soaring Today,"Now what: Investors have been bidding up Acadia's stock for years now, and surprisingly enough the stock still managed to move higher during the summer despite the company announcing that they were delaying the submission of Nuplazid from the first half of the year to the second half, noting that they needed more time to properly prepare the company for commercialization. What: Shares of ACADIA Pharmaceuticals , a clinical-stage biotech with a focus on neurological disorders, were up more than 12% at one point today (but have since settled down) after the company announced that it filed for FDA approval of its key compound. So what: Acadia has officially submitted a New Drug Application, or NDA, to the FDA for approval of Nuplazid, which the company has studied as a potential treatment for Parkinson's Disease Psychosis."
+2015-09-02,36.58000183105469,38.06999969482422,-7.230913264565081,,
+2015-09-01,35.84000015258789,35.90999984741211,4.073258034953387,,
+2015-08-31,37.65999984741211,36.630001068115234,0.19531164767354026,,
+2015-08-28,37.52999877929688,38.16999816894531,-2.734994114365759,,
+2015-08-27,38.5,37.90999984741211,1.7053008538904637,,
+2015-08-26,35.36000061035156,36.380001068115234,-1.532467928799716,,
+2015-08-25,35.5099983215332,34.13999938964844,2.884616629404325,,
+2015-08-24,33.7599983215332,33.599998474121094,-3.85806532424982,,
+2015-08-21,34.869998931884766,35.650001525878906,-0.4739332208735816,,
+2015-08-20,37.02999877929688,35.9900016784668,2.236887346964942,Acadia Pharmaceuticals (ACAD) Shares Cross Below 200 DMA,"In trading on Thursday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed below their 200 day moving average of $36.50, changing hands as low as $35.96 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $21.84 per share, with $51.99 as the 52 week high point - that compares with a last trade of $35.99. Acadia Pharmaceuticals Inc shares are currently trading down about 5.6% on the day."
+2015-08-19,38.79999923706055,38.13999938964844,-2.8085258847254884,,
+2015-08-18,39.06999969482422,38.79999923706055,-1.7010305680153164,,
+2015-08-17,37.470001220703125,39.43999862670898,-0.6910684921234849,,
+2015-08-14,37.90999984741211,37.880001068115234,5.257532270688528,Why ACADIA Pharmaceuticals (ACAD) Could Be Positioned for a Slump,"One such stock that you may want to consider dropping is ACADIA Pharmaceuticals Inc. ( ACAD ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. Also, for the current quarter, ACADIA Pharmaceuticals has seen 3 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 39 cents a share from a loss of 33 cents over the past 30 days. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here."
+2015-08-13,39.220001220703125,38.0,-0.07913157324616249,,
+2015-08-12,37.400001525878906,39.310001373291016,-3.110660843271777,3 Small-Cap Biopharma Stocks I'd Never Short,"Despite this somewhat brutal example, shorts have still poured into some of Acadia's more promising contemporaries such as Bellicum Pharmaceuticals , Exelixis , and Sarepta Therapeutics . Bellicum might leapfrog its competitors in the CAR-T space Bellicum is lagging behind its peers, including Juno Therapeutics and Kite Pharma , in the CAR-T space for blood cancers and solid tumors. Even though this positive trial result should put Cometriq on track toward taking a big slice out of Afinitor's $400 million-plus in sales moving forward, shorts haven't exactly backed off, with a nearly a quarter of the float being short, per the latest figures."
+2015-08-11,38.63999938964844,38.04999923706055,5.106951255310742,,
+2015-08-10,39.150001525878906,39.43000030517578,-1.5269155328867583,,
+2015-08-07,43.02000045776367,39.13999938964844,0.7151948106867643,Acadia Pharmaceuticals Becomes Oversold (ACAD) | Why ACADIA Pharmaceuticals Inc. is Dropping Today,"In trading on Friday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $39.01 per share. The chart below shows the one year performance of ACAD shares: Looking at the chart above, ACAD's low point in its 52 week range is $19.90 per share, with $51.99 as the 52 week high point - that compares with a last trade of $39.12. A bullish investor could look at ACAD's 29.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. | Acadia's stock has been on a stellar run for quite some time, and has surpisingly kept its upwards trajectory going even after management announced that its NDA submission would be delayed until the second half of the year. If you were bullish on Acadia's stock before today's announcement, I see no reason to change your position. The article Why ACADIA Pharmaceuticals Inc. is Dropping Today originally appeared on Fool.com."
+2015-08-06,47.90999984741211,45.150001525878906,-9.019063288770896,,
+2015-08-05,48.27999877929688,47.59999847412109,-5.760798017790615,,
+2015-08-04,48.34999847412109,47.70000076293945,-1.408451371932074,,
+2015-08-03,48.79999923706055,48.18999862670898,-1.3443593209822728,,
+2015-07-31,48.25,48.810001373291016,-1.250001270262956,,
+2015-07-30,48.59999847412109,47.81999969482422,1.1606246078570273,,
+2015-07-29,49.34999847412109,48.59999847412109,-1.6049358102597635,,
+2015-07-28,48.06999969482422,49.29999923706055,-1.5197568858959472,,
+2015-07-27,48.27000045776367,47.560001373291016,2.5587675266175722,,
+2015-07-24,48.77999877929688,48.75,-1.4708909835082902,"XLF, UBIO: Big ETF Inflows","Among the largest underlying components of UBIO, in morning trading today Acadia Pharmaceuticals ( ACAD ) is up about 0.2%, and Acceleron Pharma ( XLRN ) is lower by about 0.9%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the Financial Select Sector SPDR Fund ( XLF ), which added 27,800,000 units, or a 3.5% increase week over week. And on a percentage change basis, the ETF with the biggest increase in inflows was the ProShares UltraPro Nasdaq Biotechnology ( UBIO ), which added 350,000 units, for a 38.9% increase in outstanding units."
+2015-07-23,49.790000915527344,49.31999969482422,-0.06149811407870336,,
+2015-07-22,48.27000045776367,49.7599983215332,-0.9439670858824025,"Commit To Buy Acadia Pharmaceuticals At $32, Earn 13.8% Using Options","Selling a put does not give an investor access to ACAD's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. So unless Acadia Pharmaceuticals Inc sees its shares fall 35.2% and the contract is exercised (resulting in a cost basis of $27.60 per share before broker commissions, subtracting the $4.40 from $32), the only upside to the put seller is from collecting that premium for the 9.2% annualized rate of return. Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $32 strike is located relative to that history: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 put at the $32 strike for the 9.2% annualized rate of return represents good reward for the risks."
+2015-07-21,49.59999847412109,48.900001525878906,3.0867989426958506,"Notable ETF Outflow Detected - BIB, ACAD, XLRN, ACRX","Among the largest underlying components of BIB, in trading today Acadia Pharmaceuticals Inc (Symbol: ACAD) is off about 2.5%, Acceleron Pharma, Inc. (Symbol: XLRN) is off about 1.9%, and AcelRx Pharmaceuticals Inc (Symbol: ACRX) is up by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $31.4 million dollar outflow -- that's a 2.9% decrease week over week (from 10,350,000 to 10,050,000). For a complete list of holdings, visit the BIB Holdings page » The chart below shows the one year price performance of BIB, versus its 200 day moving average: Looking at the chart above, BIB's low point in its 52 week range is $83.38 per share, with $189.74 as the 52 week high point - that compares with a last trade of $102.70."
+2015-07-20,50.7599983215332,49.790000915527344,-1.4112842132594126,,
+2015-07-17,50.20000076293945,50.09999847412109,-1.910948459575443,,
+2015-07-16,49.68999862670898,49.9900016784668,-0.19920774362257374,,
+2015-07-15,49.18000030517578,48.90999984741211,0.6037493661683547,,
+2015-07-14,44.97999954223633,48.68999862670898,-0.5490045874100099,,
+2015-07-13,44.45000076293945,44.790000915527344,8.248108319763212,,
+2015-07-10,42.79999923706055,43.93999862670898,0.7649047171026564,,
+2015-07-09,41.02000045776367,42.18000030517578,2.663550023293702,,
+2015-07-08,41.619998931884766,40.59000015258789,2.8278884311727532,,
+2015-07-07,41.709999084472656,41.97999954223633,-2.4747688748924994,,
+2015-07-06,41.29999923706055,41.56999969482422,0.647327891848803,,
+2015-07-02,41.95000076293945,41.68999862670898,0.6537541470978697,,
+2015-07-01,42.41999816894531,41.66999816894531,-0.6197905399328947,,
+2015-06-30,40.56999969482422,41.880001068115234,-1.7680340225687645,Andreas Halvorsen Increases Stake in Esperion Therapeutics | Pabrai Funds 2014 Investor Meeting Notes,"He sold out of three other positions in the sector: Shire PLC ( SHPG ), ACADIA Pharmaceuticals Inc. ( ACAD ) and Alexion Pharmaceuticals Inc. ( ALXN ). Andreas Halvorsen ( Trades , Portfolio )'s hedge fund Viking Global Investors increased its stake in pharmaceutical company Esperion Therapeutics ( ESPR ) by 875.1% on June 18, GuruFocus Real Time Picks reported Monday. David Einhorn Undervalued Stocks David Einhorn Top Growth Companies David Einhorn High Yield stocks Martin Whitman Undervalued Stocks Martin Whitman Top Growth Companies Martin Whitman High Yield stocks Third Avenue Value Fund Undervalued Stocks Third Avenue Value Fund Top Growth Companies Third Avenue Value Fund High Yield stocks John Griffin Undervalued Stocks John Griffin Top Growth Companies John Griffin High Yield stocks Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks Esperion's share price rose more than 406% over the past 12 months as one of its treatments, ETC-1002, advanced toward FDA approval with plans to reach Phase 3 development before year end. | Pabrai Investment Funds Annual Meeting Notes - 2014 - September 21, 2014 Fund Facts : Mohnish Pabrai ( Trades , Portfolio ) is the principle investor and is a classic value investor in the tradition of Warren Buffett (Trades, Portfolio) and Charlie Munger (Trades, Portfolio) Martin Whitman Undervalued Stocks Martin Whitman Top Growth Companies Martin Whitman High Yield stocks Third Avenue Value Fund Undervalued Stocks Third Avenue Value Fund Top Growth Companies Third Avenue Value Fund High Yield stocks John Griffin Undervalued Stocks John Griffin Top Growth Companies John Griffin High Yield stocks Andreas Halvorsen Undervalued Stocks Andreas Halvorsen Top Growth Companies Andreas Halvorsen High Yield stocks Mohnish Pabrai Undervalued Stocks Mohnish Pabrai Top Growth Companies Mohnish Pabrai High Yield stocks Pabrai Funds ( PF1 through 4 ) have a combined capital of $690 Million under management Inception : 2000 Value Proposition : No leverage / no margin / no short positions No management fees, only performance fees. Dhandho Holdings : Founded in Q4 2013 Raised $152.4 Million Setup as a SPAC ( Special purpose acquisition vehicle ) Flexible vehicle - Ability to buy and hold fully owned subsidiaries for long term and portfolio of stocks Time limit (sunset) to invest funds raised from investors in proposed investment (Stone Trust Insurance ) Headquartered in Porte Rico - for tax benefits First acquisition : Stone Trust Insurance Proposed date for IPO : 2015 Stone Trust Insurance - quick facts : Mutual insurance company with 5000+ policy holders Primarily into workers comp insurance Serving five starts in U.S in 2014 ( expected to expand to ten or fifteen stats in ten years ) Earned $70 million in annual premium ( compared to $20 million in premiums in 2009 and $10 million in premiums 2004 ) Expect combined ratio of 95 or lower over long term Dandho Holdings will infuse a capital of $30 million after acquiring Stone Trust Insurance for $35 million Dhandho + Stone Trust Advantage : Dhandho's cash surplus and backing will allow Stone Trust Insurance to grow without capital constraints. Boost's Stone Trust's credit rating from B+ to A- post acquisition Single investor ( Mohnish Pabrai (Trades, Portfolio) himself ) managing investments for Stone Trust ( Clone of Buffet's model for Berkshire ) Environment where the focus is on under writing discipline and not growth Dhandho will provide a non-institutional environment, which is important for success in insurance business ( Q ) Why did you invest in Chesapeake Energy and what were your reasons to exit ?"
+2015-06-29,41.400001525878906,39.86000061035156,3.2289903454402564,,
+2015-06-26,42.970001220703125,41.93000030517578,-3.719808837602815,,
+2015-06-25,43.040000915527344,42.7599983215332,-2.4202952896968197,,
+2015-06-24,42.900001525878906,42.70000076293945,-0.6505636339174086,,
+2015-06-23,43.0,42.91999816894531,-0.4662022280321018,,
+2015-06-22,42.11000061035156,42.58000183105469,-0.1860507698946221,,
+2015-06-19,41.68999862670898,41.75,1.1161273186673581,,
+2015-06-18,40.15999984741211,41.56999969482422,0.14392270392780115,,
+2015-06-17,39.59999847412109,40.15999984741211,3.5109558086887516,,
+2015-06-16,40.11000061035156,39.560001373291016,1.4141449365382883,,
+2015-06-15,39.2400016784668,39.060001373291016,-1.371227196936525,,
+2015-06-12,39.54999923706055,39.400001525878906,-0.4587163544250243,,
+2015-06-11,39.29999923706055,39.77999877929688,-0.3792609711129512,,
+2015-06-10,39.36000061035156,39.18999862670898,1.2213729047192647,,
+2015-06-09,40.63999938964844,39.130001068115234,-0.4319156021503598,,
+2015-06-08,42.15999984741211,40.88999938964844,-3.715547106818659,,
+2015-06-05,41.13999938964844,42.15999984741211,-3.0123350625240284,,
+2015-06-04,41.5099983215332,41.13999938964844,2.479339992455912,,
+2015-06-03,41.84999847412109,41.70000076293945,-0.8913489444610014,,
+2015-06-02,41.130001068115234,41.54999923706055,-0.35841748303620147,,
+2015-06-01,41.400001525878906,41.290000915527344,1.021147965082119,,
+2015-05-29,40.15999984741211,41.20000076293945,-0.26570194757795296,,
+2015-05-28,40.66999816894531,40.18999862670898,2.589643723801859,,
+2015-05-27,40.130001068115234,40.81999969482422,-1.1802300561765258,,
+2015-05-26,40.470001220703125,40.09999847412109,1.7194084434181929,"The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases","Stocks recently featured in the blog include the Johnson & Johnson ( JNJ ), AstraZeneca plc ( AZN ), ACADIA Pharmaceuticals Inc. ( ACAD ), Actavis plc ( ACT ) and Alkermes plc ( ALKS ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, ACADIA Pharmaceuticals Inc. ( ACAD ) is evaluating its lead candidate Nuplazid (pimavanserin) for the treatment of schizophrenia."
+2015-05-22,40.290000915527344,40.54999923706055,-0.9142642338067365,,
+2015-05-21,39.68999862670898,40.220001220703125,0.6453172390795416,,
+2015-05-20,40.22999954223633,39.83000183105469,1.3353555362370004,,
+2015-05-19,40.33000183105469,40.2400016784668,-0.9942771954588129,,
+2015-05-18,39.0099983215332,40.310001373291016,-0.22315930697178696,,
+2015-05-15,39.150001525878906,39.16999816894531,3.3324868179761524,,
+2015-05-14,39.02000045776367,39.04999923706055,0.05107699179318826,,
+2015-05-13,38.880001068115234,38.91999816894531,0.07688052010493057,,
+2015-05-12,38.150001525878906,38.86000061035156,0.1028731988973092,,
+2015-05-11,38.0099983215332,38.369998931884766,1.8610722308648693,"Acadia Pharmaceuticals Moves Up In Market Cap Rank, Passing QEP Resources","In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example QEP Resources Inc (Symbol: QEP), according to The Online Investor . Below is a three month price history chart comparing the stock performance of ACAD vs. QEP: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.85B, versus QEP Resources Inc (Symbol: QEP) at $3.61B."
+2015-05-08,37.27000045776367,37.93999862670898,0.9471208267526207,,
+2015-05-07,36.650001525878906,36.560001373291016,1.7976875790612954,,
+2015-05-06,36.400001525878906,36.77000045776367,-0.24556657255345726,,
+2015-05-05,36.29999923706055,35.689998626708984,1.0164805394903942,,
+2015-05-04,35.59000015258789,36.560001373291016,-1.68044248807802,,
+2015-05-01,34.2599983215332,35.66999816894531,2.7254881049293624,,
+2015-04-30,35.529998779296875,34.16999816894531,4.115586446266379,,
+2015-04-29,35.86000061035156,35.86000061035156,-3.8277530455307165,,
+2015-04-28,36.22999954223633,36.02000045776367,0.0,,
+2015-04-27,38.34000015258789,36.04999923706055,-0.5796276211040048,,
+2015-04-24,38.790000915527344,38.36000061035156,-5.9728766468791274,,
+2015-04-23,38.43999862670898,38.900001525878906,-1.1085338876691169,,
+2015-04-22,39.04999923706055,38.54999923706055,1.1966777200931236,,
+2015-04-21,38.369998931884766,38.75,-1.2804097561299645,,
+2015-04-20,38.52999877929688,38.119998931884766,0.9903598610722412,,
+2015-04-17,38.04999923706055,38.02999877929688,-1.064105529202403,,
+2015-04-16,38.5099983215332,38.66999816894531,-0.05256362198342544,"Health Care Sector Update for 04/16/2015: ACAD, RCPT, HZNP","In health-care stocks news, ACADIA Pharmaceuticals ( ACAD ) shares were initiated by Leerink Partners with outperform rating and $48 price target. Top Health-care stocks: JNJ: flat PFE: flat ABT: flat MRK: flat AMGN: flat Health-care shares were mainly flat in pre-market trade Thursday. Shares in the company were unchanged at $37.50 during pre-market trading ."
+2015-04-15,37.20000076293945,37.5,0.4154761214898419,,
+2015-04-14,37.5,36.810001373291016,0.8064495454511428,,
+2015-04-13,37.43000030517578,37.459999084472656,-1.8399963378906248,,
+2015-04-10,35.38999938964844,37.52999877929688,0.08014635066066723,,
+2015-04-09,34.09000015258789,35.11000061035156,6.046904285266514,,
+2015-04-08,32.900001525878906,34.16999816894531,2.992081118210966,"Should AbbVie, Inc. Buy Acadia Pharmaceuticals to Help Fight Parkinson's Disease?","Fleshing this idea out further, AbbVie could take advantage of its sales force for Duopa, and their experience with this particular patient population, to help bring Nuplazid to market in a more efficient manner than Acadia could do by itself -- assuming the drug is ultimately approved by the FDA. That would put Acadia roughly into the $4.5 billion range, which might simply be too rich for AbbVie after its monstrous deal for Pharmacyclics. Indeed, Acadia selling itself appears to be beneficial to both the more than 1 million Parkinson's disease patients afflicted with this devastating disease -- and shareholders alike."
+2015-04-07,32.040000915527344,32.84000015258789,3.860171988343028,,
+2015-04-06,31.0,31.959999084472656,2.49687644881698,,
+2015-04-02,31.8700008392334,31.489999771118164,3.096771240234375,,
+2015-04-01,32.529998779296875,32.040000915527344,-1.1923472171592666,,
+2015-03-31,32.849998474121094,32.59000015258789,-1.5062953647615305,,
+2015-03-30,32.060001373291016,33.349998474121094,-0.7914713351905548,Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets,"Read on to see why our team of healthcare experts think Esperion Therapeutics (NASDAQ: ESPR), BioMarin Pharmaceuticals (NASDAQ: BMRN), and Acadia Pharmaceuticals (NASDAQ: ACAD) could be next on the auction block. George Budwell : Acadia Pharmaceuticals has repeatedly been the subject of the buyout rumor mill ever since it reported stellar late-stage results for its experimental Parkinson's disease psychosis drug Nuplazid (pimavanserin) over two years ago. And with a market cap of about $3.3 billion at present, Acadia appears to be fairly valued in light of Nuplazid's value proposition, giving any buyer a good bit of upside potential going forward."
+2015-03-27,30.40999984741211,31.959999084472656,4.0236963367842105,First Week of May 15th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $30.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $31.00 strike price has a current bid of $2.20. Below is a chart showing ACAD's trailing twelve month trading history, with the $31.00 strike highlighted in red: Considering the fact that the $31.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the May 15th expiration."
+2015-03-26,30.520000457763672,30.3700008392334,5.09700508003275,,
+2015-03-25,33.81999969482422,31.200000762939453,-0.49147973879573303,,
+2015-03-24,33.970001220703125,33.650001525878906,-7.74689223987701,,
+2015-03-23,34.09000015258789,33.9900016784668,-0.942006721592915,,
+2015-03-20,35.2400016784668,34.45000076293945,-0.29333667842035055,,
+2015-03-19,34.43000030517578,34.9900016784668,-2.241773206299446,"The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases | This Exciting Biotech Isn't Built to Last","Stocks recently featured in the blog include the Amgen ( AMGN - Free Report ), Regeneron ( REGN - Free Report ), Nektar ( NKTR - Free Report ), ACADIA ( ACAD - Free Report ) and Pharmacyclics ( PCYC - Free Report ). Get the full Report on AMGN - FREE Get the full Report on REGN - FREE Get the full Report on NKTR - FREE Get the full Report on ACAD - FREE Get the full Report on PCYC - FREE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. | Four months ago, the biotech also delayed its NDA, with Acadia's management saying the company hadn't yet prepared its FDA pitch. If you're not an investor in Acadia, you could brush off this chart and be glad you dodged a bullet. Inside Acadia's boom-to-bust cycle are some practical lessons that could be applied to coming stock picks, particularly biotechs, and provide you a better chance of finding a company built to last."
+2015-03-18,33.810001373291016,34.459999084472656,1.6264925016768936,,
+2015-03-17,34.709999084472656,34.310001373291016,1.9225012859512072,,
+2015-03-16,34.0,35.18000030517578,-1.152399083065887,,
+2015-03-13,34.689998626708984,34.45000076293945,3.4705891328699447,ACADIA Down on Nuplazid NDA Delay and CEO Resignation - Analyst Blog,"Shares of ACADIA PharmaceuticalsACAD plunged 22.2% after the company announced that its planned new drug application (NDA) on pipeline candidate Nuplazid has been delayed and that its Chief Executive Officer (CEO) has retired and resigned from the company's board. Following an assessment of its manufacturing quality systems and procedures, ACADIA Pharmaceuticals now plans to submit its NDA on Nuplazid in the second half of 2015, delayed from the previous plan of submission in the first quarter of 2015. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here."
+2015-03-12,34.599998474121094,34.81999969482422,-0.6918358987329245,"Why Acadia Pharmaceuticals Inc. Stock Crashed | US Futures Point Higher Amid Lower-Than-Expected Jobless Claims; Retail Sales Disappoint | Correction: US Futures Higher Ahead of Weekly Jobless Claims Data, Retail Sales | Pre-Market Most Active for Mar 12, 2015 : BAC, LL, ACAD, HSBC, EQM, CYBR, C, AAPL, QQQ, KO, AMRN, TVIX | US Futures Mixed Ahead of Weekly Jobless Claims Data, Retail Sales","Now what : Acadia's experimental Parkinson's disease psychosis drug is widely believed to have blockbuster potential, causing shares to soar over the last few years. What : Shares of the clinical-stage drugmaker Acadia Pharmaceuticals dropped by over 20% on extremely high volume today. Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. | Import prices rose 0.4% in February compared to the 0.2% expected gain while January was revised to have declined 3.1% from the initially reported 2.8% In equities, Acadia Pharmaceuticals ( ACAD ) dropped 21% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. (+/-) Large cap tech: mixed (+) Chip stocks: unchanged to higher (+) Software stocks: unchanged to higher (+/-) Hardware stocks: mixed (+) Internet stocks: higher (+/-) Drug stocks: mixed (+) Financial stocks: higher (+/-) Retail stocks: unchanged (+/-) Industrial stocks: mixed (+/-) Airlines: unchanged to higher (+) Autos: higher (-) INTC (-3.8%) Cuts Q1 revenue guidance (-) CUR (-2.4%) Announces results from ALS treatment study (-) CYBR (-6.4%) Prices secondary share sale (-) INGN (-17.0%) Postpones release of Q4 due to accounting audit (-) HPQ (-2.2%) Barclays downgrades to equalweightv vs. overweight; cut PT to $35 (-) BOX (-17.5%) Posts wider-than-expected Q4 net loss (-) VRA (-1.0%) Telsey Advisory cuts price target (-) TTPH (-1.0%) Prices 4.3 million share sale at $35 each (-) QIWI (-8.1%) Q4 EPS misses views (-) BVX (-16.7%) Prices 4.8-million-share-sale at 20% discount (-) LOGI (-2.2%) JP Morgan downgrades to underweight vs neutral The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. (Corrects the movement of the Dow Jones Industrial Average and the Nasdaq 100 as higher, not lower) U.S. stock futures were higher Thursday as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January. | ACADIA Pharmaceuticals Inc. ( ACAD ) is -10.26 at $34.50, with 498,950 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. The total Pre-Market volume is currently 2,615,534 shares traded. | In equities, Acadia Pharmaceuticals ( ACAD ) dropped 22% in recent pre-market trade after delaying submission of the new drug application for its Parkinson's disease psychosis treatment Nuplazid till the second half of 2015 instead of in Q1, as previously planned. U.S. stock futures were mixed Thursday, with the Dow Jones Industrial Average and Nasdaq 100 lower and the S&P 500 higher, as markets waited for data on jobless claims and retail sales that could provide further incentive for the U.S. Federal Reserve to raise interest rates. Meanwhile, export prices in February are seen down 0.1% compared to a 2.0% decline in January while import prices are seen higher 0.2% compared to a 2.8% decline in January."
+2015-03-11,45.75,44.7599983215332,0.6358417063736979,"After Hours Most Active for Mar 11, 2015 : SWKS, MSFT, MMS, FB, BAC, PETM, ACAD, HPQ, INTC, CRC, EVHC, HTZ","ACADIA Pharmaceuticals Inc. ( ACAD ) is -9.91 at $34.85, with 1,818,170 shares traded. As reported in the last short interest update the days to cover for ACAD is 11.766846; this calculation is based on the average trading volume of the stock. California Resources Corporation ( CRC ) is unchanged at $7.10, with 1,450,527 shares traded."
+2015-03-10,38.65999984741211,45.880001068115234,-2.163938095009392,,
+2015-03-09,39.060001373291016,38.93000030517578,18.67563696119991,,
+2015-03-06,39.0,38.93999862670898,-0.3328240234116538,,
+2015-03-05,38.33000183105469,39.2599983215332,-0.1538496751051865,,
+2015-03-04,37.880001068115234,38.13999938964844,2.42628866697585,,
+2015-03-03,38.220001220703125,38.13999938964844,0.6863735855383905,,
+2015-03-02,38.25,38.22999954223633,-0.20931927917195323,,
+2015-02-27,36.869998931884766,37.970001220703125,-0.05228877846711602,,
+2015-02-26,37.47999954223633,37.77999877929688,2.983461678017814,,
+2015-02-25,37.369998931884766,37.400001525878906,0.8004248685288373,Is a Surprise Coming for ACADIA Pharmaceuticals (ACAD) This Earnings Season? - Tale of the Tape,"This suggests that analysts have very recently bumped up their estimates for ACAD, giving the stock a Zacks Earnings ESP of 3.85% heading into earnings season. Given that ACAD has a Zacks Rank #2 (Buy) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. ( ACAD ) may be one such company."
+2015-02-24,38.290000915527344,37.43999862670898,0.08028524177596875,Will Allscripts (MDRX) Surprise Earnings Estimates in Q4? - Analyst Blog | Merrimack Pharmaceuticals (MACK): A Miss this Earnings? - Analyst Blog | Will Aegerion (AEGR) Miss Earnings Estimates This Season? - Analyst Blog,"Click to get this free report ALLSCRIPTS HLTH (MDRX): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2. Zacks Rank : Allscripts has a Zacks Rank #2 (Buy) which increases the predictive power of ESP. | Stocks That Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00% since the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 23 cents. | Click to get this free report AEGERION PHARMA (AEGR): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an Earnings ESP of +3.85% and carries a Zacks Rank #2. Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -220.00% since the Most Accurate estimate stands at a loss of 6 cents, while the Zacks Consensus Estimate is 5 cents."
+2015-02-23,37.5,37.619998931884766,-2.2199066818869517,Will DexCom (DXCM) Loss Better Estimates this Earnings? - Analyst Blog | Will Wright Medical (WMGI) Disappoint Earnings Again in Q4? - Analyst Blog,"Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. Zacks Rank : DexCom currently has a Zacks Rank #3 (Hold). | Click to get this free report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) with an Earnings ESP of +3.85% and a Zacks Rank #2 (Buy). Zacks Rank: Wright Medical Group has a Zacks Rank #3 (Hold) which increases the predictive power of ESP; but when combined with a -7.41% ESP, it makes surprise prediction difficult."
+2015-02-20,36.900001525878906,37.45000076293945,0.3199971516927083,Can Greatbatch (GB) Keep the Earnings Streak Alive in Q4? - Analyst Blog,Click to get this free report GREATBATCH INC (GB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals ( ACAD ) has an earnings ESP of +3.85% and a Zacks Rank #2. The combination of Greatbatch's Zacks Rank #3 and +1.70% ESP makes us reasonably confident of a positive earnings beat this quarter.
+2015-02-19,35.66999816894531,36.79999923706055,1.490512775927173,Can the Uptrend Continue for ACADIA Pharmaceuticals (ACAD)? - Tale of the Tape,"While we can never know for sure, it is pretty encouraging that estimates for ACAD have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Click to get this free report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Investors certainly have to be happy with ACADIA Pharmaceuticals Inc. ( ACAD ) and its short term performance."
+2015-02-18,35.0,35.720001220703125,3.16793138806221,Will Patterson Companies (PDCO) Earnings Disappoint in Q4? - Analyst Blog,Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Earnings Whispers Our proven model does not conclusively show that Patterson Companies is likely to beat the Zacks Consensus Estimate this quarter.
+2015-02-17,34.20000076293945,35.029998779296875,2.0571463448660716,Will Community Health Systems (CYH) Q4 Earnings Miss? - Analyst Blog,Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report COMMNTY HLTH SY (CYH): Free Stock Analysis Report BIOTELEMETRY (BEAT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and carries a Zacks Rank #2. Earnings Whispers Our proven model does not conclusively show that Community Health Systems is likely to beat the Zacks Consensus Estimate this quarter.
+2015-02-13,33.97999954223633,34.209999084472656,2.426894730531241,,
+2015-02-12,33.59000015258789,33.84000015258789,0.676867408283641,,
+2015-02-11,33.54999923706055,33.33000183105469,0.744269124335622,,
+2015-02-10,32.4900016784668,33.470001220703125,-0.6557299881033745,,
+2015-02-09,32.060001373291016,32.119998931884766,3.016311146840711,Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog,Stocks that Warrant a Look Here are three companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: ACADIA Pharmaceuticals Inc. ( ACAD ) has an earnings ESP of +3.85% and holds a Zacks Rank #2. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA is expected to report fourth-quarter 2014 earnings on Feb 26.
+2015-02-06,33.0099983215332,32.47999954223633,0.18714147231363998,,
+2015-02-05,31.540000915527344,32.5099983215332,-1.60557045212312,,
+2015-02-04,31.51000022888184,31.36000061035156,3.0754514199405856,"Myriad Genetics Q2 Earnings, Revenues Beat; Fall Y/Y - Analyst Blog","Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. Some other top-ranked med-biomed/generic stocks include Ophthotech Corporation ( OPHT ), Prothena Corporation plc ( PRTA ) and ACADIA Pharmaceuticals Inc. ( ACAD ). While Ophthotech and Prothena sport a Zacks Rank #1 (Strong Buy), ACADIA carries a Zacks Rank #2 (Buy)."
+2015-02-03,31.200000762939453,31.76000022888184,-0.47603813849798693,Acadia Pharmaceuticals Larger Than S&P 500 Component Denbury Resources,"In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (Symbol: ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Denbury Resources, Inc. (Symbol: DNR), according to The Online Investor . Below is a three month price history chart comparing the stock performance of ACAD vs. DNR: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the case of Acadia Pharmaceuticals Inc (Symbol: ACAD), the market cap is now $3.17B, versus Denbury Resources, Inc. (Symbol: DNR) at $3.04B."
+2015-02-02,31.46999931335449,31.11000061035156,1.7948700392583803,,
+2015-01-30,30.8799991607666,30.43000030517578,-1.1439425194081971,,
+2015-01-29,31.420000076293945,31.049999237060547,-1.4572502196261363,,
+2015-01-28,32.66999816894531,31.21999931335449,-1.1775965573996294,,
+2015-01-27,31.6200008392334,31.700000762939453,-4.438319365959225,,
+2015-01-26,31.920000076293945,32.279998779296875,0.2530041795786183,,
+2015-01-23,32.459999084472656,31.8799991607666,1.1278154829024898,First Week of September 18th Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $27.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $33.00 strike price has a current bid of $5.30. Below is a chart showing ACAD's trailing twelve month trading history, with the $33.00 strike highlighted in red: Considering the fact that the $33.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the September 18th expiration."
+2015-01-22,32.709999084472656,32.56999969482422,-1.7868143563303411,,
+2015-01-21,32.849998474121094,32.470001220703125,-0.4280018146343966,,
+2015-01-20,32.83000183105469,33.11000061035156,-1.1567649043190271,,
+2015-01-16,32.06999969482422,32.68000030517578,0.8528746989956528,,
+2015-01-15,33.88999938964844,32.16999816894531,1.9020911012045023,,
+2015-01-14,33.95000076293945,33.7599983215332,-5.075247128002287,,
+2015-01-13,34.7599983215332,34.459999084472656,-0.5596537176330809,,
+2015-01-12,33.54999923706055,34.25,-0.863058836440457,,
+2015-01-09,32.5,33.369998931884766,2.0864404734954713,,
+2015-01-08,32.40999984741211,32.5,2.6769197904146633,,
+2015-01-07,31.34000015258789,32.15999984741211,0.27769254246101766,,
+2015-01-06,31.31999969482422,30.979999542236328,2.6164635955067395,,
+2015-01-05,31.020000457763672,31.100000381469727,-1.085568824715146,,
+2015-01-02,32.16999816894531,31.14999961853028,0.25789788048192097,,
+2014-12-31,31.780000686645508,31.75,-3.1706515650338702,,
+2014-12-30,31.809999465942383,31.690000534057617,-0.09440115165924023,,
+2014-12-29,31.700000762939453,31.959999084472656,-0.3772365102151083,,
+2014-12-26,31.229999542236328,31.729999542236328,0.8201839598602401,,
+2014-12-24,30.14999961853028,30.950000762939453,1.601024679247228,,
+2014-12-23,32.31999969482422,30.170000076293945,2.6534034976156002,,
+2014-12-22,32.849998474121094,32.2400016784668,-6.652226605294734,,
+2014-12-19,32.86000061035156,32.97999954223633,-1.8569157503457616,,
+2014-12-18,32.06999969482422,32.849998474121094,0.3651823787457981,,
+2014-12-17,30.06999969482422,31.5,2.4321758238830262,,
+2014-12-16,29.0,30.020000457763672,4.755571399031039,,
+2014-12-15,32.86000061035156,30.34000015258789,3.517242957805765,,
+2014-12-12,32.119998931884766,32.529998779296875,-7.668899607292828,,
+2014-12-11,32.63999938964844,32.630001068115234,1.2764628301562992,,
+2014-12-10,32.779998779296875,32.29999923706055,-0.030632113113255838,,
+2014-12-09,31.84000015258789,32.779998779296875,-1.4643061626331886,,
+2014-12-08,31.21999931335449,32.189998626708984,2.952256979284541,,
+2014-12-05,30.46999931335449,31.15999984741211,3.106980572352461,,
+2014-12-04,30.350000381469727,30.459999084472656,2.2645242848929277,,
+2014-12-03,30.170000076293945,30.40999984741211,0.3624339427359272,,
+2014-12-02,29.18000030517578,30.11000061035156,0.7954914501533055,,
+2014-12-01,29.75,28.68000030517578,3.1871154744670087,,
+2014-11-28,30.15999984741211,29.8700008392334,-3.5966376296612395,,
+2014-11-26,29.65999984741211,29.950000762939453,-0.9615351778710118,,
+2014-11-25,29.63999938964844,29.530000686645508,0.9777509002672732,,
+2014-11-24,28.700000762939453,29.530000686645508,-0.37111573977072854,,
+2014-11-21,28.770000457763672,28.43000030517578,2.8919857200068106,,
+2014-11-20,27.280000686645508,27.739999771118164,-1.1817870948143854,,
+2014-11-19,27.63999938964844,27.32999992370605,1.6862136103165184,,
+2014-11-18,27.200000762939453,27.790000915527344,-1.1215610448185789,,
+2014-11-17,27.040000915527344,27.07999992370605,2.1691181472015897,,
+2014-11-14,27.89999961853028,27.13999938964844,0.14792532109619314,,
+2014-11-13,27.0,27.89999961853028,-2.7240151945273574,,
+2014-11-12,27.3799991607666,27.270000457763672,3.3333319204825207,,
+2014-11-11,26.56999969482422,27.5,-0.40174837974629757,,
+2014-11-10,27.600000381469727,28.209999084472656,3.500189370935309,"After-Hours Earnings Report for November 10, 2014 : RAX, DEI, WWD, PRAA, NPSP, CIB, ACAD, ATW, ATLS, CZR, HK, ARP","ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending September 30, 2014. The last two quarters ACAD had negative earnings surprises; the latest report they missed by -29.41%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ACAD is -32.58 vs. an industry ratio of -6.60."
+2014-11-07,27.8700008392334,27.690000534057617,2.210140197724326,,
+2014-11-06,27.36000061035156,27.940000534057617,-0.6458568344296196,,
+2014-11-05,28.049999237060547,27.190000534057617,2.11988271479284,,
+2014-11-04,27.670000076293945,27.65999984741211,-3.0659491137050447,,
+2014-11-03,27.68000030517578,27.89999961853028,-0.03614105115382184,,
+2014-10-31,28.75,27.700000762939453,0.7947951984428355,,
+2014-10-30,27.51000022888184,28.049999237060547,-3.6521712593410327,,
+2014-10-29,27.88999938964844,27.6299991607666,1.9629189519663481,,
+2014-10-28,27.290000915527344,27.88999938964844,-0.9322346166071996,,
+2014-10-27,26.64999961853028,27.040000915527344,2.1986018834455696,,
+2014-10-24,26.229999542236328,26.920000076293945,1.4634195218745423,,
+2014-10-23,26.25,26.25,2.6305777586711647,First Week of June 2015 Options Trading For Acadia Pharmaceuticals (ACAD),"Below is a chart showing the trailing twelve month trading history for Acadia Pharmaceuticals Inc, and highlighting in green where the $26.00 strike is located relative to that history: Considering the fact that the $27.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Acadia Pharmaceuticals Inc (Symbol: ACAD) saw new options become available this week, for the June 2015 expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ACAD options chain for the new June 2015 contracts and identified one put and one call contract of particular interest."
+2014-10-22,26.81999969482422,25.920000076293945,0.0,,
+2014-10-21,26.8799991607666,26.770000457763672,-3.35570331383694,,
+2014-10-20,25.93000030517578,26.57999992370605,-0.4092213781147774,3 Stocks I'll Buy if the Market Crashes,"With this in mind, I would strongly consider buying Acadia Pharmaceuticals , Gilead Sciences , and NPS Pharmaceuticals , if the market goes into a full blown crash. Acadia Pharmaceuticals has a mega blockbuster on its hands For me to buy a stock as prices plummet, I have to be reasonably comfortable that the company's core business prospects are going to be strong over the long haul. While I am not a huge fan of speculating about forward P/E ratios based on experimental drugs, Nuplazid's huge commercial potential, compared to Acadia's market cap, has this stock at the top of my watch list."
+2014-10-17,25.950000762939453,26.059999465942383,2.506747438797855,,
+2014-10-16,25.350000381469727,25.290000915527344,0.42388708966831534,,
+2014-10-15,22.34000015258789,25.11000061035156,-0.23668428023472954,,
+2014-10-14,23.309999465942383,22.8799991607666,12.399285760267949,,
+2014-10-13,23.56999969482422,22.979999542236328,-1.8447031961714249,,
+2014-10-10,23.81999969482422,23.39999961853028,-2.5031826908230714,,
+2014-10-09,25.239999771118164,24.15999984741211,-1.763224524243797,,
+2014-10-08,23.93000030517578,25.25,-4.278922082011609,,
+2014-10-07,24.6200008392334,23.979999542236328,5.516087246094678,,
+2014-10-06,25.489999771118164,24.8799991607666,-2.5995177708409787,,
+2014-10-03,25.520000457763672,25.46999931335449,-2.3930977474653927,,
+2014-10-02,24.420000076293945,25.14999961853028,-0.19592924573781476,,
+2014-10-01,24.71999931335449,24.459999084472656,2.9893511054694564,,
+2014-09-30,25.709999084472656,24.76000022888184,-1.0517808903876968,,
+2014-09-29,25.290000915527344,25.670000076293945,-3.695055968183837,,
+2014-09-26,25.959999084472656,25.88999938964844,1.5025668130098517,,
+2014-09-25,26.709999084472656,25.709999084472656,-0.269644442576594,,
+2014-09-24,26.100000381469727,26.82999992370605,-3.7439162646071775,,
+2014-09-23,25.940000534057617,26.0,2.796933071137439,,
+2014-09-22,26.420000076293945,26.14999961853028,0.2313009433581438,,
+2014-09-19,27.71999931335449,26.63999938964844,-1.0219547955487325,,
+2014-09-18,27.559999465942383,27.56999969482422,-3.8961037173826436,,
+2014-09-17,27.09000015258789,27.450000762939453,0.03628530143548749,,
+2014-09-16,26.75,27.040000915527344,1.3289059000509893,,
+2014-09-15,28.520000457763672,26.790000915527344,1.0841155720648363,,
+2014-09-12,29.15999984741211,28.239999771118164,-6.065916951152748,,
+2014-09-11,27.14999961853028,27.46999931335449,-3.155007136859068,,
+2014-09-10,27.06999969482422,27.309999465942383,1.1786360932609499,,
+2014-09-09,27.89999961853028,26.979999542236328,0.8865894858656094,,
+2014-09-08,26.96999931335449,27.93000030517578,-3.297491357967324,,
+2014-09-05,26.739999771118164,26.959999084472656,3.559514335419125,,
+2014-09-04,27.0,26.690000534057617,0.822734911135314,,
+2014-09-03,26.71999931335449,26.89999961853028,-1.1481461701569733,,
+2014-09-02,26.76000022888184,26.61000061035156,0.6736538540471776,,
+2014-08-29,23.61000061035156,23.979999542236328,-0.5605366862754628,,
+2014-08-28,23.40999984741211,23.61000061035156,1.5671280064370137,,
+2014-08-27,23.88999938964844,23.57999992370605,0.8543390185521891,,
+2014-08-26,23.200000762939453,23.809999465942383,-1.2976118621280208,,
+2014-08-25,22.530000686645508,23.14999961853028,2.629304667857444,,
+2014-08-22,22.030000686645508,22.170000076293945,2.751881548997344,,
+2014-08-21,22.690000534057617,22.020000457763672,0.6354942591232171,,
+2014-08-20,22.43000030517578,22.690000534057617,-2.9528429287089586,,
+2014-08-19,22.520000457763672,22.56999969482422,1.1591628414817285,,
+2014-08-18,22.979999542236328,22.43000030517578,0.22202147444144416,,
+2014-08-15,23.15999984741211,22.59000015258789,-2.3933822803158464,,
+2014-08-14,22.46999931335449,22.89999961853028,-2.46113859490336,,
+2014-08-13,21.520000457763672,22.3700008392334,1.9136640779522935,,
+2014-08-12,21.309999465942383,21.40999984741211,3.9498158150042038,,
+2014-08-11,21.38999938964844,21.40999984741211,0.46926505854468487,,
+2014-08-08,20.799999237060547,21.170000076293945,0.0935037790293132,,
+2014-08-07,21.420000076293945,20.940000534057617,1.7788502538699464,,
+2014-08-06,20.280000686645508,21.34000015258789,-2.2408942134764778,,
+2014-08-05,20.440000534057617,20.770000457763672,5.2268216472024,,
+2014-08-04,20.739999771118164,20.700000762939453,1.6144809935606457,,
+2014-08-01,20.31999969482422,20.6200008392334,-0.19285925082030247,,
+2014-07-31,20.790000915527344,20.270000457763672,1.476383606863902,,
+2014-07-30,21.1299991607666,21.209999084472656,-2.5012045929026447,,
+2014-07-29,20.020000457763672,20.739999771118164,0.37860826731406394,,
+2014-07-28,20.6200008392334,20.26000022888184,3.596400084373023,,
+2014-07-25,20.68000030517578,20.6200008392334,-1.7458806774953695,,
+2014-07-24,20.770000457763672,20.82999992370605,-0.29013280975322897,,
+2014-07-23,20.34000015258789,20.729999542236328,0.28887561203664736,,
+2014-07-22,20.46999931335449,20.15999984741211,1.917401114664285,,
+2014-07-21,20.1299991607666,20.309999465942383,-1.514408775481188,,
+2014-07-18,19.38999938964844,20.25,0.8941893327377883,,
+2014-07-17,19.96999931335449,19.39999961853028,4.435279202797084,,
+2014-07-16,20.90999984741211,20.25,-2.8542799921031223,,
+2014-07-15,22.14999961853028,20.770000457763672,-3.156383798318359,,
+2014-07-14,22.6200008392334,22.09000015258789,-6.230244625431626,,
+2014-07-11,21.450000762939453,22.299999237060547,-2.34306218824822,,
+2014-07-10,20.959999084472656,21.440000534057617,3.9626967081031106,,
+2014-07-09,21.57999992370605,21.780000686645508,2.2900833518668904,,
+2014-07-08,23.31999969482422,21.559999465942383,0.9267875979913788,,
+2014-07-07,23.6299991607666,23.420000076293945,-7.547170891569355,,
+2014-07-03,23.56999969482422,23.63999938964844,-0.8886969611971983,,
+2014-07-02,23.36000061035156,23.489999771118164,0.2969864053056974,,
+2014-07-01,22.65999984741211,23.420000076293945,0.5565032421660056,ACAD Makes Bullish Cross Above Critical Moving Average,"In trading on Tuesday, shares of Acadia Pharmaceuticals Inc (Symbol: ACAD) crossed above their 200 day moving average of $23.33, changing hands as high as $23.35 per share. The chart below shows the one year performance of ACAD shares, versus its 200 day moving average: Looking at the chart above, ACAD's low point in its 52 week range is $15.64 per share, with $32.00 as the 52 week high point - that compares with a last trade of $23.38. Acadia Pharmaceuticals Inc shares are currently trading up about 3.2% on the day."
+2014-06-30,22.40999984741211,22.59000015258789,3.3539286584268533,,
+2014-06-27,22.64999961853028,22.40999984741211,0.803214218658585,"Friday's ETF Movers: FNX, XBI","Among components of that ETF with the weakest showing on Friday were shares of Acadia Pharmaceuticals ( ACAD ), lower by about 3.9%, and shares of Alnylam Pharmaceuticals (ALNY), lower by about 3.8% on the day. In trading on Friday, the First Trust Mid Cap Core AlphaDEX Fund ETF ( FNX ) is outperforming other ETFs, up about 0.6% on the day. VIDEO: Friday's ETF Movers: FNX, XBI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2014-06-26,23.1299991607666,22.809999465942383,-1.0596016563365591,,
+2014-06-25,22.709999084472656,23.040000915527344,-1.3834833827707453,,
+2014-06-24,23.0,22.81999969482422,1.4531124806619533,,
+2014-06-23,23.09000015258789,22.96999931335449,-0.7826100225033968,,
+2014-06-20,23.239999771118164,23.059999465942383,-0.5197091314005577,,
+2014-06-19,23.75,23.15999984741211,-0.7745279989179654,,
+2014-06-18,23.190000534057617,23.670000076293945,-2.484211168791118,,
+2014-06-17,23.020000457763672,23.21999931335449,2.0698556756451323,,
+2014-06-16,22.950000762939453,23.040000915527344,0.8688047420232157,,
+2014-06-13,23.15999984741211,23.049999237060547,0.3921575145793736,,
+2014-06-12,23.040000915527344,23.030000686645508,-0.4749594606057561,,
+2014-06-11,22.729999542236328,22.799999237060547,-0.04340376946381319,,
+2014-06-10,22.770000457763672,23.100000381469727,0.3079617080244416,,
+2014-06-09,21.989999771118164,22.93000030517578,1.4492749981194564,,
+2014-06-06,21.780000686645508,21.989999771118164,4.274672777815219,,
+2014-06-05,21.190000534057617,21.700000762939453,0.964183093903289,,
+2014-06-04,20.049999237060547,21.200000762939453,2.4067966778110192,,
+2014-06-03,20.25,20.15999984741211,5.735668676501674,,
+2014-06-02,20.63999938964844,20.450000762939453,-0.44444519796489196,ImmunoCellular Plans To Move ICT-107 Forward Into Phase III Trials Based On New Sub-Group Analysis Presented At ASCO,The recent experience with Acadia Pharmaceutical's ( ACAD ) pimavanserin is an example of this. I would caution that the Acadia example is far from the norm. The number of patients who were on ICT-107 plus SOC that were HLA-A2 positive and had unmethylated MGMT can be calculated with the formula: (number of patients treated with ICT-107 plus SOC) x (percentage of HLA-A2 patients in the trial) x (percentage of unmethylated patients).
+2014-05-30,21.32999992370605,20.64999961853028,-0.9205360093386328,,
+2014-05-29,21.06999969482422,21.25,-3.1879995668449195,,
+2014-05-28,20.780000686645508,20.920000076293945,0.8542966672182619,,
+2014-05-27,20.059999465942383,20.700000762939453,0.6737217758534995,,
+2014-05-23,19.57999992370605,19.799999237060547,3.1904352643860068,,
+2014-05-22,19.270000457763672,19.56999969482422,1.1235920031242514,,
+2014-05-21,19.1200008392334,19.21999931335449,1.5568200826880647,,
+2014-05-20,19.1299991607666,19.040000915527344,0.5230045488068062,,
+2014-05-19,18.989999771118164,19.200000762939453,-0.4704560856637867,,
+2014-05-16,19.68000030517578,19.049999237060547,1.1058504178640327,,
+2014-05-15,19.850000381469727,19.700000762939453,-3.201224889968858,,
+2014-05-14,18.75,18.8700008392334,-0.7556655700132899,,
+2014-05-13,19.280000686645508,18.84000015258789,0.6400044759114584,,
+2014-05-12,18.56999969482422,19.420000076293945,-2.282160365079178,,
+2014-05-09,18.100000381469727,18.520000457763672,4.577277304461327,,
+2014-05-08,18.51000022888184,18.059999465942383,2.320442361558896,,
+2014-05-07,18.93000030517578,18.51000022888184,-2.4311224061321397,,
+2014-05-06,20.0,19.15999984741211,-2.2187008426994406,,
+2014-05-05,19.31999969482422,20.209999084472656,-4.200000762939453,,
+2014-05-02,20.209999084472656,19.59000015258789,4.606622172395096,,
+2014-05-01,20.01000022888184,20.1200008392334,-3.067783077541606,,
+2014-04-30,19.90999984741211,20.1299991607666,0.5497281813759669,,
+2014-04-29,19.14999961853028,19.90999984741211,1.104968935412059,,
+2014-04-28,19.489999771118164,19.14999961853028,3.9686696815723335,,
+2014-04-25,20.21999931335449,19.31999969482422,-1.744485154339113,,
+2014-04-24,20.350000381469727,20.549999237060547,-4.451036840223119,,
+2014-04-23,20.96999931335449,20.13999938964844,0.982795340745718,,
+2014-04-22,20.09000015258789,21.049999237060547,-3.9580350542857303,,
+2014-04-21,19.420000076293945,19.920000076293945,4.7784921711361665,,
+2014-04-17,19.11000061035156,19.440000534057617,2.574665283396943,,
+2014-04-16,18.530000686645508,19.280000686645508,1.7268441295983161,,
+2014-04-15,17.8700008392334,18.36000061035156,4.04749040587204,,
+2014-04-14,19.21999931335449,17.81999969482422,2.742024331875638,,
+2014-04-11,19.559999465942383,19.040000915527344,-7.284077359760979,,
+2014-04-10,22.0,20.040000915527344,-2.658479369186353,,
+2014-04-09,21.01000022888184,21.950000762939453,-8.909086747602982,,
+2014-04-08,20.75,20.989999771118164,4.474062464623023,,
+2014-04-07,21.11000061035156,20.690000534057617,1.1566254029791039,,
+2014-04-04,22.920000076293945,21.350000381469727,-1.9895787027499625,,
+2014-04-03,24.3799991607666,23.059999465942383,-6.849911385681287,,
+2014-04-02,25.299999237060547,24.3799991607666,-5.41427292970716,,
+2014-04-01,24.21999931335449,25.100000381469727,-3.6363640475778705,,
+2014-03-31,22.82999992370605,24.32999992370605,3.633365371856227,,
+2014-03-28,22.989999771118164,22.64999961853028,6.570302255859584,,
+2014-03-27,22.84000015258789,23.01000022888184,-1.4789045496860695,,
+2014-03-26,23.96999931335449,22.89999961853028,0.7443085602374087,,
+2014-03-25,24.40999984741211,23.809999465942383,-4.46391207958056,,
+2014-03-24,26.049999237060547,24.239999771118164,-2.4580105908248795,,
+2014-03-21,28.049999237060547,26.01000022888184,-6.948174736862761,,
+2014-03-20,28.100000381469727,27.850000381469727,-7.27272393463525,,
+2014-03-19,28.76000022888184,28.39999961853028,-0.889679703224702,,
+2014-03-18,27.780000686645508,28.670000076293945,-1.2517406379921834,,
+2014-03-17,27.030000686645508,27.63999938964844,3.203741424226389,,
+2014-03-14,26.75,26.8799991607666,2.2567469016170256,,
+2014-03-13,28.780000686645508,26.780000686645508,0.48597817109009933,,
+2014-03-12,27.46999931335449,28.540000915527344,-6.949270160817056,,
+2014-03-11,28.440000534057617,27.530000686645508,3.895164284378689,,
+2014-03-10,27.71999931335449,28.239999771118164,-3.199718109436607,,
+2014-03-07,27.84000015258789,27.200000762939453,1.8759035737535468,,
+2014-03-06,28.76000022888184,27.170000076293945,-2.2988483697581654,,
+2014-03-05,29.239999771118164,28.549999237060547,-5.5285123085331485,,
+2014-03-04,28.850000381469727,30.040000915527344,-2.359782966685129,,
+2014-03-03,27.299999237060547,28.190000534057617,4.124785158831233,,
+2014-02-28,29.200000762939453,28.299999237060547,3.2600781020860525,,
+2014-02-27,29.700000762939453,30.100000381469727,-3.0821969259027733,,
+2014-02-26,29.09000015258789,29.71999931335449,1.3468000277946284,,
+2014-02-25,28.1299991607666,29.059999465942383,2.16568978158136,,
+2014-02-24,28.950000762939453,28.13999938964844,3.3060801028137563,ACADIA Pharmaceuticals (ACAD) Jumps: Stock Rises 17.3% - Tale of the Tape,"Click to get this free report >> ACADIA PHARMA (ACAD): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. ACADIA Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%."
+2014-02-21,24.790000915527344,28.84000015258789,-2.7979321310690293,"Friday's ETF Movers: XBI, GDXJ","Components of that ETF showing particular strength include shares of Isis Pharmaceuticals ( ISIS ), up about 18.4% and shares of Acadia Pharmaceuticals ( ACAD ), up about 13.6% on the day. Among components of that ETF with the weakest showing on Friday were shares of Gabriel Resources (GBU.CA), lower by about 6.4%, and shares of Great Panther Silver ( GPL ), lower by about 6.2% on the day. VIDEO: Friday's ETF Movers: XBI, GDXJ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2014-02-20,24.1200008392334,24.57999992370605,16.337229074178087,,
+2014-02-19,24.209999084472656,24.0,1.907127149533187,,
+2014-02-18,23.90999984741211,24.39999961853028,-0.8674064122841765,,
+2014-02-14,24.51000022888184,23.93000030517578,2.0493507914898883,,
+2014-02-13,24.239999771118164,24.51000022888184,-2.366380735576673,,
+2014-02-12,24.8799991607666,24.64999961853028,1.113863285120075,,
+2014-02-11,24.01000022888184,24.780000686645508,-0.9244354903315611,,
+2014-02-10,23.549999237060547,23.959999084472656,3.206998960530737,,
+2014-02-07,22.799999237060547,23.46999931335449,1.7409760539053187,,
+2014-02-06,21.850000381469727,22.690000534057617,2.9385969241827063,,
+2014-02-05,22.600000381469727,21.8700008392334,3.8443942239024738,,
+2014-02-04,22.3799991607666,22.709999084472656,-3.230086415551001,,
+2014-02-03,23.31999969482422,22.309999465942383,1.47453054549065,,
+2014-01-31,23.270000457763672,23.299999237060547,-4.3310473503393805,,
+2014-01-30,23.56999969482422,23.809999465942383,0.1289161096121353,,
+2014-01-29,23.270000457763672,23.21999931335449,1.0182425720220356,,
+2014-01-28,22.489999771118164,23.65999984741211,-0.214873843685298,,
+2014-01-27,23.309999465942383,22.450000762939453,5.202312530907487,,
+2014-01-24,23.920000076293945,23.11000061035156,-3.689398209808845,,
+2014-01-23,24.209999084472656,24.229999542236328,-3.3862853819350156,,
+2014-01-22,23.809999465942383,24.309999465942383,0.08261238546059832,,
+2014-01-21,24.32999992370605,23.920000076293945,2.099958047941982,,
+2014-01-17,24.280000686645508,24.040000915527344,-1.6851617291318628,,
+2014-01-16,23.979999542236328,24.26000022888184,-0.988466904163511,,
+2014-01-15,24.31999969482422,23.989999771118164,1.1676425854485193,,
+2014-01-14,23.3799991607666,24.309999465942383,-1.3569075980551317,,
+2014-01-13,23.940000534057617,23.31999969482422,3.9777602162466783,,
+2014-01-10,23.780000686645508,24.1299991607666,-2.589811300761545,,
+2014-01-09,24.07999992370605,23.780000686645508,1.4718186039315284,,
+2014-01-08,23.5,23.90999984741211,-1.2458440116737828,,
+2014-01-07,24.790000915527344,23.61000061035156,1.7446802017536571,,
+2014-01-06,25.38999938964844,24.700000762939453,-4.759984919712874,,
+2014-01-03,25.18000030517578,25.26000022888184,-2.7176000129811024,,
+2014-01-02,24.850000381469727,25.14999961853028,0.3177121633696492,,
+2013-12-31,25.290000915527344,24.989999771118164,1.2072403720535108,,
+2013-12-30,25.32999992370605,25.3799991607666,-1.1862441026049448,,
+2013-12-27,25.31999969482422,25.299999237060547,0.19739138259434708,,
+2013-12-26,26.299999237060547,25.440000534057617,-0.07899075041363553,,
+2013-12-24,26.1299991607666,26.309999465942383,-3.269957140497045,,
+2013-12-23,24.420000076293945,25.920000076293945,0.6888645654686673,,
+2013-12-20,23.43000030517578,24.15999984741211,6.142506123315479,,
+2013-12-19,23.21999931335449,23.350000381469727,3.115661684712263,,
+2013-12-18,23.020000457763672,23.420000076293945,0.5598668043046434,,
+2013-12-17,23.32999992370605,23.0,1.7376177696615573,,
+2013-12-16,23.14999961853028,23.32999992370605,-1.4144874615740226,,
+2013-12-13,22.84000015258789,23.030000686645508,0.7775391280425352,,
+2013-12-12,22.299999237060547,22.76000022888184,0.8318762381272977,,
+2013-12-11,23.549999237060547,22.290000915527344,2.0627847872605005,,
+2013-12-10,23.479999542236328,23.600000381469727,-5.3503115174218285,,
+2013-12-09,24.489999771118164,23.479999542236328,0.5110768380448149,,
+2013-12-06,24.790000915527344,24.38999938964844,-4.124133272034413,,
+2013-12-05,24.25,24.479999542236328,-1.613559947988383,,
+2013-12-04,23.850000381469727,24.290000915527344,0.9484517205621777,,
+2013-12-03,24.71999931335449,23.8799991607666,1.8448659413836985,,
+2013-12-02,23.290000915527344,25.0,-3.3980589640797185,Sector Update: Biotech Stocks Looking Strong As NASDAQ Struggles,"Also, Acadia Pharmaceutical ( ACAD ) is up 6.5% today. Among the major biotech stocks seeing the best gains are XOMA Corp ( XOMA ), up near 13% and near 52 week highs on heavy volume of 3.3 million shares versus a 30 day 1.35 million average daily volume. The Motley Fool said Friday that XOMA could be ""in for a big post-Thanksgiving move today based on news that the biotech-focused hedge fund Baker Brothers has been snapping up the company's shares as of late."""
+2013-11-29,23.299999237060547,23.290000915527344,7.342202736164803,,
+2013-11-27,23.040000915527344,23.190000534057617,-0.04291125262055794,,
+2013-11-26,21.93000030517578,22.950000762939453,0.6510399851120848,"Sector Update: Biotechs Up Almost 1%, Adding To NASDAQ's Gain","Among the biotech stocks seeing the biggest gains today are ACADIA Pharmaceuticals ( ACAD ) and Avanir Pharmaceuticals ( AVNR ) both up near 4%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. It was noted today that ACAD and ANVR will make presentations at two healthcare conferences in the next two weeks."
+2013-11-25,22.34000015258789,21.920000076293945,4.651164813358155,,
+2013-11-22,22.61000061035156,22.34000015258789,-1.8800361388775193,,
+2013-11-21,21.280000686645508,22.46999931335449,-1.1941638676473707,,
+2013-11-20,20.75,21.1299991607666,5.592098629281423,Sector Update: Biotech Stocks Getting Injection of Buying Interest,"Also, Avanir Pharma ( AVNR ) up near 4%, ACADIA Pharma ( ACAD ) up 2.9%, and XenoPort ( XNPT ) up 3.2%. The S&P Biotech Select Index was showing some nice gains in midday trading, up 1.6% at $3,138.40. The Index is working to recover from recent selling - on November 7 the index stood at $2,954."
+2013-11-19,21.049999237060547,20.68000030517578,1.8313212567065136,,
+2013-11-18,22.84000015258789,21.030000686645508,-1.7577147044896178,,
+2013-11-15,22.89999961853028,22.82999992370605,-7.92469112894161,,
+2013-11-14,23.88999938964844,22.940000534057617,-0.30567552834187334,,
+2013-11-13,22.280000686645508,22.979999542236328,-3.9765545410706844,,
+2013-11-12,23.0,22.57999992370605,3.14182600546505,,
+2013-11-11,21.780000686645508,23.01000022888184,-1.8260872882345605,,
+2013-11-08,21.07999992370605,21.729999542236328,5.647380640306916,,
+2013-11-07,21.280000686645508,20.88999938964844,3.0834896626318455,,
+2013-11-06,22.6200008392334,21.0,-1.8327128026918544,,
+2013-11-05,22.21999931335449,22.64999961853028,-7.161807157953673,,
+2013-11-04,22.549999237060547,22.21999931335449,1.9351949525820038,,
+2013-11-01,23.709999084472656,22.5,-1.463414345326047,,
+2013-10-31,22.36000061035156,22.729999542236328,-5.1033282631590975,,
+2013-10-30,23.600000381469727,22.309999465942383,1.6547357861586023,,
+2013-10-29,23.799999237060547,23.6299991607666,-5.466105485914433,,
+2013-10-28,24.01000022888184,23.6200008392334,-0.7142860577458633,,
+2013-10-25,24.729999542236328,24.06999969482422,-1.6243206411106461,,
+2013-10-24,22.11000061035156,24.729999542236328,-2.668822723934534,,
+2013-10-23,22.25,22.020000457763672,11.849836542555888,,
+2013-10-22,23.100000381469727,22.57999992370605,-1.0337058078037218,,
+2013-10-21,24.0,23.06999969482422,-2.2510841955691374,,
+2013-10-18,24.850000381469727,23.989999771118164,-3.8750012715657554,,
+2013-10-17,24.38999938964844,24.6299991607666,-3.460766990542391,,
+2013-10-16,23.6200008392334,24.549999237060547,0.9840089262979678,,
+2013-10-15,23.6299991607666,23.1299991607666,3.937334313224911,,
+2013-10-14,20.540000915527344,23.51000022888184,-2.115954370536588,,
+2013-10-11,22.979999542236328,21.489999771118164,14.459587054396408,,
+2013-10-10,20.61000061035156,23.030000686645508,-6.483898175801108,,
+2013-10-09,23.809999465942383,19.86000061035156,11.74187289969551,,
+2013-10-08,27.6200008392334,23.299999237060547,-16.58966377231914,,
+2013-10-07,28.299999237060547,27.559999465942383,-15.640845296559212,,
+2013-10-04,28.600000381469727,28.770000457763672,-2.6148402511230104,,
+2013-10-03,29.100000381469727,28.239999771118164,0.5944058532393949,,
+2013-10-02,28.049999237060547,28.84000015258789,-2.955328519167969,,
+2013-10-01,27.850000381469727,28.09000015258789,2.8164026275037095,,
+2013-09-30,26.940000534057617,27.46999931335449,0.8617585918521218,,
+2013-09-27,26.350000381469727,27.030000686645508,1.9673302479220283,,
+2013-09-26,24.729999542236328,26.209999084472656,2.5806462820925877,,
+2013-09-25,25.030000686645508,24.670000076293945,5.9846323074476375,,
+2013-09-24,24.51000022888184,24.940000534057617,-1.4382764701386406,,
+2013-09-23,25.100000381469727,24.6200008392334,1.7543871936364912,,
+2013-09-20,24.5,24.8700008392334,-1.9123487447860423,,
+2013-09-19,23.920000076293945,24.5,1.5102075070750958,,
+2013-09-18,23.76000022888184,23.71999931335449,2.4247488371911294,,
+2013-09-17,23.26000022888184,23.76000022888184,-0.16835401995799276,,
+2013-09-16,23.5,23.290000915527344,2.149613048494953,,
+2013-09-13,22.84000015258789,23.1200008392334,-0.8936131254155586,,
+2013-09-12,22.940000534057617,22.709999084472656,1.2259224377184703,,
+2013-09-11,22.809999465942383,23.0,-1.0026218144306136,,
+2013-09-10,23.100000381469727,22.93000030517578,0.8329703573264307,,
+2013-09-09,21.549999237060547,22.790000915527344,-0.7359310540545071,,
+2013-09-06,21.3700008392334,21.40999984741211,5.754068317247583,,
+2013-09-05,20.46999931335449,21.200000762939453,0.1871736387828135,,
+2013-09-04,20.040000915527344,20.489999771118164,3.5662016320084415,,
+2013-09-03,20.299999237060547,20.530000686645508,2.245503168825473,,
+2013-08-30,20.5,19.959999084472656,1.1330121095032382,,
+2013-08-29,20.100000381469727,20.46999931335449,-2.634150807450457,,
+2013-08-28,19.959999084472656,20.11000061035156,1.840790670958721,,
+2013-08-27,20.709999084472656,19.959999084472656,0.7515106851662752,,
+2013-08-26,20.57999992370605,20.89999961853028,-3.6214390784899324,,
+2013-08-23,20.530000686645508,20.6299991607666,1.5549062002455236,,
+2013-08-22,20.229999542236328,20.46999931335449,0.4870846116734006,,
+2013-08-21,19.8700008392334,20.18000030517578,1.1863557911461509,,
+2013-08-20,19.700000762939453,19.86000061035156,1.5601381623008672,,
+2013-08-19,19.709999084472656,19.61000061035156,0.8121819351048193,,
+2013-08-16,19.530000686645508,19.700000762939453,-0.5073489536581213,,
+2013-08-15,19.96999931335449,19.6200008392334,0.8704560692114582,,
+2013-08-14,20.1200008392334,20.049999237060547,-1.7526213628211624,,
+2013-08-13,20.229999542236328,20.1200008392334,-0.3479204734243874,,
+2013-08-12,20.670000076293945,20.170000076293945,-0.5437405115767485,,
+2013-08-09,19.61000061035156,20.76000022888184,-2.4189646741871136,,
+2013-08-08,20.290000915527344,19.780000686645508,5.864352793152023,,
+2013-08-07,19.950000762939453,20.38999938964844,-2.513554489253609,,
+2013-08-06,21.850000381469727,20.68000030517578,2.2055068164526634,,
+2013-08-05,20.690000534057617,21.59000015258789,-5.354691331201002,,
+2013-08-02,19.86000061035156,20.40999984741211,4.349925545186877,,
+2013-08-01,19.8799991607666,19.89999961853028,2.7693817732003305,,
+2013-07-31,20.040000915527344,19.700000762939453,0.10060592861165761,,
+2013-07-30,20.0,19.89999961853028,-1.696607470334258,,
+2013-07-29,18.51000022888184,19.82999992370605,-0.5000019073485973,,
+2013-07-26,18.940000534057617,18.6299991607666,7.131278652090815,,
+2013-07-25,18.850000381469727,19.040000915527344,-1.636754828668436,,
+2013-07-24,19.31999969482422,18.989999771118164,1.00796037248039,,
+2013-07-23,20.14999961853028,19.21999931335449,-1.708074166245773,,
+2013-07-22,20.09000015258789,20.030000686645508,-4.615386217280857,,
+2013-07-19,20.07999992370605,20.020000457763672,-0.29865338719101003,,
+2013-07-18,19.8799991607666,20.1200008392334,-0.29880212236228687,,
+2013-07-17,19.979999542236328,19.82999992370605,1.2072519547206162,,
+2013-07-16,20.3799991607666,19.920000076293945,-0.7507488586933561,,
+2013-07-15,18.670000076293945,20.280000686645508,-2.2571104191122706,,
+2013-07-12,18.5,18.489999771118164,8.623463330328773,,
+2013-07-11,18.63999938964844,18.559999465942383,-0.05405529125316723,,
+2013-07-10,18.239999771118164,18.43000030517578,-0.42918415410724475,,
+2013-07-09,18.290000915527344,18.34000015258789,1.0416696076853602,,
+2013-07-08,18.21999931335449,18.229999542236328,0.27336924307149646,,
+2013-07-05,18.200000762939453,18.040000915527344,0.054886000322237914,,
+2013-07-03,17.440000534057617,17.90999984741211,-0.8791200038733846,,
+2013-07-02,18.190000534057617,17.690000534057617,2.6949501087265246,,
+2013-07-01,18.3799991607666,18.14999961853028,-2.748762975920956,,
+2013-06-28,18.43000030517578,18.14999961853028,-1.251357740686252,,
+2013-06-27,17.8799991607666,18.43000030517578,-1.519265773245087,,
+2013-06-26,16.899999618530273,17.81999969482422,3.0760691847012285,,
+2013-06-25,17.649999618530273,16.799999237060547,5.4437875565701,,
+2013-06-24,17.639999389648438,17.479999542236328,-4.8158662880498495,,
+2013-06-21,17.770000457763672,17.979999542236328,-0.9070286448309121,,
+2013-06-20,17.770000457763672,17.770000457763672,1.1817618405344956,,
+2013-06-19,18.450000762939453,18.09000015258789,0.0,,
+2013-06-18,19.0,18.43000030517578,-1.9512227396472324,,
+2013-06-17,19.489999771118164,18.920000076293945,-2.9999983938116777,Bulls think Acadia will keep running,"ACAD rose 4.1 percent to $19.31 and is up more than 700 percent since releasing positive data about its Pimavanserin drug for Parkinson's disease on Nov. 25. A long-term investor apparently thinks that Acadia Pharmaceuticals may keep on running after a giant move. optionMONSTER's Heat Seeker monitoring program detected the purchase of 10,000 January 2015 20 calls for $4.90 and the sale of an equal number of January 2015 35 calls for $1.35."
+2013-06-14,19.6299991607666,19.309999465942383,-2.924575174540996,,
+2013-06-13,17.8700008392334,18.549999237060547,-1.6301564366023231,,
+2013-06-12,18.68000030517578,17.760000228881836,3.8052510682272556,,
+2013-06-11,19.56999969482422,18.850000381469727,-4.92505386115564,,
+2013-06-10,17.290000915527344,19.520000457763672,-3.679097212990321,,
+2013-06-07,16.56999969482422,17.010000228881836,12.897625356593645,,
+2013-06-06,15.170000076293944,16.56999969482422,2.6554045996455575,"An Insider Buys Shares of Mining Company Freeport-McMoRan While Graphic Packaging Sees a Sale | Market Wrap for Thursday, June 6: Stocks Reverse Mid-Day; Rally to Close at Session Highs","For more insider trades, please see the chart below: Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes An important note from Jonathan Moreland, founder of Insider Insights : In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as ""insiders."" Felix Baker, a Director of biopharmaceutical company Acadia Pharmaceuticals Inc. ( ACAD ), bought 2,340,314 shares of company stock for $33,563,308. Here's a look at the most significant inside sales and purchases filed with the SEC on Wednesday, June 5, 2013. Notable Purchases : James Flores, the Vice Chairman and Director of international mining company Freeport-McMoRan Copper & Gold ( FCX ), bought 1,100,000 of company stock for $32,290,840. | ACADIA Pharmaceuticals (NASDAQ: ACAD ) jumped more than 12 percent on the day after Baker Brothers Advisors, a very successful biotech-focused hedge fund, disclosed a 22.6 percent stake in the company. The 10-Year Note yield was 2.07 percent and the 30-Year Bond was yielding 3.23 percent. JDS Uniphase (NASDAQ: JDSU ) climbed around 8 percent on the Ciena news and Finisar (NASDAQ: FNSR ) added a little less than 5 percent."
+2013-06-05,14.5,14.710000038146973,9.228738375011911,,
+2013-06-04,14.619999885559082,14.600000381469728,1.4482761251515355,,
+2013-06-03,14.18000030517578,14.529999732971191,-0.13679551467786413,,
+2013-05-31,14.279999732971191,14.06999969482422,2.4682610737861563,,
+2013-05-30,14.260000228881836,14.350000381469728,-1.470588529929033,,
+2013-05-29,14.350000381469728,14.289999961853027,0.6311371047919649,,
+2013-05-28,14.510000228881836,14.390000343322754,-0.41812137994212195,,
+2013-05-24,13.800000190734863,14.1899995803833,-0.8270150493879724,,
+2013-05-23,13.039999961853027,13.789999961853027,2.8260824946240066,,
+2013-05-22,13.84000015258789,13.420000076293944,5.751533759156717,,
+2013-05-21,14.25,13.789999961853027,-3.0346825987239083,,
+2013-05-20,13.460000038146973,14.149999618530272,-3.2280704431366507,"Biotech Companies See Insider Purchases: CEO Phillip Frost Increases Stake in OPKO and Felix Baker Buys ACADIA | Mid-Morning Market Update: Markets Fall, Yahoo To Acquire Tumblr","Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes An important note from Jonathan Moreland, founder of Insider Insights : In a victory for common sense, it has been proven profitable -- by both academic studies and (more importantly) the experience of your fellow professional investors -- to monitor the trading behavior of company executives, directors, and large shareholders in the stocks of firms of which they're registered as ""insiders."" Purchases: Felix Baker, a Director of biopharmaceutical company ACADIA Pharmaceuticals Inc. ( ACAD ), bought 1,993,000 shares of company stock for $24,912,500. ACADIA focuses on small molecule drugs that are meant to address unmet needs, especially in neurological and central nervous system disorders. | ACADIA Pharmaceuticals (NASDAQ: ACAD ) got a boost, shooting up 5.12 percent to $13.95 after the company's stock has been added to the NASDAQ Biotechnology Index. Following the market opening Monday, the Dow traded down 0.16 percent to 15,329.97, while the NASDAQ fell 0.05 percent to 3,497.34. The Spanish Ibex Index fell 1.48 percent and the Italian FTSE MIB Index dropped 1.22 percent."
+2013-05-17,13.039999961853027,13.270000457763672,5.126297016551054,,
+2013-05-16,13.170000076293944,13.010000228881836,1.763807489137145,,
+2013-05-15,13.25,13.050000190734863,-1.2148811426364985,"Pre-Market Most Active for May 15, 2013 : AINV, BAC, SPWR, SIRI, CVRR, BBRY, NOK, AMTD, SNE, RH, ACAD, TSLA","ACADIA Pharmaceuticals Inc. ( ACAD ) is +0.24 at $13.19, with 185,595 shares traded. As reported by Zacks, the current mean recommendation for ACAD is in the ""buy range"". The following are the most active stocks for the pre-market session : Apollo Investment Corporation ( AINV ) is -0.34 at $8.53, with 1,066,120 shares traded."
+2013-05-14,12.630000114440918,12.949999809265137,-1.5094325227557488,,
+2013-05-13,11.93000030517578,12.699999809265137,2.5336476003538335,,
+2013-05-10,11.890000343322754,12.020000457763672,6.454312526339972,,
+2013-05-09,11.600000381469728,11.93000030517578,1.093356692070443,,
+2013-05-08,12.100000381469728,11.649999618530272,2.844826834947396,,
+2013-05-07,12.130000114440918,12.029999732971191,-3.71901445250035,"Benzinga Market Primer: Tuesday, May 7","Earnings Notable companies expected to report earnings Tuesday include: Acadia Pharmaceuticals (NASDAQ: ACAD ) is expected to report a first quarter loss of $0.08 per share vs. a loss of $0.12 per share a year ago. Futures Flat Following RBA Rate Cut, European Bank Earnings U.S. equity futures traded near flat following a surprise rate cut from the Reserve Bank of Australia while earnings from three of Europe's largest banks reported better than expected earnings. Earnings Reported Yesterday Key companies that reported earnings Monday include: First Solar (NASDAQ: FSLR ) reported first quarter EPS of $0.69 vs. $0.75 expected on revenue of $755.0 million vs. $752.26 million expected."
+2013-05-06,12.399999618530272,12.18000030517578,-0.824405445393812,,
+2013-05-03,12.489999771118164,12.350000381469728,-1.7741880655038917,,
+2013-05-02,12.050000190734863,12.329999923706056,-1.1208918511925827,,
+2013-05-01,12.84000015258789,12.020000457763672,2.3236491994953035,,
+2013-04-30,13.149999618530272,12.890000343322754,-6.386290382239197,,
+2013-04-29,13.399999618530272,13.1899995803833,-1.977180857413416,,
+2013-04-26,13.25,13.399999618530272,-1.567164508397232,,
+2013-04-25,13.4399995803833,13.369999885559082,1.1320725926812956,,
+2013-04-24,13.729999542236328,13.5,-0.5208310789413165,,
+2013-04-23,13.199999809265137,13.550000190734863,-1.6751605965375438,,
+2013-04-22,12.1899995803833,13.149999618530272,2.6515180797507267,,
+2013-04-19,12.199999809265137,12.09000015258789,7.875308213232808,,
+2013-04-18,12.31999969482422,12.18000030517578,-0.9016365442375518,What's behind call activity in Acadia,"Acadia Pharmaceuticals has been explosive, and one investor is using options to smooth the ride. ACAD is down 1.95 percent to $12.08 in midday trading. Our Heat Seeker monitoring program detected the purchase of 30,000 January 2015 12 calls for $4.04 and the sale of an equal number of January 2015 15 calls for $2.64."
+2013-04-17,12.260000228881836,12.31999969482422,-1.1363587103598427,,
+2013-04-16,12.300000190734863,12.390000343322754,0.4893920458585244,,
+2013-04-15,12.5,12.15999984741211,0.7317085462785962,,
+2013-04-12,12.739999771118164,12.539999961853027,-2.720001220703125,"Mid-Morning Market Update: Markets Plummet on Bad Data, Rite Aid Continues to Rally","Equities Trading DOWN ACADIA Pharma (NASDAQ: ACAD ) traded down 2.44 percent to $12.78 as traders looked to take profits following its incredible rally Thursday. Economics In economic news for Friday, retail sales came in down at -0.4 percent, below the projected 0.0 percent and the prior release of 1.10 percent. Retail sales ex autos and gas came in at -0.10 percent, missing expectations of 0.30 percent and the prior figure of 0.40 percent."
+2013-04-11,11.109999656677246,13.100000381469728,-1.5698572437853595,"Mid-Morning Market Update: Markets Continue to March Upwards, PC Makers Get Blasted | Pre-Market Most Active for Apr 11, 2013 : PCS, RAD, SGYP, INFI, MSFT, ACAD, RLGY, QQQ, FTNT, NOK, BAC, HPQ | Market Wrap for Thursday, April 11: Stock Market Rally Continues | Mid-Afternoon Market Update: Rite Aid Posts Massive Rally, While Hewlett-Packard Takes a Hit | Mid-Day Market Update: ACADIA Posts Massive Rally as AMD Falls","Equities Trading UP ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot up 46.54 percent to $11.68 after the company announced it had received an expedited FDA review path for its lead drug Shares of Rite Aid (NYSE: RAD ) shot up 16.49 percent to $2.09 after the company crushed expectations on the bottom line in its earnings release this morning. Following the market opening Thursday, the Dow traded up 0.19 percent to 14,830.98 while the NASDAQ fell 0.04 percent to 3,295.44. Commodities In commodity news, oil traded down 0.67 percent to $94.01, while gold traded down 0.53 percent to $1,567.50. | The consensus earnings per share forecast is 0.75 per share, which represents a 60 percent increase over the EPS one Year Ago ACADIA Pharmaceuticals Inc. ( ACAD ) is +3.39 at $11.36, with 1,294,828 shares traded. As reported by Zacks, the current mean recommendation for ACAD is in the ""buy range"". The consensus earnings per share forecast is -0.06 per share, which represents a -11 percent increase over the EPS one Year Ago Bank of America Corporation ( BAC ) is unchanged at $12.32, with 380,050 shares traded. | Stock Movers Heading into the closing bell, shares of Acadia Pharmaceuticals (NASDAQ: ACAD ) were up more than 66 percent after the FDA decided that data from a late-stage study, along with supportive data from other studies, are sufficient to support the filing of a new drug application for its pimavanserin drug for the treatment of Parkinson's disease psychosis. The yield on the 2-Year Note was unchanged at 0.23 percent while the yield on the 5-Year Note fell one basis point to 0.73 percent. The 10-Year Note yield lost one basis point to 1.79 percent while the 30-Year Bond yield was unchanged at 3.00 percent. | Equities Trading UP ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot up 67.13 percent to $13.32 after the company announced it had received an expedited FDA review path for its lead drug Shares of Rite Aid (NYSE: RAD ) shot up 18.99 percent to $2.13 after the company crushed expectations on the bottom line in its earnings release this morning. Toward the end of Thursday, the Dow traded up 0.46 percent to 14,870.98 while the NASDAQ rose 0.12 percent to 3,301.44. Commodities In commodity news, oil traded down 1.28 percent to $93.43, while gold traded up 0.26 percent to $1,562.50. | Equities Trading UP ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot up 56.71 percent to $12.49 after the company announced it had received an expedited FDA review path for its lead drug Shares of Rite Aid (NYSE: RAD ) shot up 18.99 percent to $2.13 after the company crushed expectations on the bottom line in its earnings release this morning. Midway through trading Thursday, the Dow traded up 0.43 percent to 14,865.98 while the NASDAQ rose 0.05 percent to 3,299.44. Commodities In commodity news, oil traded down 1.46 percent to $93.26, while gold traded up 0.40 percent to $1,565.50."
+2013-04-10,8.029999732971191,7.96999979019165,17.911798256415494,,
+2013-04-09,8.050000190734863,7.929999828338623,-0.7471973197356553,,
+2013-04-08,7.789999961853027,7.980000019073486,-1.4906876963102993,,
+2013-04-05,7.510000228881836,7.699999809265137,2.439025136724945,,
+2013-04-04,7.550000190734863,7.690000057220459,2.5299543887176394,,
+2013-04-03,7.820000171661377,7.590000152587891,1.8543028205138246,,
+2013-04-02,7.880000114440918,7.75,-2.9411766499312275,,
+2013-04-01,7.929999828338623,7.900000095367432,-1.649747621230097,,
+2013-03-28,8.050000190734863,7.940000057220459,-0.37830685524083435,,
+2013-03-27,8.239999771118164,8.109999656677246,-1.3664612535165999,,
+2013-03-26,8.4399995803833,8.229999542236328,-1.5776713355815666,,
+2013-03-25,7.949999809265137,8.3100004196167,-2.488152234451125,,
+2013-03-22,8.229999542236328,7.570000171661377,4.528309672812928,,
+2013-03-21,7.130000114440918,8.239999771118164,-8.01943386737553,"Market Wrap for Thursday, March 21: Stocks Give Back Wednesday's Gains | Mid-Morning Market Update: Markets Tumble, Oracle Posts Downbeat Results | Mid-Day Market Update: Herman Miller Surges On Upbeat Earnings, Scholastic Falls | Mid-Afternoon Market Update: Markets Remain in the Red, DryShips Posts Strong Rally","Shares of ACADIA Pharmaceuticals (NASDAQ: ACAD ) were up around 24 percent heading into the close after the company reported data from its late-stage Parkinson's disease psychosis study with Pimavanserin. While the yield on the 2-Year Note was unchanged at 0.25 percent, the yield on the 5-Year Note fell one basis point to 0.80 percent. The 10-Year Note yield fell three basis points to 1.93 percent and the 30-Year Bond yield was down five basis points to 3.15 percent. | Equities Trading UP ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot up 7.67 percent to $7.16 after phase III pimavanserin study data. Following the market opening Thursday, the Dow traded down 0.38 percent to 14,456.47 while the NASDAQ dropped 0.65 percent to 3,232.90. Equities Trading DOWN Scholastic (NASDAQ: SCHL ) shares tumbled 13.55 percent to $26.86 after the company reported a wider fiscal third-quarter. | Equities Trading UP ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot up 27.91 percent to $8.51 after phase III pimavanserin study data. Midway through trading Thursday, the Dow traded down 0.23 percent to 14,477.96 while the NASDAQ dropped 0.61 percent to 3,234.34. Oracle's quarterly earnings came in at $2.5 billion, or $0.52 per share, versus $2.5 billion, or $0.49 per share, in the year-ago period. | Equities Trading UP ACADIA Pharmaceuticals (NASDAQ: ACAD ) shot up 29.09 percent to $8.58 after phase III pimavanserin study data. Toward the end of trading Thursday, the Dow traded down 0.54 percent to 14,433.96 while the NASDAQ dropped 0.89 percent to 3,225.34. Oracle's quarterly earnings came in at $2.5 billion, or $0.52 per share, versus $2.5 billion, or $0.49 per share, in the year-ago period."
+2013-03-20,6.679999828338623,6.650000095367432,15.568017375330493,,
+2013-03-19,6.5,6.579999923706055,-0.44909781051076186,,
+2013-03-18,6.289999961853027,6.179999828338623,1.2307680570162258,,
+2013-03-15,6.389999866485596,6.260000228881836,-1.7488097644121188,,
+2013-03-14,6.159999847412109,6.389999866485596,-2.0344231661973042,,
+2013-03-13,6.28000020980835,6.090000152587891,3.733766635888995,,
+2013-03-12,6.440000057220459,6.309999942779541,-3.0254785170820453,"Benzinga Market Primer: Tuesday, March 12 | After-Hours Earnings Report for March 12, 2013 : KW, DOLE, ACAD, GCA, GNMK, AVID, WSR, KTOS, GERN, ACRX, FOLD, GCAP","Earnings Notable companies expected to report earnings Tuesday include: Acadia Pharmaceuticals (NASDAQ: ACAD ) is expected to report a fourth quarter loss of $0.09 per share vs. a loss of $0.10 per share a year ago. U.K. January industrial production fell 1.2 percent, well worse than forecasts of a 0.1 percent gain and also much worse than December's 1.1 percent gain. The Japanese Nikkei Index fell 0.28 percent and the Shanghai Composite Index fell 1.04 percent while the Hang Seng Index fell 0.87 percent. | ACADIA Pharmaceuticals Inc. ( ACAD ) is reporting for the quarter ending December 31, 2012. ACAD missed the consensus earnings per share in the 1st calendar quarter of 2012 by -9.09%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for ACAD is -18.51 vs. an industry ratio of -11.40."
+2013-03-11,6.519999980926514,6.480000019073486,-2.018635299469652,,
+2013-03-08,6.599999904632568,6.53000020980835,-0.6134963492337805,,
+2013-03-07,6.5,6.539999961853027,-1.0606014520558653,,
+2013-03-06,6.400000095367432,6.510000228881836,0.6153840285081129,,
+2013-03-05,6.440000057220459,6.369999885559082,1.7187520605511657,,
+2013-03-04,6.369999885559082,6.329999923706055,-1.086959177630651,,
+2013-03-01,6.090000152587891,6.360000133514404,-0.6279428975141438,,
+2013-02-28,6.050000190734863,6.070000171661377,4.433497112668866,,
+2013-02-27,5.860000133514404,6.079999923706055,0.3305781867105094,,
+2013-02-26,5.900000095367432,5.860000133514404,3.7542625457196097,,
+2013-02-25,6.130000114440918,5.869999885559082,-0.6779654441774425,,
+2013-02-22,6.050000190734863,6.130000114440918,-4.2414392174207824,,
+2013-02-21,6.079999923706055,6.03000020980835,1.3223127468420377,,
+2013-02-20,6.239999771118164,6.090000152587891,-0.8223637257420856,,
+2013-02-19,6.090000152587891,6.289999961853027,-2.4038401287215843,,
+2013-02-15,6.25,6.090000152587891,3.2840690353701976,,
+2013-02-14,6.019999980926514,6.269999980926514,-2.55999755859375,,
+2013-02-13,6.090000152587891,6.059999942779541,4.152823933423394,,
+2013-02-12,6.019999980926514,6.050000190734863,-0.49261427022462867,,
+2013-02-11,5.929999828338623,6.050000190734863,0.49834235719935,,
+2013-02-08,6.0,6.0,2.0236149387859275,,
+2013-02-07,6.150000095367432,5.989999771118164,0.0,,
+2013-02-06,6.28000020980835,6.130000114440918,-2.6016312482627426,,
+2013-02-05,6.130000114440918,6.28000020980835,-2.3885364706382592,,
+2013-02-04,6.010000228881836,6.130000114440918,2.4469835655315038,,
+2013-02-01,6.099999904632568,6.019999980926514,1.9966702327631707,,
+2013-01-31,6.170000076293945,6.03000020980835,-1.3114741796192448,,
+2013-01-30,6.28000020980835,6.150000095367432,-2.2690415681435065,,
+2013-01-29,6.75,6.28000020980835,-2.0700654474163667,,
+2013-01-28,6.5,6.659999847412109,-6.962959854691117,,
+2013-01-25,6.0,6.190000057220459,2.4615361140324516,,
+2013-01-24,5.940000057220459,5.900000095367432,3.166667620340983,,
+2013-01-23,6.0,5.869999885559082,-0.6734000247088343,,
+2013-01-22,5.230000019073486,5.670000076293945,-2.1666685740152998,,
+2013-01-18,5.360000133514404,5.21999979019165,8.413002975445622,,
+2013-01-17,5.480000019073486,5.380000114440918,-2.6119466387206884,,
+2013-01-16,5.760000228881836,5.389999866485596,-1.8248157716151892,,
+2013-01-15,5.559999942779541,5.809999942779541,-6.423617147460892,,
+2013-01-14,5.039999961853027,5.610000133514404,4.4964029239723455,,
+2013-01-11,5.0,5.010000228881836,11.309527301103556,,
+2013-01-10,4.989999771118164,4.980000019073486,0.20000457763671872,,
+2013-01-09,4.960000038146973,4.949999809265137,-0.2003958417504492,,
+2013-01-08,4.820000171661377,4.920000076293945,-0.20161751622832577,,
+2013-01-07,4.889999866485596,4.869999885559082,2.0746867442143677,,
+2013-01-04,4.789999961853027,4.949999809265137,-0.40899757612646925,,
+2013-01-03,4.659999847412109,4.75,3.340289116624813,,
+2013-01-02,4.78000020980835,4.730000019073486,1.931333809761205,,
+2012-12-31,4.46999979019165,4.650000095367432,-1.0460290489583053,,
+2012-12-28,4.460000038146973,4.510000228881836,4.026852653790925,,
+2012-12-27,4.570000171661377,4.539999961853027,1.1210805001615471,,
+2012-12-26,4.650000095367432,4.559999942779541,-0.6564597085659045,,
+2012-12-24,4.5,4.550000190734863,-1.9354871127326079,,
+2012-12-21,4.599999904632568,4.510000228881836,1.1111153496636283,,
+2012-12-20,4.829999923706055,4.75,-1.9565147307958755,,
+2012-12-19,4.789999961853027,4.699999809265137,-1.6563131463710423,,
+2012-12-18,4.909999847412109,4.829999923706055,-1.8789176055248602,,
+2012-12-17,4.809999942779541,4.869999885559082,-1.6293263990266693,,
+2012-12-14,4.710000038146973,4.760000228881836,1.247400072625968,,
+2012-12-13,4.929999828338623,4.78000020980835,1.0615751662400106,,
+2012-12-12,4.960000038146973,5.010000228881836,-3.0425887171039174,,
+2012-12-11,4.199999809265137,4.429999828338623,1.0080683538370105,,
+2012-12-10,4.5,4.179999828338623,5.476191179011717,,
+2012-12-07,4.650000095367432,4.550000190734863,-7.111114925808376,,
+2012-12-06,4.539999961853027,4.650000095367432,-2.150535539390491,,
+2012-12-05,4.989999771118164,4.670000076293945,2.4229104501909973,,
+2012-12-04,5.110000133514404,5.0,-6.4128198296993695,,
+2012-12-03,5.239999771118164,5.119999885559082,-2.152644435231192,,
+2012-11-30,5.150000095367432,5.199999809265137,-2.2900742519207253,,
+2012-11-29,5.150000095367432,5.369999885559082,0.9708682130449126,,
+2012-11-28,4.920000076293945,5.139999866485596,4.271840507139919,,
+2012-11-27,6.5,5.429999828338623,4.471540381710078,"Pre-Market Most Active for Nov 27, 2012 : ACAD, RAH, BAC, FB, NOK, SNE, GLW, SID, QQQ, AAPL, EBAY, ZNGA | After Hours Most Active for Nov 27, 2012 : ACAD, GMCR, CIG, DISH, EFII, NOK, T, BAC, JEF, MSFT, DTV, HAL","Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2012. The following are the most active stocks for the pre-market session : ACADIA Pharmaceuticals Inc. ( ACAD ) is +4.62 at $6.92, with 5,460,144 shares traded. As reported by Zacks, the current mean recommendation for ACAD is in the ""buy range"". | The following are the most active stocks for the after hours session : ACADIA Pharmaceuticals Inc. ( ACAD ) is unchanged at $5.43, with 5,560,675 shares traded. EPS View Comp En De Mn Cemig ADS ( CIG ) is +0.4349 at $11.88, with 3,741,658 shares traded. AT&T Inc. ( T ) is +0.12 at $33.74, with 1,815,923 shares traded."
+2012-11-26,2.2300000190734863,2.299999952316284,-16.46154110248272,,
+2012-11-23,2.190000057220459,2.220000028610229,3.1390104324699157,,
+2012-11-21,2.190000057220459,2.150000095367432,1.3698616715036038,,
+2012-11-20,2.3499999046325684,2.130000114440918,-1.8264822286714788,,
+2012-11-19,1.9600000381469729,2.259999990463257,-9.361693579559876,,
+2012-11-16,1.9700000286102293,1.909999966621399,15.30611971823789,,
+2012-11-15,1.940000057220459,1.950000047683716,-3.045688381596544,,
+2012-11-14,2.0899999141693115,1.940000057220459,0.51546341073745,,
+2012-11-13,2.119999885559082,2.109999895095825,-7.177026943011683,,
+2012-11-12,2.289999961853028,2.180000066757202,-0.47169768882415103,,
+2012-11-09,2.180000066757202,2.2699999809265137,-4.803488948830185,,
+2012-11-08,2.319999933242798,2.240000009536743,4.128436303361603,,
+2012-11-07,2.380000114440918,2.299999952316284,-3.4482726727597,,
+2012-11-06,2.400000095367432,2.4200000762939453,-3.361351188145909,,
+2012-11-05,2.200000047683716,2.2699999809265137,0.8333325054910591,,
+2012-11-02,2.3299999237060547,2.180000066757202,3.1818150784359176,,
+2012-11-01,2.3499999046325684,2.3299999237060547,-6.437762311608386,,
+2012-10-31,2.2799999713897705,2.3499999046325684,-0.8510630526872615,,
+2012-10-26,2.319999933242798,2.2699999809265137,3.070172549174617,,
+2012-10-25,2.2100000381469727,2.3499999046325684,-2.1551704204748128,,
+2012-10-24,2.309999942779541,2.180000066757202,6.334835478237455,,
+2012-10-23,2.220000028610229,2.289999961853028,-5.627700400109735,,
+2012-10-22,2.4200000762939453,2.2699999809265137,3.153150105435823,,
+2012-10-19,2.549999952316284,2.400000095367432,-6.198350852829142,,
+2012-10-18,2.5899999141693115,2.4800000190734863,-5.882347441324468,,
+2012-10-17,2.4600000381469727,2.549999952316284,-4.247100337495778,,
+2012-10-16,2.400000095367432,2.440000057220459,3.6585330395809725,,
+2012-10-15,2.440000057220459,2.4100000858306885,1.6666650109821366,,
+2012-10-12,2.490000009536743,2.400000095367432,-1.2295069953377444,,
+2012-10-11,2.430000066757202,2.450000047683716,-3.6144543704662593,,
+2012-10-10,2.490000009536743,2.380000114440918,0.8230444599618197,,
+2012-10-09,2.630000114440918,2.5,-4.417666452792116,,
+2012-10-08,2.619999885559082,2.5899999141693115,-4.942969915746685,,
+2012-10-05,2.7699999809265137,2.619999885559082,-1.1450371259603627,,
+2012-10-04,2.549999952316284,2.759999990463257,-5.415165935028613,,
+2012-10-03,2.470000028610229,2.4800000190734863,8.235295767602654,,
+2012-10-02,2.490000009536743,2.400000095367432,0.4048579088026925,,
+2012-10-01,2.5199999809265137,2.470000028610229,-3.6144543704662593,,
+2012-09-28,2.5199999809265137,2.5299999713897705,-1.9841251069335895,,
+2012-09-27,2.650000095367432,2.549999952316284,0.3968250213867144,,
+2012-09-26,2.5199999809265137,2.5299999713897705,-3.773590168014033,,
+2012-09-25,2.7300000190734863,2.5299999713897705,0.3968250213867144,,
+2012-09-24,2.650000095367432,2.690000057220459,-7.326009021479505,,
+2012-09-21,2.809999942779541,2.619999885559082,1.5094324684347138,,
+2012-09-20,2.5299999713897705,2.759999990463257,-6.7615680103010405,,
+2012-09-19,2.25,2.440000057220459,9.090909947605397,,
+2012-09-18,2.25,2.2100000381469727,8.444446987575954,,
+2012-09-17,2.150000095367432,2.220000028610229,-1.7777760823567708,,
+2012-09-14,2.0899999141693115,2.119999885559082,3.255810704084368,,
+2012-09-13,2.0999999046325684,2.0899999141693115,1.4354053886023366,,
+2012-09-12,2.0999999046325684,2.0999999046325684,-0.47619004368509765,,
+2012-09-11,2.0799999237060547,2.049999952316284,0.0,,
+2012-09-10,1.940000057220459,2.049999952316284,-1.442306369719372,,
+2012-09-07,1.7300000190734863,1.919999957084656,5.670097518111823,,
+2012-09-06,1.850000023841858,1.75,10.982655255282914,,
+2012-09-05,1.7999999523162842,1.820000052452088,-5.405406624492354,,
+2012-09-04,1.7899999618530271,1.75,1.1111167036458678,,
+2012-08-31,1.7899999618530271,1.7799999713897705,-2.234634788015232,,
+2012-08-30,1.75,1.7899999618530271,-0.5586586970037987,,
+2012-08-29,1.7899999618530271,1.7799999713897705,2.285712105887264,,
+2012-08-28,1.820000052452088,1.7999999523162842,-0.5586586970037987,,
+2012-08-27,1.7999999523162842,1.809999942779541,-1.0989065691980464,,
+2012-08-24,1.850000023841858,1.7999999523162842,0.5555550404536735,,
+2012-08-23,1.7899999618530271,1.7899999618530271,-2.7027065341188257,,
+2012-08-22,1.7599999904632568,1.7699999809265137,0.0,,
+2012-08-21,1.7699999809265137,1.7699999809265137,0.5681812794001605,,
+2012-08-20,1.7000000476837158,1.7400000095367432,0.0,,
+2012-08-17,1.6200000047683716,1.690000057220459,2.3529388665328623,,
+2012-08-16,1.6100000143051147,1.659999966621399,4.320990879385587,,
+2012-08-15,1.6699999570846558,1.6299999952316284,3.10558707279667,,
+2012-08-14,1.7100000381469729,1.7000000476837158,-2.3952073581400493,,
+2012-08-13,1.600000023841858,1.7100000381469729,-0.5847947508874598,,
+2012-08-10,1.5099999904632568,1.590000033378601,6.87500079162419,,
+2012-08-09,1.5199999809265137,1.5099999904632568,5.298016120569697,,
+2012-08-08,1.5099999904632568,1.5,-0.657894117680275,,
+2012-08-07,1.559999942779541,1.5199999809265137,-0.6622510282393388,,
+2012-08-06,1.5199999809265137,1.5700000524520874,-2.5641002128344392,,
+2012-08-03,1.559999942779541,1.5099999904632568,3.289478431117891,,
+2012-08-02,1.5399999618530271,1.5700000524520874,-3.205125266043049,,
+2012-08-01,1.6100000143051147,1.5299999713897705,1.9480578793626877,,
+2012-07-31,1.6699999570846558,1.6100000143051147,-4.9689467207783045,,
+2012-07-30,1.6200000047683716,1.649999976158142,-3.5928110372100743,,
+2012-07-27,1.5700000524520874,1.600000023841858,1.8518500803374947,,
+2012-07-26,1.5800000429153442,1.5499999523162842,1.9108261393313575,,
+2012-07-25,1.590000033378601,1.5499999523162842,-1.8987398597600829,,
+2012-07-24,1.5299999713897705,1.5700000524520874,-2.515728315886917,,
+2012-07-23,1.5,1.5299999713897705,2.6143844320456395,,
+2012-07-20,1.5800000429153442,1.559999942779541,1.9999980926513672,,
+2012-07-19,1.590000033378601,1.590000033378601,-1.265829088137235,,
+2012-07-18,1.6200000047683716,1.5800000429153442,0.0,,
+2012-07-17,1.5700000524520874,1.6100000143051147,-2.4691334404499927,,
+2012-07-16,1.5499999523162842,1.5700000524520874,2.5477681857751433,,
+2012-07-13,1.6799999475479126,1.6200000047683716,1.2903290807148435,,
+2012-07-12,1.7599999904632568,1.7699999809265137,-3.5714252769540553,,
+2012-07-11,1.8600000143051147,1.75,0.5681812794001605,,
+2012-07-10,1.8899999856948853,1.840000033378601,-5.913979218231894,,
+2012-07-09,1.940000057220459,1.8799999952316284,-2.6455001425780957,,
+2012-07-06,1.870000004768372,1.830000042915344,-3.0927866092331895,,
+2012-07-05,1.870000004768372,1.870000004768372,-2.1390353877556603,,
+2012-07-03,1.850000023841858,1.8600000143051147,0.0,,
+2012-07-02,1.75,1.809999942779541,0.5405400180747055,,
+2012-06-29,1.850000023841858,1.7599999904632568,3.428568158830915,,
+2012-06-28,1.649999976158142,1.7799999713897705,-4.864866606417649,,
+2012-06-27,1.5399999618530271,1.6200000047683716,7.878787703641079,,
+2012-06-26,1.5299999713897705,1.5499999523162842,5.194808110195227,,
+2012-06-25,1.5,1.5099999904632568,1.30718832029433,,
+2012-06-22,1.5299999713897705,1.5,0.6666660308837891,,
+2012-06-21,1.590000033378601,1.4600000381469729,-1.960782480441495,,
+2012-06-20,1.5800000429153442,1.600000023841858,-8.176100157393734,,
+2012-06-19,1.5299999713897705,1.5299999713897705,1.265821543245696,,
+2012-06-18,1.4800000190734863,1.5299999713897705,0.0,,
+2012-06-15,1.4199999570846558,1.4900000095367432,3.3783751129669097,,
+2012-06-14,1.3600000143051147,1.3899999856948853,4.9295813075798725,,
+2012-06-13,1.350000023841858,1.3799999952316284,2.2058802260453536,,
+2012-06-12,1.340000033378601,1.350000023841858,2.222220063700145,,
+2012-06-11,1.3600000143051147,1.3799999952316284,0.7462679264300778,,
+2012-06-08,1.3300000429153442,1.3600000143051147,1.4705868173635692,,
+2012-06-07,1.340000033378601,1.3300000429153442,2.255636873816254,,
+2012-06-06,1.2999999523162842,1.340000033378601,-0.7462679264300778,,
+2012-06-05,1.3300000429153442,1.309999942779541,3.0769294253470134,,
+2012-06-04,1.3300000429153442,1.3300000429153442,-1.5037668789816911,,
+2012-06-01,1.350000023841858,1.309999942779541,0.0,,
+2012-05-31,1.4199999570846558,1.3799999952316284,-2.9629689152511154,,
+2012-05-30,1.399999976158142,1.409999966621399,-2.816898807176702,,
+2012-05-29,1.4600000381469729,1.409999966621399,0.7142850452539758,,
+2012-05-25,1.399999976158142,1.4600000381469729,-3.424662343778694,,
+2012-05-24,1.4800000190734863,1.3700000047683716,4.28571878647327,,
+2012-05-23,1.3899999856948853,1.4500000476837158,-7.432433303208824,,
+2012-05-22,1.3899999856948853,1.3899999856948853,4.3165512666415955,,
+2012-05-21,1.4199999570846558,1.3899999856948853,0.0,,
+2012-05-18,1.5099999904632568,1.4199999570846558,-2.112674105382526,,
+2012-05-17,1.5499999523162842,1.5,-5.960267148809036,,
+2012-05-16,1.5800000429153442,1.559999942779541,-3.225803474481751,,
+2012-05-15,1.600000023841858,1.5800000429153442,-1.265829088137235,,
+2012-05-14,1.5199999809265137,1.590000033378601,-1.2499987892806712,,
+2012-05-11,1.4900000095367432,1.5199999809265137,4.605266666478442,,
+2012-05-10,1.4800000190734863,1.5,2.0134208857554183,,
+2012-05-09,1.5,1.5,1.3513500451867637,,
+2012-05-08,1.4900000095367432,1.5399999618530271,0.0,,
+2012-05-07,1.5,1.5,3.355701476259015,,
+2012-05-04,1.5399999618530271,1.5,0.0,,
+2012-05-03,1.590000033378601,1.5499999523162842,-2.597400184666017,,
+2012-05-02,1.5299999713897705,1.5700000524520874,-2.515728315886917,,
+2012-05-01,1.5099999904632568,1.559999942779541,2.6143844320456395,,
+2012-04-30,1.5499999523162842,1.5,3.3112551411966935,,
+2012-04-27,1.440000057220459,1.5099999904632568,-3.225803474481751,,
+2012-04-26,1.2899999618530271,1.4500000476837158,4.861106282031287,,
+2012-04-25,1.5,1.4900000095367432,12.40310779551154,,
+2012-04-24,1.4500000476837158,1.4600000381469729,-0.6666660308837891,,
+2012-04-23,1.4500000476837158,1.4600000381469729,0.6896544920278738,,
+2012-04-20,1.4800000190734863,1.4800000190734863,0.6896544920278738,,
+2012-04-19,1.5,1.4800000190734863,0.0,,
+2012-04-18,1.5,1.5,-1.3333320617675781,,
+2012-04-17,1.5499999523162842,1.5,0.0,,
+2012-04-16,1.5800000429153442,1.5499999523162842,-3.225803474481751,,
+2012-04-13,1.600000023841858,1.5399999618530271,-1.8987398597600829,,
+2012-04-12,1.6200000047683716,1.6399999856948853,-3.750003818422513,,
+2012-04-11,1.590000033378601,1.6399999856948853,1.2345667202249964,,
+2012-04-10,1.7200000286102295,1.5800000429153442,3.14465102305935,,
+2012-04-09,1.75,1.7200000286102295,-8.13953391663639,,
+2012-04-05,1.8899999856948853,1.820000052452088,-1.7142840794154575,,
+2012-04-04,1.9299999475479128,1.8899999856948853,-3.7037001996092984,,
+2012-04-03,2.0899999141693115,2.0299999713897705,-2.072536939902407,,
+2012-04-02,2.0799999237060547,2.109999895095825,-2.870810777204673,,
+2012-03-30,2.1600000858306885,2.150000095367432,1.442306369719372,,
+2012-03-29,2.150000095367432,2.130000114440918,-0.4629625030505781,,
+2012-03-28,2.2100000381469727,2.180000066757202,-0.9302316297384231,,
+2012-03-27,2.180000066757202,2.200000047683716,-1.3574647453365973,,
+2012-03-26,2.2300000190734863,2.140000104904175,0.9174302896359119,,
+2012-03-23,2.2699999809265137,2.180000066757202,-4.035870556032749,,
+2012-03-22,2.259999990463257,2.2699999809265137,-3.964753961477019,,
+2012-03-21,2.0999999046325684,2.25,0.44247745599357413,,
+2012-03-20,1.8600000143051147,2.069999933242798,7.142862008542651,,
+2012-03-19,1.8600000143051147,1.870000004768372,11.290318135623126,,
+2012-03-16,1.919999957084656,1.870000004768372,0.5376338917391471,,
+2012-03-15,2.0,1.919999957084656,-2.604164241347396,,
+2012-03-14,2.009999990463257,1.9900000095367432,-4.000002145767201,,
+2012-03-13,1.75,2.039999961853028,-0.9950239314132612,,
+2012-03-12,1.600000023841858,1.7100000381469729,16.571426391601587,,
+2012-03-09,1.590000033378601,1.600000023841858,6.87500079162419,,
+2012-03-08,1.5800000429153442,1.600000023841858,0.6289302046118699,,
+2012-03-07,1.4800000190734863,1.5700000524520874,1.265821543245696,,
+2012-03-06,1.5199999809265137,1.4800000190734863,6.08108325802206,,
+2012-03-05,1.600000023841858,1.559999942779541,-2.6315764707211,,
+2012-03-02,1.649999976158142,1.590000033378601,-2.5000050291418283,,
+2012-03-01,1.6799999475479126,1.649999976158142,-3.6363602210010213,,
+2012-02-29,1.7400000095367432,1.6699999570846558,-1.7857126384770277,,
+2012-02-28,1.7799999713897705,1.7000000476837158,-4.022991498185347,,
+2012-02-27,1.7799999713897705,1.7599999904632568,-4.494377808534073,,
+2012-02-24,1.75,1.7599999904632568,-1.1235944521335182,,
+2012-02-23,1.690000057220459,1.7300000190734863,0.5714280264718192,,
+2012-02-22,1.7200000286102295,1.649999976158142,2.366861567970313,,
+2012-02-21,1.7799999713897705,1.7200000286102295,-4.069770423704462,,
+2012-02-17,1.8600000143051147,1.7899999618530271,-3.3707833564005543,,
+2012-02-16,1.870000004768372,1.830000042915344,-3.7634436512754137,,
+2012-02-15,1.850000023841858,1.850000023841858,-2.1390353877556603,,
+2012-02-14,1.870000004768372,1.850000023841858,0.0,,
+2012-02-13,1.7999999523162842,1.870000004768372,-1.069517693877836,,
+2012-02-10,1.7799999713897705,1.7999999523162842,3.888891905914223,,
+2012-02-09,1.7899999618530271,1.809999942779541,1.1235944521335182,,
+2012-02-08,1.7999999523162842,1.7699999809265137,1.1173173940076344,,
+2012-02-07,1.850000023841858,1.7799999713897705,-1.6666651213610204,,
+2012-02-06,1.7899999618530271,1.830000042915344,-3.7837865702682367,,
+2012-02-03,1.7599999904632568,1.7699999809265137,2.2346414477522325,,
+2012-02-02,1.600000023841858,1.7400000095367432,0.5681812794001605,,
+2012-02-01,1.5399999618530271,1.600000023841858,8.749998975545182,,
+2012-01-31,1.5499999523162842,1.5099999904632568,3.896108017862211,,
+2012-01-30,1.6200000047683716,1.5299999713897705,-2.580642779585401,,
+2012-01-27,1.5700000524520874,1.600000023841858,-5.555557599610584,,
+2012-01-26,1.600000023841858,1.5299999713897705,1.9108261393313575,,
+2012-01-25,1.4299999475479126,1.559999942779541,-4.3750032130628345,,
+2012-01-24,1.4299999475479126,1.440000057220459,9.090909090909092,,
+2012-01-23,1.4600000381469729,1.4299999475479126,0.6993083943600166,Zacks #1 Rank Additions for Monday - Tale of the Tape,"Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: ACADIA Pharma ( ACAD ) Arena Pharma ( ARNA ) AMETEK, Inc ( AME ) BJ's Restaurants ( BJRI ) Calamos Asset ( CLMS ) View the entire Zacks #1 Rank List . ACADIA PHARMA ( ACAD ): Free Stock Analysis Report AMETEK INC ( AME ): Free Stock Analysis Report ARENA PHARMA ( ARNA ): Free Stock Analysis Report BJ'S RESTAURANT ( BJRI ): Free Stock Analysis Report CALAMOS ASSET-A ( CLMS ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2012-01-20,1.4199999570846558,1.4800000190734863,-2.0548006722750705,,
+2012-01-19,1.559999942779541,1.399999976158142,4.225356605785697,Zacks #1 Rank Additions for Thursday - Tale of the Tape,"ACADIA PHARMA ( ACAD ): Free Stock Analysis Report AMETEK INC ( AME ): Free Stock Analysis Report CARDTRONICS INC ( CATM ): Free Stock Analysis Report CARLISLE COS IN ( CSL ): Free Stock Analysis Report BANK OZARKS ( OZRK ): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: ACADIA Pharma ( ACAD ) AMETEK Inc ( AME ) Bank of the Ozarks ( OZRK ) Cardtronics Inc ( CATM ) Carlisle Co ( CSL ) View the entire Zacks #1 Rank List . Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2012-01-18,1.2699999809265137,1.5399999618530271,-10.256408492959162,,
+2012-01-17,1.2799999713897705,1.2699999809265137,21.25984133712649,Zacks #1 Rank Additions for Tuesday - Tale of the Tape,"Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: ACADIA Pharma ( ACAD ) Arena Pharma ( ARNA ) Barrett Business ( BBSI ) Baytex Energy ( BTE ) Crane Co ( CR ) View the entire Zacks #1 Rank List . ACADIA PHARMA ( ACAD ): Free Stock Analysis Report ARENA PHARMA ( ARNA ): Free Stock Analysis Report BARRETT BUS SVS ( BBSI ): Free Stock Analysis Report BAYTEX ENERGY ( BTE ): Free Stock Analysis Report CRANE CO ( CR ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2012-01-13,1.3300000429153442,1.2599999904632568,-0.7812492724042223,Zacks #1 Rank Additions for Friday - Tale of the Tape,"Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: ACADIA Pharma ( ACAD ) American Water Works ( AWK ) AMETEK Inc ( AME ) CoBiz Financial ( COBZ ) Entropic Comm ( ENTR ) View the entire Zacks #1 Rank List . ACADIA PHARMA ( ACAD ): Free Stock Analysis Report AMETEK INC ( AME ): Free Stock Analysis Report AMER WATER WORK ( AWK ): Free Stock Analysis Report COBIZ FINL INC ( COBZ ): Free Stock Analysis Report ENTROPIC COMMUN ( ENTR ): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc."
+2012-01-12,1.3200000524520874,1.3200000524520874,-5.263161668675448,,
+2012-01-11,1.2899999618530271,1.309999942779541,0.0,,
+2012-01-10,1.2100000381469729,1.2799999713897705,1.55038616418134,,
+2012-01-09,1.149999976158142,1.190000057220459,5.785118267433895,,
+2012-01-06,1.1100000143051147,1.149999976158142,3.478267990573966,,
+2012-01-05,1.090000033378601,1.100000023841858,3.603600120498037,,
+2012-01-04,1.1200000047683716,1.090000033378601,0.9174302896359119,,
+2012-01-03,1.100000023841858,1.1100000143051147,-2.6785688626827135,,
+2011-12-30,1.1100000143051147,1.0800000429153442,0.9090900224102623,,
+2011-12-29,1.090000033378601,1.1200000047683716,-2.7027000903735274,,
+2011-12-28,1.149999976158142,1.100000023841858,2.7522908689077354,,
+2011-12-27,1.2300000190734863,1.149999976158142,-4.347822030685715,,
+2011-12-23,1.3300000429153442,1.2400000095367432,-6.504068428844849,,
+2011-12-22,1.25,1.3200000524520874,-6.766919584552951,,
+2011-12-21,1.3200000524520874,1.2599999904632568,5.600004196166992,,
+2011-12-20,1.1299999952316284,1.3200000524520874,-4.545459060957758,,
+2011-12-19,1.0499999523162842,1.1100000143051147,16.814164426745208,,
+2011-12-16,1.0299999713897705,1.0499999523162842,5.714291877487359,,
+2011-12-15,1.0099999904632568,1.0399999618530271,1.9417457749564655,,
+2011-12-14,1.0,1.0099999904632568,2.9702942250534274,,
+2011-12-13,1.0499999523162842,1.0099999904632568,0.9999990463256836,,
+2011-12-12,1.0299999713897705,1.0299999713897705,-3.809520349480781,,
+2011-12-09,1.0099999904632568,1.0499999523162842,0.0,,
+2011-12-08,1.0,1.0099999904632568,3.9603923000712657,,
+2011-12-07,1.0499999523162842,1.0499999523162842,0.9999990463256836,,
+2011-12-06,1.0199999809265137,1.0399999618530271,0.0,,
+2011-12-05,1.0,1.0099999904632568,1.9607824804414733,,
+2011-12-02,0.9399999976158142,0.9800000190734864,0.9999990463256836,,
+2011-12-01,0.9800000190734864,0.949999988079071,4.255321442460319,,
+2011-11-30,0.9900000095367432,0.9800000190734864,-3.0612275929114863,,
+2011-11-29,0.9700000286102296,0.9700000286102296,-1.0101000370632403,,
+2011-11-28,1.0099999904632568,0.9700000286102296,0.0,,
+2011-11-25,1.0,0.9900000095367432,-3.9603923000712546,,
+2011-11-23,1.0299999713897705,1.0,-0.9999990463256836,,
+2011-11-22,1.0399999618530271,1.0199999809265137,-2.9126186624346984,,
+2011-11-21,1.0299999713897705,1.0399999618530271,-1.9230751596258084,,
+2011-11-18,1.0499999523162842,1.059999942779541,0.9708728874782111,,
+2011-11-17,1.0800000429153442,1.0299999713897705,0.9523800873701953,,
+2011-11-16,1.0700000524520874,1.0700000524520874,-4.629636068402729,,
+2011-11-15,1.1100000143051147,1.059999942779541,0.0,,
+2011-11-14,1.1200000047683716,1.100000023841858,-4.504510890198043,,
+2011-11-11,1.1799999475479126,1.1100000143051147,-1.785712575121809,,
+2011-11-10,1.2000000476837158,1.1299999952316284,-5.932197996132164,,
+2011-11-09,1.1799999475479126,1.2000000476837158,-5.833337472544612,,
+2011-11-08,1.2000000476837158,1.190000057220459,1.6949238156632322,,
+2011-11-07,1.1799999475479126,1.190000057220459,-0.8333325054910776,,
+2011-11-04,1.149999976158142,1.159999966621399,0.8474669590729236,,
+2011-11-03,1.1799999475479126,1.149999976158142,0.8695644061371431,,
+2011-11-02,1.2000000476837158,1.1799999475479126,-2.5423705697709273,,
+2011-11-01,1.190000057220459,1.1699999570846558,-1.666674945089223,,
+2011-10-31,1.190000057220459,1.2300000190734863,-1.6806806028663923,,
+2011-10-28,1.1799999475479126,1.190000057220459,3.361341170559033,,
+2011-10-27,1.1299999952316284,1.2000000476837158,0.8474669590729236,,
+2011-10-26,1.1299999952316284,1.1100000143051147,6.194694933404732,,
+2011-10-25,1.1399999856948853,1.1299999952316284,-1.7699098239742965,,
+2011-10-24,1.1399999856948853,1.149999976158142,-0.8771921569070334,,
+2011-10-21,1.1299999952316284,1.1299999952316284,0.8771921569070334,,
+2011-10-20,1.1100000143051147,1.1299999952316284,0.0,,
+2011-10-19,1.0800000429153442,1.1200000047683716,1.8018000602490185,,
+2011-10-18,1.0800000429153442,1.090000033378601,3.70370002440479,,
+2011-10-17,1.1399999856948853,1.090000033378601,0.9259250061011975,,
+2011-10-14,1.100000023841858,1.1399999856948853,-4.3859607845351665,,
+2011-10-13,1.0499999523162842,1.100000023841858,3.636360089641049,,
+2011-10-12,1.0,1.0499999523162842,4.761911790117163,,
+2011-10-11,0.9800000190734864,1.0,4.999995231628418,,
+2011-10-10,0.9800000190734864,1.0,2.0408143405366443,,
+2011-10-07,1.0199999809265137,0.9900000095367432,2.0408143405366443,,
+2011-10-06,1.100000023841858,1.0199999809265137,-2.941173720662243,,
+2011-10-05,1.0,1.0299999713897705,-7.272731016490004,,
+2011-10-04,0.8999999761581421,0.9900000095367432,2.999997138977051,,
+2011-10-03,1.0700000524520874,0.9200000166893004,10.00000397364309,,
+2011-09-30,1.1299999952316284,1.0800000429153442,-14.018694243896187,,
+2011-09-29,1.2300000190734863,1.1399999856948853,-4.424774559935741,,
+2011-09-28,1.25,1.2000000476837158,-7.317075770973953,,
+2011-09-27,1.25,1.2400000095367432,-3.9999961853027344,,
+2011-09-26,1.2100000381469729,1.2000000476837158,-0.7999992370605469,,
+2011-09-23,1.190000057220459,1.190000057220459,-0.8264454667762917,,
+2011-09-22,1.190000057220459,1.2000000476837158,0.0,,
+2011-09-21,1.2000000476837158,1.25,0.8403352926397583,,
+2011-09-20,1.3300000429153442,1.1799999475479126,4.166662527455388,,
+2011-09-19,1.4199999570846558,1.2999999523162842,-11.278202295289647,,
+2011-09-16,1.3300000429153442,1.3799999952316284,-8.45070481655075,,
+2011-09-15,1.350000023841858,1.3200000524520874,3.759394789693757,,
+2011-09-14,1.340000033378601,1.3300000429153442,-2.222220063700145,,
+2011-09-13,1.4299999475479126,1.350000023841858,-0.7462679264300778,,
+2011-09-12,1.399999976158142,1.4299999475479126,-5.59440046436605,,
+2011-09-09,1.309999942779541,1.2899999618530271,2.1428551357619274,,
+2011-09-08,1.309999942779541,1.2999999523162842,-1.5267161679471672,,
+2011-09-07,1.340000033378601,1.309999942779541,-0.7633580839735752,,
+2011-09-06,1.2599999904632568,1.2999999523162842,-2.23881267550565,,
+2011-09-02,1.340000033378601,1.2999999523162842,3.174600171093715,,
+2011-09-01,1.3899999856948853,1.3600000143051147,-2.985080601935728,,
+2011-08-31,1.409999966621399,1.3600000143051147,-2.158271345216813,,
+2011-08-30,1.4299999475479126,1.399999976158142,-3.546095992902228,,
+2011-08-29,1.2899999618530271,1.399999976158142,-2.0979001741372687,,
+2011-08-26,1.25,1.2599999904632568,8.527133144027763,,
+2011-08-25,1.2799999713897705,1.2699999809265137,0.7999992370605469,,
+2011-08-24,1.2699999809265137,1.25,-0.7812492724042223,,
+2011-08-23,1.2599999904632568,1.25,-1.57480167140813,,
+2011-08-22,1.3799999952316284,1.2599999904632568,-0.7936500427734288,,
+2011-08-19,1.3799999952316284,1.340000033378601,-8.695652549493667,,
+2011-08-18,1.4900000095367432,1.409999966621399,-2.898547970379774,,
+2011-08-17,1.5,1.5099999904632568,-5.369130362637857,,
+2011-08-16,1.4500000476837158,1.5,0.6666660308837891,,
+2011-08-15,1.4199999570846558,1.4700000286102295,3.4482724601392922,,
+2011-08-12,1.3700000047683716,1.409999966621399,3.5211319039915216,,
+2011-08-11,1.340000033378601,1.3600000143051147,2.919705234584303,,
+2011-08-10,1.399999976158142,1.350000023841858,1.4925358528601556,,
+2011-08-09,1.3600000143051147,1.399999976158142,-3.571425226269879,,
+2011-08-08,1.1200000047683716,1.309999942779541,2.9411736347271384,,
+2011-08-05,1.5199999809265137,1.340000033378601,16.964280107343708,,
+2011-08-04,1.600000023841858,1.5,-11.842101960961466,,
+2011-08-03,1.5700000524520874,1.600000023841858,-6.2500013969838415,,
+2011-08-02,1.6299999952316284,1.559999942779541,1.9108261393313575,,
+2011-08-01,1.649999976158142,1.6399999856948853,-4.294481758089831,,
+2011-07-29,1.6299999952316284,1.6299999952316284,-0.6060600368335035,,
+2011-07-28,1.559999942779541,1.6200000047683716,0.0,,
+2011-07-27,1.659999966621399,1.5700000524520874,3.8461579608730645,,
+2011-07-26,1.6699999570846558,1.6699999570846558,-5.4216816854815075,,
+2011-07-25,1.659999966621399,1.6699999570846558,0.0,,
+2011-07-22,1.6699999570846558,1.6699999570846558,0.6024090761646119,,
+2011-07-21,1.690000057220459,1.6799999475479126,0.0,,
+2011-07-20,1.6799999475479126,1.659999966621399,-0.5917224457964548,,
+2011-07-19,1.7000000476837158,1.6399999856948853,-1.1904750923180183,,
+2011-07-18,1.6799999475479126,1.6699999570846558,-3.529415312110247,,
+2011-07-15,1.7100000381469729,1.7000000476837158,-0.5952375461590091,,
+2011-07-14,1.7100000381469729,1.7000000476837158,-0.5847947508874598,,
+2011-07-13,1.690000057220459,1.7100000381469729,-0.5847947508874598,,
+2011-07-12,1.649999976158142,1.6799999475479126,1.1834307839851697,,
+2011-07-11,1.809999942779541,1.7000000476837158,1.8181801105005106,,
+2011-07-08,1.8600000143051147,1.830000042915344,-6.077342462613727,,
+2011-07-07,1.809999942779541,1.8600000143051147,-1.6129016752173815,,
+2011-07-06,1.8600000143051147,1.7899999618530271,2.7624349782459507,,
+2011-07-05,1.7000000476837158,1.830000042915344,-3.7634436512754137,,
+2011-07-01,1.649999976158142,1.7100000381469729,7.647058328542743,,
+2011-06-30,1.6299999952316284,1.6299999952316284,3.6363674458065667,,
+2011-06-29,1.649999976158142,1.6200000047683716,0.0,7 Biotech Penny Stocks to Buy,"If you're looking to play biotech penny stocks, consider these seven picks: Acadia Pharmaceuticals Focusing on treatments for central nervous system disorders, Acadia Pharmaceuticals (NASDAQ: ACAD ) has experienced a 31% increase in stock value year-to-date. ACAD has more than doubled its 52-week low of 65 cents but, based on my fundamental and quatitative screens, remains an affordable stock for penny-stock investors, with more upside AEterna Zentaris, Inc. Oncology and endocrine therapy drug development company AEterna Zentaris, Inc. (NASDAQ: AEZS ) is up 27% year-to-date and 81% in the last 12 months. Of course, penny stocks by nature are aggressive, and biotech penny stocks are just as risky."
+2011-06-28,1.5700000524520874,1.600000023841858,-1.8181801105005106,,
+2011-06-27,1.6100000143051147,1.5700000524520874,1.9108261393313575,,
+2011-06-24,1.600000023841858,1.6200000047683716,-2.484469658237336,,
+2011-06-23,1.5700000524520874,1.6100000143051147,1.2499987892806712,,
+2011-06-22,1.600000023841858,1.600000023841858,2.5477681857751433,,
+2011-06-21,1.6299999952316284,1.600000023841858,0.0,,
+2011-06-20,1.5,1.6100000143051147,-1.8404890477013416,,
+2011-06-17,1.6399999856948853,1.5199999809265137,7.333334287007649,,
+2011-06-16,1.7000000476837158,1.6299999952316284,-7.317073525310204,,
+2011-06-15,1.75,1.7100000381469729,-4.117650028743462,,
+2011-06-14,1.75,1.7599999904632568,-2.285712105887264,,
+2011-06-13,1.7699999809265137,1.7400000095367432,0.5714280264718192,,
+2011-06-10,1.6399999856948853,1.75,-1.6949136561044988,,
+2011-06-09,1.659999966621399,1.649999976158142,6.707318003939286,,
+2011-06-08,1.649999976158142,1.659999966621399,-0.6024090761646119,,
+2011-06-07,1.7400000095367432,1.649999976158142,0.6060600368335035,,
+2011-06-06,1.8600000143051147,1.7100000381469729,-5.17241568306443,,
+2011-06-03,1.909999966621399,1.899999976158142,-8.064514785188374,,
+2011-06-02,1.940000057220459,1.919999957084656,-0.5235597192677354,,
+2011-06-01,1.899999976158142,1.919999957084656,-1.030932966283424,,
+2011-05-31,1.940000057220459,1.8899999856948853,1.0526305882884517,,
+2011-05-27,2.0199999809265137,1.940000057220459,-2.5773231984957508,,
+2011-05-26,1.8799999952316284,1.9900000095367432,-3.9603923000712657,,
+2011-05-25,1.870000004768372,1.8799999952316284,5.851064605538045,,
+2011-05-24,1.870000004768372,1.870000004768372,0.5347588469388824,,
+2011-05-23,2.0199999809265137,1.899999976158142,0.0,,
+2011-05-20,2.0199999809265137,2.0299999713897705,-5.940594351556933,,
+2011-05-19,2.049999952316284,2.0199999809265137,0.4950490375089082,,
+2011-05-18,2.0299999713897705,2.039999961853028,-1.4634132725648943,,
+2011-05-17,2.1700000762939453,2.049999952316284,0.4926103745908492,,
+2011-05-16,2.240000009536743,2.140000104904175,-5.529959435881885,,
+2011-05-13,2.380000114440918,2.2699999809265137,-4.464281437804522,,
+2011-05-12,2.299999952316284,2.369999885559082,-4.621854127105546,,
+2011-05-11,2.299999952316284,2.359999895095825,3.043475421480001,,
+2011-05-10,2.5,2.4600000381469727,2.6086932184114295,,
+2011-05-09,2.4200000762939453,2.4600000381469727,-1.5999984741210938,,
+2011-05-06,2.299999952316284,2.380000114440918,1.652890933552547,,
+2011-05-05,2.25,2.25,3.478267990573966,,
+2011-05-04,2.640000104904175,2.2799999713897705,0.0,,
+2011-05-03,2.809999942779541,2.7100000381469727,-13.636368151866849,,
+2011-05-02,2.799999952316284,2.8299999237060547,-3.5587155398178547,,
+2011-04-29,2.9800000190734863,2.75,1.0714275678809637,,
+2011-04-28,2.8399999141693115,2.940000057220459,-7.7181213960191775,,
+2011-04-27,2.9100000858306885,2.799999952316284,3.5211319039915216,,
+2011-04-26,2.859999895095825,2.890000104904175,-3.7800732051526267,,
+2011-04-25,2.2799999713897705,2.7300000190734863,1.0489584233828948,,
+2011-04-21,2.2300000190734863,2.240000009536743,19.73684444431896,,
+2011-04-20,1.9700000286102293,2.190000057220459,0.44843006178141653,,
+2011-04-19,1.909999966621399,1.9299999475479128,11.167513980465907,,
+2011-04-18,1.7599999904632568,1.909999966621399,1.0471194385354825,,
+2011-04-15,1.7400000095367432,1.7699999809265137,8.522725964257532,,
+2011-04-14,1.7300000190734863,1.75,1.724136277318624,,
+2011-04-13,1.75,1.7300000190734863,1.1560682489023788,,
+2011-04-12,1.830000042915344,1.7300000190734863,-1.1428560529436385,,
+2011-04-11,1.7300000190734863,1.809999942779541,-5.464482049003083,,
+2011-04-08,1.690000057220459,1.7300000190734863,4.624272995609515,,
+2011-04-07,1.6799999475479126,1.690000057220459,2.366861567970313,,
+2011-04-06,1.6299999952316284,1.6699999570846558,0.5952446419502754,,
+2011-04-05,1.659999966621399,1.6299999952316284,2.453985396935122,,
+2011-04-04,1.6699999570846558,1.6699999570846558,-1.8072272284938358,,
+2011-04-01,1.7400000095367432,1.649999976158142,0.0,,
+2011-03-31,1.600000023841858,1.6200000047683716,-5.17241568306443,,
+2011-03-30,1.649999976158142,1.590000033378601,1.2499987892806712,,
+2011-03-29,1.7100000381469729,1.649999976158142,-3.6363602210010213,,
+2011-03-28,1.649999976158142,1.7000000476837158,-3.508775476628021,,
+2011-03-25,1.6200000047683716,1.6200000047683716,3.0303074089730497,,
+2011-03-24,1.600000023841858,1.600000023841858,0.0,,
+2011-03-23,1.5700000524520874,1.5700000524520874,0.0,,
+2011-03-22,1.5399999618530271,1.559999942779541,0.0,,
+2011-03-21,1.5,1.5199999809265137,1.2987000923330303,,
+2011-03-18,1.5399999618530271,1.4700000286102295,1.3333320617675781,,
+2011-03-17,1.5499999523162842,1.4700000286102295,-4.545450323165541,,
+2011-03-16,1.5399999618530271,1.5399999618530271,-5.161285559170802,,
+2011-03-15,1.4600000381469729,1.5299999713897705,0.0,,
+2011-03-14,1.6100000143051147,1.5,4.794515850262669,,
+2011-03-11,1.659999966621399,1.6399999856948853,-6.832298964456307,,
+2011-03-10,1.830000042915344,1.7300000190734863,-1.2048181523292238,,
+2011-03-09,1.8600000143051147,1.820000052452088,-5.464482049003083,,
+2011-03-08,1.7799999713897705,1.8600000143051147,-2.1505355669564565,,
+2011-03-07,1.7300000190734863,1.75,4.494384505685279,,
+2011-03-04,1.6200000047683716,1.7400000095367432,1.1560682489023788,,
+2011-03-03,1.5,1.6100000143051147,7.4074076799480775,,
+2011-03-02,1.399999976158142,1.4800000190734863,7.333334287007649,,
+2011-03-01,1.5,1.4299999475479126,5.714288876981205,,
+2011-02-28,1.5800000429153442,1.5099999904632568,-4.666670163472494,,
+2011-02-25,1.5199999809265137,1.559999942779541,-4.430382946251475,,
+2011-02-24,1.4900000095367432,1.5,2.6315764707211,,
+2011-02-23,1.5700000524520874,1.5299999713897705,0.671140295251806,,
+2011-02-22,1.659999966621399,1.5700000524520874,-2.5477757787232687,,
+2011-02-18,1.7100000381469729,1.6699999570846558,-5.4216816854815075,,
+2011-02-17,1.6799999475479126,1.7000000476837158,-2.339185974853127,,
+2011-02-16,1.7000000476837158,1.7100000381469729,1.1904821881092846,,
+2011-02-15,1.7400000095367432,1.690000057220459,0.5882347166332287,,
+2011-02-14,1.7000000476837158,1.7300000190734863,-2.8735604621977067,,
+2011-02-11,1.75,1.7100000381469729,1.7647041498996467,,
+2011-02-10,1.7300000190734863,1.75,-2.285712105887264,,
+2011-02-09,1.75,1.7000000476837158,1.1560682489023788,,
+2011-02-08,1.870000004768372,1.75,-2.857140132359096,,
+2011-02-07,1.7999999523162842,1.830000042915344,-6.417112538095199,,
+2011-02-04,1.690000057220459,1.7799999713897705,1.6666717440994918,,
+2011-02-03,1.6699999570846558,1.7000000476837158,5.325438527933205,,
+2011-02-02,1.6799999475479126,1.7100000381469729,1.7964126568860321,,
+2011-02-01,1.6799999475479126,1.7200000286102295,1.7857197342683069,,
+2011-01-31,1.690000057220459,1.7000000476837158,2.3809572804273027,,
+2011-01-28,1.7100000381469729,1.7100000381469729,0.5917153919925783,,
+2011-01-27,1.7899999618530271,1.75,0.0,,
+2011-01-26,1.7200000286102295,1.75,-2.234634788015232,,
+2011-01-25,1.7400000095367432,1.7100000381469729,1.7441843541136839,,
+2011-01-24,1.7000000476837158,1.7400000095367432,-1.7241362773186113,,
+2011-01-21,1.6299999952316284,1.6699999570846558,2.3529388665328623,,
+2011-01-20,1.559999942779541,1.6100000143051147,2.453985396935122,,
+2011-01-19,1.6200000047683716,1.600000023841858,3.205132907664455,,
+2011-01-18,1.559999942779541,1.6200000047683716,-1.2345667202249964,,
+2011-01-14,1.6799999475479126,1.6299999952316284,3.8461579608730645,,
+2011-01-13,1.7000000476837158,1.6399999856948853,-2.9761877307950457,,
+2011-01-12,1.6399999856948853,1.7000000476837158,-3.529415312110247,,
+2011-01-11,1.5,1.590000033378601,3.6585403970846935,,
+2011-01-10,1.2000000476837158,1.5700000524520874,6.000002225240072,,
+2011-01-07,1.2000000476837158,1.149999976158142,30.83333250549108,,
+2011-01-06,1.2100000381469729,1.190000057220459,-4.166672461562456,,
+2011-01-05,1.2000000476837158,1.2000000476837158,-1.652890933552565,,
+2011-01-04,1.2200000286102295,1.1799999475479126,0.0,,
+2011-01-03,1.190000057220459,1.2200000286102295,-3.278695092153664,,
+2010-12-31,1.190000057220459,1.2000000476837158,2.521005877919275,,
+2010-12-30,1.059999942779541,1.2300000190734863,0.8403352926397583,,
+2010-12-29,1.1100000143051147,1.059999942779541,16.03774391234113,,
+2010-12-28,1.340000033378601,1.149999976158142,-4.504510890198043,,
+2010-12-27,1.409999966621399,1.2999999523162842,-14.179108394602311,,
+2010-12-23,1.1200000047683716,1.440000057220459,-7.801419638944644,,
+2010-12-22,0.9100000262260436,1.100000023841858,28.57143313300851,,
+2010-12-21,0.8399999737739563,0.9200000166893004,20.879120015389802,,
+2010-12-20,0.7799999713897705,0.8299999833106995,9.523814930126665,,
+2010-12-17,0.7099999785423279,0.7699999809265137,6.410258173707503,,
+2010-12-16,0.6899999976158142,0.7099999785423279,8.45070481655075,,
+2010-12-15,0.699999988079071,0.6899999976158142,2.898547970379774,,
+2010-12-14,0.6800000071525574,0.699999988079071,-1.4285700905079517,,
+2010-12-13,0.699999988079071,0.699999988079071,2.9411736347271384,,
+2010-12-10,0.7099999785423279,0.699999988079071,0.0,,
+2010-12-09,0.699999988079071,0.7099999785423279,-1.408449403588351,,
+2010-12-08,0.7300000190734863,0.7300000190734863,1.4285700905079517,,
+2010-12-07,0.7099999785423279,0.7300000190734863,0.0,,
+2010-12-06,0.7400000095367432,0.7300000190734863,2.816907202197346,,
+2010-12-03,0.6899999976158142,0.7400000095367432,-1.3513500451867637,,
+2010-12-02,0.6700000166893005,0.699999988079071,7.246378564303781,,
+2010-12-01,0.7099999785423279,0.6800000071525574,4.477607558580467,,
+2010-11-30,0.6899999976158142,0.6700000166893005,-4.225348210765052,,
+2010-11-29,0.699999988079071,0.6800000071525574,-2.898547970379774,,
+2010-11-26,0.7099999785423279,0.699999988079071,-2.8571401810159034,,
+2010-11-24,0.699999988079071,0.6899999976158142,-1.408449403588351,,
+2010-11-23,0.6800000071525574,0.699999988079071,-1.4285700905079517,,
+2010-11-22,0.7099999785423279,0.6800000071525574,2.9411736347271384,,
+2010-11-19,0.6899999976158142,0.699999988079071,-4.225348210765052,,
+2010-11-18,0.699999988079071,0.6899999976158142,1.449273985189887,,
+2010-11-17,0.699999988079071,0.699999988079071,-1.4285700905079517,,
+2010-11-16,0.7200000286102295,0.7200000286102295,0.0,,
+2010-11-15,0.6499999761581421,0.6800000071525574,0.0,,
+2010-11-12,0.6800000071525574,0.6600000262260437,4.615389553047677,,
+2010-11-11,0.7099999785423279,0.699999988079071,-2.9411736347271384,,
+2010-11-10,0.7099999785423279,0.7300000190734863,-1.408449403588351,,
+2010-11-09,0.7200000286102295,0.7400000095367432,2.816907202197346,,
+2010-11-08,0.7200000286102295,0.7200000286102295,2.7777750183035925,,
+2010-11-05,0.7599999904632568,0.7400000095367432,0.0,,
+2010-11-04,0.75,0.7599999904632568,-2.6315764707211,,
+2010-11-03,0.7200000286102295,0.7400000095367432,1.3333320617675781,,
+2010-11-02,0.7900000214576721,0.7200000286102295,2.7777750183035925,,
+2010-11-01,0.800000011920929,0.7900000214576721,-8.860758347611412,,
+2010-10-29,0.7599999904632568,0.7599999904632568,-1.2499987892806712,,
+2010-10-28,0.8799999952316284,0.7599999904632568,0.0,,
+2010-10-27,0.8999999761581421,0.8799999952316284,-13.636364252114102,,
+2010-10-26,0.8700000047683716,0.8999999761581421,-2.222220161814694,,
+2010-10-25,0.8700000047683716,0.8700000047683716,3.448272554637248,,
+2010-10-22,0.8999999761581421,0.8700000047683716,0.0,,
+2010-10-21,0.8799999952316284,0.8999999761581421,-3.333330242722041,,
+2010-10-20,0.8799999952316284,0.8799999952316284,2.272725117600642,,
+2010-10-19,0.8700000047683716,0.8799999952316284,0.0,,
+2010-10-18,0.8899999856948853,0.8899999856948853,1.1494241848790827,,
+2010-10-15,0.8899999856948853,0.8799999952316284,0.0,,
+2010-10-14,0.8899999856948853,0.8899999856948853,-1.1235944521335182,,
+2010-10-13,0.8999999761581421,0.8999999761581421,0.0,,
+2010-10-12,0.8899999856948853,0.8999999761581421,0.0,,
+2010-10-11,0.9100000262260436,0.8999999761581421,1.1235944521335182,,
+2010-10-08,0.8799999952316284,0.8999999761581421,-1.0989065691979982,,
+2010-10-07,0.8999999761581421,0.8799999952316284,2.272725117600642,,
+2010-10-06,0.9100000262260436,0.8999999761581421,-2.222220161814694,,
+2010-10-05,0.9200000166893004,0.9100000262260436,-1.0989065691979982,,
+2010-10-04,0.9399999976158142,0.9100000262260436,-1.086955465418649,,
+2010-10-01,0.9200000166893004,0.9200000166893004,-3.1914863261554878,,
+2010-09-30,0.959999978542328,0.9100000262260436,0.0,,
+2010-09-29,0.949999988079071,0.949999988079071,-5.208328482694838,,
+2010-09-28,0.949999988079071,0.9399999976158142,0.0,,
+2010-09-27,1.0,0.959999978542328,-1.0526305882884401,,
+2010-09-24,0.9800000190734864,0.9800000190734864,-4.000002145767201,,
+2010-09-23,0.9800000190734864,0.9700000286102296,0.0,,
+2010-09-22,1.0199999809265137,1.0,-1.0204071702683277,,
+2010-09-21,1.059999942779541,1.0199999809265137,-1.960782480441495,,
+2010-09-20,1.0499999523162842,1.0700000524520874,-3.7735815105932082,,
+2010-09-17,1.0700000524520874,1.0299999713897705,1.9047715280065776,,
+2010-09-16,1.059999942779541,1.0499999523162842,-3.738325149671712,,
+2010-09-15,1.0800000429153442,1.059999942779541,-0.9433953776483021,,
+2010-09-14,1.0700000524520874,1.100000023841858,-1.8518610500991368,,
+2010-09-13,1.0299999713897705,1.0700000524520874,2.80373550646287,,
+2010-09-10,1.0399999618530271,1.0199999809265137,3.883503123630685,,
+2010-09-09,1.0399999618530271,1.0399999618530271,-1.9230751596258084,,
+2010-09-08,1.0199999809265137,1.0199999809265137,0.0,,
+2010-09-07,1.0299999713897705,1.0099999904632568,0.0,,
+2010-09-03,1.0499999523162842,1.0299999713897705,-1.9417457749564655,,
+2010-09-02,1.0,1.0399999618530271,-1.9047601747403906,,
+2010-09-01,1.0199999809265137,1.0199999809265137,3.999996185302712,,
+2010-08-31,1.0099999904632568,1.0099999904632568,0.0,,
+2010-08-30,1.0299999713897705,1.0099999904632568,0.0,,
+2010-08-27,1.0099999904632568,1.0299999713897705,-1.9417457749564655,,
+2010-08-26,1.0399999618530271,1.0099999904632568,1.9801961500356329,,
+2010-08-25,1.0399999618530271,1.0399999618530271,-2.8846127394387238,,
+2010-08-24,1.0199999809265137,1.059999942779541,0.0,,
+2010-08-23,1.0299999713897705,1.0299999713897705,3.92156496088299,,
+2010-08-20,1.0399999618530271,1.0499999523162842,0.0,,
+2010-08-19,1.0499999523162842,1.0700000524520874,0.9615375798129364,,
+2010-08-18,1.0199999809265137,1.0399999618530271,1.9047715280065776,,
+2010-08-17,1.0499999523162842,1.0099999904632568,1.9607824804414733,,
+2010-08-16,1.0399999618530271,1.0199999809265137,-3.809520349480781,,
+2010-08-13,1.0399999618530271,1.0700000524520874,-1.9230751596258084,,
+2010-08-12,1.0499999523162842,1.0499999523162842,2.8846242018708743,,
+2010-08-11,1.1100000143051147,1.100000023841858,0.0,,
+2010-08-10,1.1299999952316284,1.1100000143051147,-0.9009000301245093,,
+2010-08-09,1.2000000476837158,1.159999966621399,-1.7699098239742965,,
+2010-08-06,1.1200000047683716,1.2000000476837158,-3.3333399560713786,,
+2010-08-05,1.2100000381469729,1.149999976158142,7.1428609441737585,,
+2010-08-04,1.2000000476837158,1.190000057220459,-4.958682652664749,,
+2010-08-03,1.2200000286102295,1.1799999475479126,-0.8333325054910776,,
+2010-08-02,1.2699999809265137,1.2100000381469729,-3.278695092153664,,
+2010-07-30,1.2000000476837158,1.2200000286102295,-4.724405014224374,,
+2010-07-29,1.149999976158142,1.2999999523162842,1.6666650109821552,,
+2010-07-28,1.1100000143051147,1.0800000429153442,13.043476458082539,,
+2010-07-27,1.1200000047683716,1.100000023841858,-2.7027000903735274,,
+2010-07-26,1.0499999523162842,1.100000023841858,-1.785712575121809,,
+2010-07-23,1.0299999713897705,1.059999942779541,4.761911790117163,,
+2010-07-22,1.090000033378601,1.059999942779541,2.9126186624346984,,
+2010-07-21,1.059999942779541,1.0800000429153442,-2.7523018055394695,,
+2010-07-20,1.0299999713897705,1.0499999523162842,1.8868020014566025,,
+2010-07-19,1.0700000524520874,1.0399999618530271,1.9417457749564655,,
+2010-07-16,1.0499999523162842,1.0499999523162842,-2.8037466475174426,,
+2010-07-15,1.059999942779541,1.090000033378601,0.0,,
+2010-07-14,1.1100000143051147,1.0700000524520874,2.830197379104905,,
+2010-07-13,1.059999942779541,1.090000033378601,-3.603600120498037,,
+2010-07-12,1.0800000429153442,1.059999942779541,2.830197379104905,,
+2010-07-09,1.0700000524520874,1.0499999523162842,-1.8518610500991368,,
+2010-07-08,1.090000033378601,1.0399999618530271,-1.8691681453631321,,
+2010-07-07,1.0499999523162842,1.059999942779541,-4.587162384811314,,
+2010-07-06,1.1399999856948853,1.0499999523162842,0.9523800873701953,,
+2010-07-02,1.0499999523162842,1.1399999856948853,-7.894739869118656,,
+2010-07-01,1.0700000524520874,1.0199999809265137,8.571432139597944,,
+2010-06-30,1.1299999952316284,1.090000033378601,-4.672903651826002,,
+2010-06-29,1.190000057220459,1.1299999952316284,-3.539819647948593,,
+2010-06-28,1.2000000476837158,1.2100000381469729,-5.042021773425426,,
+2010-06-25,1.2200000286102295,1.2200000286102295,0.8333325054910962,,
+2010-06-24,1.2300000190734863,1.2200000286102295,0.0,,
+2010-06-23,1.2400000095367432,1.2300000190734863,-0.8130073421291051,,
+2010-06-22,1.2699999809265137,1.2200000286102295,-0.8064508376086847,,
+2010-06-21,1.2699999809265137,1.2300000190734863,-3.9370041785203256,,
+2010-06-18,1.2999999523162842,1.2699999809265137,-3.14960334281626,,
+2010-06-17,1.3300000429153442,1.309999942779541,-2.307690191550995,,
+2010-06-16,1.2799999713897705,1.3300000429153442,-1.5037668789816911,,
+2010-06-15,1.25,1.2999999523162842,3.906255675247066,,
+2010-06-14,1.2999999523162842,1.2699999809265137,3.9999961853027344,,
+2010-06-11,1.25,1.2999999523162842,-2.307690191550995,,
+2010-06-10,1.1799999475479126,1.2699999809265137,3.9999961853027344,,
+2010-06-09,1.2100000381469729,1.1799999475479126,7.627121811795395,,
+2010-06-08,1.2699999809265137,1.2100000381469729,-2.4793462523359286,,
+2010-06-07,1.2899999618530271,1.2799999713897705,-4.724405014224374,,
+2010-06-04,1.340000033378601,1.2899999618530271,-0.7751930820906441,,
+2010-06-03,1.350000023841858,1.3300000429153442,-3.7313485283658214,,
+2010-06-02,1.3200000524520874,1.350000023841858,-1.4814800424667633,,
+2010-06-01,1.2999999523162842,1.3300000429153442,2.2727250149756664,,
+2010-05-28,1.2999999523162842,1.340000033378601,2.307699361496682,,
+2010-05-27,1.2999999523162842,1.2899999618530271,3.0769294253470134,,
+2010-05-26,1.350000023841858,1.2699999809265137,-0.7692300638503489,,
+2010-05-25,1.2899999618530271,1.2999999523162842,-5.925929000184642,,
+2010-05-24,1.3300000429153442,1.3700000047683716,0.7751930820906785,,
+2010-05-21,1.25,1.309999942779541,3.0075158317550055,,
+2010-05-20,1.350000023841858,1.2999999523162842,4.799995422363281,,
+2010-05-19,1.4199999570846558,1.3799999952316284,-3.703708936484497,,
+2010-05-18,1.5,1.4199999570846558,-2.816898807176702,,
+2010-05-17,1.4800000190734863,1.4800000190734863,-5.333336194356283,,
+2010-05-14,1.4800000190734863,1.4500000476837158,0.0,,
+2010-05-13,1.4900000095367432,1.4500000476837158,-2.0270250677801456,,
+2010-05-12,1.5700000524520874,1.4800000190734863,-2.684561181007224,,
+2010-05-11,1.5499999523162842,1.5499999523162842,-5.732486010942198,,
+2010-05-10,1.5,1.5700000524520874,0.0,,
+2010-05-07,1.5,1.3899999856948853,4.666670163472494,,
+2010-05-06,1.590000033378601,1.4800000190734863,-7.333334287007649,,
+2010-05-05,1.5499999523162842,1.5800000429153442,-6.918239748170006,,
+2010-05-04,1.649999976158142,1.5700000524520874,1.9354897756111937,,
+2010-05-03,1.659999966621399,1.6699999570846558,-4.848480294668028,,
+2010-04-30,1.649999976158142,1.659999966621399,0.6024090761646119,,
+2010-04-29,1.590000033378601,1.590000033378601,0.6060600368335035,,
+2010-04-28,1.6100000143051147,1.590000033378601,0.0,,
+2010-04-27,1.6799999475479126,1.6200000047683716,-1.242234829118668,,
+2010-04-26,1.7200000286102295,1.649999976158142,-3.5714252769540553,,
+2010-04-23,1.7200000286102295,1.7000000476837158,-4.069770423704462,,
+2010-04-22,1.7000000476837158,1.7599999904632568,-1.1627895694091224,,
+2010-04-21,1.75,1.690000057220459,3.5294082997992935,,
+2010-04-20,1.6699999570846558,1.7200000286102295,-3.428568158830915,,
+2010-04-19,1.7300000190734863,1.6699999570846558,2.994016335956057,,
+2010-04-16,1.7699999809265137,1.7000000476837158,-3.468211637417439,,
+2010-04-15,1.7699999809265137,1.7699999809265137,-3.954798530910498,,
+2010-04-14,1.940000057220459,1.7699999809265137,0.0,,
+2010-04-13,1.5299999713897705,1.7599999904632568,-8.762890272153571,,
+2010-04-12,1.5499999523162842,1.5299999713897705,15.032681266298752,,
+2010-04-09,1.5499999523162842,1.5299999713897705,-1.2903213897927004,,
+2010-04-08,1.5199999809265137,1.5399999618530271,-1.2903213897927004,,
+2010-04-07,1.6100000143051147,1.5399999618530271,1.3157882353605355,,
+2010-04-06,1.5700000524520874,1.590000033378601,-4.347829306218984,,
+2010-04-05,1.4800000190734863,1.5499999523162842,1.2738840928875717,,
+2010-04-01,1.5299999713897705,1.5099999904632568,4.7297251581536734,,
+2010-03-31,1.559999942779541,1.5099999904632568,-1.30718832029433,,
+2010-03-30,1.5800000429153442,1.5399999618530271,-3.205125266043049,,
+2010-03-29,1.5800000429153442,1.5800000429153442,-2.531650631382945,,
+2010-03-26,1.6799999475479126,1.5499999523162842,0.0,,
+2010-03-25,1.6399999856948853,1.6399999856948853,-7.738095195858385,,
+2010-03-24,1.6100000143051147,1.600000023841858,0.0,,
+2010-03-23,1.5700000524520874,1.5800000429153442,-0.621117414559334,,
+2010-03-22,1.6299999952316284,1.5700000524520874,0.6369420464437858,,
+2010-03-19,1.6299999952316284,1.6299999952316284,-3.680978095402683,,
+2010-03-18,1.590000033378601,1.6100000143051147,0.0,,
+2010-03-17,1.6699999570846558,1.5700000524520874,1.2578604092237398,,
+2010-03-16,1.7200000286102295,1.6399999856948853,-5.988018395350124,,
+2010-03-15,1.5499999523162842,1.690000057220459,-4.651165208409023,,
+2010-03-12,1.409999966621399,1.5499999523162842,9.03226511039319,,
+2010-03-11,1.3899999856948853,1.409999966621399,9.929077234685982,,
+2010-03-10,1.3799999952316284,1.3700000047683716,1.4388475634778752,,
+2010-03-09,1.2999999523162842,1.409999966621399,-0.7246369925949435,,
+2010-03-08,1.3300000429153442,1.3600000143051147,8.461539872299337,,
+2010-03-05,1.3600000143051147,1.340000033378601,2.255636873816254,,
+2010-03-04,1.399999976158142,1.350000023841858,-1.4705868173635692,,
+2010-03-03,1.2999999523162842,1.3899999856948853,-3.571425226269879,,
+2010-03-02,1.2899999618530271,1.3300000429153442,6.923079744598673,,
+2010-03-01,1.2899999618530271,1.3300000429153442,3.1007815693931335,,
+2010-02-26,1.2799999713897705,1.309999942779541,3.1007815693931335,,
+2010-02-25,1.2799999713897705,1.2699999809265137,2.343747817212667,,
+2010-02-24,1.3200000524520874,1.2699999809265137,-0.7812492724042223,,
+2010-02-23,1.2999999523162842,1.309999942779541,-3.7878840559658693,,
+2010-02-22,1.2899999618530271,1.309999942779541,0.7692300638503318,,
+2010-02-19,1.309999942779541,1.3200000524520874,1.55038616418134,,
+2010-02-18,1.2999999523162842,1.340000033378601,0.7633671839197399,,
+2010-02-17,1.350000023841858,1.3300000429153442,3.0769294253470134,,
+2010-02-16,1.3700000047683716,1.340000033378601,-1.4814800424667633,,
+2010-02-12,1.2799999713897705,1.3899999856948853,-2.189778925938227,,
+2010-02-11,1.2799999713897705,1.2799999713897705,8.593751309672399,,
+2010-02-10,1.2599999904632568,1.2799999713897705,0.0,,
+2010-02-09,1.2799999713897705,1.2999999523162842,1.5873000855468575,,
+2010-02-08,1.3799999952316284,1.2699999809265137,1.5624985448084445,,
+2010-02-05,1.3300000429153442,1.3799999952316284,-7.971015556898724,,
+2010-02-04,1.4600000381469729,1.3600000143051147,3.759394789693757,,
+2010-02-03,1.4199999570846558,1.4600000381469729,-6.849316522537754,,
+2010-02-02,1.3200000524520874,1.399999976158142,2.816907202197362,,
+2010-02-01,1.25,1.350000023841858,6.06060003993511,,
+2010-01-29,1.2999999523162842,1.25,8.000001907348633,,
+2010-01-28,1.2400000095367432,1.2999999523162842,-3.8461503192516595,,
+2010-01-27,1.2799999713897705,1.2699999809265137,4.838705025652108,,
+2010-01-26,1.2699999809265137,1.25,-0.7812492724042223,,
+2010-01-25,1.3300000429153442,1.2999999523162842,-1.57480167140813,,
+2010-01-22,1.3600000143051147,1.340000033378601,-2.255645836920442,,
+2010-01-21,1.3899999856948853,1.3799999952316284,-1.4705868173635692,,
+2010-01-20,1.3799999952316284,1.3700000047683716,-0.7194237817389376,,
+2010-01-19,1.4299999475479126,1.3899999856948853,-0.7246369925949435,,
+2010-01-15,1.5199999809265137,1.4500000476837158,-2.797200232183025,,
+2010-01-14,1.399999976158142,1.5499999523162842,-4.6052588237619245,,
+2010-01-13,1.440000057220459,1.399999976158142,10.714284193759035,,
+2010-01-12,1.4800000190734863,1.409999966621399,-2.777783296726149,,
+2010-01-11,1.4700000286102295,1.4700000286102295,-4.7297332128352965,,
+2010-01-08,1.3899999856948853,1.440000057220459,0.0,,
+2010-01-07,1.309999942779541,1.3700000047683716,3.5971274849026575,,
+2010-01-06,1.3600000143051147,1.3300000429153442,4.580157603787615,,
+2010-01-05,1.3600000143051147,1.340000033378601,-2.2058802260453536,,
+2010-01-04,1.3200000524520874,1.3600000143051147,-1.4705868173635692,,
+2009-12-31,1.2599999904632568,1.3200000524520874,3.030300019967555,,
+2009-12-30,1.3200000524520874,1.2899999618530271,4.76190971769537,,
+2009-12-29,1.3300000429153442,1.350000023841858,-2.2727340459821086,,
+2009-12-28,1.3700000047683716,1.3300000429153442,1.5037579158775027,,
+2009-12-24,1.3200000524520874,1.350000023841858,-2.919705234584303,,
+2009-12-23,1.3799999952316284,1.350000023841858,2.2727250149756664,,
+2009-12-22,1.3899999856948853,1.3799999952316284,-2.1739109777848307,,
+2009-12-21,1.340000033378601,1.3700000047683716,-0.7194237817389376,,
+2009-12-18,1.350000023841858,1.340000033378601,2.2388037792902336,,
+2009-12-17,1.399999976158142,1.2999999523162842,-0.7407400212333817,,
+2009-12-16,1.340000033378601,1.399999976158142,-7.142858967489158,,
+2009-12-15,1.1799999475479126,1.340000033378601,4.477607558580467,,
+2009-12-14,1.1799999475479126,1.1799999475479126,13.559329910410172,,
+2009-12-11,1.2100000381469729,1.1799999475479126,0.0,,
+2009-12-10,1.2000000476837158,1.1799999475479126,-2.4793462523359286,,
+2009-12-09,1.2100000381469729,1.190000057220459,-1.666674945089223,,
+2009-12-08,1.2000000476837158,1.190000057220459,-1.652890933552565,,
+2009-12-07,1.2000000476837158,1.2100000381469729,-0.8333325054910776,,
+2009-12-04,1.2000000476837158,1.2100000381469729,0.8333325054910962,,
+2009-12-03,1.2000000476837158,1.1799999475479126,0.8333325054910962,,
+2009-12-02,1.190000057220459,1.2100000381469729,-1.666674945089223,,
+2009-12-01,1.2100000381469729,1.2300000190734863,1.6806705852795354,,
+2009-11-30,1.309999942779541,1.2300000190734863,1.6528909335525284,,
+2009-11-27,1.2400000095367432,1.2899999618530271,-6.1068646717886015,,
+2009-11-25,1.3300000429153442,1.350000023841858,4.032254188043406,,
+2009-11-24,1.309999942779541,1.3200000524520874,1.5037579158775027,,
+2009-11-23,1.3300000429153442,1.340000033378601,0.7633671839197399,,
+2009-11-20,1.3700000047683716,1.3300000429153442,0.7518789579387514,,
+2009-11-19,1.350000023841858,1.4199999570846558,-2.919705234584303,,
+2009-11-18,1.3799999952316284,1.3600000143051147,5.1851801486336715,,
+2009-11-17,1.4500000476837158,1.399999976158142,-1.449273985189887,,
+2009-11-16,1.4299999475479126,1.4500000476837158,-3.448280681469336,,
+2009-11-13,1.4500000476837158,1.4500000476837158,1.3986084524057727,,
+2009-11-12,1.4700000286102295,1.3899999856948853,0.0,,
+2009-11-11,1.559999942779541,1.5099999904632568,-5.442179684239737,,
+2009-11-10,1.6299999952316284,1.5800000429153442,-3.205125266043049,,
+2009-11-09,1.399999976158142,1.3899999856948853,-3.0674817461689026,,
+2009-11-06,1.3300000429153442,1.3300000429153442,-0.7142850452539758,,
+2009-11-05,1.340000033378601,1.399999976158142,0.0,,
+2009-11-04,1.2899999618530271,1.2799999713897705,4.477607558580467,,
+2009-11-03,1.2400000095367432,1.309999942779541,-0.7751930820906441,,
+2009-11-02,1.2999999523162842,1.309999942779541,5.645155863260793,,
+2009-10-30,1.399999976158142,1.2999999523162842,0.7692300638503318,,
+2009-10-29,1.3899999856948853,1.3600000143051147,-7.142858967489158,,
+2009-10-28,1.4600000381469729,1.3200000524520874,-2.158271345216813,,
+2009-10-27,1.4900000095367432,1.4800000190734863,-9.589039865545002,,
+2009-10-26,1.5700000524520874,1.5,-0.671140295251806,,
+2009-10-23,1.6100000143051147,1.600000023841858,-4.458601918054626,,
+2009-10-22,1.6200000047683716,1.6200000047683716,-0.621117414559334,,
+2009-10-21,1.6200000047683716,1.659999966621399,0.0,,
+2009-10-20,1.7100000381469729,1.649999976158142,2.4691334404499927,,
+2009-10-19,1.7400000095367432,1.7400000095367432,-3.508775476628021,,
+2009-10-16,1.809999942779541,1.7799999713897705,0.0,,
+2009-10-15,1.850000023841858,1.820000052452088,-1.6574570352582891,,
+2009-10-14,1.850000023841858,1.8899999856948853,-1.6216200542240808,,
+2009-10-13,1.7699999809265137,1.7999999523162842,2.162160072298822,,
+2009-10-12,1.7400000095367432,1.7200000286102295,1.6949136561044988,,
+2009-10-09,1.7899999618530271,1.7699999809265137,-1.1494241848790827,,
+2009-10-08,1.850000023841858,1.7899999618530271,-1.1173173940076098,,
+2009-10-07,1.809999942779541,1.820000052452088,-3.2432465521935434,,
+2009-10-06,1.8799999952316284,1.899999976158142,0.5524922645682687,,
+2009-10-05,1.6200000047683716,1.649999976158142,1.0638287753851585,,
+2009-10-02,1.5099999904632568,1.649999976158142,1.8518500803374947,,
+2009-10-01,1.6399999856948853,1.5800000429153442,9.271522290005729,,
+2009-09-30,1.7200000286102295,1.7100000381469729,-3.6585331282255105,,
+2009-09-29,1.7999999523162842,1.7300000190734863,-0.5813947847045484,,
+2009-09-28,1.75,1.7999999523162842,-3.8888852831757146,,
+2009-09-25,1.7699999809265137,1.75,2.857140132359096,,
+2009-09-24,1.850000023841858,1.809999942779541,-1.1299424374029994,,
+2009-09-23,1.8799999952316284,1.850000023841858,-2.1621665160441204,,
+2009-09-22,1.8899999856948853,1.909999966621399,-1.595743163077738,,
+2009-09-21,1.940000057220459,1.899999976158142,1.0582000570312384,,
+2009-09-18,1.950000047683716,1.940000057220459,-2.0618597877583125,,
+2009-09-17,1.950000047683716,1.919999957084656,-0.5128200112166882,,
+2009-09-16,1.8799999952316284,1.940000057220459,-1.5384661469467809,,
+2009-09-15,1.8899999856948853,1.8600000143051147,3.1914926670751487,,
+2009-09-14,1.9299999475479128,1.8899999856948853,-1.5873000855468575,,
+2009-09-11,1.9700000286102293,1.9299999475479128,-2.072536939902407,,
+2009-09-10,1.9600000381469729,1.950000047683716,-2.030460938141976,,
+2009-09-09,1.9800000190734863,1.940000057220459,-0.5102035851341639,,
+2009-09-08,2.009999990463257,1.9700000286102293,-2.020200074126503,,
+2009-09-04,2.049999952316284,2.0299999713897705,-1.9900478628265332,,
+2009-09-03,2.2100000381469727,2.0299999713897705,-0.9756088483765962,,
+2009-09-02,2.150000095367432,2.150000095367432,-8.144799260190398,,
+2009-09-01,1.7200000286102295,2.0,0.0,,
+2009-08-31,5.860000133514404,5.840000152587891,16.27906783327278,,
+2009-08-28,6.130000114440918,5.980000019073486,-0.34129659506541904,,
+2009-08-27,6.139999866485596,6.050000190734863,-2.4469835655315038,,
+2009-08-26,6.079999923706055,6.150000095367432,-1.4657927965435984,,
+2009-08-25,6.289999961853027,6.039999961853027,1.1513186272987395,,
+2009-08-24,5.75,6.230000019073486,-3.974562822196747,,
+2009-08-21,5.789999961853027,5.639999866485596,8.347826418669326,,
+2009-08-20,5.809999942779541,5.730000019073486,-2.5906752393039003,,
+2009-08-19,5.659999847412109,5.800000190734863,-1.3769350171074566,,
+2009-08-18,5.75,5.75,2.4735043656717677,,
+2009-08-17,5.769999980926514,5.730000019073486,0.0,,
+2009-08-14,6.199999809265137,6.21999979019165,-0.693240242378725,,
+2009-08-13,5.389999866485596,6.110000133514404,0.3225803474481751,,
+2009-08-12,5.480000019073486,5.289999961853027,13.358075785969644,,
+2009-08-11,5.5,5.380000114440918,-3.467154316772843,,
+2009-08-10,4.639999866485596,5.360000133514404,-2.1818161010742188,,
+2009-08-07,4.5,4.619999885559082,15.517247580745028,,
+2009-08-06,4.409999847412109,4.369999885559082,2.6666641235351562,,
+2009-08-05,4.929999828338623,4.739999771118164,-0.9070286448309121,,
+2009-08-04,4.769999980926514,4.900000095367432,-3.8539566701057617,,
+2009-08-03,4.400000095367432,4.670000076293945,2.7253692863886982,,
+2009-07-31,4.510000228881836,4.070000171661377,6.136363069873223,,
+2009-07-30,4.53000020980835,4.5,-9.756098334601376,,
+2009-07-29,4.239999771118164,4.389999866485596,-0.6622562564874324,,
+2009-07-28,4.590000152587891,4.380000114440918,3.5377382892611315,,
+2009-07-27,4.139999866485596,4.400000095367432,-4.575164077686847,,
+2009-07-24,2.5999999046325684,3.4100000858306885,6.28019896779725,,
+2009-07-23,2.470000028610229,2.5999999046325684,31.153854265721183,,
+2009-07-22,2.400000095367432,2.4200000762939453,5.263152814434787,,
+2009-07-21,2.4200000762939453,2.440000057220459,0.8333325054910591,,
+2009-07-20,2.3399999141693115,2.3399999141693115,0.8264454667762735,,
+2009-07-17,2.25,2.289999961853028,0.0,,
+2009-07-16,2.119999885559082,2.2100000381469727,1.7777760823567905,,
+2009-07-15,2.150000095367432,2.0999999046325684,4.245290445577358,,
+2009-07-14,2.069999933242798,2.059999942779541,-2.325590163581772,,
+2009-07-13,1.9900000095367432,2.059999942779541,-0.4830913423070096,,
+2009-07-10,2.009999990463257,2.009999990463257,3.5175845682077815,,
+2009-07-09,1.919999957084656,1.9800000190734863,0.0,,
+2009-07-08,2.0,1.9299999475479128,3.12500329843418,,
+2009-07-07,1.9299999475479128,2.0,-3.500002622604359,,
+2009-07-06,2.009999990463257,1.919999957084656,3.6269458214764745,,
+2009-07-02,2.039999961853028,2.009999990463257,-4.477613622170117,,
+2009-07-01,2.190000057220459,2.140000104904175,-1.4705868603311427,,
+2009-06-30,2.069999933242798,2.190000057220459,-2.283102785839374,,
+2009-06-29,2.119999885559082,2.009999990463257,5.7971076254902405,,
+2009-06-26,2.180000066757202,2.0799999237060547,-5.188674577065661,,
+2009-06-25,1.899999976158142,2.190000057220459,-4.587162384811293,,
+2009-06-24,1.9700000286102293,1.9299999475479128,15.26316235270202,,
+2009-06-23,1.9700000286102293,1.940000057220459,-2.030460938141976,,
+2009-06-22,2.2100000381469727,1.9700000286102293,-1.5228411651818243,,
+2009-06-19,2.259999990463257,2.2300000190734863,-10.859728750863603,,
+2009-06-18,2.240000009536743,2.200000047683716,-1.3274323679807223,,
+2009-06-17,2.259999990463257,2.190000057220459,-1.785712575121809,,
+2009-06-16,2.200000047683716,2.200000047683716,-3.097342191955019,,
+2009-06-15,2.119999885559082,2.2300000190734863,0.0,,
+2009-06-12,2.2100000381469727,2.1600000858306885,5.18868582322566,,
+2009-06-11,2.3399999141693115,2.1700000762939453,-2.2624412422276623,,
+2009-06-10,2.319999933242798,2.2799999713897705,-7.264950603030912,,
+2009-06-09,2.359999895095825,2.2799999713897705,-1.72413633637985,,
+2009-06-08,2.4800000190734863,2.3399999141693115,-3.389827426361236,,
+2009-06-05,2.490000009536743,2.470000028610229,-5.645165476913102,,
+2009-06-04,1.9800000190734863,2.369999885559082,-0.8032120823258571,,
+2009-06-03,1.9600000381469729,1.9700000286102293,19.696962764075668,,
+2009-06-02,1.9600000381469729,1.9600000381469729,0.5102035851341413,,
+2009-06-01,1.9600000381469729,1.9700000286102293,0.0,,
+2009-05-29,1.8600000143051147,1.9600000381469729,0.5102035851341413,,
+2009-05-28,1.909999966621399,1.8600000143051147,5.376345326492784,,
+2009-05-27,1.9900000095367432,1.8899999856948853,-2.617798596338677,,
+2009-05-26,1.8600000143051147,2.0,-5.0251268021419335,,
+2009-05-22,1.870000004768372,1.8600000143051147,7.526880893449264,,
+2009-05-21,1.820000052452088,1.850000023841858,-0.5347588469389298,,
+2009-05-20,1.7999999523162842,1.870000004768372,1.648350028855815,,
+2009-05-19,1.820000052452088,1.7699999809265137,3.888891905914223,,
+2009-05-18,1.649999976158142,1.690000057220459,-2.747256598053898,,
+2009-05-15,1.6699999570846558,1.6100000143051147,2.424247372139546,,
+2009-05-14,1.7799999713897705,1.7400000095367432,-3.5928110372100743,,
+2009-05-13,1.7400000095367432,1.7599999904632568,-2.2471889042670363,,
+2009-05-12,1.9600000381469729,1.7000000476837158,1.1494241848790827,,
+2009-05-11,1.809999942779541,1.9299999475479128,-13.265305377701257,,
+2009-05-08,1.7899999618530271,1.809999942779541,6.6298347271819695,,
+2009-05-07,2.0,1.7400000095367432,1.1173173940076344,,
+2009-05-06,2.3399999141693115,1.909999966621399,-12.999999523162842,,
+2009-05-05,2.690000057220459,2.299999952316284,-18.376066808556292,,
+2009-05-04,1.8799999952316284,2.3399999141693115,-14.498144855326014,,
+2009-05-01,0.9800000190734864,1.0,24.468080856617664,,
+2009-04-30,1.0299999713897705,0.9900000095367432,2.0408143405366443,,
+2009-04-29,0.959999978542328,1.0099999904632568,-3.883491549912931,,
+2009-04-28,0.9100000262260436,0.9399999976158142,5.208334691512107,,
+2009-04-27,0.9399999976158142,0.9200000166893004,3.296700057711717,,
+2009-04-24,0.9700000286102296,0.949999988079071,-2.127657550770329,,
+2009-04-23,1.0,0.9300000071525574,-2.0618597877583236,,
+2009-04-22,1.0499999523162842,1.0099999904632568,-6.999999284744263,,
+2009-04-21,1.0,1.059999942779541,-3.809520349480781,,
+2009-04-20,1.0499999523162842,1.0,5.999994277954102,,
+2009-04-17,1.059999942779541,1.090000033378601,-4.7619004368509765,,
+2009-04-16,1.1200000047683716,1.0499999523162842,2.830197379104905,,
+2009-04-15,0.959999978542328,1.090000033378601,-6.2500046566128535,,
+2009-04-14,1.0299999713897705,0.9800000190734864,13.541672681458417,,
+2009-04-13,1.100000023841858,1.0700000524520874,-4.854364437391153,,
+2009-04-09,1.1399999856948853,1.100000023841858,-2.7272700672307866,,
+2009-04-08,1.0499999523162842,1.1299999952316284,-3.508768627628134,,
+2009-04-07,1.0199999809265137,1.0299999713897705,7.61905205222775,,
+2009-04-06,1.0499999523162842,1.0199999809265137,0.9803912402207475,,
+2009-04-03,1.0499999523162842,1.0399999618530271,-2.857140262110586,,
+2009-04-02,1.1299999952316284,1.059999942779541,-0.9523800873702163,,
+2009-04-01,0.949999988079071,1.0800000429153442,-6.194694933404732,,
+2009-03-31,1.0700000524520874,0.949999988079071,13.684216470269359,,
+2009-03-30,1.0,1.0499999523162842,-11.214958737433308,,
+2009-03-27,1.1100000143051147,1.059999942779541,4.999995231628418,,
+2009-03-26,1.0700000524520874,1.149999976158142,-4.504510890198043,,
+2009-03-25,1.0,1.0399999618530271,7.47662801723432,,
+2009-03-24,0.800000011920929,0.949999988079071,3.999996185302712,,
+2009-03-23,0.949999988079071,1.0499999523162842,18.749996740371035,,
+2009-03-20,1.0199999809265137,0.9300000071525574,10.526312157057612,,
+2009-03-19,1.0099999904632568,1.0,-8.823527005579463,,
+2009-03-18,0.9800000190734864,0.9900000095367432,-0.9900980750178164,,
+2009-03-17,0.9700000286102296,0.9800000190734864,1.0204071702683166,,
+2009-03-16,1.0099999904632568,0.9800000190734864,1.0309268214748768,,
+2009-03-13,1.0,0.9900000095367432,-2.9702942250534385,,
+2009-03-12,0.8999999761581421,1.0,-0.9999990463256836,,
+2009-03-11,1.0,0.9100000262260436,11.111114054550438,,
+2009-03-10,0.8600000143051147,0.9800000190734864,-8.99999737739564,,
+2009-03-09,0.7699999809265137,0.8100000023841858,13.953488694454549,,
+2009-03-06,0.800000011920929,0.800000011920929,5.194808110195212,,
+2009-03-05,0.8299999833106995,0.7900000214576721,0.0,,
+2009-03-04,0.8399999737739563,0.8600000143051147,-4.819272609316895,,
+2009-03-03,0.800000011920929,0.8199999928474426,2.3809572804273027,,
+2009-03-02,0.8100000023841858,0.7699999809265137,2.4999975785613424,,
+2009-02-27,0.7799999713897705,0.8299999833106995,-4.938274239498084,,
+2009-02-26,0.8199999928474426,0.8100000023841858,6.410258173707503,,
+2009-02-25,0.8799999952316284,0.8100000023841858,-1.219511042741837,,
+2009-02-24,0.8299999833106995,0.8999999761581421,-7.954544684857372,,
+2009-02-23,0.8399999737739563,0.8100000023841858,8.433734247587214,,
+2009-02-20,0.8199999928474426,0.8299999833106995,-3.5714252769540553,,
+2009-02-19,0.8799999952316284,0.8299999833106995,1.219511042741837,,
+2009-02-18,0.9800000190734864,0.8700000047683716,-5.68181956725673,,
+2009-02-17,0.9399999976158142,0.9399999976158142,-11.224491037164599,,
+2009-02-13,0.9800000190734864,0.9800000190734864,0.0,,
+2009-02-12,0.9399999976158142,0.9800000190734864,0.0,,
+2009-02-11,0.949999988079071,0.959999978542328,4.255321442460319,,
+2009-02-10,0.949999988079071,0.949999988079071,1.0526305882884517,,
+2009-02-09,1.0099999904632568,0.9700000286102296,0.0,,
+2009-02-06,0.9900000095367432,1.0,-3.9603923000712546,,
+2009-02-05,1.0,1.0,1.0101000370632516,,
+2009-02-04,1.0,0.9900000095367432,0.0,,
+2009-02-03,1.0199999809265137,1.0,-0.9999990463256836,,
+2009-02-02,0.9800000190734864,1.0099999904632568,-1.960782480441495,,
+2009-01-30,1.0299999713897705,1.0099999904632568,3.061221510804972,,
+2009-01-29,1.159999966621399,1.0199999809265137,-1.9417457749564655,,
+2009-01-28,1.2300000190734863,1.1399999856948853,-12.068964631322139,,
+2009-01-27,1.25,1.2000000476837158,-7.317075770973953,,
+2009-01-26,1.1200000047683716,1.2300000190734863,-3.9999961853027344,,
+2009-01-23,1.0099999904632568,1.0800000429153442,9.821429806856472,,
+2009-01-22,1.059999942779541,1.059999942779541,6.930698328024783,,
+2009-01-21,1.059999942779541,1.100000023841858,0.0,,
+2009-01-20,1.159999966621399,1.0499999523162842,3.7735927567532066,,
+2009-01-16,1.1699999570846558,1.190000057220459,-9.482760126752364,,
+2009-01-15,1.1200000047683716,1.190000057220459,1.7094103307181667,,
+2009-01-14,1.1299999952316284,1.1200000047683716,6.2500046566128535,,
+2009-01-13,1.159999966621399,1.1399999856948853,-0.8849549119871483,,
+2009-01-12,1.1100000143051147,1.1699999570846558,-1.72413633637985,,
+2009-01-09,1.2200000286102295,1.1200000047683716,5.405400180747055,,
+2009-01-08,1.149999976158142,1.2000000476837158,-8.196723073504641,,
+2009-01-07,1.1699999570846558,1.159999966621399,4.347832396711109,,
+2009-01-06,1.2300000190734863,1.2100000381469729,-0.8547000709448132,,
+2009-01-05,1.149999976158142,1.2000000476837158,-1.626014684258192,,
+2009-01-02,0.9100000262260436,1.1100000143051147,4.347832396711109,,
+2008-12-31,0.8399999737739563,0.8999999761581421,21.97802003462704,,
+2008-12-30,0.8399999737739563,0.8600000143051147,7.142857649699376,,
+2008-12-29,0.8700000047683716,0.8399999737739563,2.3809572804273027,,
+2008-12-26,0.800000011920929,0.8399999737739563,-3.4482794057458057,,
+2008-12-24,0.8500000238418579,0.8500000238418579,4.999995157122685,,
+2008-12-23,0.8700000047683716,0.8500000238418579,0.0,,
+2008-12-22,0.8600000143051147,0.8500000238418579,-2.2988483697581654,,
+2008-12-19,1.0099999904632568,0.8500000238418579,-1.1627895694091224,,
+2008-12-18,1.100000023841858,0.9700000286102296,-15.841581003185132,,
+2008-12-17,1.1299999952316284,1.0199999809265137,-11.818181128541305,,
+2008-12-16,1.1699999570846558,1.149999976158142,-9.734514581353325,,
+2008-12-15,1.25,1.1399999856948853,-1.7094001418896263,,
+2008-12-12,1.159999966621399,1.2899999618530271,-8.80000114440918,,
+2008-12-11,1.340000033378601,1.2000000476837158,11.206896463132194,,
+2008-12-10,1.4199999570846558,1.3600000143051147,-10.447759866236506,,
+2008-12-09,1.600000023841858,1.3899999856948853,-4.225348210765052,,
+2008-12-08,1.5499999523162842,1.6200000047683716,-13.125002188608018,,
+2008-12-05,1.4199999570846558,1.5099999904632568,4.516132555196595,,
+2008-12-04,1.309999942779541,1.4500000476837158,6.338030711168223,,
+2008-12-03,1.2899999618530271,1.3300000429153442,10.687031375522382,,
+2008-12-02,1.059999942779541,1.3200000524520874,3.1007815693931335,,
+2008-12-01,1.2400000095367432,1.0299999713897705,24.52831355733585,,
+2008-11-28,1.2799999713897705,1.2799999713897705,-16.935486817086996,,
+2008-11-26,1.1100000143051147,1.2999999523162842,0.0,,
+2008-11-25,1.0199999809265137,1.149999976158142,17.117111311941173,,
+2008-11-24,0.8799999952316284,1.0,12.745097810055187,,
+2008-11-21,0.8399999737739563,0.8600000143051147,13.636364252114102,,
+2008-11-20,0.9900000095367432,0.8299999833106995,2.3809572804273027,,
+2008-11-19,1.1799999475479126,0.9900000095367432,-16.161618655025418,,
+2008-11-18,1.409999966621399,1.190000057220459,-16.101690377698485,,
+2008-11-17,1.409999966621399,1.399999976158142,-15.602830823329548,,
+2008-11-14,1.659999966621399,1.4299999475479126,-0.7092191985804456,,
+2008-11-13,1.4600000381469729,1.7000000476837158,-13.85542311435137,,
+2008-11-12,1.690000057220459,1.4500000476837158,16.438356388082713,,
+2008-11-11,1.820000052452088,1.7200000286102295,-14.201183515429634,,
+2008-11-10,1.899999976158142,1.820000052452088,-5.494506646146984,,
+2008-11-07,1.850000023841858,1.840000033378601,-4.210522353153725,,
+2008-11-06,1.870000004768372,1.820000052452088,-0.5405400180747055,,
+2008-11-05,1.9800000190734863,1.820000052452088,-2.673794234694519,,
+2008-11-04,1.9800000190734863,1.9700000286102293,-8.08080631717711,,
+2008-11-03,1.899999976158142,1.8899999856948853,-0.5050500185316369,,
+2008-10-31,1.870000004768372,1.899999976158142,-0.5263152941442201,,
+2008-10-30,1.830000042915344,1.8799999952316284,1.6042765408166946,,
+2008-10-29,1.649999976158142,1.7599999904632568,2.732237767417222,,
+2008-10-28,1.4500000476837158,1.649999976158142,6.6666676299740715,,
+2008-10-27,1.4800000190734863,1.409999966621399,13.793098061887212,,
+2008-10-24,1.409999966621399,1.4800000190734863,-4.7297332128352965,,
+2008-10-23,1.649999976158142,1.5,4.964542844622862,,
+2008-10-22,1.7400000095367432,1.6399999856948853,-9.090907777308086,,
+2008-10-21,1.9700000286102293,1.7899999618530271,-5.747127775503971,,
+2008-10-20,1.919999957084656,2.0,-9.137059093556783,,
+2008-10-17,1.8899999856948853,1.870000004768372,4.1666689949731435,,
+2008-10-16,1.7899999618530271,1.9700000286102293,-1.0582000570312147,,
+2008-10-15,2.25,1.8600000143051147,10.055869865542576,,
+2008-10-14,2.490000009536743,2.240000009536743,-17.333332697550453,,
+2008-10-13,1.6200000047683716,2.430000066757202,-10.040160604116293,,
+2008-10-10,1.1299999952316284,1.5099999904632568,50.000003679299056,,
+2008-10-09,1.4700000286102295,1.25,33.62831830399571,,
+2008-10-08,1.5,1.440000057220459,-14.965988049552786,,
+2008-10-07,1.809999942779541,1.5199999809265137,-3.9999961853027344,,
+2008-10-06,2.0799999237060547,1.7699999809265137,-16.022097846461065,,
+2008-10-03,2.539999961853028,2.0999999046325684,-14.903843949532286,,
+2008-10-02,2.6700000762939453,2.5,-17.322837158606195,,
+2008-10-01,2.680000066757202,2.690000057220459,-6.36704387401784,,
+2008-09-30,2.700000047683716,2.680000066757202,0.3731339632150389,,
+2008-09-29,2.720000028610229,2.680000066757202,-0.7407400212333817,,
+2008-09-26,2.799999952316284,2.789999961853028,-1.470586817363553,,
+2008-09-25,2.819999933242798,2.930000066757202,-0.35714252262697205,,
+2008-09-24,2.640000104904175,2.859999895095825,3.9007140467521935,,
+2008-09-23,2.6600000858306885,2.630000114440918,8.333325054910777,,
+2008-09-22,3.140000104904175,2.6600000858306885,-1.127818436908127,,
+2008-09-19,3.109999895095825,3.150000095367432,-15.28662430054711,,
+2008-09-18,2.5999999046325684,2.9600000381469727,1.2861801164264801,,
+2008-09-17,2.859999895095825,2.549999952316284,13.846159489197346,,
+2008-09-16,2.559999942779541,2.9600000381469727,-10.83915923602348,,
+2008-09-15,2.559999942779541,2.5999999046325684,15.625004074536356,,
+2008-09-12,2.6700000762939453,2.609999895095825,1.5624985448084445,,
+2008-09-11,2.470000028610229,2.700000047683716,-2.2471977334698243,,
+2008-09-10,2.630000114440918,2.640000104904175,9.311741555035473,,
+2008-09-09,2.7300000190734863,2.5299999713897705,0.38022775772322054,,
+2008-09-08,2.880000114440918,2.7300000190734863,-7.326009021479505,,
+2008-09-05,2.450000047683716,2.819999933242798,-5.208336437741792,,
+2008-09-04,2.6600000858306885,2.400000095367432,15.102035851341638,,
+2008-09-03,2.3299999237060547,2.690000057220459,-9.77443541630794,,
+2008-09-02,2.569999933242798,2.359999895095825,15.450650012974881,,
+2008-08-29,2.609999895095825,2.549999952316284,-8.171207922250678,,
+2008-08-28,2.569999933242798,2.609999895095825,-2.2988484747559017,,
+2008-08-27,2.430000066757202,2.509999990463257,1.5564187895738903,,
+2008-08-26,2.319999933242798,2.430000066757202,3.292177839847279,,
+2008-08-25,2.640000104904175,2.380000114440918,4.741385201707776,,
+2008-08-22,2.700000047683716,2.619999885559082,-9.848484095900979,,
+2008-08-21,2.7100000381469727,2.690000057220459,-2.9629689152511154,,
+2008-08-20,2.9100000858306885,2.7300000190734863,-0.7380066658666594,,
+2008-08-19,2.9100000858306885,2.9100000858306885,-6.185569121927339,,
+2008-08-18,3.0899999141693115,2.970000028610229,0.0,,
+2008-08-15,3.289999961853028,3.0999999046325684,-3.883491549912945,,
+2008-08-14,3.0899999141693115,3.2100000381469727,-5.7750777940266484,,
+2008-08-13,3.0999999046325684,3.0799999237060547,3.8834992657247667,,
+2008-08-12,3.180000066757202,3.109999895095825,-0.6451606948963502,,
+2008-08-11,2.9800000190734863,3.180000066757202,-2.2012632135809818,,
+2008-08-08,2.5799999237060547,2.970000028610229,6.711410953141468,,
+2008-08-07,2.9100000858306885,2.569999933242798,15.11628358282882,,
+2008-08-06,2.690000057220459,2.990000009536743,-11.683853696204762,,
+2008-08-05,2.900000095367432,2.680000066757202,11.152414347019386,,
+2008-08-04,3.039999961853028,2.809999942779541,-7.5862076336365005,,
+2008-08-01,2.9200000762939453,2.9800000190734863,-7.565790196039693,,
+2008-07-31,3.0899999141693115,2.9800000190734863,2.0547925072554363,,
+2008-07-30,3.2699999809265137,3.130000114440918,-3.5598672540868534,,
+2008-07-29,3.309999942779541,3.259999990463257,-4.2813415077124395,,
+2008-07-28,3.470000028610229,3.309999942779541,-1.5105726036447358,,
+2008-07-25,3.380000114440918,3.509999990463257,-4.610953444134977,,
+2008-07-24,3.549999952316284,3.3499999046325684,3.8461500479517587,,
+2008-07-23,3.640000104904175,3.5299999713897705,-5.633804235778114,,
+2008-07-22,3.4200000762939453,3.640000104904175,-3.021981602863171,,
+2008-07-21,3.5,3.430000066757202,6.432749231065244,,
+2008-07-18,3.7300000190734863,3.490000009536743,-1.9999980926513672,,
+2008-07-17,3.450000047683716,3.7200000286102295,-6.434316576662055,,
+2008-07-16,3.390000104904175,3.4200000762939453,7.826086295499852,,
+2008-07-15,3.150000095367432,3.369999885559082,0.8849548808677254,,
+2008-07-14,3.309999942779541,3.200000047683716,6.984120112097586,,
+2008-07-11,3.359999895095825,3.2799999713897705,-3.323259728018419,,
+2008-07-10,3.380000114440918,3.400000095367432,-2.3809501846360366,,
+2008-07-09,3.509999990463257,3.390000104904175,0.5917153919925914,,
+2008-07-08,3.7300000190734863,3.509999990463257,-3.4188001676673565,,
+2008-07-07,3.4600000381469727,3.259999990463257,-5.898124061266799,,
+2008-07-03,3.3299999237060547,3.430000066757202,-5.780348135222196,,
+2008-07-02,3.440000057220459,3.309999942779541,3.003007367635443,,
+2008-07-01,3.640000104904175,3.4600000381469727,-3.7790730313521816,,
+2008-06-30,3.7899999618530273,3.690000057220459,-4.9450566365283315,,
+2008-06-27,3.869999885559082,3.819999933242798,-2.6385199377066977,,
+2008-06-26,3.9800000190734863,3.910000085830689,-1.291988470151102,,
+2008-06-25,3.930000066757202,4.019999980926514,-1.7587922841038792,,
+2008-06-24,3.910000085830689,3.950000047683716,2.2900741129903848,,
+2008-06-23,3.990000009536743,3.890000104904175,1.0230169047305484,,
+2008-06-20,3.819999933242798,4.079999923706055,-2.506263268008834,,
+2008-06-19,4.059999942779541,3.829999923706055,6.80628259180473,,
+2008-06-18,4.400000095367432,4.090000152587891,-5.665025180173382,,
+2008-06-17,4.519999980926514,4.460000038146973,-7.045453092283485,,
+2008-06-16,4.340000152587891,4.829999923706055,-1.3274323679807223,,
+2008-06-13,8.289999961853027,8.489999771118164,11.290316909919532,,
+2008-06-12,8.289999961853027,8.359999656677246,2.412542945542205,,
+2008-06-11,8.180000305175781,8.239999771118164,0.8443871549617236,,
+2008-06-10,8.34000015258789,8.180000305175781,0.7334897763319028,,
+2008-06-09,8.329999923706055,8.420000076293945,-1.9184633631266979,,
+2008-06-06,8.510000228881836,8.34000015258789,1.0804340145521774,,
+2008-06-05,8.369999885559082,8.529999732971191,-1.9976506665297977,,
+2008-06-04,8.210000038146973,8.359999656677246,1.9115872114665151,,
+2008-06-03,8.460000038146973,8.329999923706055,1.827035539991653,,
+2008-06-02,8.75,8.4399995803833,-1.5366443718053742,,
+2008-05-30,8.670000076293945,8.800000190734863,-3.5428619384765625,,
+2008-05-29,8.460000038146973,8.680000305175781,1.4994246055011278,,
+2008-05-28,8.569999694824219,8.5,2.6004759578818644,,
+2008-05-27,8.229999542236328,8.520000457763672,-0.8167992685751727,,
+2008-05-23,8.140000343322754,8.210000038146973,3.523705123421454,,
+2008-05-22,8.050000190734863,8.199999809265137,0.8599470745924419,,
+2008-05-21,8.289999961853027,8.029999732971191,1.8633492543629413,,
+2008-05-20,8.229999542236328,8.25,-3.136311581160963,,
+2008-05-19,8.260000228881836,8.25,0.2430189413866866,,
+2008-05-16,8.239999771118164,8.279999732971191,-0.12106814291444248,,
+2008-05-15,8.09000015258789,8.180000305175781,0.4854364437391164,,
+2008-05-14,8.180000305175781,8.069999694824219,1.1124864139724484,,
+2008-05-13,8.25,8.180000305175781,-1.3447506876248054,,
+2008-05-12,8.09000015258789,8.25,-0.8484811493844696,,
+2008-05-09,8.039999961853027,8.0600004196167,1.9777483855909126,,
+2008-05-08,8.050000190734863,8.119999885559082,0.24876191366376885,,
+2008-05-07,8.399999618530273,8.029999732971191,0.8695614057846209,,
+2008-05-06,8.130000114440918,8.390000343322754,-4.4047607424037,,
+2008-05-05,8.119999885559082,8.0600004196167,3.198034750577806,,
+2008-05-02,8.170000076293945,8.010000228881836,-0.7389096895073626,,
+2008-05-01,7.940000057220459,8.0600004196167,-1.9583824469765259,,
+2008-04-30,8.029999732971191,8.0,1.5113395658872142,,
+2008-04-29,8.029999732971191,7.989999771118164,-0.3735956907696081,,
+2008-04-28,7.980000019073486,8.020000457763672,-0.49813154649043684,,
+2008-04-25,8.079999923706055,8.010000228881836,0.5012586290047374,,
+2008-04-24,7.739999771118164,8.050000190734863,-0.8663328649155727,,
+2008-04-23,8.039999961853027,7.78000020980835,4.005173498498887,,
+2008-04-22,8.029999732971191,8.0,-3.2338277770930985,,
+2008-04-21,8.140000343322754,8.079999923706055,-0.3735956907696081,,
+2008-04-18,8.1899995803833,8.220000267028809,-0.7371058610079494,,
+2008-04-17,8.25,8.039999961853027,0.36630876901832204,,
+2008-04-16,7.960000038146973,8.25,-2.5454550078420928,,
+2008-04-15,8.1899995803833,7.900000095367432,3.643215583709182,,
+2008-04-14,8.34000015258789,8.149999618530273,-3.540897434359781,,
+2008-04-11,8.789999961853027,8.369999885559082,-2.2781838199206783,,
+2008-04-10,8.550000190734863,8.90999984741211,-4.7781578852863245,,
+2008-04-09,9.039999961853027,8.539999961853027,4.2105222063896175,,
+2008-04-08,9.100000381469728,8.949999809265137,-5.530973474667024,,
+2008-04-07,9.18000030517578,9.170000076293944,-1.648357867215443,,
+2008-04-04,8.6899995803833,9.100000381469728,-0.10893495151844063,,
+2008-04-03,8.899999618530273,8.6899995803833,4.718076189692326,,
+2008-04-02,9.380000114440918,8.989999771118164,-2.3595510915499522,,
+2008-04-01,9.380000114440918,9.119999885559082,-4.157786125421592,,
+2008-03-31,9.079999923706056,9.0600004196167,-2.7718574169477277,,
+2008-03-28,9.789999961853027,9.06999969482422,-0.220258857460368,,
+2008-03-27,9.529999732971191,9.8100004196167,-7.354446065723241,,
+2008-03-26,9.390000343322754,9.479999542236328,2.9380975287625883,,
+2008-03-25,9.300000190734863,9.420000076293944,0.9584578873585751,,
+2008-03-24,9.029999732971191,9.229999542236328,1.2903213236342759,,
+2008-03-20,8.390000343322754,9.0,2.214837377401889,,
+2008-03-19,8.09000015258789,8.270000457763672,7.270555801141522,,
+2008-03-18,8.09000015258789,8.050000190734863,2.224972827944897,,
+2008-03-17,8.0,7.929999828338623,-0.49443709639772815,,
+2008-03-14,8.40999984741211,8.170000076293945,-0.8750021457672119,,
+2008-03-13,8.3100004196167,8.319999694824219,-2.853742871256006,,
+2008-03-12,8.09000015258789,8.399999618530273,0.12032821543444339,,
+2008-03-11,8.319999694824219,8.029999732971191,3.8318845500048333,,
+2008-03-10,8.359999656677246,8.15999984741211,-3.4855765924298434,,
+2008-03-07,8.649999618530273,8.319999694824219,-2.392342314337228,,
+2008-03-06,9.0600004196167,8.739999771118164,-3.8150281879680032,,
+2008-03-05,9.260000228881836,9.300000190734863,-3.5320158242561477,,
+2008-03-04,9.729999542236328,9.329999923706056,0.43196502013323845,,
+2008-03-03,9.949999809265137,9.8100004196167,-4.110993189608479,,
+2008-02-29,10.1899995803833,9.920000076293944,-1.407029068664648,,
+2008-02-28,10.579999923706056,10.329999923706056,-2.649651768476335,,
+2008-02-27,10.40999984741211,10.460000038146973,-2.3629489773420316,,
+2008-02-26,10.40999984741211,10.529999732971191,0.4803092360015083,,
+2008-02-25,10.390000343322754,10.420000076293944,1.1527366697216004,,
+2008-02-22,10.300000190734863,10.369999885559082,0.2887365926842272,,
+2008-02-21,10.579999923706056,10.239999771118164,0.6796086750288162,,
+2008-02-20,10.539999961853027,10.520000457763672,-3.2136120514147803,,
+2008-02-19,10.68000030517578,10.59000015258789,-0.18974861633528295,,
+2008-02-15,10.5,10.520000457763672,-0.8426980338593497,,
+2008-02-14,10.90999984741211,10.5,0.19048055013020831,,
+2008-02-13,11.1899995803833,10.859999656677246,-3.7580188189403394,,
+2008-02-12,10.710000038146973,11.020000457763672,-2.9490610909813,,
+2008-02-11,10.869999885559082,10.630000114440918,2.8944950374653313,,
+2008-02-08,11.079999923706056,10.84000015258789,-2.207909601149182,,
+2008-02-07,11.229999542236328,11.119999885559082,-2.166062931143869,,
+2008-02-06,11.81999969482422,11.300000190734863,-0.9795161278817016,,
+2008-02-05,13.079999923706056,11.75,-4.39931909911179,,
+2008-02-04,12.5,13.380000114440918,-10.168195194677168,,
+2008-02-01,11.93000030517578,12.800000190734863,7.040000915527343,,
+2008-01-31,10.56999969482422,11.859999656677246,7.292538669773865,,
+2008-01-30,10.890000343322754,10.6899995803833,12.204351930915342,,
+2008-01-29,10.9399995803833,10.979999542236328,-1.836554239064688,,
+2008-01-28,10.899999618530272,10.899999618530272,0.36563037831145767,,
+2008-01-25,11.109999656677246,10.899999618530272,0.0,,
+2008-01-24,11.609999656677246,10.970000267028809,-1.8901894206698904,,
+2008-01-23,11.0600004196167,11.520000457763672,-5.512484139311368,,
+2008-01-22,11.1899995803833,11.510000228881836,4.159132194345022,,
+2008-01-18,11.84000015258789,11.75,2.859702059859898,,
+2008-01-17,12.229999542236328,11.829999923706056,-0.7601364140879603,,
+2008-01-16,11.9399995803833,12.34000015258789,-3.270642955863344,,
+2008-01-15,11.90999984741211,11.960000038146973,3.35008866216182,,
+2008-01-14,12.260000228881836,12.079999923706056,0.4198168881230312,,
+2008-01-11,11.619999885559082,12.15999984741211,-1.4681916950681515,,
+2008-01-10,11.449999809265137,11.649999618530272,4.647159786327708,,
+2008-01-09,11.520000457763672,11.609999656677246,1.7467232541200453,,
+2008-01-08,11.109999656677246,11.539999961853027,0.7812430150809679,,
+2008-01-07,10.510000228881836,11.029999732971191,3.8703899051639103,,
+2008-01-04,10.59000015258789,10.449999809265137,4.9476640605618565,,
+2008-01-03,10.850000381469728,10.670000076293944,-1.3220051114781322,,
+2008-01-02,11.020000457763672,10.850000381469728,-1.6589889294676887,,
+2007-12-31,11.0,11.06999969482422,-1.5426503560095337,,
+2007-12-28,11.43000030517578,11.039999961853027,0.6363608620383684,,
+2007-12-27,12.199999809265137,11.40999984741211,-3.4120764034113855,,
+2007-12-26,12.279999732971191,12.270000457763672,-6.475409624622058,,
+2007-12-24,12.4399995803833,12.369999885559082,-0.08142732430744255,,
+2007-12-21,12.279999732971191,12.449999809265137,-0.5626985304292262,,
+2007-12-20,11.920000076293944,12.09000015258789,1.3843654722361558,,
+2007-12-19,11.520000457763672,11.779999732971191,1.426175127565955,,
+2007-12-18,11.380000114440918,11.489999771118164,2.2569380631603906,,
+2007-12-17,12.010000228881836,11.279999732971191,0.9666050577421301,,
+2007-12-14,11.890000343322754,12.029999732971191,-6.078272123218849,,
+2007-12-13,12.220000267028809,11.989999771118164,1.1774548831452225,,
+2007-12-12,12.18000030517578,12.220000267028809,-1.8821644098586197,,
+2007-12-11,12.279999732971191,11.199999809265137,0.32840690353703444,,
+2007-12-10,12.40999984741211,12.239999771118164,-8.794787843572246,,
+2007-12-07,12.649999618530272,12.350000381469728,-1.3698636453198336,,
+2007-12-06,11.8100004196167,12.600000381469728,-2.371535542349672,,
+2007-12-05,11.630000114440918,11.770000457763672,6.689245840676008,,
+2007-12-04,11.40999984741211,11.520000457763672,1.2037862592014605,,
+2007-12-03,11.34000015258789,11.5,0.9640719703998211,,
+2007-11-30,11.229999542236328,11.34000015258789,1.4109333797107222,,
+2007-11-29,10.550000190734863,11.220000267028809,0.9795246200843309,,
+2007-11-28,10.100000381469728,10.600000381469728,6.350711508823928,,
+2007-11-27,10.020000457763672,10.029999732971191,4.950494862528323,,
+2007-11-26,10.260000228881836,9.989999771118164,0.09979316118465761,,
+2007-11-23,10.31999969482422,10.270000457763672,-2.631583350296838,,
+2007-11-21,10.5,10.260000228881836,-0.48448874553382715,,
+2007-11-20,10.960000038146973,10.520000457763672,-2.285712105887277,,
+2007-11-19,11.229999542236328,10.960000038146973,-4.014594697553417,,
+2007-11-16,11.239999771118164,11.279999732971191,-2.4042699474196785,,
+2007-11-15,10.979999542236328,11.210000038146973,0.3558715539817855,,
+2007-11-14,11.3100004196167,10.989999771118164,2.0947222723089447,,
+2007-11-13,11.729999542236328,11.25,-2.8293601823701797,,
+2007-11-12,11.289999961853027,11.640000343322754,-4.0920678684426965,,
+2007-11-09,11.449999809265137,11.270000457763672,3.1000919632623365,,
+2007-11-08,12.93000030517578,11.770000457763672,-1.5720467641913194,,
+2007-11-07,13.020000457763672,12.949999809265137,-8.971382985565505,,
+2007-11-06,13.800000190734863,13.31999969482422,-0.537639370487077,,
+2007-11-05,15.029999732971191,15.0,-3.478264415046231,,
+2007-11-02,15.09000015258789,15.229999542236328,-0.19959902531056758,,
+2007-11-01,15.130000114440918,15.0,0.9277626788123525,,
+2007-10-31,15.15999984741211,15.380000114440918,-0.8592208424165085,,
+2007-10-30,15.15999984741211,15.170000076293944,1.4511891111025557,,
+2007-10-29,15.489999771118164,15.260000228881836,0.06596457112459174,,
+2007-10-26,15.289999961853027,15.539999961853027,-1.4848259886044228,,
+2007-10-25,15.369999885559082,15.140000343322754,1.635055595969419,,
+2007-10-24,15.010000228881836,15.380000114440918,-1.4964186333691825,,
+2007-10-23,15.4399995803833,15.140000343322754,2.4650225177687757,,
+2007-10-22,15.1899995803833,15.359999656677246,-1.9430002928348484,,
+2007-10-19,15.100000381469728,14.949999809265137,1.1191578735360017,,
+2007-10-18,15.149999618530272,15.100000381469728,-0.9933812477824031,,
+2007-10-17,15.0,15.239999771118164,-0.33002797570627157,,
+2007-10-16,15.239999771118164,14.829999923706056,1.5999984741210938,,
+2007-10-15,15.979999542236328,15.25,-2.6902877530819396,,
+2007-10-12,15.84000015258789,15.949999809265137,-4.568207529085874,,
+2007-10-11,15.699999809265137,15.84000015258789,0.6944422703132025,,
+2007-10-10,15.979999542236328,15.739999771118164,0.8917219428253411,,
+2007-10-09,15.09000015258789,15.949999809265137,-1.5018759574042966,,
+2007-10-08,15.229999542236328,15.079999923706056,5.699136169523224,,
+2007-10-05,15.079999923706056,15.289999961853027,-0.984895752060188,,
+2007-10-04,15.239999771118164,14.93000030517578,1.392573204306498,,
+2007-10-03,14.880000114440918,15.199999809265137,-2.034117261142451,,
+2007-10-02,15.550000190734863,14.960000038146973,2.150535566956493,,
+2007-10-01,15.079999923706056,15.5600004196167,-3.7942131533826586,,
+2007-09-28,15.3100004196167,15.050000190734863,3.183027177314985,,
+2007-09-27,15.279999732971191,15.350000381469728,-1.6982378952040897,,
+2007-09-26,15.579999923706056,15.270000457763672,0.45811943535240707,,
+2007-09-25,15.609999656677246,15.539999961853027,-1.9897270055226302,,
+2007-09-24,15.710000038146973,15.699999809265137,-0.4484285481343753,,
+2007-09-21,15.960000038146973,15.729999542236328,-0.0636551805063871,,
+2007-09-20,15.68000030517578,15.81999969482422,-1.4411058606573075,,
+2007-09-19,15.4399995803833,15.68000030517578,0.892853232931564,,
+2007-09-18,14.949999809265137,15.34000015258789,1.55440888157408,,
+2007-09-17,15.31999969482422,14.899999618530272,2.6086979819294345,,
+2007-09-14,15.68000030517578,15.380000114440918,-2.741514912926817,,
+2007-09-13,15.989999771118164,15.760000228881836,-1.9132664853063495,,
+2007-09-12,15.390000343322754,15.880000114440918,-1.4383961571516926,,
+2007-09-11,15.149999618530272,15.420000076293944,3.18388408178795,,
+2007-09-10,15.149999618530272,15.039999961853027,1.78218128423864,,
+2007-09-07,15.4399995803833,15.079999923706056,-0.726070359386026,,
+2007-09-06,15.09000015258789,15.510000228881836,-2.3316040573901833,,
+2007-09-05,15.229999542236328,15.079999923706056,2.78330067625557,,
+2007-09-04,14.420000076293944,15.270000457763672,-0.984895752060188,,
+2007-08-31,14.359999656677246,14.390000343322754,5.894593460280933,,
+2007-08-30,14.029999732971191,14.210000038146973,0.20891843567390206,,
+2007-08-29,14.09000015258789,14.170000076293944,1.2829672744239022,,
+2007-08-28,14.479999542236328,14.039999961853027,0.5677780187345096,,
+2007-08-27,14.779999732971191,14.5,-3.0386712313068633,,
+2007-08-24,14.779999732971191,14.800000190734863,-1.8944501896476265,,
+2007-08-23,14.8100004196167,14.800000190734863,0.13532109692163863,,
+2007-08-22,15.050000190734863,14.800000190734863,-0.0675234881735051,,
+2007-08-21,15.0,15.079999923706056,-1.6611295470541316,,
+2007-08-20,15.010000228881836,15.06999969482422,0.5333328247070431,,
+2007-08-17,15.579999923706056,15.050000190734863,0.39972994688524555,,
+2007-08-16,15.0,15.210000038146973,-3.4017954786043463,,
+2007-08-15,15.729999542236328,15.15999984741211,1.4000002543131511,,
+2007-08-14,15.800000190734863,15.800000190734863,-3.623647243559818,,
+2007-08-13,16.459999084472656,15.84000015258789,0.0,,
+2007-08-10,16.110000610351562,16.399999618530273,-3.766700889246308,,
+2007-08-09,16.510000228881836,16.530000686645508,1.8001179217359595,,
+2007-08-08,16.520000457763672,16.790000915527344,0.12114147478135096,,
+2007-08-07,15.25,16.3700008392334,1.6343852922642237,,
+2007-08-06,14.989999771118164,15.229999542236328,7.344267798251793,,
+2007-08-03,14.5600004196167,14.869999885559082,1.6010658758019547,,
+2007-08-02,14.300000190734863,14.600000381469728,2.1291171497819485,,
+2007-08-01,13.920000076293944,14.220000267028809,2.097903403730293,,
+2007-07-31,14.239999771118164,14.039999961853027,2.1551737722025717,,
+2007-07-30,13.960000038146973,14.170000076293944,-1.4044930651668976,,
+2007-07-27,14.170000076293944,14.0,1.5042982634178126,,
+2007-07-26,13.920000076293944,14.1899995803833,-1.1997182454384698,,
+2007-07-25,13.75,13.920000076293944,1.9396515992063257,,
+2007-07-24,13.550000190734863,13.6899995803833,1.2363641912286802,,
+2007-07-23,13.699999809265137,13.68000030517578,1.0332058131199542,,
+2007-07-20,13.899999618530272,13.68000030517578,-0.14598178370653578,,
+2007-07-19,13.470000267028809,13.770000457763672,-1.5827289164901,,
+2007-07-18,13.510000228881836,13.4399995803833,2.227172864051003,,
+2007-07-17,13.520000457763672,13.65999984741211,-0.5181395063849589,,
+2007-07-16,13.779999732971191,13.5600004196167,1.0354984090850736,,
+2007-07-13,13.5,13.699999809265137,-1.5965117388798147,,
+2007-07-12,13.640000343322754,13.489999771118164,1.4814800686306424,,
+2007-07-11,13.5,13.529999732971191,-1.0997109122363053,,
+2007-07-10,13.649999618530272,13.550000190734863,0.22222024423104747,,
+2007-07-09,13.760000228881836,13.449999809265137,-0.7325965610992125,,
+2007-07-06,13.579999923706056,13.760000228881836,-2.2529099888095745,,
+2007-07-05,13.90999984741211,13.630000114440918,1.3254808997572984,,
+2007-07-03,13.960000038146973,13.979999542236328,-2.012938433089085,,
+2007-07-02,13.68000030517578,13.920000076293944,0.14326292288470632,,
+2007-06-29,14.020000457763672,13.670000076293944,1.7543842526623408,,
+2007-06-28,14.199999809265137,14.0,-2.4964363055773884,,
+2007-06-27,14.020000457763672,14.170000076293944,-1.4084493799404276,,
+2007-06-26,14.15999984741211,14.18000030517578,1.06989738682361,,
+2007-06-25,14.40999984741211,14.100000381469728,0.1412461721694538,,
+2007-06-22,14.550000190734863,14.31999969482422,-2.151280147293366,,
+2007-06-21,14.75,14.510000228881836,-1.580759401344216,,
+2007-06-20,15.020000457763672,14.850000381469728,-1.6271170923265361,,
+2007-06-19,14.989999771118164,15.050000190734863,-1.1318247078086632,,
+2007-06-18,15.1899995803833,15.029999732971191,0.40026964998561537,,
+2007-06-15,15.239999771118164,15.119999885559082,-1.0533235801977026,,
+2007-06-14,14.5600004196167,15.020000457763672,-0.787400835704065,,
+2007-06-13,14.390000343322754,14.56999969482422,3.1593408302874373,,
+2007-06-12,14.449999809265137,14.279999732971191,1.2508641223555625,,
+2007-06-11,14.489999771118164,14.460000038146973,-1.1764711317500756,,
+2007-06-08,13.239999771118164,13.960000038146973,-0.20703749789553233,,
+2007-06-07,14.119999885559082,13.260000228881836,5.438068576099394,,
+2007-06-06,14.100000381469728,13.81999969482422,-6.090649175973377,,
+2007-06-05,12.5,12.43000030517578,-1.9858204189376176,,
+2007-06-04,12.600000381469728,12.579999923706056,-0.5599975585937642,,
+2007-06-01,12.8100004196167,12.699999809265137,-0.15873378696944865,,
+2007-05-31,12.93000030517578,12.789999961853027,-0.8587088739131669,,
+2007-05-30,12.789999961853027,12.93000030517578,-1.0827559166159577,,
+2007-05-29,13.260000228881836,12.899999618530272,1.0946078478523211,,
+2007-05-25,13.079999923706056,13.170000076293944,-2.7149366827870844,,
+2007-05-24,13.210000038146973,13.0,0.6880745650829228,,
+2007-05-23,13.399999618530272,13.25,-1.5897050532971104,,
+2007-05-22,13.350000381469728,13.350000381469728,-1.1194001701525707,,
+2007-05-21,13.239999771118164,13.43000030517578,0.0,,
+2007-05-18,13.350000381469728,13.279999732971191,1.4350493756962446,,
+2007-05-17,12.920000076293944,13.31999969482422,-0.5243494119723046,,
+2007-05-16,13.039999961853027,13.020000457763672,3.0959722613640683,,
+2007-05-15,13.289999961853027,12.869999885559082,-0.15337043058176109,,
+2007-05-14,13.479999542236328,13.329999923706056,-3.160271463502583,,
+2007-05-11,14.09000015258789,13.609999656677246,-1.1127568518105957,,
+2007-05-10,13.920000076293944,13.8100004196167,-3.406674880855012,,
+2007-05-09,13.710000038146973,14.06999969482422,-0.7902274143272174,,
+2007-05-08,13.1899995803833,13.640000343322754,2.6258180574440395,,
+2007-05-07,13.5,13.0600004196167,3.4116814045143142,,
+2007-05-04,13.399999618530272,13.489999771118164,-3.2592561509874134,,
+2007-05-03,13.479999542236328,13.31999969482422,0.6716429488806488,,
+2007-05-02,13.460000038146973,13.699999809265137,-1.1869425285274429,,
+2007-05-01,13.619999885559082,13.5,1.7830592157353713,,
+2007-04-30,13.699999809265137,13.65999984741211,-0.881056435883782,,
+2007-04-27,13.84000015258789,13.649999618530272,-0.29197052853953964,,
+2007-04-26,14.210000038146973,13.890000343322754,-1.3728362136043146,,
+2007-04-25,14.380000114440918,14.220000267028809,-2.251933103203198,,
+2007-04-24,14.359999656677246,14.359999656677246,-1.1126553973489313,,
+2007-04-23,14.550000190734863,14.449999809265137,0.0,,
+2007-04-20,14.859999656677246,14.600000381469728,-0.6872878361431549,,
+2007-04-19,15.050000190734863,14.729999542236328,-1.7496586891957884,,
+2007-04-18,15.489999771118164,14.979999542236328,-2.1262501291896005,,
+2007-04-17,15.449999809265137,15.5,-3.2924482660920074,,
+2007-04-16,15.56999969482422,15.479999542236328,0.32362583399437267,,
+2007-04-13,15.600000381469728,15.470000267028809,-0.5780356734227186,,
+2007-04-12,15.800000190734863,15.630000114440918,-0.833334046551299,,
+2007-04-11,15.699999809265137,15.649999618530272,-1.0759498369729992,,
+2007-04-10,16.040000915527344,15.59000015258789,-0.3184725563204029,,
+2007-04-09,15.649999618530272,16.139999389648438,-2.80549088063851,,
+2007-04-05,15.890000343322754,15.649999618530272,3.130989029149784,,
+2007-04-04,16.43000030517578,15.600000381469728,-1.5103884179167724,,
+2007-04-03,14.720000267028809,16.40999984741211,-5.051734073581157,,
+2007-04-02,14.989999771118164,14.640000343322754,11.480975201941504,,
+2007-03-30,16.450000762939453,15.020000457763672,-2.334886145026954,,
+2007-03-29,15.850000381469728,16.5,-8.693010570537227,,
+2007-03-28,16.110000610351562,15.420000076293944,4.100943866791244,,
+2007-03-27,15.140000343322754,16.3700008392334,-4.2830571565233555,,
+2007-03-26,14.449999809265137,15.25,8.124177463794549,,
+2007-03-23,13.529999732971191,14.449999809265137,5.536333572972882,,
+2007-03-22,13.75,13.579999923706056,6.799705058766568,,
+2007-03-21,13.949999809265137,13.720000267028809,-1.2363641912286802,,
+2007-03-20,13.239999771118164,14.550000190734863,-1.648742260796089,,
+2007-03-19,11.109999656677246,13.609999656677246,9.894263159085122,,
+2007-03-16,6.75,6.690000057220459,22.502250920390168,,
+2007-03-15,6.900000095367432,6.730000019073486,-0.8888880411783854,,
+2007-03-14,6.96999979019165,7.039999961853027,-2.4637691875987233,,
+2007-03-13,6.940000057220459,6.989999771118164,1.0043066537804328,,
+2007-03-12,6.760000228881836,7.0,0.7204569666492262,,
+2007-03-09,6.940000057220459,6.760000228881836,3.55029235195547,,
+2007-03-08,6.889999866485596,6.860000133514404,-2.593657447471475,,
+2007-03-07,7.070000171661377,6.78000020980835,-0.4354097757986382,,
+2007-03-06,6.769999980926514,6.989999771118164,-4.101838116149301,,
+2007-03-05,6.829999923706055,6.760000228881836,3.249627633847381,,
+2007-03-02,6.769999980926514,6.940000057220459,-1.024885733618514,,
+2007-03-01,6.730000019073486,6.860000133514404,2.5110794205745304,,
+2007-02-28,7.150000095367432,6.960000038146973,1.9316510263370694,,
+2007-02-27,7.5,7.179999828338623,-2.6573434221848786,,
+2007-02-26,7.980000019073486,7.579999923706055,-4.266668955485026,,
+2007-02-23,7.610000133514404,7.840000152587891,-5.0125325114206385,,
+2007-02-22,7.360000133514404,7.489999771118164,3.022339225206677,,
+2007-02-21,7.179999828338623,7.340000152587891,1.7662993919224952,,
+2007-02-20,7.179999828338623,7.179999828338623,2.228416825551512,,
+2007-02-16,7.03000020980835,7.130000114440918,0.0,,
+2007-02-15,7.050000190734863,7.010000228881836,1.422473707654335,,
+2007-02-14,6.980000019073486,7.050000190734863,-0.5673753300829047,,
+2007-02-13,6.929999828338623,7.0,1.0028677861045143,,
+2007-02-12,7.019999980926514,6.929999828338623,1.0101035121981898,,
+2007-02-09,7.070000171661377,7.050000190734863,-1.2820534591513235,,
+2007-02-08,7.199999809265137,7.090000152587891,-0.2828851547511898,,
+2007-02-07,7.190000057220459,7.119999885559082,-1.5277730498783602,,
+2007-02-06,7.159999847412109,7.150000095367432,-0.9735767886549631,,
+2007-02-05,7.289999961853027,7.099999904632568,-0.13966134438245856,,
+2007-02-02,7.300000190734863,7.329999923706055,-2.6063108122728074,,
+2007-02-01,7.150000095367432,7.300000190734863,0.41095523544323975,,
+2007-01-31,7.019999980926514,7.150000095367432,2.0979034037302804,,
+2007-01-30,7.059999942779541,7.03000020980835,1.851853487095883,,
+2007-01-29,7.0,7.059999942779541,-0.42492539963648257,,
+2007-01-26,7.050000190734863,7.019999980926514,0.8571420397077287,,
+2007-01-25,7.039999961853027,7.050000190734863,-0.4255348793859041,,
+2007-01-24,7.090000152587891,7.059999942779541,0.14204870647760254,,
+2007-01-23,7.210000038146973,7.079999923706055,-0.42313412077148355,,
+2007-01-22,7.21999979019165,7.25,-1.8030528953274325,,
+2007-01-19,7.369999885559082,7.25,0.4155153833813792,,
+2007-01-18,7.070000171661377,7.369999885559082,-1.6282209962338274,,
+2007-01-17,6.840000152587891,7.099999904632568,4.243277321267847,,
+2007-01-16,7.429999828338623,6.840000152587891,3.801165880768405,,
+2007-01-12,7.75,7.440000057220459,-7.940776438519228,,
+2007-01-11,7.75,7.789999961853027,-3.9999992616714968,,
+2007-01-10,7.880000114440918,7.889999866485596,0.5161285400390625,,
+2007-01-09,8.09000015258789,7.900000095367432,0.12690040481537748,,
+2007-01-08,8.279999732971191,8.069999694824219,-2.3485791549667687,,
+2007-01-05,8.710000038146973,8.300000190734863,-2.536232426563332,,
+2007-01-04,8.770000457763672,8.640000343322754,-4.707231292955719,,
+2007-01-03,8.890000343322754,8.770000457763672,-1.4823273392857688,,
+2006-12-29,8.850000381469727,8.789999961853027,-1.3498299316626403,,
+2006-12-28,9.050000190734863,8.890000343322754,-0.6779708139033425,,
+2006-12-27,9.100000381469728,9.079999923706056,-1.767954077790106,,
+2006-12-26,8.890000343322754,9.0600004196167,-0.21978524093689794,,
+2006-12-22,8.84000015258789,8.920000076293945,1.9122617517290843,,
+2006-12-21,9.010000228881836,9.0,0.904976496891065,,
+2006-12-20,8.979999542236328,8.979999542236328,-0.11099032883239994,,
+2006-12-19,9.18000030517578,8.920000076293945,0.0,,
+2006-12-18,9.25,9.260000228881836,-2.832246407826842,,
+2006-12-15,9.260000228881836,9.15999984741211,0.10811058250633446,,
+2006-12-14,9.1899995803833,9.25,-1.079917699762323,,
+2006-12-13,8.779999732971191,9.149999618530272,0.6528881649219476,,
+2006-12-12,8.930000305175781,8.760000228881836,4.214121831571749,,
+2006-12-11,8.979999542236328,8.970000267028809,-1.9036961980327611,,
+2006-12-08,8.960000038146973,8.960000038146973,-0.11135050910068721,,
+2006-12-07,9.050000190734863,9.0,0.0,,
+2006-12-06,9.100000381469728,9.06999969482422,-0.5524882837687902,,
+2006-12-05,9.149999618530272,9.119999885559082,-0.32967786140534694,,
+2006-12-04,9.239999771118164,9.1899995803833,-0.32786594778031664,,
+2006-12-01,9.449999809265137,9.289999961853027,-0.5411276187598063,,
+2006-11-30,9.149999618530272,9.359999656677246,-1.693120112608251,,
+2006-11-29,9.0,9.18000030517578,2.29508247980349,,
+2006-11-28,9.010000228881836,8.979999542236328,2.000003390841994,,
+2006-11-27,9.210000038146973,9.039999961853027,-0.3329709864971998,,
+2006-11-24,9.239999771118164,9.300000190734863,-1.8458205818655877,,
+2006-11-22,9.720000267028809,9.31999969482422,0.6493552067419409,,
+2006-11-21,9.800000190734863,9.739999771118164,-4.115232111272971,,
+2006-11-20,9.699999809265137,9.800000190734863,-0.6122491678461899,,
+2006-11-17,9.84000015258789,9.739999771118164,1.0309317880007516,,
+2006-11-16,9.81999969482422,9.84000015258789,-1.0162640235673854,,
+2006-11-15,9.609999656677246,9.800000190734863,0.20367065565400824,,
+2006-11-14,9.170000076293944,9.600000381469728,1.9771128079656122,,
+2006-11-13,9.229999542236328,9.1899995803833,4.689207214811382,,
+2006-11-10,9.43000030517578,9.289999961853027,-0.4333690556536668,,
+2006-11-09,9.8100004196167,9.449999809265137,-1.4846271345920434,,
+2006-11-08,9.920000076293944,9.760000228881836,-3.6697308354001943,,
+2006-11-07,10.4399995803833,9.93000030517578,-1.6129016752173517,,
+2006-11-06,9.979999542236328,10.399999618530272,-4.885050725153352,,
+2006-11-03,9.350000381469728,9.829999923706056,4.208417791167849,,
+2006-11-02,9.079999923706056,9.300000190734863,5.133684734255347,,
+2006-11-01,9.539999961853027,9.170000076293944,2.4229104501909777,,
+2006-10-31,9.449999809265137,9.479999542236328,-3.8784055245133975,,
+2006-10-30,9.56999969482422,9.449999809265137,0.3174574981660691,,
+2006-10-27,9.68000030517578,9.56999969482422,-1.2539173394538747,,
+2006-10-26,9.380000114440918,9.670000076293944,-1.1363699058226573,,
+2006-10-25,9.539999961853027,9.350000381469728,3.091683990563689,,
+2006-10-24,9.800000190734863,9.5,-1.991609865231005,,
+2006-10-23,9.989999771118164,9.800000190734863,-3.061226376490177,,
+2006-10-20,10.470000267028809,10.039999961853027,-1.901897745109102,,
+2006-10-19,10.40999984741211,10.399999618530272,-4.106975111833568,,
+2006-10-18,10.300000190734863,10.40999984741211,-0.09606367942765856,,
+2006-10-17,10.0,10.199999809265137,1.0679578120415363,,
+2006-10-16,10.18000030517578,10.010000228881836,1.9999980926513672,,
+2006-10-13,9.869999885559082,10.100000381469728,-1.6699417602916087,,
+2006-10-12,9.390000343322754,9.8100004196167,2.330298871098903,,
+2006-10-11,9.600000381469728,9.329999923706056,4.472844099442532,,
+2006-10-10,9.34000015258789,9.510000228881836,-2.8125046566126874,,
+2006-10-09,8.800000190734863,9.270000457763672,1.8201292667735383,,
+2006-10-06,8.90999984741211,8.850000381469727,5.34091200956622,,
+2006-10-05,8.6899995803833,8.970000267028809,-0.6733946910202195,,
+2006-10-04,8.380000114440918,8.649999618530273,3.2221024184808704,,
+2006-10-03,8.279999732971191,8.369999885559082,3.221951078784309,,
+2006-10-02,8.600000381469727,8.34000015258789,1.086958399642303,,
+2006-09-29,8.619999885559082,8.640000343322754,-3.023258341267682,,
+2006-09-28,8.630000114440918,8.630000114440918,0.23202387504874855,,
+2006-09-27,8.369999885559082,8.569999694824219,0.0,,
+2006-09-26,8.300000190734863,8.380000114440918,2.389484014333144,,
+2006-09-25,7.900000095367432,8.199999809265137,0.9638544803331104,,
+2006-09-22,7.989999771118164,7.880000114440918,3.7974646870400064,,
+2006-09-21,8.289999961853027,8.050000190734863,-1.3767166436583282,,
+2006-09-20,8.100000381469727,8.220000267028809,-2.895051534650646,,
+2006-09-19,8.40999984741211,8.020000457763672,1.4814799988603002,,
+2006-09-18,8.510000228881836,8.4399995803833,-4.637329330849472,,
+2006-09-15,8.579999923706055,8.630000114440918,-0.8225692904327082,,
+2006-09-14,8.319999694824219,8.520000457763672,0.5827528109495151,,
+2006-09-13,8.300000190734863,8.380000114440918,2.4038554119643947,,
+2006-09-12,8.020000457763672,8.329999923706055,0.9638544803331104,,
+2006-09-11,7.630000114440918,7.980000019073486,3.8653297786571983,,
+2006-09-08,8.050000190734863,7.71999979019165,4.587154644600084,,
+2006-09-07,7.869999885559082,8.0,-4.0993837605498,,
+2006-09-06,7.710000038146973,7.960000038146973,1.651843917805633,,
+2006-09-05,8.510000228881836,7.809999942779541,3.242542137004777,,
+2006-09-01,8.720000267028809,8.359999656677246,-8.22562006198995,,
+2006-08-31,8.75,8.65999984741211,-4.128447239993338,,
+2006-08-30,8.079999923706055,8.630000114440918,-1.0285731724330358,,
+2006-08-29,8.100000381469727,8.329999923706055,6.806933117922538,,
+2006-08-28,8.59000015258789,8.050000190734863,2.8395003877097995,,
+2006-08-25,8.25,8.550000190734863,-6.286378955305871,,
+2006-08-24,7.75,8.149999618530273,3.636365948301373,,
+2006-08-23,7.420000076293945,7.710000038146973,5.161285400390625,,
+2006-08-22,7.260000228881836,7.400000095367432,3.908355240851603,,
+2006-08-21,7.559999942779541,7.300000190734863,1.9283727558113049,,
+2006-08-18,7.409999847412109,7.579999923706055,-3.439150185351524,,
+2006-08-17,6.949999809265137,7.349999904632568,2.294198107889525,,
+2006-08-16,6.389999866485596,6.900000095367432,5.755397213596844,,
+2006-08-15,5.78000020980835,6.320000171661377,7.981224405914243,,
+2006-08-14,5.400000095367432,5.489999771118164,9.342559554525213,,
+2006-08-11,5.269999980926514,5.389999866485596,1.6666606326163145,,
+2006-08-10,5.5,5.260000228881836,2.277037684884108,,
+2006-08-09,6.050000190734863,5.559999942779541,-4.3636322021484375,,
+2006-08-08,6.0,6.03000020980835,-8.099177396815989,,
+2006-08-07,5.75,5.920000076293945,0.5000034968058269,,
+2006-08-04,6.309999942779541,5.800000190734863,2.9565230659816577,,
+2006-08-03,6.289999961853027,6.190000057220459,-8.08240501853355,,
+2006-08-02,6.199999809265137,6.320000171661377,-1.5898236127033056,,
+2006-08-01,6.409999847412109,6.199999809265137,1.9354897756111937,,
+2006-07-31,6.650000095367432,6.429999828338623,-3.2761317183456,,
+2006-07-28,6.380000114440918,6.630000114440918,-3.308274644718677,,
+2006-07-27,6.639999866485596,6.53000020980835,3.9184952275178384,,
+2006-07-26,6.769999980926514,6.630000114440918,-1.6566213688113591,,
+2006-07-25,6.840000152587891,6.769999980926514,-2.0679448579028787,,
+2006-07-24,6.519999980926514,6.840000152587891,-1.0233942997046956,,
+2006-07-21,6.320000171661377,6.489999771118164,4.907978107323611,,
+2006-07-20,6.590000152587891,6.329999923706055,2.689867006951335,,
+2006-07-19,6.46999979019165,6.550000190734863,-3.9453751572332503,,
+2006-07-18,6.829999923706055,6.460000038146973,1.2364822741492416,,
+2006-07-17,7.46999979019165,6.769999980926514,-5.417275105302122,,
+2006-07-14,7.659999847412109,7.519999980926514,-9.370814309583501,,
+2006-07-13,8.420000076293945,7.690000057220459,-1.8276745336084297,,
+2006-07-12,8.59000015258789,8.390000343322754,-8.669833877184418,,
+2006-07-11,8.229999542236328,8.5600004196167,-2.3282864460122648,,
+2006-07-10,8.329999923706055,8.220000267028809,4.009731418413911,,
+2006-07-07,8.420000076293945,8.069999694824219,-1.3205241018574554,,
+2006-07-06,8.350000381469727,8.420000076293945,-4.156774089054152,,
+2006-07-05,8.489999771118164,8.350000381469727,0.8383196601950064,,
+2006-07-03,8.460000038146973,8.600000381469727,-1.6489916775345104,,
+2006-06-30,8.149999618530273,8.4399995803833,1.6548503864240967,,
+2006-06-29,7.820000171661377,8.180000305175781,3.5582819070772467,,
+2006-06-28,7.630000114440918,7.78000020980835,4.603582168949255,,
+2006-06-27,8.149999618530273,7.619999885559082,1.9659252046868778,,
+2006-06-26,7.96999979019165,8.170000076293945,-6.503064512618574,,
+2006-06-23,8.119999885559082,7.96999979019165,2.5094139443821195,,
+2006-06-22,8.399999618530273,8.119999885559082,-1.8472918409050416,,
+2006-06-21,8.380000114440918,8.40999984741211,-3.3333303057956836,,
+2006-06-20,8.569999694824219,8.390000343322754,0.35799203534011975,,
+2006-06-19,8.890000343322754,8.579999923706055,-2.1003425660583623,,
+2006-06-16,9.15999984741211,8.869999885559082,-3.487068702416186,,
+2006-06-15,8.779999732971191,9.170000076293944,-3.1659385009155687,,
+2006-06-14,8.569999694824219,8.729999542236328,4.441917485010836,,
+2006-06-13,8.899999618530273,8.579999923706055,1.8669761156320692,,
+2006-06-12,9.149999618530272,9.039999961853027,-3.59550234314575,,
+2006-06-09,9.220000267028809,9.149999618530272,-1.202182090308252,,
+2006-06-08,9.739999771118164,9.220000267028809,-0.7592261005551467,,
+2006-06-07,9.93000030517578,9.829999923706056,-5.338804068879961,,
+2006-06-06,10.039999961853027,9.9399995803833,-1.0070531560568046,,
+2006-06-05,10.329999923706056,9.970000267028809,-0.9960197395386249,,
+2006-06-02,10.510000228881836,10.350000381469728,-3.484991861917576,,
+2006-06-01,10.329999923706056,10.40999984741211,-1.5223581724805544,,
+2006-05-31,10.279999732971191,10.359999656677246,0.7744426359816625,,
+2006-05-30,10.5,10.260000228881836,0.7782093947869452,,
+2006-05-26,10.489999771118164,10.489999771118164,-2.285712105887277,,
+2006-05-25,9.9399995803833,10.390000343322754,0.0,,
+2006-05-24,9.859999656677246,9.8100004196167,4.527170844428753,,
+2006-05-23,10.40999984741211,9.880000114440918,-0.5070916714148881,,
+2006-05-22,10.149999618530272,10.329999923706056,-5.09125591488791,,
+2006-05-19,10.640000343322754,10.239999771118164,1.773402088086472,,
+2006-05-18,10.59000015258789,10.59000015258789,-3.7594037527979447,,
+2006-05-17,10.920000076293944,10.609999656677246,0.0,,
+2006-05-16,11.420000076293944,11.039999961853027,-2.8388316616377365,,
+2006-05-15,10.75,11.350000381469728,-3.327496601595778,,
+2006-05-12,11.029999732971191,10.859999656677246,5.5813988973928215,,
+2006-05-11,11.989999771118164,11.130000114440918,-1.5412518622804334,,
+2006-05-10,11.6899995803833,11.59000015258789,-7.172641143403827,,
+2006-05-09,11.90999984741211,11.850000381469728,-0.8554271290412767,,
+2006-05-08,11.960000038146973,11.979999542236328,-0.5037738598747182,,
+2006-05-05,11.800000190734863,12.020000457763672,0.1672199333241315,,
+2006-05-04,11.890000343322754,11.779999732971191,1.864409012480768,,
+2006-05-03,11.75,11.899999618530272,-0.9251522891110529,,
+2006-05-02,11.850000381469728,11.859999656677246,1.2765924981299717,,
+2006-05-01,11.40999984741211,11.899999618530272,0.08438206654536469,,
+2006-04-28,12.0,11.56999969482422,4.294476579062344,,
+2006-04-27,13.369999885559082,12.720000267028809,-3.583335876464829,,
+2006-04-26,14.260000228881836,13.550000190734863,-4.861627704517313,,
+2006-04-25,14.09000015258789,14.149999618530272,-4.978962319432204,,
+2006-04-24,14.8100004196167,14.140000343322754,0.42583012982693985,,
+2006-04-21,15.25,15.15999984741211,-4.523970677316738,,
+2006-04-20,15.199999809265137,15.109999656677246,-0.5901649350025615,,
+2006-04-19,15.609999656677246,15.279999732971191,-0.5921062744555508,,
+2006-04-18,14.84000015258789,15.149999618530272,-2.114029026034576,,
+2006-04-17,14.760000228881836,14.899999618530272,2.0889451668120196,,
+2006-04-13,14.979999542236328,14.899999618530272,0.9485053352132743,,
+2006-04-12,14.600000381469728,14.90999984741211,-0.5340449008726302,,
+2006-04-11,15.25,14.710000038146973,2.1232839578266813,,
+2006-04-10,15.300000190734863,15.260000228881836,-3.540983356413294,,
+2006-04-07,15.760000228881836,15.239999771118164,-0.261437655910945,,
+2006-04-06,16.190000534057617,15.800000190734863,-3.299495242460194,,
+2006-04-05,15.850000381469728,16.1299991607666,-2.4088964203697287,,
+2006-04-04,15.56999969482422,15.93000030517578,1.7665537700820528,,
+2006-04-03,16.0,15.56999969482422,2.3121426936908054,,
+2006-03-31,15.859999656677246,15.979999542236328,-2.6875019073486217,,
+2006-03-30,15.81999969482422,15.699999809265137,0.7566197235607169,,
+2006-03-29,15.18000030517578,15.699999809265137,-0.7585327931349062,,
+2006-03-28,14.84000015258789,14.899999618530272,3.4255566115638216,,
+2006-03-27,14.619999885559082,14.579999923706056,0.4043090655354067,,
+2006-03-24,15.300000190734863,14.8100004196167,-0.27359755243593104,,
+2006-03-23,15.510000228881836,15.579999923706056,-3.202612843200424,,
+2006-03-22,15.270000457763672,15.619999885559082,0.4513197536507517,,
+2006-03-21,15.25,15.460000038146973,2.2920721499877965,,
+2006-03-20,16.270000457763672,14.960000038146973,1.3770494304719518,,
+2006-03-17,17.93000030517578,16.34000015258789,-8.051631117143558,,
+2006-03-16,17.100000381469727,17.799999237060547,-8.867819997353328,,
+2006-03-15,16.350000381469727,16.860000610351562,4.093560467690797,,
+2006-03-14,15.350000381469728,16.350000381469727,3.119267382157646,,
+2006-03-13,15.300000190734863,15.369999885559082,6.5146578185573345,,
+2006-03-10,14.779999732971191,15.239999771118164,0.4575143395528065,,
+2006-03-09,14.59000015258789,14.829999923706056,3.1123142520821943,,
+2006-03-08,14.800000190734863,14.649999618530272,1.644960716985298,,
+2006-03-07,14.949999809265137,14.8100004196167,-1.0135173666990585,,
+2006-03-06,15.220000267028809,14.989999771118164,-0.9364507788265928,,
+2006-03-03,14.949999809265137,15.229999542236328,-1.5111727455675292,,
+2006-03-02,14.640000343322754,14.8100004196167,1.8729079367456842,,
+2006-03-01,14.970000267028809,14.630000114440918,1.161202679694483,,
+2006-02-28,14.859999656677246,14.970000267028809,-2.271210063614599,,
+2006-02-27,14.699999809265137,14.729999542236328,0.7402463855517952,,
+2006-02-24,14.6899995803833,14.739999771118164,0.20407981877852227,,
+2006-02-23,14.699999809265137,14.739999771118164,0.34036890512667156,,
+2006-02-22,14.90999984741211,14.760000228881836,0.2721085875648523,,
+2006-02-21,15.09000015258789,14.829999923706056,-1.006033669117096,,
+2006-02-17,14.920000076293944,15.09000015258789,-1.7229968605218662,,
+2006-02-16,15.1899995803833,14.880000114440918,1.1394106931946766,,
+2006-02-15,15.449999809265137,15.119999885559082,-2.040812867057106,,
+2006-02-14,14.9399995803833,15.43000030517578,-2.1359218626537366,,
+2006-02-13,14.619999885559082,14.720000267028809,3.2797907533803774,,
+2006-02-10,14.399999618530272,14.489999771118164,0.6839971426299534,,
+2006-02-09,13.979999542236328,14.010000228881836,0.625001076195016,,
+2006-02-08,13.800000190734863,13.760000228881836,0.2145971933323019,,
+2006-02-07,13.75,13.56999969482422,-0.2898547920302406,,
+2006-02-06,14.529999732971191,13.8100004196167,-1.3090931285511234,,
+2006-02-03,15.0600004196167,14.329999923706056,-4.955260334387232,,
+2006-02-02,15.170000076293944,15.399999618530272,-4.847280714280501,,
+2006-02-01,13.140000343322754,14.449999809265137,1.516147271454183,,
+2006-01-31,12.970000267028809,13.050000190734863,9.969554274845011,,
+2006-01-30,10.18000030517578,10.289999961853027,0.6168074175713276,,
+2006-01-27,10.520000457763672,10.239999771118164,1.080546693317103,,
+2006-01-26,10.90999984741211,10.550000190734863,-2.6616033694073624,,
+2006-01-25,10.050000190734863,10.90999984741211,-3.299721922201853,,
+2006-01-24,9.949999809265137,10.09000015258789,8.557210351797638,,
+2006-01-23,10.399999618530272,9.93000030517578,1.4070386533313282,,
+2006-01-20,10.93000030517578,10.390000343322754,-4.519224332634279,,
+2006-01-19,10.859999656677246,10.859999656677246,-4.940530162632426,,
+2006-01-18,10.829999923706056,10.770000457763672,0.0,,
+2006-01-17,11.0,10.739999771118164,-0.5540116931215324,,
+2006-01-13,10.640000343322754,10.710000038146973,-2.3636384443803267,,
+2006-01-12,10.6899995803833,10.710000038146973,0.6578918474203604,,
+2006-01-11,10.989999771118164,10.800000190734863,0.18709502851968063,,
+2006-01-10,10.699999809265137,10.989999771118164,-1.7288406218407908,,
+2006-01-09,10.5,10.6899995803833,2.7102800656306196,,
+2006-01-06,10.06999969482422,10.460000038146973,1.8095198131742933,,
+2006-01-05,10.050000190734863,10.010000228881836,3.8728932983305304,,
+2006-01-04,10.130000114440918,9.970000267028809,-0.39800956312322733,,
+2006-01-03,10.0,9.989999771118164,-1.5794654057705297,,
+2005-12-30,10.0,9.850000381469728,-0.10000228881835936,,
+2005-12-29,10.0,9.9399995803833,-1.4999961853027166,,
+2005-12-28,9.869999885559082,9.970000267028809,-0.6000041961669922,,
+2005-12-27,10.050000190734863,9.710000038146973,1.013175102626276,,
+2005-12-23,10.029999732971191,9.899999618530272,-3.3830860311956825,,
+2005-12-22,10.0,10.0,-1.2961128404976514,,
+2005-12-21,9.760000228881836,9.93000030517578,0.0,,
+2005-12-20,9.760000228881836,9.670000076293944,1.741804019541706,,
+2005-12-19,9.600000381469728,9.75,-0.9221326893165797,,
+2005-12-16,9.729999542236328,9.710000038146973,1.5624959642689848,,
+2005-12-15,9.869999885559082,9.6899995803833,-0.2055447587899764,,
+2005-12-14,10.130000114440918,9.970000267028809,-1.8237113197857469,,
+2005-12-13,9.81999969482422,10.0600004196167,-1.5794654057705297,,
+2005-12-12,9.56999969482422,9.81999969482422,2.443999310091371,,
+2005-12-09,9.920000076293944,9.670000076293944,2.612330281841163,,
+2005-12-08,9.899999618530272,9.789999961853027,-2.5201612709402172,,
+2005-12-07,9.81999969482422,9.9399995803833,-1.1111076860180182,,
+2005-12-06,9.850000381469728,9.90999984741211,1.2219947992699838,,
+2005-12-05,9.93000030517578,9.9399995803833,0.6091316103424197,,
+2005-12-02,10.15999984741211,9.859999656677246,0.10069763242916942,,
+2005-12-01,9.039999961853027,10.289999961853027,-2.952757827169431,,
+2005-11-30,9.329999923706056,8.770000457763672,13.82743368666756,,
+2005-11-29,9.359999656677246,9.25,-6.002137947713315,,
+2005-11-28,9.279999732971191,9.25,-1.175210050341983,,
+2005-11-25,9.25,9.300000190734863,-0.3232729939054249,,
+2005-11-23,9.550000190734863,9.350000381469728,0.5405426025390625,,
+2005-11-22,9.43000030517578,9.489999771118164,-2.094238798645984,,
+2005-11-21,9.420000076293944,9.5,0.6362615482573536,,
+2005-11-18,9.890000343322754,9.489999771118164,0.8492560834195914,,
+2005-11-17,9.649999618530272,9.760000228881836,-4.044495028502712,,
+2005-11-16,9.699999809265137,9.470000267028809,1.1399027430046442,,
+2005-11-15,10.369999885559082,9.670000076293944,-2.3711293480298807,,
+2005-11-14,10.43000030517578,10.369999885559082,-6.750239315237939,,
+2005-11-11,10.420000076293944,10.289999961853027,-0.5752676688506217,,
+2005-11-10,10.5,10.489999771118164,-1.2476018569008784,,
+2005-11-09,10.4399995803833,10.470000267028809,-0.09524027506510416,,
+2005-11-08,9.9399995803833,10.289999961853027,0.287362910453358,,
+2005-11-07,9.800000190734863,10.0600004196167,3.52113074693138,,
+2005-11-04,10.300000190734863,10.100000381469728,2.653063508382846,,
+2005-11-03,10.34000015258789,10.220000267028809,-1.9417456850635821,,
+2005-11-02,10.350000381469728,10.31999969482422,-1.1605404621686444,,
+2005-11-01,10.380000114440918,10.289999961853027,-0.28986169603645595,,
+2005-10-31,10.300000190734863,10.5,-0.8670534835802183,,
+2005-10-28,10.75,10.5,1.9417456850635995,,
+2005-10-27,11.010000228881836,10.619999885559082,-2.3255813953488373,,
+2005-10-26,11.270000457763672,11.06999969482422,-3.542237377068265,,
+2005-10-25,11.15999984741211,11.239999771118164,-1.7746295902026779,,
+2005-10-24,11.1899995803833,11.270000457763672,0.7168452042999433,,
+2005-10-21,11.220000267028809,11.15999984741211,0.7149319068842249,,
+2005-10-20,11.40999984741211,11.1899995803833,-0.5347630854610314,,
+2005-10-19,11.039999961853027,11.470000267028809,-1.928135582567134,,
+2005-10-18,11.489999771118164,11.18000030517578,3.89493031396358,,
+2005-10-17,11.489999771118164,11.40999984741211,-2.697993665079217,,
+2005-10-14,11.050000190734863,11.020000457763672,-0.6962569651841637,,
+2005-10-13,10.829999923706056,10.979999542236328,-0.2714907914331567,,
+2005-10-12,10.039999961853027,10.869999885559082,1.385038038660866,,
+2005-10-11,10.75,10.149999618530272,8.266931542426681,,
+2005-10-10,10.789999961853027,10.800000190734863,-5.5813988973928215,,
+2005-10-07,10.510000228881836,10.800000190734863,0.09268052749945091,,
+2005-10-06,11.020000457763672,10.619999885559082,2.759276456113651,,
+2005-10-05,11.149999618530272,11.020000457763672,-3.629769106976638,,
+2005-10-04,11.4399995803833,11.149999618530272,-1.1659117956430523,,
+2005-10-03,11.5,11.3100004196167,-2.534964794494447,,
+2005-09-30,11.279999732971191,11.369999885559082,-1.6521702642026153,,
+2005-09-29,10.779999732971191,11.130000114440918,0.7978737120429369,,
+2005-09-28,10.770000457763672,10.869999885559082,3.2467568658580954,,
+2005-09-27,11.06999969482422,10.949999809265137,0.9284997543646758,,
+2005-09-26,11.0,10.989999771118164,-1.0840098361989094,,
+2005-09-23,10.970000267028809,10.869999885559082,-0.09091117165305397,,
+2005-09-22,10.609999656677246,10.899999618530272,-0.9115804834598364,,
+2005-09-21,11.300000190734863,10.710000038146973,2.7332702284351007,,
+2005-09-20,11.140000343322754,11.3100004196167,-5.2212402002581,,
+2005-09-19,10.9399995803833,11.0600004196167,1.5260329538126296,,
+2005-09-16,11.149999618530272,11.020000457763672,1.0968998522502138,,
+2005-09-15,10.84000015258789,11.039999961853027,-1.1659117956430523,,
+2005-09-14,10.920000076293944,10.75,1.8450166646666484,,
+2005-09-13,11.100000381469728,10.869999885559082,-1.5567772445624248,,
+2005-09-12,11.079999923706056,11.039999961853027,-2.0720764685252417,,
+2005-09-09,11.210000038146973,11.010000228881836,-0.3610104885239915,,
+2005-09-08,10.5,11.0,-1.784119612707842,,
+2005-09-07,10.18000030517578,10.350000381469728,4.761904761904762,,
+2005-09-06,10.199999809265137,10.130000114440918,1.669941760291661,,
+2005-09-02,9.90999984741211,10.06999969482422,-0.6862715307174295,,
+2005-09-01,9.5,9.90999984741211,1.6145292621159162,,
+2005-08-31,9.399999618530272,9.56999969482422,4.315787867495889,,
+2005-08-30,9.510000228881836,9.449999809265137,1.8085115233284346,,
+2005-08-29,9.0600004196167,9.390000343322754,-0.6309192236870632,,
+2005-08-26,9.539999961853027,9.239999771118164,3.6423830951656395,,
+2005-08-25,9.449999809265137,9.550000190734863,-3.14465609994187,,
+2005-08-24,9.260000228881836,9.460000038146973,1.0582051162761126,,
+2005-08-23,9.229999542236328,9.270000457763672,2.159825100666192,,
+2005-08-22,8.970000267028809,9.239999771118164,0.43337938798696807,,
+2005-08-19,8.539999961853027,8.880000114440918,3.0100278266634786,,
+2005-08-18,8.649999618530273,8.5600004196167,3.981266441529546,,
+2005-08-17,8.899999618530273,8.65999984741211,-1.040453212515471,,
+2005-08-16,8.930000305175781,8.859999656677246,-2.6966267573593123,,
+2005-08-15,8.90999984741211,9.020000457763672,-0.7838818153003102,,
+2005-08-12,8.899999618530273,8.8100004196167,1.2345747725631213,,
+2005-08-11,8.829999923706055,8.979999542236328,-1.0112269974280794,,
+2005-08-10,9.0,8.6899995803833,1.6987499414078913,,
+2005-08-09,8.800000190734863,8.869999885559082,-3.4444491068522134,,
+2005-08-08,9.229999542236328,8.890000343322754,0.795451060307003,,
+2005-08-05,9.329999923706056,9.09000015258789,-3.6836318068895175,,
+2005-08-04,9.18000030517578,9.470000267028809,-2.572344834734289,,
+2005-08-03,9.6899995803833,9.25,3.159040873773437,,
+2005-08-02,9.800000190734863,9.670000076293944,-4.540759540114407,,
+2005-08-01,9.649999618530272,9.640000343322754,-1.326531754191441,,
+2005-07-29,9.579999923706056,9.550000190734863,-0.10361943629838899,,
+2005-07-28,9.4399995803833,9.510000228881836,-0.3131496159718933,,
+2005-07-27,9.609999656677246,9.479999542236328,0.7415323263784812,,
+2005-07-26,9.350000381469728,9.489999771118164,-1.3527587834052723,,
+2005-07-25,9.170000076293944,9.449999809265137,1.497319614295344,,
+2005-07-22,9.1899995803833,9.329999923706056,3.053432177116787,,
+2005-07-21,9.550000190734863,9.210000038146973,1.5233987999476764,,
+2005-07-20,9.0600004196167,9.5,-3.5602109507573525,,
+2005-07-19,8.829999923706055,9.270000457763672,4.8565072848188215,,
+2005-07-18,8.890000343322754,8.829999923706055,4.983018548803608,,
+2005-07-15,8.970000267028809,8.979999542236328,-0.6749203295786744,,
+2005-07-14,9.06999969482422,9.039999961853027,0.11147463667614421,,
+2005-07-13,8.869999885559082,8.949999809265137,-0.3307578167650047,,
+2005-07-12,9.0,8.989999771118164,0.9019157242188874,,
+2005-07-11,9.0,9.06999969482422,-0.11111365424262153,,
+2005-07-08,8.0,9.0,0.7777743869357836,,
+2005-07-07,8.100000381469727,8.100000381469727,12.5,,
+2005-07-06,8.399999618530273,8.289999961853027,0.0,,
+2005-07-05,8.34000015258789,8.359999656677246,-1.3095197818174718,,
+2005-07-01,8.329999923706055,8.34000015258789,0.23980220291902093,,
+2005-06-30,8.850000381469727,8.399999618530273,0.12005076798832419,,
+2005-06-29,8.880000114440918,8.760000228881836,-5.084754164323789,,
+2005-06-28,8.720000267028809,8.84000015258789,-1.3513500451867637,,
+2005-06-27,9.210000038146973,8.800000190734863,1.3761454344538677,,
+2005-06-24,9.100000381469728,9.199999809265137,-4.451681278109964,,
+2005-06-23,9.119999885559082,9.020000457763672,1.0988947648731593,,
+2005-06-22,9.0,9.020000457763672,-1.0964849676561144,,
+2005-06-21,9.0,9.100000381469728,0.22222730848524305,,
+2005-06-20,9.380000114440918,9.06999969482422,1.1111153496636483,,
+2005-06-17,9.31999969482422,9.199999809265137,-3.304908484376651,,
+2005-06-16,9.0,9.31999969482422,-1.287552462321696,,
+2005-06-15,9.0,8.890000343322754,3.5555521647135615,,
+2005-06-14,8.880000114440918,9.0,-1.2222184075249565,,
+2005-06-13,8.720000267028809,8.899999618530273,1.3513500451867637,,
+2005-06-10,8.760000228881836,8.510000228881836,2.064212683364935,,
+2005-06-09,8.529999732971191,8.850000381469727,-2.8538812039724233,,
+2005-06-08,9.0,8.5,3.751473136178771,,
+2005-06-07,8.850000381469727,8.920000076293945,-5.555555555555555,,
+2005-06-06,8.59000015258789,8.789999961853027,0.7909569695701397,,
+2005-06-03,8.609999656677246,8.75,2.3282864460122648,,
+2005-06-02,8.819999694824219,8.819999694824219,1.6260203124884045,,
+2005-06-01,8.819999694824219,8.710000038146973,0.0,,
+2005-05-31,8.579999923706055,8.729999542236328,-1.2471616834839172,,
+2005-05-27,9.020000457763672,8.649999618530273,1.7482473177631734,,
+2005-05-26,9.100000381469728,8.520000457763672,-4.102004661373739,,
+2005-05-25,9.0,8.819999694824219,-6.373625268050609,,
+2005-05-24,8.109999656677246,9.149999618530272,-2.000003390842014,,
+2005-05-23,7.909999847412109,7.909999847412109,12.823674548453983,,
+2005-05-20,8.0,7.570000171661377,0.0,,
+2005-05-19,7.380000114440918,7.739999771118164,-5.374997854232788,,
+2005-05-18,7.199999809265137,7.369999885559082,4.87804405277463,,
+2005-05-17,7.199999809265137,7.210000038146973,2.361112233297354,,
+2005-05-16,7.050000190734863,7.199999809265137,0.13889207148266028,,
+2005-05-13,7.199999809265137,7.190000057220459,2.127654105987167,,
+2005-05-12,7.630000114440918,7.199999809265137,-0.13888544874417647,,
+2005-05-11,7.5,7.429999828338623,-5.635652670069313,,
+2005-05-10,7.260000228881836,7.269999980926514,-0.9333356221516927,,
+2005-05-09,7.389999866485596,7.400000095367432,0.13773762712701548,,
+2005-05-06,7.5,7.400000095367432,0.13532109692163863,,
+2005-05-05,7.900000095367432,7.5,-1.3333320617675781,,
+2005-05-04,7.539999961853027,7.539999961853027,-5.063292285299998,,
+2005-05-03,7.960000038146973,7.5,0.0,,
+2005-05-02,7.75,7.699999809265137,-5.778894923900744,,
+2005-04-29,7.510000228881836,7.460000038146973,-0.6451637514175907,,
+2005-04-28,7.949999809265137,7.510000228881836,-0.66578148083902,,
+2005-04-27,7.949999809265137,7.739999771118164,-5.534586049555798,,
+2005-04-26,7.639999866485596,7.670000076293945,-2.6415099771729946,,
+2005-04-25,7.25,7.28000020980835,0.3926729101128862,,
+2005-04-22,7.190000057220459,7.159999847412109,0.4137959973565464,,
+2005-04-21,6.599999904632568,7.199999809265137,-0.4172490899804975,,
+2005-04-20,6.539999961853027,6.739999771118164,9.090907777308086,,
+2005-04-19,6.460000038146973,6.860000133514404,3.0581010769374575,,
+2005-04-18,7.0,7.150000095367432,6.191951904108196,,
+2005-04-15,7.329999923706055,6.920000076293945,2.1428585052490234,,
+2005-04-14,6.25,6.900000095367432,-5.593449545423911,,
+2005-04-13,6.690000057220459,6.5,10.400001525878906,,
+2005-04-12,6.78000020980835,6.570000171661377,-2.8400606217543087,,
+2005-04-11,6.659999847412109,6.75,-3.097345599535147,,
+2005-04-08,6.889999866485596,6.619999885559082,1.3513536734218121,,
+2005-04-07,7.050000190734863,6.909999847412109,-3.918722585755773,,
+2005-04-06,6.809999942779541,6.949999809265137,-1.9858204189376176,,
+2005-04-05,6.769999980926514,6.929999828338623,2.055798350395491,,
+2005-04-04,6.929999828338623,6.849999904632568,2.363365551889004,,
+2005-04-01,6.900000095367432,6.849999904632568,-1.1544000820737916,,
+2005-03-31,7.070000171661377,6.900000095367432,-0.7246404354172798,,
+2005-03-30,7.130000114440918,7.139999866485596,-2.4045271876421617,,
+2005-03-29,6.949999809265137,7.0,0.140248974532616,,
+2005-03-28,7.0,7.010000228881836,0.7194272245620404,,
+2005-03-24,7.159999847412109,6.960000038146973,0.14286041259765625,,
+2005-03-23,7.010000228881836,7.190000057220459,-2.793293485019055,,
+2005-03-22,6.949999809265137,7.090000152587891,2.5677578097217095,,
+2005-03-21,7.260000228881836,7.050000190734863,2.014393484387116,,
+2005-03-18,7.179999828338623,7.28000020980835,-2.8925624177193208,,
+2005-03-17,7.170000076293945,7.170000076293945,1.3927630064145224,,
+2005-03-16,7.150000095367432,7.179999828338623,0.0,,
+2005-03-15,7.079999923706055,7.110000133514404,0.41957667931541126,,
+2005-03-14,7.300000190734863,7.090000152587891,0.4237317815202162,,
+2005-03-11,7.010000228881836,7.010000228881836,-2.8767127761654585,,
+2005-03-10,7.119999885559082,6.949999809265137,0.0,,
+2005-03-09,7.0,7.170000076293945,-2.387641559359329,,
+2005-03-08,7.010000228881836,7.150000095367432,2.428572518484933,,
+2005-03-07,7.079999923706055,7.050000190734863,1.9971449631168852,,
+2005-03-04,7.900000095367432,7.210000038146973,-0.4237250465320333,,
+2005-03-03,8.0,7.53000020980835,-8.734177834061999,,
+2005-03-02,8.199999809265137,7.550000190734863,-5.87499737739563,,
+2005-03-01,7.599999904632568,7.730000019073486,-7.92682480060356,,
+2005-02-28,7.650000095367432,7.519999980926514,1.7105278430553217,,
+2005-02-25,7.599999904632568,7.639999866485596,-1.699347880003837,,
+2005-02-24,7.639999866485596,7.610000133514404,0.5263152941442201,,
+2005-02-23,7.769999980926514,7.75,-0.39266666878871687,,
+2005-02-22,8.1899995803833,7.800000190734863,-0.2574000125560982,,
+2005-02-18,8.010000228881836,7.639999866485596,-4.761897553481744,,
+2005-02-17,8.029999732971191,8.050000190734863,-4.619230359845955,,
+2005-02-16,8.050000190734863,8.109999656677246,0.24907171144165752,,
+2005-02-15,8.0600004196167,8.079999923706055,0.7453349629909216,,
+2005-02-14,8.0,8.1899995803833,0.24813279216065556,,
+2005-02-11,8.369999885559082,8.180000305175781,2.3749947547912598,,
+2005-02-10,8.3100004196167,8.029999732971191,-2.2700069651268526,,
+2005-02-09,8.149999618530273,8.289999961853027,-3.369442509106671,,
+2005-02-08,7.670000076293945,8.069999694824219,1.7177957039953924,,
+2005-02-07,7.400000095367432,7.5,5.215118833786877,,
+2005-02-04,7.25,7.340000152587891,1.3513500451867637,,
+2005-02-03,7.400000095367432,7.449999809265137,1.241381415005388,,
+2005-02-02,7.25,7.349999904632568,0.675671800720733,,
+2005-02-01,7.150000095367432,7.150000095367432,1.379309029414736,,
+2005-01-31,7.150000095367432,7.070000171661377,0.0,,
+2005-01-28,7.0,6.960000038146973,-1.1188800369091962,,
+2005-01-27,6.599999904632568,7.0,-0.5714280264718192,,
+2005-01-26,6.53000020980835,6.739999771118164,6.060607593140567,,
+2005-01-25,6.320000171661377,6.559999942779541,3.2159196717082152,,
+2005-01-24,6.739999771118164,6.420000076293945,3.7974646297370884,,
+2005-01-21,6.789999961853027,6.639999866485596,-4.747770114109824,,
+2005-01-20,6.610000133514404,6.650000095367432,-2.20913249204932,,
+2005-01-19,6.75,6.619999885559082,0.6051431323006671,,
+2005-01-18,7.239999771118164,6.800000190734863,-1.9259276213469327,,
+2005-01-14,7.110000133514404,7.059999942779541,-6.077342462613727,,
+2005-01-13,7.360000133514404,7.199999809265137,-0.7032375498725718,,
+2005-01-12,7.25,7.420000076293945,-2.1739174096029172,,
+2005-01-11,6.590000152587891,7.019999980926514,2.3448286385371766,,
+2005-01-10,6.5,6.429999828338623,6.525035180306669,,
+2005-01-07,6.429999828338623,6.5,-1.0769257178673377,,
+2005-01-06,6.349999904632568,6.340000152587891,1.0886496660990352,,
+2005-01-05,6.25,6.260000228881836,-0.1574764125174637,,
+2005-01-04,6.650000095367432,6.28000020980835,0.160003662109375,,
+2005-01-03,6.820000171661377,6.389999866485596,-5.563907973728209,,
+2004-12-31,6.039999961853027,6.769999980926514,-6.304989653263185,,
+2004-12-30,6.25,6.059999942779541,12.086093107350413,,
+2004-12-29,5.889999866485596,6.130000114440918,-3.0400009155273438,,
+2004-12-28,6.050000190734863,5.900000095367432,4.074707188381041,,
+2004-12-27,6.139999866485596,6.170000076293945,-2.479340341131657,,
+2004-12-23,6.75,6.309999942779541,0.4886027762329755,,
+2004-12-22,6.949999809265137,6.900000095367432,-6.518519366229023,,
+2004-12-21,6.980000019073486,6.929999828338623,-0.7194203635955471,,
+2004-12-20,6.78000020980835,6.71999979019165,-0.7163351088572092,,
+2004-12-17,6.809999942779541,6.809999942779541,-0.8849619138639415,,
+2004-12-16,6.909999847412109,6.809999942779541,0.0,,
+2004-12-15,6.989999771118164,6.900000095367432,-1.4471766547146845,,
+2004-12-14,7.0,7.039999961853027,-1.2875490514692178,,
+2004-12-13,6.809999942779541,6.989999771118164,0.5714280264718192,,
+2004-12-10,6.789999961853027,6.800000190734863,2.6431693076513456,,
+2004-12-09,6.739999771118164,6.820000171661377,0.14727877670130093,,
+2004-12-08,6.909999847412109,6.829999923706055,1.1869496032629812,,
+2004-12-07,6.800000190734863,6.800000190734863,-1.1577413237717475,,
+2004-12-06,6.900000095367432,6.789999961853027,0.0,,
+2004-12-03,6.909999847412109,6.800000190734863,-1.5942048115080016,,
+2004-12-02,6.71999979019165,6.809999942779541,-1.591890869844845,,
+2004-12-01,6.699999809265137,6.690000057220459,1.3392880267534037,,
+2004-11-30,6.920000076293945,6.78000020980835,-0.1492500347664117,,
+2004-11-29,6.900000095367432,6.820000171661377,-2.023119435579163,,
+2004-11-26,6.909999847412109,6.809999942779541,-1.1594191681209625,,
+2004-11-24,6.710000038146973,6.679999828338623,-1.4471766547146845,,
+2004-11-23,6.650000095367432,6.610000133514404,-0.4470970139760899,,
+2004-11-22,6.900000095367432,6.670000076293945,-0.6015031771336723,,
+2004-11-19,7.0,6.679999828338623,-3.3333335636894454,,
+2004-11-18,7.079999923706055,7.070000171661377,-4.571431023733957,,
+2004-11-17,7.25,7.130000114440918,-0.14123943718128354,,
+2004-11-16,7.03000020980835,7.199999809265137,-1.6551708352976833,,
+2004-11-15,7.070000171661377,7.079999923706055,2.4182019115675333,,
+2004-11-12,7.150000095367432,7.090000152587891,0.14143920511854666,,
+2004-11-11,7.309999942779541,7.099999904632568,-0.8391600276818971,,
+2004-11-10,7.480000019073486,7.349999904632568,-2.872777562117499,,
+2004-11-09,7.380000114440918,7.400000095367432,-1.7379694399655963,,
+2004-11-08,7.150000095367432,7.389999866485596,0.27100244737636836,,
+2004-11-05,7.25,7.190000057220459,3.3566401107275885,,
+2004-11-04,7.230000019073486,7.199999809265137,-0.8275854176488416,,
+2004-11-03,7.309999942779541,7.230000019073486,-0.4149406601549925,,
+2004-11-02,7.369999885559082,7.360000133514404,-1.0943902097437728,,
+2004-11-01,7.599999904632568,7.590000152587891,-0.13568184803193062,,
+2004-10-29,7.46999979019165,7.630000114440918,-0.1315756864494485,,
+2004-10-28,7.639999866485596,7.630000114440918,2.141905337927226,,
+2004-10-27,6.849999904632568,7.639999866485596,-0.13088680915484918,,
+2004-10-26,7.349999904632568,6.900000095367432,11.532846319001559,,
+2004-10-25,7.110000133514404,7.0,-6.1224464639994105,,
+2004-10-22,7.320000171661377,7.110000133514404,-1.5471185857774703,,
+2004-10-21,7.329999923706055,7.550000190734863,-2.868852912872408,,
+2004-10-20,7.21999979019165,7.539999961853027,3.0013679306776346,,
+2004-10-19,7.46999979019165,7.429999828338623,4.432135470365197,,
+2004-10-18,7.460000038146973,7.46999979019165,-0.5354747386412056,,
+2004-10-15,7.579999923706055,7.730000019073486,0.1340449328893251,,
+2004-10-14,7.340000152587891,7.75,1.978893098643895,,
+2004-10-13,7.460000038146973,7.670000076293945,5.585828867694972,,
+2004-10-12,7.559999942779541,7.659999847412109,2.815013901784585,,
+2004-10-11,7.699999809265137,7.630000114440918,1.3227500712890479,,
+2004-10-08,7.869999885559082,7.650000095367432,-0.9090869682878511,,
+2004-10-07,7.800000190734863,7.800000190734863,-2.795423041813954,,
+2004-10-06,7.75,7.800000190734863,0.0,,
+2004-10-05,7.800000190734863,7.800000190734863,0.6451637514175907,,
+2004-10-04,7.800000190734863,7.849999904632568,0.0,,
+2004-10-01,7.800000190734863,7.800000190734863,0.6410219573724708,,
+2004-09-30,7.800000190734863,7.800000190734863,0.0,,
+2004-09-29,7.980000019073486,7.800000190734863,0.0,,
+2004-09-28,7.389999866485596,7.230000019073486,-2.2556369412079507,,
+2004-09-27,7.25,7.199999809265137,-2.1650859310258586,,
+2004-09-24,7.019999980926514,7.0,-0.6896578032394935,,
+2004-09-23,7.019999980926514,7.25,-0.2849000139722797,,
+2004-09-22,7.019999980926514,7.090000152587891,3.2763535569572815,,
+2004-09-21,7.409999847412109,7.25,0.9971534451790439,,
+2004-09-20,7.800000190734863,7.489999771118164,-2.159242249755082,,
+2004-09-17,7.809999942779541,7.75,-3.9743642568743716,,
+2004-09-16,7.900000095367432,7.710000038146973,-0.7682451116406452,,
+2004-09-15,7.889999866485596,7.949999809265137,-2.4050639864153323,,
+2004-09-14,7.75,7.760000228881836,0.7604555614050535,,
+2004-09-13,7.360000133514404,7.760000228881836,0.12903521137852822,,
+2004-09-10,7.349999904632568,7.409999847412109,5.4347838058588644,,
+2004-09-09,7.5,7.389999866485596,0.8163257626945568,,
+2004-09-08,7.5,7.389999866485596,-1.4666684468587239,,
+2004-09-07,7.460000038146973,7.400000095367432,-1.4666684468587239,,
+2004-09-03,7.110000133514404,7.449999809265137,-0.8042887730928847,,
+2004-09-02,6.940000057220459,6.949999809265137,4.781992536794425,,
+2004-09-01,6.449999809265137,6.889999866485596,0.14408864498889842,,
+2004-08-31,6.25,6.449999809265137,6.821706515222195,,
+2004-08-30,6.0,6.199999809265137,3.1999969482421875,,
+2004-08-27,5.809999942779541,5.909999847412109,3.3333301544189453,,
+2004-08-26,5.699999809265137,5.940000057220459,1.7211687713843207,,
+2004-08-25,5.650000095367432,5.710000038146973,4.21053080677671,,
+2004-08-24,5.699999809265137,5.599999904632568,1.061945871978593,,
+2004-08-23,5.699999809265137,5.699999809265137,-1.7543843505051042,,
+2004-08-20,5.5,5.699999809265137,0.0,,
+2004-08-19,5.699999809265137,5.599999904632568,3.6363601684570312,,
+2004-08-18,5.699999809265137,5.699999809265137,-1.7543843505051042,,
+2004-08-17,5.300000190734863,5.699999809265137,0.0,,
+2004-08-16,5.159999847412109,5.28000020980835,7.547162342173654,,
+2004-08-13,5.349999904632568,5.449999809265137,2.3255884873024546,,
+2004-08-12,5.400000095367432,5.46999979019165,1.8691571292548694,,
+2004-08-11,5.130000114440918,5.119999885559082,1.2962906219996235,,
+2004-08-10,5.199999809265137,5.460000038146973,-0.1949362311647003,,
+2004-08-09,5.070000171661377,5.150000095367432,5.000004584972843,,
+2004-08-06,5.230000019073486,5.389999866485596,1.5779077119802087,,
+2004-08-05,5.800000190734863,5.230000019073486,3.0592704938546813,,
+2004-08-04,5.960000038146973,5.849999904632568,-9.827588843392048,,
+2004-08-03,6.329999923706055,5.960000038146973,-1.8456398122541708,,
+2004-08-02,6.0,6.25,-5.845179937102692,,
+2004-07-30,6.150000095367432,6.21999979019165,4.166666666666666,,
+2004-07-29,6.079999923706055,6.289999961853027,1.1382064022559437,,
+2004-07-28,6.150000095367432,6.289999961853027,3.453948039179702,,
+2004-07-27,6.289999961853027,6.300000190734863,2.2764205579614942,,
+2004-07-26,5.96999979019165,6.110000133514404,0.15898615170881306,,
+2004-07-23,6.300000190734863,6.170000076293945,2.3450644596799823,,
+2004-07-22,6.199999809265137,6.300000190734863,-2.0634938175415214,,
+2004-07-21,6.019999980926514,6.010000228881836,1.6129094281630187,,
+2004-07-20,6.03000020980835,6.199999809265137,-0.16610883847774885,,
+2004-07-19,6.050000190734863,6.03000020980835,2.8192304069951297,,
+2004-07-16,6.349999904632568,6.300000190734863,-0.3305781867105094,,
+2004-07-15,6.150000095367432,6.199999809265137,-0.7873970810807158,,
+2004-07-14,6.150000095367432,6.150000095367432,0.8130034654043017,,
+2004-07-13,6.300000190734863,6.300000190734863,0.0,,
+2004-07-12,6.25,6.380000114440918,0.0,,
+2004-07-09,6.010000228881836,6.0,2.0800018310546875,,
+2004-07-08,6.300000190734863,6.070000171661377,-0.16639315309471273,,
+2004-07-07,6.170000076293945,6.079999923706055,-3.650793843018249,,
+2004-07-06,6.150000095367432,6.150000095367432,-1.4586734436792723,,
+2004-07-02,6.349999904632568,6.300000190734863,0.0,,
+2004-07-01,6.320000171661377,6.300000190734863,-0.7873970810807158,,
+2004-06-30,6.269999980926514,6.199999809265137,-0.316455385811424,,
+2004-06-29,6.400000095367432,6.269999980926514,-1.1164301734341167,,
+2004-06-28,6.440000057220459,6.150000095367432,-2.0312517578713334,,
+2004-06-25,6.480000019073486,6.0,-4.503104957706988,,
+2004-06-24,6.25,6.199999809265137,-7.4074076799480775,,
+2004-06-23,6.840000152587891,6.400000095367432,-0.8000030517578125,,
+2004-06-22,6.599999904632568,6.349999904632568,-6.432749231065244,,
+2004-06-21,6.809999942779541,6.599999904632568,-3.7878788426121632,,
+2004-06-18,6.949999809265137,6.619999885559082,-3.0837010266003015,,
+2004-06-17,6.5,6.849999904632568,-4.748200471403285,,
+2004-06-16,6.400000095367432,6.400000095367432,5.3846139174241285,,
+2004-06-15,6.110000133514404,6.400000095367432,0.0,,
+2004-06-14,6.150000095367432,6.199999809265137,4.7463167842227625,,
+2004-06-10,6.199999809265137,6.099999904632568,0.8130034654043017,,
+2004-06-09,6.300000190734863,5.960000038146973,-1.6129017372408756,,
+2004-06-08,6.489999771118164,6.099999904632568,-5.396827655464425,,
+2004-06-07,6.099999904632568,6.099999904632568,-6.0092431469901655,,
+2004-06-04,6.599999904632568,6.019999980926514,0.0,,
+2004-06-03,6.25,6.25,-8.787877758891334,,
+2004-06-02,6.400000095367432,6.300000190734863,0.0,,
+2004-06-01,6.590000152587891,6.5,-1.562498486600839,,
+2004-05-28,6.880000114440918,6.610000133514404,-1.365707898391286,,
+2004-05-27,7.440000057220459,6.699999809265137,-3.924418262142055,,